

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization  
International Bureau



(43) International Publication Date  
17 January 2002 (17.01.2002)

PCT

(10) International Publication Number  
WO 02/04612 A2

(51) International Patent Classification<sup>7</sup>: C12N 9/00

(21) International Application Number: PCT/US01/21324

(22) International Filing Date: 5 July 2001 (05.07.2001)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:

60/216,804	7 July 2000 (07.07.2000)	US
60/218,948	14 July 2000 (14.07.2000)	US
60/220,037	21 July 2000 (21.07.2000)	US
60/221,837	28 July 2000 (28.07.2000)	US

(71) Applicant (for all designated States except US): INCYTE GENOMICS, INC. [US/US]; 3160 Porter Drive, Palo Alto, CA 94304 (US).

(72) Inventors; and

(75) Inventors/Applicants (for US only): BAUGHN, Mariah, R. [US/US]; 14244 Santiago Road, San Leandro, CA 94577 (US). BRUNS, Christopher, M. [US/US]; 575 S. Rengstorff Avenue #126, Mountain View, CA 94040 (US). DAS, Debopriya [IN/US]; 1179 Bonita Avenue, Apt. 3, Mountain View, CA 94040 (US). DING, Li [CN/US]; 3353 Alma Street #146, Palo Alto, CA 94306 (US). ELLIOTT, Vicki, S. [US/US]; 3770 Polton Place Way, San Jose, CA 95121 (US). GANDHI, Ameena, R. [US/US]; 837 Roble Avenue #1, Redwood City, CA 94134 (US). HAFALIA, April, J., A. [US/US]; 2227 Calle de Primavera, Santa Clara, CA 95054 (US). KEARNEY, Liam [IE/US]; 50 Woodside Avenue, San Francisco, CA 94127 (US). KHAN, Farrah, A. [IN/US]; 3617 Central Road #102, Glenview, IL 60025 (US). LAL, Preeti [IN/US]; P.O. Box 5142, Santa Clara, CA 95056 (US). LEE, Ernestine, A. [US/US]; 624 Kains Street, Albany, CA 94706 (US). LU, Dyung, Aina, M. [US/US]; 233 Coy Drive, San Jose, CA 95123 (US). LU, Yan [CN/US]; 3885 Corrina Way, Palo Alto, CA 94303 (US). NGUYEN, Danniell, B. [US/US]; 1403 Ridgewood Drive, San Jose, CA 95118 (US). PATERSON, Chandra [US/US]; 490 Sherwood Way #1, Menlo Park, CA 94025 (US). RAMKUMAR, Jayalaxmi

[IN/US]; 34359 Maybird Circle, Fremont, CA 94555 (US). RING, Huijun, Z. [US/US]; 625 Orange Avenue, Los Altos, CA 94022 (US). SANJANWALA, Madhu, S. [US/US]; 210 Sylvia Court, Los Altos, CA 94024 (US). TANG, Y., Tom [US/US]; 4230 Ranwick Court, San Jose, CA 95118 (US). THANGAVELU, Kavitha [IN/US]; 1950 Montecito Avenue 23, Mountain View, CA 94043 (US). THORNTON, Michael [US/US]; 9 Medway Road, Woodside, CA 94062 (US). TRIBOULEY, Catherine, M. [FR/US]; 1121 Tennessee Street #5, San Francisco, CA 94107 (US). WALIA, Narinder, K. [US/US]; 890 Davis Street #205, San Leandro, CA 94577 (US). XU, Yuming [US/US]; 1739 Walnut Drive, Mountain View, CA 94040 (US). YANG, Jumming [CN/US]; 7125 Bark Lane, San Jose, CA 95129 (US). YAO, Monique, G. [US/US]; 111 Frederick Court, Mountain View, CA 94043 (US). YUE, Henry [US/US]; 826 Lois Avenue, Sunnyvale, CA 94087 (US).

(74) Agents: HAMLET COX, Diana et al.; Incyte Genomics, Inc., 3160 Porter Drive, Palo Alto, CA 94304 (US).

(81) Designated States (national): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW.

(84) Designated States (regional): ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).

Published:

— without international search report and to be republished upon receipt of that report

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

WO 02/04612 A2

(54) Title: DRUG METABOLIZING ENZYMES

(57) Abstract: The invention provides human drug metabolizing enzymes (DME) and polynucleotides which identify and encode DME. The invention also provides expression vectors, host cells, antibodies, agonists, and antagonists. The invention also provides methods for diagnosing, treating, or preventing disorders associated with aberrant expression of DME.

## DRUG METABOLIZING ENZYMES

### TECHNICAL FIELD

This invention relates to nucleic acid and amino acid sequences of drug metabolizing enzymes and to the use of these sequences in the diagnosis, treatment, and prevention of 5 autoimmune/inflammatory, cell proliferative, developmental, endocrine, eye, metabolic, and gastrointestinal disorders, including liver disorders.

### BACKGROUND OF THE INVENTION

10 The metabolism of a drug and its movement through the body (pharmacokinetics) are important in determining its effects, toxicity, and interactions with other drugs. The three processes governing pharmacokinetics are the absorption of the drug, distribution to various tissues, and elimination of drug metabolites. These processes are intimately coupled to drug metabolism, since a variety of metabolic modifications alter most of the physicochemical and pharmacological properties of drugs, including 15 solubility, binding to receptors, and excretion rates. The metabolic pathways which modify drugs also accept a variety of naturally occurring substrates such as steroids, fatty acids, prostaglandins, leukotrienes, and vitamins. The enzymes in these pathways are therefore important sites of biochemical and pharmacological interaction between natural compounds, drugs, carcinogens, mutagens, and xenobiotics.

20 It has long been appreciated that inherited differences in drug metabolism lead to drastically different levels of drug efficacy and toxicity among individuals. For drugs with narrow therapeutic indices, or drugs which require bioactivation (such as codeine), these polymorphisms can be critical. Moreover, promising new drugs are frequently eliminated in clinical trials based on toxicities which may only affect a segment of the patient group. Advances in pharmacogenomics research, of which 25 drug metabolizing enzymes constitute an important part, are promising to expand the tools and information that can be brought to bear on questions of drug efficacy and toxicity (See Evans, W.E. and R.V. Relling (1999) *Science* 286:487-491).

30 Drug metabolic reactions are categorized as Phase I, which functionalize the drug molecule and prepare it for further metabolism, and Phase II, which are conjugative. In general, Phase I reaction products are partially or fully inactive, and Phase II reaction products are the chief excreted species. However, Phase I reaction products are sometimes more active than the original administered drugs; this metabolic activation principle is exploited by pro-drugs (e.g. L-dopa). Additionally, some nontoxic compounds (e.g. aflatoxin, benzo[a]pyrene) are metabolized to toxic intermediates through these pathways. Phase I reactions are usually rate-limiting in drug metabolism. Prior exposure to the

compound, or other compounds, can induce the expression of Phase I enzymes however, and thereby increase substrate flux through the metabolic pathways. (See Klaassen, C.D., Amdur, M.O. and J. Doull (1996) Casarett and Doull's Toxicology: The Basic Science of Poisons, McGraw-Hill, New York, NY, pp. 113-186; B.G. Katzung (1995) Basic and Clinical Pharmacology, Appleton and Lange, 5 Norwalk, CT, pp. 48-59; G.G. Gibson and P. Skett (1994) Introduction to Drug Metabolism, Blackie Academic and Professional, London.)

Drug metabolizing enzymes (DMEs) have broad substrate specificities. This can be contrasted to the immune system, where a large and diverse population of antibodies are highly specific for their antigens. The ability of DMEs to metabolize a wide variety of molecules creates the potential for drug 10 interactions at the level of metabolism. For example, the induction of a DME by one compound may affect the metabolism of another compound by the enzyme.

DMEs have been classified according to the type of reaction they catalyze and the cofactors involved. The major classes of Phase I enzymes include, but are not limited to, cytochrome P450 and 15 flavin-containing monooxygenase. Other enzyme classes involved in Phase I-type catalytic cycles and reactions include, but are not limited to, NADPH cytochrome P450 reductase (CPR), the microsomal cytochrome b5/NADH cytochrome b5 reductase system, the ferredoxin/ferredoxin reductase redox pair, aldo/keto reductases, and alcohol dehydrogenases. The major classes of Phase II enzymes include, but are not limited to, UDP glucuronyltransferase, sulfotransferase, glutathione S-transferase, N-acyltransferase, and N-acetyl transferase.

20 Cytochrome P450 and P450 catalytic cycle-associated enzymes

Members of the cytochrome P450 superfamily of enzymes catalyze the oxidative metabolism of a variety of substrates, including natural compounds such as steroids, fatty acids, prostaglandins, leukotrienes, and vitamins, as well as drugs, carcinogens, mutagens, and xenobiotics. Cytochromes P450, also known as P450 heme-thiolate proteins, usually act as terminal oxidases in multi-component 25 electron transfer chains, called P450-containing monooxygenase systems. Specific reactions catalyzed include hydroxylation, epoxidation, N-oxidation, sulfoxidation, N-, S-, and O-dealkylations, desulfation, deamination, and reduction of azo, nitro, and N-oxide groups. These reactions are involved in steroidogenesis of glucocorticoids, cortisols, estrogens, and androgens in animals; insecticide resistance in insects; herbicide resistance and flower coloring in plants; and environmental 30 bioremediation by microorganisms. Cytochrome P450 actions on drugs, carcinogens, mutagens, and xenobiotics can result in detoxification or in conversion of the substance to a more toxic product. Cytochromes P450 are abundant in the liver, but also occur in other tissues; the enzymes are located in microsomes. (See ExPASY ENZYME EC 1.14.14.1; Prosite PDO00081 Cytochrome P450 cysteine heme-iron ligand signature; PRINTS EP450I E-Class P450 Group I signature; Graham-Lorence, S. and

Peterson, J.A. (1996) FASEB J. 10:206-214.)

Four hundred cytochromes P450 have been identified in diverse organisms including bacteria, fungi, plants, and animals (Graham-Lorence, supra). The B-class is found in prokaryotes and fungi, while the E-class is found in bacteria, plants, insects, vertebrates, and mammals. Five subclasses or 5 groups are found within the larger family of E-class cytochromes P450 (PRINTS EP450I E-Class P450 Group I signature).

All cytochromes P450 use a heme cofactor and share structural attributes. Most cytochromes P450 are 400 to 530 amino acids in length. The secondary structure of the enzyme is about 70% alpha-helical and about 22% beta-sheet. The region around the heme-binding site in the C-terminal part 10 of the protein is conserved among cytochromes P450. A ten amino acid signature sequence in this heme-iron ligand region has been identified which includes a conserved cysteine involved in binding the heme iron in the fifth coordination site. In eukaryotic cytochromes P450, a membrane-spanning region is usually found in the first 15-20 amino acids of the protein, generally consisting of approximately 15 hydrophobic residues followed by a positively charged residue. (See Prosite PDOC00081, supra; 15 Graham-Lorence, supra.)

Cytochrome P450 enzymes are involved in cell proliferation and development. The enzymes have roles in chemical mutagenesis and carcinogenesis by metabolizing chemicals to reactive intermediates that form adducts with DNA (Nebert, D.W. and Gonzalez, F.J. (1987) Ann. Rev. Biochem. 56:945-993). These adducts can cause nucleotide changes and DNA rearrangements that 20 lead to oncogenesis. Cytochrome P450 expression in liver and other tissues is induced by xenobiotics such as polycyclic aromatic hydrocarbons, peroxisomal proliferators, phenobarbital, and the glucocorticoid dexamethasone (Dogra, S.C. et al. (1998) Clin. Exp. Pharmacol. Physiol. 25:1-9). A cytochrome P450 protein may participate in eye development as mutations in the P450 gene CYP1B1 cause primary congenital glaucoma (Online Mendelian Inheritance in Man (OMIM) \*601771 25 Cytochrome P450, subfamily I (dioxin-inducible), polypeptide 1; CYP1B1).

Cytochromes P450 are associated with inflammation and infection. Hepatic cytochrome P450 activities are profoundly affected by various infections and inflammatory stimuli, some of which are suppressed and some induced (Morgan, E.T. (1997) Drug Metab. Rev. 29:1129-1188). Effects observed in vivo can be mimicked by proinflammatory cytokines and interferons. Autoantibodies to 30 two cytochrome P450 proteins were found in patients with autoimmune polyenocrinopathy-candidiasis-ectodermal dystrophy (APECED), a polyglandular autoimmune syndrome (OMIM \*240300 Autoimmune polyenocrinopathy-candidiasis-ectodermal dystrophy).

Mutations in cytochromes P450 have been linked to metabolic disorders, including congenital adrenal hyperplasia, the most common adrenal disorder of infancy and childhood; pseudovitamin D-

deficiency rickets; cerebrotendinous xanthomatosis, a lipid storage disease characterized by progressive neurologic dysfunction, premature atherosclerosis, and cataracts; and an inherited resistance to the anticoagulant drugs coumarin and warfarin (Isselbacher, K.J. et al. (1994) Harrison's Principles of Internal Medicine, McGraw-Hill, Inc. New York, NY, pp. 1968-1970; Takeyama, K. et al. (1997) 5 Science 277:1827-1830; Kitanaka, S. et al. (1998) N. Engl. J. Med. 338:653-661; OMIM \*213700 Cerebrotendinous xanthomatosis; and OMIM #122700 Coumarin resistance). Extremely high levels of expression of the cytochrome P450 protein aromatase were found in a fibrolamellar hepatocellular carcinoma from a boy with severe gynecomastia (feminization) (Agarwal, V.R. (1998) J. Clin. Endocrinol. Metab. 83:1797-1800).

10 The cytochrome P450 catalytic cycle is completed through reduction of cytochrome P450 by NADPH cytochrome P450 reductase (CPR). Another microsomal electron transport system consisting of cytochrome b5 and NADPH cytochrome b5 reductase has been widely viewed as a minor contributor of electrons to the cytochrome P450 catalytic cycle. However, a recent report by Lamb, D.C. et al. (1999; FEBS Lett. 462:283-288) identifies a Candida albicans cytochrome P450 (CYP51) which can 15 be efficiently reduced and supported by the microsomal cytochrome b5/NADPH cytochrome b5 reductase system. Therefore, there are likely many cytochromes P450 which are supported by this alternative electron donor system.

20 Cytochrome b5 reductase is also responsible for the reduction of oxidized hemoglobin (methemoglobin, or ferrihemoglobin, which is unable to carry oxygen) to the active hemoglobin (ferrohemoglobin) in red blood cells. Methemoglobinemia results when there is a high level of oxidant drugs or an abnormal hemoglobin (hemoglobin M) which is not efficiently reduced. Methemoglobinemia can also result from a hereditary deficiency in red cell cytochrome b5 reductase (Reviewed in Mansour, A. and Lurie, A.A. (1993) Am. J. Hematol. 42:7-12).

25 Members of the cytochrome P450 family are also closely associated with vitamin D synthesis and catabolism. Vitamin D exists as two biologically equivalent prohormones, ergocalciferol (vitamin D<sub>2</sub>), produced in plant tissues, and cholecalciferol (vitamin D<sub>3</sub>), produced in animal tissues. The latter form, cholecalciferol, is formed upon the exposure of 7-dehydrocholesterol to near ultraviolet light (i.e., 290-310 nm), normally resulting from even minimal periods of skin exposure to sunlight (reviewed in Miller, W.L. and Portale, A.A. (2000) Trends Endocrinol. Metab. 11:315-319).

30 Both prohormone forms are further metabolized in the liver to 25-hydroxyvitamin D (25(OH)D) by the enzyme 25-hydroxylase. 25(OH)D is the most abundant precursor form of vitamin D which must be further metabolized in the kidney to the active form, 1 $\alpha$ ,25-dihydroxyvitamin D (1 $\alpha$ ,25(OH)<sub>2</sub>D), by the enzyme 25-hydroxyvitamin D 1 $\alpha$ -hydroxylase (1 $\alpha$ -hydroxylase). Regulation of 1 $\alpha$ ,25(OH)<sub>2</sub>D production is primarily at this final step in the synthetic pathway. The activity of

1 $\alpha$ -hydroxylase depends upon several physiological factors including the circulating level of the enzyme product (1 $\alpha$ ,25(OH)<sub>2</sub>D) and the levels of parathyroid hormone (PTH), calcitonin, insulin, calcium, phosphorus, growth hormone, and prolactin. Furthermore, extrarenal 1 $\alpha$ -hydroxylase activity has been reported, suggesting that tissue-specific, local regulation of 1 $\alpha$ ,25(OH)<sub>2</sub>D production may also be 5 biologically important. The catalysis of 1 $\alpha$ ,25(OH)<sub>2</sub>D to 24,25-dihydroxyvitamin D (24,25(OH)<sub>2</sub>D), involving the enzyme 25-hydroxyvitamin D 24-hydroxylase (24-hydroxylase), also occurs in the kidney. 24-hydroxylase can also use 25(OH)D as a substrate (Shinki, T. *et al.* (1997) Proc. Natl. Acad. Sci. U.S.A. 94:12920-12925; Miller, W.L. and Portale, A.A. *supra*; and references within).

Vitamin D 25-hydroxylase, 1 $\alpha$ -hydroxylase, and 24-hydroxylase are all NADPH-dependent, 10 type I (mitochondrial) cytochrome P450 enzymes that show a high degree of homology with other members of the family. Vitamin D 25-hydroxylase also shows a broad substrate specificity and may also perform 26-hydroxylation of bile acid intermediates and 25, 26, and 27-hydroxylation of cholesterol (Dilworth, F.J. *et al.* (1995) J. Biol. Chem. 270:16766-16774; Miller, W.L. and Portale, A.A. *supra*; and references within).

15 The active form of vitamin D (1 $\alpha$ ,25(OH)<sub>2</sub>D) is involved in calcium and phosphate homeostasis and promotes the differentiation of myeloid and skin cells. Vitamin D deficiency resulting from deficiencies in the enzymes involved in vitamin D metabolism (e.g., 1 $\alpha$ -hydroxylase) causes hypocalcemia, hypophosphatemia, and vitamin D-dependent (sensitive) rickets, a disease characterized by loss of bone density and distinctive clinical features, including bandy or bow leggedness 20 accompanied by a waddling gait. Deficiencies in vitamin D 25-hydroxylase cause cerebrotendinous xanthomatosis, a lipid-storage disease characterized by the deposition of cholesterol and cholestanol in the Achilles' tendons, brain, lungs, and many other tissues. The disease presents with progressive neurologic dysfunction, including postpubescent cerebellar ataxia, atherosclerosis, and cataracts. Vitamin D 25-hydroxylase deficiency does not result in rickets, suggesting the existence of alternative 25 pathways for the synthesis of 25(OH)D (Griffin, J.E. and Zerwekh, J.E. (1983) J. Clin. Invest. 72:1190-1199; Gamblin, G.T. *et al.* (1985) J. Clin. Invest. 75:954-960; and W.L. and Portale, A.A. *supra*).

Ferredoxin and ferredoxin reductase are electron transport accessory proteins which support at 30 least one human cytochrome P450 species, cytochrome P450c27 encoded by the CYP27 gene (Dilworth, F.J. *et al.* (1996) Biochem. J. 320:267-71). A *Streptomyces griseus* cytochrome P450, CYP104D1, was heterologously expressed in *E. coli* and found to be reduced by the endogenous ferredoxin and ferredoxin reductase enzymes (Taylor, M. *et al.* (1999) Biochem. Biophys. Res. Commun. 263:838-42), suggesting that many cytochrome P450 species may be supported by the ferredoxin/ferredoxin reductase pair. Ferredoxin reductase has also been found in a model drug

metabolism system to reduce actinomycin D, an antitumor antibiotic, to a reactive free radical species (Flitter, W.D. and Mason, R.P. (1988) Arch. Biochem. Biophys. 267:632-639).

Flavin-containing monooxygenase (FMO)

5 Flavin-containing monooxygenases oxidize the nucleophilic nitrogen, sulfur, and phosphorus heteroatom of an exceptional range of substrates. Like cytochromes P450, FMOs are microsomal and use NADPH and O<sub>2</sub>; there is also a great deal of substrate overlap with cytochromes P450. The tissue distribution of FMOs includes liver, kidney, and lung.

10 There are five different known isoforms of FMO in mammals (FMO1, FMO2, FMO3, FMO4, and FMO5), which are expressed in a tissue-specific manner. The isoforms differ in their substrate specificities and other properties such as inhibition by various compounds and stereospecificity of reaction. FMOs have a 13 amino acid signature sequence, the components of which span the N-terminal two-thirds of the sequences and include the FAD binding region and the FATGY motif which has been found in many N-hydroxylating enzymes (Stehr, M. et al. (1998) Trends Biochem. Sci. 23:56-57; PRINTS FMOXYGENASE Flavin-containing monooxygenase signature).

15 Specific reactions include oxidation of nucleophilic tertiary amines to N-oxides, secondary amines to hydroxylamines and nitrones, primary amines to hydroxylamines and oximes, and sulfur-containing compounds and phosphines to S- and P-oxides. Hydrazines, iodides, selenides, and boron-containing compounds are also substrates. Although FMOs appear similar to cytochromes P450 in their chemistry, they can generally be distinguished from cytochromes P450 in vitro based on, for 20 example, the higher heat lability of FMOs and the nonionic detergent sensitivity of cytochromes P450; however, use of these properties in identification is complicated by further variation among FMO isoforms with respect to thermal stability and detergent sensitivity.

25 FMOs play important roles in the metabolism of several drugs and xenobiotics. FMO (FMO3 in liver) is predominantly responsible for metabolizing (S)-nicotine to (S)-nicotine N-1'-oxide, which is excreted in urine. FMO is also involved in S-oxygénéation of cimetidine, an H<sub>2</sub>-antagonist widely used for the treatment of gastric ulcers. Liver-expressed forms of FMO are not under the same regulatory control as cytochrome P450. In rats, for example, phenobarbital treatment leads to the induction of cytochrome P450, but the repression of FMO1.


30 Endogenous substrates of FMO include cysteamine, which is oxidized to the disulfide, cystamine, and trimethylamine (TMA), which is metabolized to trimethylamine N-oxide. TMA smells like rotting fish, and mutations in the FMO3 isoform lead to large amounts of the malodorous free amine being excreted in sweat, urine, and breath. These symptoms have led to the designation fish-odor syndrome (OMIM 602079 Trimethylaminuria).

Lysyl oxidase:

Lysyl oxidase (lysine 6-oxidase, LO) is a copper-dependent amine oxidase involved in the formation of connective tissue matrices by crosslinking collagen and elastin. LO is secreted as a N-glycosylated precursor protein of approximately 50 kDa and cleaved to the mature form of the enzyme by a metalloprotease, although the precursor form is also active. The copper atom in LO is involved in the transport of electron to and from oxygen to facilitate the oxidative deamination of lysine residues in these extracellular matrix proteins. While the coordination of copper is essential to LO activity, insufficient dietary intake of copper does not influence the expression of the apoenzyme. However, the absence of the functional LO is linked to the skeletal and vascular tissue disorders that are associated with dietary copper deficiency. LO is also inhibited by a variety of semicarbazides, hydrazines, and amino nitrites, as well as heparin. Beta-aminopropionitrile is a commonly used inhibitor. LO activity is increased in response to ozone, cadmium, and elevated levels of hormones released in response to local tissue trauma, such as transforming growth factor-beta, platelet-derived growth factor, angiotensin II, and fibroblast growth factor. Abnormalities in LO activity have been linked to Menkes syndrome and occipital horn syndrome. Cytosolic forms of the enzyme have been implicated in abnormal cell proliferation (reviewed in Rucker, R.B. et al. (1998) Am. J. Clin. Nutr. 67:996S-1002S and Smith-Mungo, L.I. and Kagan, H.M. (1998) Matrix Biol. 16:387-398).

#### Dihydrofolate reductases

Dihydrofolate reductases (DHFR) are ubiquitous enzymes that catalyze the NADPH-dependent reduction of dihydrofolate to tetrahydrofolate, an essential step in the *de novo* synthesis of glycine and purines as well as the conversion of deoxyuridine monophosphate (dUMP) to deoxythymidine monophosphate (dTMP). The basic reaction is as follows:



The enzymes can be inhibited by a number of dihydrofolate analogs, including trimethoprim and methotrexate. Since an abundance of TMP is required for DNA synthesis, rapidly dividing cells require the activity of DHFR. The replication of DNA viruses (i.e., herpesvirus) also requires high levels of DHFR activity. As a result, drugs that target DHFR have been used for cancer chemotherapy and to inhibit DNA virus replication. (For similar reasons, thymidylate synthetases are also target enzymes.) Drugs that inhibit DHFR are preferentially cytotoxic for rapidly dividing cells (or DNA virus-infected cells) but have no specificity, resulting in the indiscriminate destruction of dividing cells. Furthermore, cancer cells may become resistant to drugs such as methotrexate as a result of acquired transport defects or the duplication of one or more DHFR genes (Stryer, L. (1988) *Biochemistry*. W.H Freeman and Co., Inc. New York. pp. 511-5619).

Aldo/keto reductases

5 Aldo/keto reductases are monomeric NADPH-dependent oxidoreductases with broad substrate specificities (Bohren, K.M. et al. (1989) J. Biol. Chem. 264:9547-9551). These enzymes catalyze the reduction of carbonyl-containing compounds, including carbonyl-containing sugars and aromatic compounds, to the corresponding alcohols. Therefore, a variety of carbonyl-containing drugs and xenobiotics are likely metabolized by enzymes of this class.

10 One known reaction catalyzed by a family member, aldose reductase, is the reduction of glucose to sorbitol, which is then further metabolized to fructose by sorbitol dehydrogenase. Under normal conditions, the reduction of glucose to sorbitol is a minor pathway. In hyperglycemic states, however, the accumulation of sorbitol is implicated in the development of diabetic complications (OMIM \*103880 Aldo-keto reductase family 1, member B1). Members of this enzyme family are also highly expressed in some liver cancers (Cao, D. et al. (1998) J. Biol. Chem. 273:11429-11435).

Alcohol dehydrogenases

15 Alcohol dehydrogenases (ADHs) oxidize simple alcohols to the corresponding aldehydes. ADH is a cytosolic enzyme, prefers the cofactor NAD<sup>+</sup>, and also binds zinc ion. Liver contains the highest levels of ADH, with lower levels in kidney, lung, and the gastric mucosa.

20 Known ADH isoforms are dimeric proteins composed of 40 kDa subunits. There are five known gene loci which encode these subunits (a, b, g, p, c), and some of the loci have characterized allelic variants (b<sub>1</sub>, b<sub>2</sub>, b<sub>3</sub>, g<sub>1</sub>, g<sub>2</sub>). The subunits can form homodimers and heterodimers; the subunit composition determines the specific properties of the active enzyme. The holoenzymes have therefore been categorized as Class I (subunit compositions aa, ab, ag, bg, gg), Class II (pp), and Class III (cc). Class I ADH isozymes oxidize ethanol and other small aliphatic alcohols, and are inhibited by pyrazole. Class II isozymes prefer longer chain aliphatic and aromatic alcohols, are unable to oxidize methanol, and are not inhibited by pyrazole. Class III isozymes prefer even longer chain aliphatic alcohols (five 25 carbons and longer) and aromatic alcohols, and are not inhibited by pyrazole.

25 The short-chain alcohol dehydrogenases include a number of related enzymes with a variety of substrate specificities. Included in this group are the mammalian enzymes D-beta-hydroxybutyrate dehydrogenase, (R)-3-hydroxybutyrate dehydrogenase, 15-hydroxyprostaglandin dehydrogenase, NADPH-dependent carbonyl reductase, corticosteroid 11-beta-dehydrogenase, and estradiol 17-beta-dehydrogenase, as well as the bacterial enzymes acetoacetyl-CoA reductase, glucose 1-dehydrogenase, 3-beta-hydroxysteroid dehydrogenase, 20-beta-hydroxysteroid dehydrogenase, ribitol dehydrogenase, 3-oxoacyl reductase, 2,3-dihydro-2,3-dihydroxybenzoate dehydrogenase, sorbitol-6-phosphate 2-dehydrogenase, 7-alpha-hydroxysteroid dehydrogenase, cis-1,2-dihydroxy-3,4-cyclohexadiene-1-carboxylate dehydrogenase, cis-toluene dihydrodiol dehydrogenase, cis-benzene glycol dehydrogenase,

biphenyl-2,3-dihydro-2,3-diol dehydrogenase, N-acylmannosamine 1-dehydrogenase, and 2-deoxy-D-gluconate 3-dehydrogenase (Krozowski, Z. (1994) *J. Steroid Biochem. Mol. Biol.* 51:125-130; Krozowski, Z. (1992) *Mol. Cell Endocrinol.* 84:C25-31; and Marks, A.R. et al. (1992) *J. Biol. Chem.* 267:15459-15463).

5 UDP glucuronyltransferase

Members of the UDP glucuronyltransferase family (UGTs) catalyze the transfer of a glucuronic acid group from the cofactor uridine diphosphate-glucuronic acid (UDP-glucuronic acid) to a substrate. The transfer is generally to a nucleophilic heteroatom (O, N, or S). Substrates include xenobiotics which have been functionalized by Phase I reactions, as well as endogenous compounds 10 such as bilirubin, steroid hormones, and thyroid hormones. Products of glucuronidation are excreted in urine if the molecular weight of the substrate is less than about 250 g/mol, whereas larger glucuronidated substrates are excreted in bile.

UGTs are located in the microsomes of liver, kidney, intestine, skin, brain, spleen, and nasal mucosa, where they are on the same side of the endoplasmic reticulum membrane as cytochrome P450 15 enzymes and flavin-containing monooxygenases, and therefore are ideally located to access products of Phase I drug metabolism. UGTs have a C-terminal membrane-spanning domain which anchors them in the endoplasmic reticulum membrane, and a conserved signature domain of about 50 amino acid residues in their C terminal section (Prosite PDOC00359 UDP-glycosyltransferase signature).

UGTs involved in drug metabolism are encoded by two gene families, UGT1 and UGT2. 20 Members of the UGT1 family result from alternative splicing of a single gene locus, which has a variable substrate binding domain and constant region involved in cofactor binding and membrane insertion. Members of the UGT2 family are encoded by separate gene loci, and are divided into two families, UGT2A and UGT2B. The 2A subfamily is expressed in olfactory epithelium, and the 2B subfamily is expressed in liver microsomes. Mutations in UGT genes are associated with 25 hyperbilirubinemia (OMIM #143500 Hyperbilirubinemia I); Crigler-Najjar syndrome, characterized by intense hyperbilirubinemia from birth (OMIM #218800 Crigler-Najjar syndrome); and a milder form of hyperbilirubinemia termed Gilbert's disease (OMIM \*191740 UGT1).

Sulfotransferase

Sulfate conjugation occurs on many of the same substrates which undergo O-glucuronidation to 30 produce a highly water-soluble sulfuric acid ester. Sulfotransferases (ST) catalyze this reaction by transferring  $\text{SO}_3^-$  from the cofactor 3'-phosphoadenosine-5'-phosphosulfate (PAPS) to the substrate. ST substrates are predominantly phenols and aliphatic alcohols, but also include aromatic amines and aliphatic amines, which are conjugated to produce the corresponding sulfamates. The products of these reactions are excreted mainly in urine.

5           STs are found in a wide range of tissues, including liver, kidney, intestinal tract, lung, platelets, and brain. The enzymes are generally cytosolic, and multiple forms are often co-expressed. For example, there are more than a dozen forms of ST in rat liver cytosol. These biochemically characterized STs fall into five classes based on their substrate preference: arylsulfotransferase, alcohol sulfotransferase, estrogen sulfotransferase, tyrosine ester sulfotransferase, and bile salt sulfotransferase.

10           ST enzyme activity varies greatly with sex and age in rats. The combined effects of developmental cues and sex-related hormones are thought to lead to these differences in ST expression profiles, as well as the profiles of other DMEs such as cytochromes P450. Notably, the high expression of STs in cats partially compensates for their low level of UDP glucuronyltransferase activity.

15           Several forms of ST have been purified from human liver cytosol and cloned. There are two phenol sulfotransferases with different thermal stabilities and substrate preferences. The thermostable enzyme catalyzes the sulfation of phenols such as para-nitrophenol, minoxidil, and acetaminophen; the thermolabile enzyme prefers monoamine substrates such as dopamine, epinephrine, and levadopa. Other cloned STs include an estrogen sulfotransferase and an N-acetylglucosamine-6-O-  
20           sulfotransferase. This last enzyme is illustrative of the other major role of STs in cellular biochemistry, the modification of carbohydrate structures that may be important in cellular differentiation and maturation of proteoglycans. Indeed, an inherited defect in a sulfotransferase has been implicated in macular corneal dystrophy, a disorder characterized by a failure to synthesize mature keratan sulfate proteoglycans (Nakazawa, K. et al. (1984) J. Biol. Chem. 259:13751-13757; OMIM \*217800 Macular dystrophy, corneal).

#### Galactosyltransferases

25           Galactosyltransferases are a subset of glycosyltransferases that transfer galactose (Gal) to the terminal N-acetylglucosamine (GlcNAc) oligosaccharide chains that are part of glycoproteins or glycolipids that are free in solution (Kolbinger, F. et al. (1998) J. Biol. Chem. 273:433-440; Amado, M. et al. (1999) Biochim. Biophys. Acta 1473:35-53). Galactosyltransferases have been detected on the cell surface and as soluble extracellular proteins, in addition to being present in the Golgi.  $\beta$ 1,3-galactosyltransferases form Type I carbohydrate chains with Gal ( $\beta$ 1-3)GlcNAc linkages. Known human and mouse  $\beta$ 1,3-galactosyltransferases appear to have a short cytosolic domain, a single transmembrane domain, and a catalytic domain with eight conserved regions. (Kolbinger, F., *supra* and Hennet, T. et al. (1998) J. Biol. Chem. 273:58-65). In mouse UDP-galactose: $\beta$ -N-acetylglucosamine  $\beta$ 1,3-galactosyltransferase-I region 1 is located at amino acid residues 78-83, region 2 is located at amino acid residues 93-102, region 3 is located at amino acid residues 116-119, region 4 is located at amino acid residues 147-158, region 5 is located at amino acid residues 172-183, region 6 is located at amino acid residues 203-206, region 7 is located at amino acid residues 236-246, and region 8 is

located at amino acid residues 264-275. A variant of a sequence found within mouse UDP-galactose:β-N-acetylglucosamine β1,3-galactosyltransferase-I region 8 is also found in bacterial galactosyltransferases, suggesting that this sequence defines a galactosyltransferase sequence motif (Hennet, T. *supra*). Recent work suggests that brainiac protein is a β1,3-galactosyltransferase (Yuan, 5 Y. et al. (1997) *Cell* 88:9-11; and Hennet, T. *supra*).

UDP-Gal:GlcNAc-1,4-galactosyltransferase (-1,4-GalT) (Sato, T. et al., (1997) *EMBO J.* 16:1850-1857) catalyzes the formation of Type II carbohydrate chains with Gal (β1-4)GlcNAc linkages. As is the case with the β1,3-galactosyltransferase, a soluble form of the enzyme is formed by cleavage of the membrane-bound form. Amino acids conserved among β1,4-galactosyltransferases 10 include two cysteines linked through a disulfide-bonded and a putative UDP-galactose-binding site in the catalytic domain (Yadav, S. and Brew, K. (1990) *J. Biol. Chem.* 265:14163-14169; Yadav, S.P. and Brew, K. (1991) *J. Biol. Chem.* 266:698-703; and Shaper, N.L. et al. (1997) *J. Biol. Chem.* 272:31389-31399). β1,4-galactosyltransferases have several specialized roles in addition to synthesizing carbohydrate chains on glycoproteins or glycolipids. In mammals a β1,4- 15 galactosyltransferase, as part of a heterodimer with α-lactalbumin, functions in lactating mammary gland lactose production. A β1,4-galactosyltransferase on the surface of sperm functions as a receptor that specifically recognizes the egg. Cell surface β1,4-galactosyltransferases also function in cell adhesion, cell/basal lamina interaction, and normal and metastatic cell migration. (Shur, B. (1993) *Curr. Opin. Cell Biol.* 5:854-863; and Shaper, J. (1995) *Adv. Exp. Med. Biol.* 376:95-104).

20 Glutathione S-transferase

The basic reaction catalyzed by glutathione S-transferases (GST) is the conjugation of an electrophile with reduced glutathione (GSH). GSTs are homodimeric or heterodimeric proteins localized mainly in the cytosol, but some level of activity is present in microsomes as well. The major isozymes share common structural and catalytic properties; in humans they have been classified into 25 four major classes, Alpha, Mu, Pi, and Theta. The two largest classes, Alpha and Mu, are identified by their respective protein isoelectric points; pI ~ 7.5-9.0 (Alpha), and pI ~ 6.6 (Mu). Each GST possesses a common binding site for GSH and a variable hydrophobic binding site. The hydrophobic binding site in each isozyme is specific for particular electrophilic substrates. Specific amino acid residues within GSTs have been identified as important for these binding sites and for catalytic activity. 30 Residues Q67, T68, D101, E104, and R131 are important for the binding of GSH (Lee, H.-C. et al. (1995) *J. Biol. Chem.* 270:99-109). Residues R13, R20, and R69 are important for the catalytic activity of GST (Stenberg, G. et al. (1991) *Biochem. J.* 274:549-555).

In most cases, GSTs perform the beneficial function of deactivation and detoxification of potentially mutagenic and carcinogenic chemicals. However, in some cases their action is detrimental

and results in activation of chemicals with consequent mutagenic and carcinogenic effects. Some forms of rat and human GSTs are reliable preneoplastic markers that aid in the detection of carcinogenesis. Expression of human GSTs in bacterial strains, such as Salmonella typhimurium used in the well-known Ames test for mutagenicity, has helped to establish the role of these enzymes in mutagenesis.

5 Dihalomethanes, which produce liver tumors in mice, are believed to be activated by GST. This view is supported by the finding that dihalomethanes are more mutagenic in bacterial cells expressing human GST than in untransfected cells (Thier, R. et al. (1993) Proc. Natl. Acad. Sci. USA 90:8567-8580). The mutagenicity of ethylene dibromide and ethylene dichloride is increased in bacterial cells expressing the human Alpha GST, A1-1, while the mutagenicity of aflatoxin B1 is substantially reduced by

10 enhancing the expression of GST (Simula, T.P. et al. (1993) Carcinogenesis 14:1371-1376). Thus, control of GST activity may be useful in the control of mutagenesis and carcinogenesis.

GST has been implicated in the acquired resistance of many cancers to drug treatment, the phenomenon known as multi-drug resistance (MDR). MDR occurs when a cancer patient is treated with a cytotoxic drug such as cyclophosphamide and subsequently becomes resistant to this drug and to

15 a variety of other cytotoxic agents as well. Increased GST levels are associated with some of these drug resistant cancers, and it is believed that this increase occurs in response to the drug agent which is then deactivated by the GST catalyzed GSH conjugation reaction. The increased GST levels then protect the cancer cells from other cytotoxic agents which bind to GST. Increased levels of A1-1 in tumors has been linked to drug resistance induced by cyclophosphamide treatment (Dirven H.A. et al.

20 (1994) Cancer Res. 54: 6215-6220). Thus control of GST activity in cancerous tissues may be useful in treating MDR in cancer patients.

#### Gamma-glutamyl transpeptidase

Gamma-glutamyl transpeptidases are ubiquitously expressed enzymes that initiate extracellular glutathione (GSH) breakdown by cleaving gamma-glutamyl amide bonds. The breakdown of GSH

25 provides cells with a regional cysteine pool for biosynthetic pathways. Gamma-glutamyl transpeptidases also contribute to cellular antioxidant defenses and expression is induced by oxidative stress. The cell surface-localized glycoproteins are expressed at high levels in cancer cells. Studies have suggested that the high level of gamma-glutamyl transpeptidase activity present on the surface of cancer cells could be exploited to activate precursor drugs, resulting in high local concentrations of anti-

30 cancer therapeutic agents (Hanigan, M.H. (1998) Chem. Biol. Interact. 111-112:333-42; Taniguchi, N. and Ikeda, Y. (1998) Adv. Enzymol. Relat. Areas Mol. Biol. 72:239-78; Chikhi, N. et al. (1999) Comp. Biochem. Physiol. B. Biochem. Mol. Biol. 122:367-380).

#### Acyltransferase

N-acyltransferase enzymes catalyze the transfer of an amino acid conjugate to an activated

carboxylic group. Endogenous compounds and xenobiotics are activated by acyl-CoA synthetases in the cytosol, microsomes, and mitochondria. The acyl-CoA intermediates are then conjugated with an amino acid (typically glycine, glutamine, or taurine, but also ornithine, arginine, histidine, serine, aspartic acid, and several dipeptides) by N-acetyltransferases in the cytosol or mitochondria to form a metabolite with an amide bond. This reaction is complementary to O-glucuronidation, but amino acid conjugation does not produce the reactive and toxic metabolites which often result from glucuronidation.

5 One well-characterized enzyme of this class is the bile acid-CoA:amino acid N-acetyltransferase (BAT) responsible for generating the bile acid conjugates which serve as detergents in the 10 gastrointestinal tract (Falany, C.N. et al. (1994) *J. Biol. Chem.* 269:19375-19379; Johnson, M.R. et al. (1991) *J. Biol. Chem.* 266:10227-10233). BAT is also useful as a predictive indicator for prognosis of hepatocellular carcinoma patients after partial hepatectomy (Furutani, M. et al. (1996) *Hepatology* 24:1441-1445).

#### Acetyltransferases

15 Acetyltransferases have been extensively studied for their role in histone acetylation. Histone acetylation results in the relaxing of the chromatin structure in eukaryotic cells, allowing transcription factors to gain access to promoter elements of the DNA templates in the affected region of the genome (or the genome in general). In contrast, histone deacetylation results in a reduction in transcription by closing the chromatin structure and limiting access of transcription factors. To this end, a common 20 means of stimulating cell transcription is the use of chemical agents that inhibit the deacetylation of histones (e.g., sodium butyrate), resulting in a global (albeit artifactual) increase in gene expression. The modulation of gene expression by acetylation also results from the acetylation of other proteins, including but not limited to, p53, GATA-1, MyoD, ACTR, TFIIE, TFIIF and the high mobility group 25 proteins (HMG). In the case of p53, acetylation results in increased DNA binding, leading to the stimulation of transcription of genes regulated by p53. The prototypic histone acetylase (HAT) is Gcn5 from *Saccharomyces cerevisiae*. Gcn5 is a member of a family of acetylases that includes Tetrahymena p55, human Gcn5, and human p300/CBP. Histone acetylation is reviewed in (Cheung, W.L. et al. (2000) *Curr. Opin. Cell Biol.* 12:326-333 and Berger, S.L (1999) *Curr. Opin. Cell Biol.* 11:336-341). Some acetyltransferase enzymes posses the alpha/beta hydrolase fold (Center of Applied Molecular 30 Engineering Inst. of Chemistry and Biochemistry - University of Salzburg, <http://predict.sanger.ac.uk/irbm-course97/Docs/ms/>) common to several other major classes of enzymes, including but not limited to, acetylcholinesterases and carboxylesterases (Structural Classification of Proteins, <http://scop.mrc-lmb.cam.ac.uk/scop/index.html>).

#### N-acetyltransferase

5 Aromatic amines and hydrazine-containing compounds are subject to N-acetylation by the N-acetyltransferase enzymes of liver and other tissues. Some xenobiotics can be O-acetylated to some extent by the same enzymes. N-acetyltransferases are cytosolic enzymes which utilize the cofactor acetyl-coenzyme A (acetyl-CoA) to transfer the acetyl group in a two step process. In the first step, the acetyl group is transferred from acetyl-CoA to an active site cysteine residue; in the second step, the acetyl group is transferred to the substrate amino group and the enzyme is regenerated.

10 In contrast to most other DME classes, there are a limited number of known N-acetyltransferases. In humans, there are two highly similar enzymes, NAT1 and NAT2; mice appear to have a third form of the enzyme, NAT3. The human forms of N-acetyltransferase have independent regulation (NAT1 is widely-expressed, whereas NAT2 is in liver and gut only) and overlapping substrate preferences. Both enzymes appear to accept most substrates to some extent, but NAT1 does prefer some substrates (para-aminobenzoic acid, para-aminosalicylic acid, sulfamethoxazole, and sulfanilamide), while NAT2 prefers others (isoniazid, hydralazine, procainamide, dapsone, aminoglutethimide, and sulfamethazine).

15 Clinical observations of patients taking the antituberculosis drug isoniazid in the 1950s led to the description of fast and slow acetylators of the compound. These phenotypes were shown subsequently to be due to mutations in the NAT2 gene which affected enzyme activity or stability. The slow isoniazid acetylator phenotype is very prevalent in Middle Eastern populations (approx. 70%), and is less prevalent in Caucasian (approx. 50%) and Asian (<25%) populations. More recently, functional 20 polymorphism in NAT1 has been detected, with approximately 8% of the population tested showing a slow acetylator phenotype (Butcher, N. J. et al. (1998) Pharmacogenetics 8:67-72). Since NAT1 can activate some known aromatic amine carcinogens, polymorphism in the widely-expressed NAT1 enzyme may be important in determining cancer risk (OMIM \*108345 N-acetyltransferase 1).

#### Aminotransferases

25 Aminotransferases comprise a family of pyridoxal 5'-phosphate (PLP) -dependent enzymes that catalyze transformations of amino acids. Aspartate aminotransferase (AspAT) is the most extensively studied PLP-containing enzyme. It catalyzes the reversible transamination of dicarboxylic L-amino acids, aspartate and glutamate, and the corresponding 2-oxo acids, oxalacetate and 2-oxoglutarate. Other members of the family included pyruvate aminotransferase, branched-chain amino acid 30 aminotransferase, tyrosine aminotransferase, aromatic aminotransferase, alanine:glyoxylate aminotransferase (AGT), and kynurenine aminotransferase (Vacca, R.A. et al. (1997) J. Biol. Chem. 272:21932-21937).

Primary hyperoxaluria type-1 is an autosomal recessive disorder resulting in a deficiency in the liver-specific peroxisomal enzyme, alanine:glyoxylate aminotransferase-1. The phenotype of the

disorder is a deficiency in glyoxylate metabolism. In the absence of AGT, glyoxylate is oxidized to oxalate rather than being transaminated to glycine. The result is the deposition of insoluble calcium oxalate in the kidneys and urinary tract, ultimately causing renal failure (Lumb, M.J. et al. (1999) *J. Biol. Chem.* 274:20587-20596).

5           Kynurenine aminotransferase catalyzes the irreversible transamination of the L-tryptophan metabolite L-kynurenine to form kynurenic acid. The enzyme may also catalyze the reversible transamination reaction between L-2-amino adipate and 2-oxoglutarate to produce 2-oxoadipate and L-glutamate. Kynurenic acid is a putative modulator of glutamatergic neurotransmission, thus a deficiency in kynurenine aminotransferase may be associated with pleiotrophic effects (Buchli, R. et al. 10           (1995) *J. Biol. Chem.* 270:29330-29335).

Catechol-O-methyltransferase

15           Catechol-O-methyltransferase (COMT) catalyzes the transfer of the methyl group of S-adenosyl-L-methionine (AdoMet; SAM) donor to one of the hydroxyl groups of the catechol substrate (e.g., L-dopa, dopamine, or DBA). Methylation of the 3'-hydroxyl group is favored over methylation of the 4'-hydroxyl group and the membrane bound isoform of COMT is more regiospecific than the soluble form. Translation of the soluble form of the enzyme results from utilization of an internal start codon in a full-length mRNA (1.5 kb) or from the translation of a shorter mRNA (1.3 kb), transcribed from an internal promoter. The proposed S<sub>N</sub>2-like methylation reaction requires Mg<sup>++</sup> and is inhibited by Ca<sup>++</sup>. The binding of the donor and substrate to COMT occurs sequentially. AdoMet first binds 20           COMT in a Mg<sup>++</sup>-independent manner, followed by the binding of Mg<sup>++</sup> and the binding of the catechol substrate.

25           The amount of COMT in tissues is relatively high compared to the amount of activity normally required, thus inhibition is problematic. Nonetheless, inhibitors have been developed for in vitro use (e.g., gallates, tropolone, U-0521, and 3',4'-dihydroxy-2-methyl-propiophetropolone) and for clinical use (e.g., nitrocatechol-based compounds and tolcapone). Administration of these inhibitors results in the increased half-life of L-dopa and the consequent formation of dopamine. Inhibition of COMT is also likely to increase the half-life of various other catechol-structure compounds, including but not limited to epinephrine/norepinephrine, isoprenaline, rimiterol, dobutamine, fenoldopam, apomorphine, and  $\alpha$ -methyldopa. A deficiency in norepinephrine has been linked to clinical depression, hence the use 30           of COMT inhibitors could be useful in the treatment of depression. COMT inhibitors are generally well tolerated with minimal side effects and are ultimately metabolized in the liver with only minor accumulation of metabolites in the body (Männistö, P.T. and Kaakkola, S. (1999) *Pharmacol. Rev.* 51:593-628).

Copper-zinc superoxide dismutases

Copper-zinc superoxide dismutases are compact homodimeric metalloenzymes involved in cellular defenses against oxidative damage. The enzymes contain one atom of zinc and one atom of copper per subunit and catalyze the dismutation of superoxide anions into  $O_2$  and  $H_2O_2$ . The rate of dismutation is diffusion-limited and consequently enhanced by the presence of favorable electrostatic interactions between the substrate and enzyme active site. Examples of this class of enzyme have been identified in the cytoplasm of all the eukaryotic cells as well as in the periplasm of several bacterial species. Copper-zinc superoxide dismutases are robust enzymes that are highly resistant to proteolytic digestion and denaturing by urea and SDS. In addition to the compact structure of the enzymes, the presence of the metal ions and intrasubunit disulfide bonds is believed to be responsible for enzyme stability. The enzymes undergo reversible denaturation at temperatures as high as 70°C (Battistoni, A. et al. (1998) *J. Biol. Chem.* 273:5655-5661).

Overexpression of superoxide dismutase has been implicated in enhancing freezing tolerance of transgenic Alfalfa as well as providing resistance to environmental toxins such as the diphenyl ether herbicide, acifluorfen (McKersie, B.D. et al. (1993) *Plant Physiol.* 103:1155-1163). In addition, yeast cells become more resistant to freeze-thaw damage following exposure to hydrogen peroxide which causes the yeast cells to adapt to further peroxide stress by upregulating expression of superoxide dismutases. In this study, mutations to yeast superoxide dismutase genes had a more detrimental effect on freeze-thaw resistance than mutations which affected the regulation of glutathione metabolism, long suspected of being important in determining an organisms survival through the process of cryopreservation (Jong-In Park, J.-I. et al. (1998) *J. Biol. Chem.* 273:22921-22928).

Expression of superoxide dismutase is also associated with Mycobacterium tuberculosis, the organism that causes tuberculosis. Superoxide dismutase is one of the ten major proteins secreted by M. tuberculosis and its expression is upregulated approximately 5-fold in response to oxidative stress. M. tuberculosis expresses almost two orders of magnitude more superoxide dismutase than the nonpathogenic mycobacterium M. smegmatis, and secretes a much higher proportion of the expressed enzyme. The result is the secretion of ~350-fold more enzyme by M. tuberculosis than M. smegmatis, providing substantial resistance to oxidative stress (Harth, G. and Horwitz, M.A. (1999) *J. Biol. Chem.* 274:4281-4292).

The reduced expression of copper-zinc superoxide dismutases, as well as other enzymes with anti-oxidant capabilities, has been implicated in the early stages of cancer. The expression of copper-zinc superoxide dismutases has been shown to be lower in prostatic intraepithelial neoplasia and prostate carcinomas, compared to normal prostate tissue (Bostwick, D.G. (2000) *Cancer* 89:123-134). Phosphodiesterases

Phosphodiesterases make up a class of enzymes which catalyze the hydrolysis of one of the two

ester bonds in a phosphodiester compound. Phosphodiesterases are therefore crucial to a variety of cellular processes. Phosphodiesterases include DNA and RNA endonucleases and exonucleases, which are essential for cell growth and replication, and topoisomerases, which break and rejoin nucleic acid strands during topological rearrangement of DNA. A Tyr-DNA phosphodiesterase functions in DNA repair by hydrolyzing dead-end covalent intermediates formed between topoisomerase I and DNA (Pouliot, J.J. et al. (1999) *Science* 286:552-555; Yang, S.-W. (1996) *Proc. Natl. Acad. Sci. USA* 93:11534-11539).

10 Acid sphingomyelinase is a phosphodiesterase which hydrolyzes the membrane phospholipid sphingomyelin to produce ceramide and phosphorylcholine. Phosphorylcholine is used in the synthesis of phosphatidylcholine, which is involved in numerous intracellular signaling pathways, while ceramide is an essential precursor for the generation of gangliosides, membrane lipids found in high concentration in neural tissue. Defective acid sphingomyelinase leads to a build-up of sphingomyelin molecules in lysosomes, resulting in Niemann-Pick disease (Schuchman, E.H. and S.R. Miranda (1997) *Genet. Test.* 1:13-19).

15 Glycerophosphoryl diester phosphodiesterase (also known as glycerophosphodiester phosphodiesterase) is a phosphodiesterase which hydrolyzes deacetylated phospholipid glycerophosphodiesters to produce sn-glycerol-3-phosphate and an alcohol. Glycerophosphocholine, glycerophosphoethanolamine, glycerophosphoglycerol, and glycerophosphoinositol are examples of substrates for glycerophosphoryl diester phosphodiesterases. A glycerophosphoryl diester phosphodiesterase from *E. coli* has broad specificity for glycerophosphodiester substrates (Larson, T.J. et al. (1983) *J. Biol. Chem.* 248:5428-5432).

20 Cyclic nucleotide phosphodiesterases (PDEs) are crucial enzymes in the regulation of the cyclic nucleotides cAMP and cGMP. cAMP and cGMP function as intracellular second messengers to transduce a variety of extracellular signals including hormones, light, and neurotransmitters. PDEs 25 degrade cyclic nucleotides to their corresponding monophosphates, thereby regulating the intracellular concentrations of cyclic nucleotides and their effects on signal transduction. Due to their roles as regulators of signal transduction, PDEs have been extensively studied as chemotherapeutic targets (Perry, M.J. and G.A. Higgs (1998) *Curr. Opin. Chem. Biol.* 2:472-481; Torphy, J.T. (1998) *Am. J. Resp. Crit. Care Med.* 157:351-370).

30 Families of mammalian PDEs have been classified based on their substrate specificity and affinity, sensitivity to cofactors, and sensitivity to inhibitory agents (Beavo, J.A. (1995) *Physiol. Rev.* 75:725-748; Conti, M. et al. (1995) *Endocrine Rev.* 16:370-389). Several of these families contain distinct genes, many of which are expressed in different tissues as splice variants. Within PDE families, there are multiple isozymes and multiple splice variants of these isozymes (Conti, M. and S.-

L.C. Jin (1999) *Prog. Nucleic Acid Res. Mol. Biol.* 63:1-38). The existence of multiple PDE families, isozymes, and splice variants is an indication of the variety and complexity of the regulatory pathways involving cyclic nucleotides (Houslay, M.D. and G. Milligan (1997) *Trends Biochem. Sci.* 22:217-224).

5        Type 1 PDEs (PDE1s) are  $\text{Ca}^{2+}$ /calmodulin-dependent and appear to be encoded by at least three different genes, each having at least two different splice variants (Kakkar, R. et al. (1999) *Cell Mol. Life Sci.* 55:1164-1186). PDE1s have been found in the lung, heart, and brain. Some PDE1 isozymes are regulated *in vitro* by phosphorylation/dephosphorylation. Phosphorylation of these PDE1 isozymes decreases the affinity of the enzyme for calmodulin, decreases PDE activity, and increases 10 steady state levels of cAMP (Kakkar, *supra*). PDE1s may provide useful therapeutic targets for disorders of the central nervous system, and the cardiovascular and immune systems due to the involvement of PDE1s in both cyclic nucleotide and calcium signaling (Perry, M.J. and G.A. Higgs (1998) *Curr. Opin. Chem. Biol.* 2:472-481).

15        PDE2s are cGMP-stimulated PDEs that have been found in the cerebellum, neocortex, heart, kidney, lung, pulmonary artery, and skeletal muscle (Sadhu, K. et al. (1999) *J. Histochem. Cytochem.* 47:895-906). PDE2s are thought to mediate the effects of cAMP on catecholamine secretion, participate in the regulation of aldosterone (Beavo, *supra*), and play a role in olfactory signal transduction (Juifls, D.M. et al. (1997) *Proc. Natl. Acad. Sci. USA* 94:3388-3395).

20        PDE3s have high affinity for both cGMP and cAMP, and so these cyclic nucleotides act as competitive substrates for PDE3s. PDE3s play roles in stimulating myocardial contractility, inhibiting platelet aggregation, relaxing vascular and airway smooth muscle, inhibiting proliferation of T-lymphocytes and cultured vascular smooth muscle cells, and regulating catecholamine-induced release of free fatty acids from adipose tissue. The PDE3 family of phosphodiesterases are sensitive to specific 25 inhibitors such as cilostamide, enoximone, and lixazinone. Isozymes of PDE3 can be regulated by cAMP-dependent protein kinase, or by insulin-dependent kinases (Degerman, E. et al. (1997) *J. Biol. Chem.* 272:6823-6826).

30        PDE4s are specific for cAMP; are localized to airway smooth muscle, the vascular endothelium, and all inflammatory cells; and can be activated by cAMP-dependent phosphorylation. Since elevation of cAMP levels can lead to suppression of inflammatory cell activation and to relaxation of bronchial smooth muscle, PDE4s have been studied extensively as possible targets for novel anti-inflammatory agents, with special emphasis placed on the discovery of asthma treatments. PDE4 inhibitors are currently undergoing clinical trials as treatments for asthma, chronic obstructive pulmonary disease, and atopic eczema. All four known isozymes of PDE4 are susceptible to the inhibitor rolipram, a compound which has been shown to improve behavioral memory in mice (Barad,

M. et al. (1998) Proc. Natl. Acad. Sci. USA 95:15020-15025). PDE4 inhibitors have also been studied as possible therapeutic agents against acute lung injury, endotoxemia, rheumatoid arthritis, multiple sclerosis, and various neurological and gastrointestinal indications (Doherty, A.M. (1999) Curr. Opin. Chem. Biol. 3:466-473).

5 PDE5 is highly selective for cGMP as a substrate (Turko, I.V. et al. (1998) Biochemistry 37:4200-4205), and has two allosteric cGMP-specific binding sites (McAllister-Lucas, L.M. et al. (1995) J. Biol. Chem. 270:30671-30679). Binding of cGMP to these allosteric binding sites seems to be important for phosphorylation of PDE5 by cGMP-dependent protein kinase rather than for direct regulation of catalytic activity. High levels of PDE5 are found in vascular smooth muscle, platelets, 10 lung, and kidney. The inhibitor zaprinast is effective against PDE5 and PDE1s. Modification of zaprinast to provide specificity against PDE5 has resulted in sildenafil (VIAGRA; Pfizer, Inc., New York NY), a treatment for male erectile dysfunction (Terrett, N. et al. (1996) Bioorg. Med. Chem. Lett. 6:1819-1824). Inhibitors of PDE5 are currently being studied as agents for cardiovascular therapy (Perry, M.J. and G.A. Higgs (1998) Curr. Opin. Chem. Biol. 2:472-481).

15 PDE6s, the photoreceptor cyclic nucleotide phosphodiesterases, are crucial components of the phototransduction cascade. In association with the G-protein transducin, PDE6s hydrolyze cGMP to regulate cGMP-gated cation channels in photoreceptor membranes. In addition to the cGMP-binding active site, PDE6s also have two high-affinity cGMP-binding sites which are thought to play a regulatory role in PDE6 function (Artemyev, N.O. et al. (1998) Methods 14:93-104). Defects in 20 PDE6s have been associated with retinal disease. Retinal degeneration in the rd mouse (Yan, W. et al. (1998) Invest. Ophthalmol. Vis. Sci. 39:2529-2536), autosomal recessive retinitis pigmentosa in humans (Danciger, M. et al. (1995) Genomics 30:1-7), and rod/cone dysplasia 1 in Irish Setter dogs (Suber, M.L. et al. (1993) Proc. Natl. Acad. Sci. USA 90:3968-3972) have been attributed to mutations in the PDE6B gene.

25 The PDE7 family of PDEs consists of only one known member having multiple splice variants (Bloom, T.J. and J.A. Beavo (1996) Proc. Natl. Acad. Sci. USA 93:14188-14192). PDE7s are cAMP specific, but little else is known about their physiological function. Although mRNAs encoding PDE7s are found in skeletal muscle, heart, brain, lung, kidney, and pancreas, expression of PDE7 proteins is restricted to specific tissue types (Han, P. et al. (1997) J. Biol. Chem. 272:16152-16157; Perry, M.J. 30 and G.A. Higgs (1998) Curr. Opin. Chem. Biol. 2:472-481). PDE7s are very closely related to the PDE4 family; however, PDE7s are not inhibited by rolipram, a specific inhibitor of PDE4s (Beavo, supra).

PDE8s are cAMP specific, and are closely related to the PDE4 family. PDE8s are expressed in thyroid gland, testis, eye, liver, skeletal muscle, heart, kidney, ovary, and brain. The cAMP-

hydrolyzing activity of PDE8s is not inhibited by the PDE inhibitors rolipram, vinpocetine, milrinone, IBMX (3-isobutyl-1-methylxanthine), or zaprinast, but PDE8s are inhibited by dipyridamole (Fisher, D.A. et al. (1998) *Biochem. Biophys. Res. Commun.* 246:570-577; Hayashi, M. et al. (1998) *Biochem. Biophys. Res. Commun.* 250:751-756; Soderling, S.H. et al. (1998) *Proc. Natl. Acad. Sci. USA* 95:8991-8996).

5 PDE9s are cGMP specific and most closely resemble the PDE8 family of PDEs. PDE9s are expressed in kidney, liver, lung, brain, spleen, and small intestine. PDE9s are not inhibited by sildenafil (VIAGRA; Pfizer, Inc., New York NY), rolipram, vinpocetine, dipyridamole, or IBMX (3-isobutyl-1-methylxanthine), but they are sensitive to the PDE5 inhibitor zaprinast (Fisher, D.A. et al. (1998) *J. 10 Biol. Chem.* 273:15559-15564; Soderling, S.H. et al. (1998) *J. Biol. Chem.* 273:15553-15558).

10 PDE10s are dual-substrate PDEs, hydrolyzing both cAMP and cGMP. PDE10s are expressed in brain, thyroid, and testis. (Soderling, S.H. et al. (1999) *Proc. Natl. Acad. Sci. USA* 96:7071-7076; Fujishige, K. et al. (1999) *J. Biol. Chem.* 274:18438-18445; Loughney, K. et al (1999) *Gene* 234:109-117).

15 PDEs are composed of a catalytic domain of about 270-300 amino acids, an N-terminal regulatory domain responsible for binding cofactors, and, in some cases, a hydrophilic C-terminal domain of unknown function (Conti, M. and S.-L.C. Jin (1999) *Prog. Nucleic Acid Res. Mol. Biol.* 63:1-38). A conserved, putative zinc-binding motif, HDXXHXGXXN, has been identified in the catalytic domain of all PDEs. N-terminal regulatory domains include non-catalytic cGMP-binding 20 domains in PDE2s, PDE5s, and PDE6s; calmodulin-binding domains in PDE1s; and domains containing phosphorylation sites in PDE3s and PDE4s. In PDE5, the N-terminal cGMP-binding domain spans about 380 amino acid residues and comprises tandem repeats of the conserved sequence motif N(R/K)XnFX<sub>3</sub>DE (McAllister-Lucas, L.M. et al. (1993) *J. Biol. Chem.* 268:22863-22873). The NKXnD motif has been shown by mutagenesis to be important for cGMP binding (Turko, I.V. et al. 25 (1996) *J. Biol. Chem.* 271:22240-22244). PDE families display approximately 30% amino acid identity within the catalytic domain; however, isozymes within the same family typically display about 85-95% identity in this region (e.g. PDE4A vs PDE4B). Furthermore, within a family there is extensive similarity (>60%) outside the catalytic domain; while across families, there is little or no sequence similarity outside this domain.

30 Many of the constituent functions of immune and inflammatory responses are inhibited by agents that increase intracellular levels of cAMP (Vergheese, M.W. et al. (1995) *Mol. Pharmacol.* 47:1164-1171). A variety of diseases have been attributed to increased PDE activity and associated with decreased levels of cyclic nucleotides. For example, a form of diabetes insipidus in mice has been associated with increased PDE4 activity, an increase in low-K<sub>m</sub> cAMP PDE activity has been reported

in leukocytes of atopic patients, and PDE3 has been associated with cardiac disease.

Many inhibitors of PDEs have been identified and have undergone clinical evaluation (Perry, M.J. and G.A. Higgs (1998) *Curr. Opin. Chem. Biol.* 2:472-481; Torphy, T.J. (1998) *Am. J. Respir. Crit. Care Med.* 157:351-370). PDE3 inhibitors are being developed as antithrombotic agents, 5 antihypertensive agents, and as cardiotonic agents useful in the treatment of congestive heart failure. Rolipram, a PDE4 inhibitor, has been used in the treatment of depression, and other inhibitors of PDE4 are undergoing evaluation as anti-inflammatory agents. Rolipram has also been shown to inhibit lipopolysaccharide (LPS) induced TNF- $\alpha$  which has been shown to enhance HIV-1 replication *in vitro*. Therefore, rolipram may inhibit HIV-1 replication (Angel, J.B. et al. (1995) *AIDS* 9:1137-1144).

10 Additionally, rolipram, based on its ability to suppress the production of cytokines such as TNF- $\alpha$  and  $\beta$  and interferon  $\gamma$ , has been shown to be effective in the treatment of encephalomyelitis. Rolipram may also be effective in treating tardive dyskinesia and was effective in treating multiple sclerosis in an experimental animal model (Sommer, N. et al. (1995) *Nat. Med.* 1:244-248; Sasaki, H. et al. (1995) *Eur. J. Pharmacol.* 282:71-76).

15 Theophylline is a nonspecific PDE inhibitor used in the treatment of bronchial asthma and other respiratory diseases. Theophylline is believed to act on airway smooth muscle function and in an anti-inflammatory or immunomodulatory capacity in the treatment of respiratory diseases (Banner, K.H. and C.P. Page (1995) *Eur. Respir. J.* 8:996-1000). Pentoxifylline is another nonspecific PDE inhibitor used in the treatment of intermittent claudication and diabetes-induced peripheral vascular 20 disease. Pentoxifylline is also known to block TNF- $\alpha$  production and may inhibit HIV-1 replication (Angel et al., *supra*).

25 PDEs have been reported to affect cellular proliferation of a variety of cell types (Conti et al. (1995) *Endocrine Rev.* 16:370-389) and have been implicated in various cancers. Growth of prostate carcinoma cell lines DU145 and LNCaP was inhibited by delivery of cAMP derivatives and PDE inhibitors (Bang, Y.J. et al. (1994) *Proc. Natl. Acad. Sci. USA* 91:5330-5334). These cells also showed a permanent conversion in phenotype from epithelial to neuronal morphology. It has also been suggested that PDE inhibitors have the potential to regulate mesangial cell proliferation (Matousovic, K. et al. (1995) *J. Clin. Invest.* 96:401-410) and lymphocyte proliferation (Joulain, C. et al. (1995) *J. Lipid Mediat. Cell Signal.* 11:63-79). A cancer treatment has been described that involves intracellular 30 delivery of PDEs to particular cellular compartments of tumors, resulting in cell death (Deonarain, M.P. and A.A. Epenetos (1994) *Br. J. Cancer* 70:786-794).

#### Phosphotriesterases

Phosphotriesterases (PTE, paraoxonases) are enzymes that hydrolyze toxic organophosphorus compounds and have been isolated from a variety of tissues. The enzymes appear to be lacking in birds

and insects and abundant in mammals, explaining the reduced tolerance of birds and insects to organophosphorus compounds (Vilanova, E. and Sogorb, M.A. (1999) *Crit. Rev. Toxicol.* 29:21-57). Phosphotriesterases play a central role in the detoxification of insecticides by mammals. Phosphotriesterase activity varies among individuals and is lower in infants than adults. Knockout mice 5 are markedly more sensitive to the organophosphate-based toxins diazoxon and chlorpyrifos oxon (Furlong, C.E., et al. (2000) *Neurotoxicology* 21:91-100). PTEs have attracted interest as enzymes capable of the detoxification of organophosphate-containing chemical waste and warfare reagents (e.g., parathion), in addition to pesticides and insecticides. Some studies have also implicated phosphotriesterase in atherosclerosis and diseases involving lipoprotein metabolism.

10 **Thioesterases**

Two soluble thioesterases involved in fatty acid biosynthesis have been isolated from mammalian tissues, one which is active only toward long-chain fatty-acyl thioesters and one which is active toward thioesters with a wide range of fatty-acyl chain-lengths. These thioesterases catalyze the chain-terminating step in the *de novo* biosynthesis of fatty acids. Chain termination involves the 15 hydrolysis of the thioester bond which links the fatty acyl chain to the 4'-phosphopantetheine prosthetic group of the acyl carrier protein (ACP) subunit of the fatty acid synthase (Smith, S. (1981a) *Methods Enzymol.* 71:181-188; Smith, S. (1981b) *Methods Enzymol.* 71:188-200).

*E. coli* contains two soluble thioesterases, thioesterase I which is active only toward long-chain acyl thioesters, and thioesterase II (TEII) which has a broad chain-length specificity (Naggert, J. et al. 20 (1991) *J. Biol. Chem.* 266:11044-11050). *E. coli* TEII does not exhibit sequence similarity with either of the two types of mammalian thioesterases which function as chain-terminating enzymes in *de novo* fatty acid biosynthesis. Unlike the mammalian thioesterases, *E. coli* TEII lacks the characteristic serine active site gly-X-ser-X-gly sequence motif and is not inactivated by the serine modifying agent diisopropyl fluorophosphate. However, modification of histidine 58 by iodoacetamide and 25 diethylpyrocarbonate abolished TEII activity. Overexpression of TEII did not alter fatty acid content in *E. coli*, which suggests that it does not function as a chain-terminating enzyme in fatty acid biosynthesis (Naggert et al., *supra*). For that reason, Naggert et al. (*supra*) proposed that the physiological substrates for *E. coli* TEII may be coenzyme A (CoA)-fatty acid esters instead of ACP-phosphopantetheine-fatty acid esters.

30 **Carboxylesterases**

Mammalian carboxylesterases constitute a multigene family expressed in a variety of tissues and cell types. Isozymes have significant sequence homology and are classified primarily on the basis of amino acid sequence. Acetylcholinesterase, butyrylcholinesterase, and carboxylesterase are grouped into the serine super family of esterases (B-esterases). Other carboxylesterases included thyroglobulin,

thrombin, Factor IX, gliotactin, and plasminogen. Carboxylesterases catalyze the hydrolysis of ester- and amide- groups from molecules and are involved in detoxification of drugs, environmental toxins, and carcinogens. Substrates for carboxylesterases include short- and long-chain acyl-glycerols, acylcarnitine, carbonates, dipivefrin hydrochloride, cocaine, salicylates, capsaicin, palmitoyl-coenzyme A, imidapril, haloperidol, pyrrolizidine alkaloids, steroids, p-nitrophenyl acetate, malathion, butanilicaine, and isocarboxazide. The enzymes often demonstrate low substrate specificity. Carboxylesterases are also important for the conversion of prodrugs to their respective free acids, which may be the active form of the drug (e.g., lovastatin, used to lower blood cholesterol) (reviewed in Satoh, T. and Hosokawa, M. (1998) *Annu. Rev. Pharmacol. Toxicol.* 38:257-288).

10       Neuroligins are a class of molecules that (i) have N-terminal signal sequences, (ii) resemble cell-surface receptors, (iii) contain carboxylesterase domains, (iv) are highly expressed in the brain, and (v) bind to neurexins in a calcium-dependent manner. Despite the homology to carboxylesterases, neuroligins lack the active site serine residue, implying a role in substrate binding rather than catalysis (Ichtchenko, K. et al. (1996) *J. Biol. Chem.* 271:2676-2682).

15       Squalene epoxidase

          Squalene epoxidase (squalene monooxygenase, SE) is a microsomal membrane-bound, FAD-dependent oxidoreductase that catalyzes the first oxygenation step in the sterol biosynthetic pathway of eukaryotic cells. Cholesterol is an essential structural component of cytoplasmic membranes acquired via the LDL receptor-mediated pathway or the biosynthetic pathway. In the latter case, all 27 carbon atoms in the cholesterol molecule are derived from acetyl-CoA (Stryer, L., *supra*). SE converts squalene to 2,3(*S*)-oxidosqualene, which is then converted to lanosterol and then cholesterol. The steps involved in cholesterol biosynthesis are summarized below (Stryer, L (1988) *Biochemistry*. W.H. Freeman and Co., Inc. New York. pp. 554-560 and Sakakibara, J. et al. (1995) 270:17-20): acetate (from Acetyl-CoA) → 3-hydroxy-3-methyl-glutaryl CoA → mevalonate → 5-phosphomevalonate → 5-pyrophosphomevalonate → isopentenyl pyrophosphate → dimethylallyl pyrophosphate → geranyl pyrophosphate → farnesyl pyrophosphate → squalene → squalene epoxide → lanosterol → cholesterol.

          While cholesterol is essential for the viability of eukaryotic cells, inordinately high serum cholesterol levels results in the formation of atherosclerotic plaques in the arteries of higher organisms. This deposition of highly insoluble lipid material onto the walls of essential blood vessels (e.g., coronary arteries) results in decreased blood flow and potential necrosis of the tissues deprived of adequate blood flow. HMG-CoA reductase is responsible for the conversion of 3-hydroxy-3-methyl-glutaryl CoA (HMG-CoA) to mevalonate, which represents the first committed step in cholesterol biosynthesis. HMG-CoA is the target of a number of pharmaceutical compounds designed to lower plasma cholesterol levels. However, inhibition of HMG-CoA also results in the reduced synthesis of

non-sterol intermediates (e.g., mevalonate) required for other biochemical pathways. SE catalyzes a rate-limiting reaction that occurs later in the sterol synthesis pathway and cholesterol is the only end product of the pathway following the step catalyzed by SE. As a result, SE is the ideal target for the design of anti-hyperlipidemic drugs that do not cause a reduction in other necessary intermediates

5 (Nakamura, Y. et al. (1996) 271:8053-8056).

#### Epoxide hydrolases

Epoxide hydrolases catalyze the addition of water to epoxide-containing compounds, thereby hydrolyzing epoxides to their corresponding 1,2-diols. They are related to bacterial haloalkane dehalogenases and show sequence similarity to other members of the  $\alpha/\beta$  hydrolase fold family of enzymes (e.g., bromoperoxidase A2 from *Streptomyces aureofaciens*, hydroxymuconic semialdehyde hydrolases from *Pseudomonas putida*, and haloalkane dehalogenase from *Xanthobacter autotrophicus*).

10

Epoxide hydrolases are ubiquitous in nature and have been found in mammals, invertebrates, plants, fungi, and bacteria. This family of enzymes is important for the detoxification of xenobiotic epoxide compounds which are often highly electrophilic and destructive when introduced into an organism.

15 Examples of epoxide hydrolase reactions include the hydrolysis of cis-9,10-epoxyoctadec-9(Z)-enoic acid (leukotoxin) to form its corresponding diol, threo-9,10-dihydroxyoctadec-12(Z)-enoic acid (leukotoxin diol), and the hydrolysis of cis-12,13-epoxyoctadec-9(Z)-enoic acid (isoleukotoxin) to form its corresponding diol threo-12,13-dihydroxyoctadec-9(Z)-enoic acid (isoleukotoxin diol). Leukotoxins alter membrane permeability and ion transport and cause inflammatory responses. In addition, epoxide carcinogens are known to be produced by cytochrome P450 as intermediates in the detoxification of

20 drugs and environmental toxins.

The enzymes possess a catalytic triad composed of Asp (the nucleophile), Asp (the histidine-supporting acid), and His (the water-activating histidine). The reaction mechanism of epoxide hydrolase proceeds via a covalently bound ester intermediate initiated by the nucleophilic attack of one of the Asp residues on the primary carbon atom of the epoxide ring of the target molecule, leading to a covalently bound ester intermediate (Michael Arand, M. et al. (1996) J. Biol. Chem. 271:4223-4229; Rink, R. et al. (1997) J. Biol. Chem. 272:14650-14657; Argiriadi, M.A. et al. (2000) J. Biol. Chem. 275:15265-15270).

25

#### Enzymes involved in tyrosine catalysis

30 The degradation of the amino acid tyrosine to either succinate and pyruvate or fumarate and acetoacetate, requires a large number of enzymes and generates a large number of intermediate compounds. In addition, many xenobiotic compounds may be metabolized using one or more reactions that are part of the tyrosine catabolic pathway. While the pathway has been studied primarily in bacteria, tyrosine degradation is known to occur in a variety of organisms and is likely to involve many

of the same biological reactions.

The enzymes involved in the degradation of tyrosine to succinate and pyruvate (e.g., in *Arthrobacter* species) include 4-hydroxyphenylpyruvate oxidase, 4-hydroxyphenylacetate 3-hydroxylase, 3,4-dihydroxyphenylacetate 2,3-dioxygenase, 5-carboxymethyl-2-hydroxymuconic 5 semialdehyde dehydrogenase, *trans,cis*-5-carboxymethyl-2-hydroxymuconate isomerase, homoprotocatechuate isomerase/decarboxylase, *cis*-2-oxohept-3-ene-1,7-dioate hydratase, 2,4-dihydroxyhept-*trans*-2-ene-1,7-dioate aldolase, and succinic semialdehyde dehydrogenase.

The enzymes involved in the degradation of tyrosine to fumarate and acetoacetate (e.g., in *Pseudomonas* species) include 4-hydroxyphenylpyruvate dioxygenase, homogentisate 1,2-dioxygenase, 10 maleylacetoacetate isomerase, and fumarylacetoacetate. 4-hydroxyphenylacetate 1-hydroxylase may also be involved if intermediates from the succinate/pyruvate pathway are accepted.

Additional enzymes associated with tyrosine metabolism in different organisms include 4-chlorophenylacetate-3,4-dioxygenase, aromatic aminotransferase, 5-oxopent-3-ene-1,2,5-tricarboxylate decarboxylase, 2-oxo-hept-3-ene-1,7-dioate hydratase, and 15 5-carboxymethyl-2-hydroxymuconate isomerase (Ellis, L.B.M. et al. (1999) *Nucleic Acids Res.* 27:373-376; Wackett, L.P. and Ellis, L.B.M. (1996) *J. Microbiol. Meth.* 25:91-93; and Schmidt, M. (1996) *Amer. Soc. Microbiol. News* 62:102).

In humans, acquired or inherited genetic defects in enzymes of the tyrosine degradation pathway may result in hereditary tyrosinemia. One form of this disease, hereditary tyrosinemia 1 20 (HT1) is caused by a deficiency in the enzyme fumarylacetoacetate hydrolase, the last enzyme in the pathway in organisms that metabolize tyrosine to fumarate and acetoacetate. HT1 is characterized by progressive liver damage beginning at infancy, and increased risk for liver cancer (Endo, F. et al. (1997) *J. Biol. Chem.* 272:24426-24432).

The discovery of new drug metabolizing enzymes, and the polynucleotides encoding them, 25 satisfies a need in the art by providing new compositions which are useful in the diagnosis, prevention, and treatment of autoimmune/inflammatory, cell proliferative, developmental, endocrine, eye, metabolic, and gastrointestinal disorders, including liver disorders, and in the assessment of the effects of exogenous compounds on the expression of nucleic acid and amino acid sequences of drug metabolizing enzymes.

30

## SUMMARY OF THE INVENTION

The invention features purified polypeptides, referred to collectively as "DME" and individually as "DME-1," "DME-2," "DME-3," "DME-4," "DME-5," "DME-6," "DME-7," "DME-8," "DME-9," "DME-10" "DME-11," "DME-12," "DME-13," "DME-14" "DME-15," "DME-16,"

“DME-17,” and “DME-18.” In one aspect, the invention provides an isolated polypeptide selected from the group consisting of a) a polypeptide comprising an amino acid sequence selected from the group consisting of SEQ ID NO:1-18, b) a polypeptide comprising a naturally occurring amino acid sequence at least 90% identical to an amino acid sequence selected from the group consisting of SEQ ID NO:1-18, c) a biologically active fragment of a polypeptide having an amino acid sequence selected from the group consisting of SEQ ID NO:1-18, and d) an immunogenic fragment of a polypeptide having an amino acid sequence selected from the group consisting of SEQ ID NO:1-18. In one alternative, the invention provides an isolated polypeptide comprising the amino acid sequence of SEQ ID NO:1-18.

The invention further provides an isolated polynucleotide encoding a polypeptide selected from the group consisting of a) a polypeptide comprising an amino acid sequence selected from the group consisting of SEQ ID NO:1-18, b) a polypeptide comprising a naturally occurring amino acid sequence at least 90% identical to an amino acid sequence selected from the group consisting of SEQ ID NO:1-18, c) a biologically active fragment of a polypeptide having an amino acid sequence selected from the group consisting of SEQ ID NO:1-18, and d) an immunogenic fragment of a polypeptide having an amino acid sequence selected from the group consisting of SEQ ID NO:1-18. In one alternative, the polynucleotide encodes a polypeptide selected from the group consisting of SEQ ID NO:1-18. In another alternative, the polynucleotide is selected from the group consisting of SEQ ID NO:19-36.

Additionally, the invention provides a recombinant polynucleotide comprising a promoter sequence operably linked to a polynucleotide encoding a polypeptide selected from the group consisting of a) a polypeptide comprising an amino acid sequence selected from the group consisting of SEQ ID NO:1-18, b) a polypeptide comprising a naturally occurring amino acid sequence at least 90% identical to an amino acid sequence selected from the group consisting of SEQ ID NO:1-18, c) a biologically active fragment of a polypeptide having an amino acid sequence selected from the group consisting of SEQ ID NO:1-18, and d) an immunogenic fragment of a polypeptide having an amino acid sequence selected from the group consisting of SEQ ID NO:1-18. In one alternative, the invention provides a cell transformed with the recombinant polynucleotide. In another alternative, the invention provides a transgenic organism comprising the recombinant polynucleotide.

The invention also provides a method for producing a polypeptide selected from the group consisting of a) a polypeptide comprising an amino acid sequence selected from the group consisting of SEQ ID NO:1-18, b) a polypeptide comprising a naturally occurring amino acid sequence at least 90% identical to an amino acid sequence selected from the group consisting of SEQ ID NO:1-18, c) a biologically active fragment of a polypeptide having an amino acid sequence selected from the group consisting of SEQ ID NO:1-18, and d) an immunogenic fragment of a polypeptide having an amino

acid sequence selected from the group consisting of SEQ ID NO:1-18. The method comprises a) culturing a cell under conditions suitable for expression of the polypeptide, wherein said cell is transformed with a recombinant polynucleotide comprising a promoter sequence operably linked to a polynucleotide encoding the polypeptide, and b) recovering the polypeptide so expressed.

5        Additionally, the invention provides an isolated antibody which specifically binds to a polypeptide selected from the group consisting of a) a polypeptide comprising an amino acid sequence selected from the group consisting of SEQ ID NO:1-18, b) a polypeptide comprising a naturally occurring amino acid sequence at least 90% identical to an amino acid sequence selected from the group consisting of SEQ ID NO:1-18, c) a biologically active fragment of a polypeptide having an 10      amino acid sequence selected from the group consisting of SEQ ID NO:1-18, and d) an immunogenic fragment of a polypeptide having an amino acid sequence selected from the group consisting of SEQ ID NO:1-18.

15      The invention further provides an isolated polynucleotide selected from the group consisting of a) a polynucleotide comprising a polynucleotide sequence selected from the group consisting of SEQ ID NO:19-36, b) a polynucleotide comprising a naturally occurring polynucleotide sequence at least 90% identical to a polynucleotide sequence selected from the group consisting of SEQ ID NO:19-36, c) a polynucleotide complementary to the polynucleotide of a), d) a polynucleotide complementary to the polynucleotide of b), and e) an RNA equivalent of a)-d). In one alternative, the polynucleotide comprises at least 60 contiguous nucleotides.

20      Additionally, the invention provides a method for detecting a target polynucleotide in a sample, said target polynucleotide having a sequence of a polynucleotide selected from the group consisting of a) a polynucleotide comprising a polynucleotide sequence selected from the group consisting of SEQ ID NO:19-36, b) a polynucleotide comprising a naturally occurring polynucleotide sequence at least 90% identical to a polynucleotide sequence selected from the group consisting of SEQ ID NO:19-36, 25      c) a polynucleotide complementary to the polynucleotide of a), d) a polynucleotide complementary to the polynucleotide of b), and e) an RNA equivalent of a)-d). The method comprises a) hybridizing the sample with a probe comprising at least 20 contiguous nucleotides comprising a sequence complementary to said target polynucleotide in the sample, and which probe specifically hybridizes to said target polynucleotide, under conditions whereby a hybridization complex is formed between said 30      probe and said target polynucleotide or fragments thereof, and b) detecting the presence or absence of said hybridization complex, and optionally, if present, the amount thereof. In one alternative, the probe comprises at least 60 contiguous nucleotides.

      The invention further provides a method for detecting a target polynucleotide in a sample, said target polynucleotide having a sequence of a polynucleotide selected from the group consisting of a) a

polynucleotide comprising a polynucleotide sequence selected from the group consisting of SEQ ID NO:19-36, b) a polynucleotide comprising a naturally occurring polynucleotide sequence at least 90% identical to a polynucleotide sequence selected from the group consisting of SEQ ID NO:19-36, c) a polynucleotide complementary to the polynucleotide of a), d) a polynucleotide complementary to the polynucleotide of b), and e) an RNA equivalent of a)-d). The method comprises a) amplifying said target polynucleotide or fragment thereof using polymerase chain reaction amplification, and b) detecting the presence or absence of said amplified target polynucleotide or fragment thereof, and, optionally, if present, the amount thereof.

The invention further provides a composition comprising an effective amount of a polypeptide selected from the group consisting of a) a polypeptide comprising an amino acid sequence selected from the group consisting of SEQ ID NO:1-18, b) a polypeptide comprising a naturally occurring amino acid sequence at least 90% identical to an amino acid sequence selected from the group consisting of SEQ ID NO:1-18, c) a biologically active fragment of a polypeptide having an amino acid sequence selected from the group consisting of SEQ ID NO:1-18, and d) an immunogenic fragment of a polypeptide having an amino acid sequence selected from the group consisting of SEQ ID NO:1-18, and a pharmaceutically acceptable excipient. In one embodiment, the composition comprises an amino acid sequence selected from the group consisting of SEQ ID NO:1-18. The invention additionally provides a method of treating a disease or condition associated with decreased expression of functional DME, comprising administering to a patient in need of such treatment the composition.

The invention also provides a method for screening a compound for effectiveness as an agonist of a polypeptide selected from the group consisting of a) a polypeptide comprising an amino acid sequence selected from the group consisting of SEQ ID NO:1-18, b) a polypeptide comprising a naturally occurring amino acid sequence at least 90% identical to an amino acid sequence selected from the group consisting of SEQ ID NO:1-18, c) a biologically active fragment of a polypeptide having an amino acid sequence selected from the group consisting of SEQ ID NO:1-18, and d) an immunogenic fragment of a polypeptide having an amino acid sequence selected from the group consisting of SEQ ID NO:1-18. The method comprises a) exposing a sample comprising the polypeptide to a compound, and b) detecting agonist activity in the sample. In one alternative, the invention provides a composition comprising an agonist compound identified by the method and a pharmaceutically acceptable excipient. In another alternative, the invention provides a method of treating a disease or condition associated with decreased expression of functional DME, comprising administering to a patient in need of such treatment the composition.

Additionally, the invention provides a method for screening a compound for effectiveness as

an antagonist of a polypeptide selected from the group consisting of a) a polypeptide comprising an amino acid sequence selected from the group consisting of SEQ ID NO:1-18, b) a polypeptide comprising a naturally occurring amino acid sequence at least 90% identical to an amino acid sequence selected from the group consisting of SEQ ID NO:1-18, c) a biologically active fragment of a polypeptide having an amino acid sequence selected from the group consisting of SEQ ID NO:1-18, and d) an immunogenic fragment of a polypeptide having an amino acid sequence selected from the group consisting of SEQ ID NO:1-18. The method comprises a) exposing a sample comprising the polypeptide to a compound, and b) detecting antagonist activity in the sample. In one alternative, the invention provides a composition comprising an antagonist compound identified by the method and a pharmaceutically acceptable excipient. In another alternative, the invention provides a method of treating a disease or condition associated with overexpression of functional DME, comprising administering to a patient in need of such treatment the composition.

The invention further provides a method of screening for a compound that specifically binds to a polypeptide selected from the group consisting of a) a polypeptide comprising an amino acid sequence selected from the group consisting of SEQ ID NO:1-18, b) a polypeptide comprising a naturally occurring amino acid sequence at least 90% identical to an amino acid sequence selected from the group consisting of SEQ ID NO:1-18, c) a biologically active fragment of a polypeptide having an amino acid sequence selected from the group consisting of SEQ ID NO:1-18, and d) an immunogenic fragment of a polypeptide having an amino acid sequence selected from the group consisting of SEQ ID NO:1-18. The method comprises a) combining the polypeptide with at least one test compound under suitable conditions, and b) detecting binding of the polypeptide to the test compound, thereby identifying a compound that specifically binds to the polypeptide.

The invention further provides a method of screening for a compound that modulates the activity of a polypeptide selected from the group consisting of a) a polypeptide comprising an amino acid sequence selected from the group consisting of SEQ ID NO:1-18, b) a polypeptide comprising a naturally occurring amino acid sequence at least 90% identical to an amino acid sequence selected from the group consisting of SEQ ID NO:1-18, c) a biologically active fragment of a polypeptide having an amino acid sequence selected from the group consisting of SEQ ID NO:1-18, and d) an immunogenic fragment of a polypeptide having an amino acid sequence selected from the group consisting of SEQ ID NO:1-18. The method comprises a) combining the polypeptide with at least one test compound under conditions permissive for the activity of the polypeptide, b) assessing the activity of the polypeptide in the presence of the test compound, and c) comparing the activity of the polypeptide in the presence of the test compound with the activity of the polypeptide in the absence of the test compound, wherein a change in the activity of the polypeptide in the presence of the test

compound is indicative of a compound that modulates the activity of the polypeptide.

The invention further provides a method for screening a compound for effectiveness in altering expression of a target polynucleotide, wherein said target polynucleotide comprises a sequence selected from the group consisting of SEQ ID NO:19-36, the method comprising a) 5 exposing a sample comprising the target polynucleotide to a compound, and b) detecting altered expression of the target polynucleotide.

The invention further provides a method for assessing toxicity of a test compound, said method comprising a) treating a biological sample containing nucleic acids with the test compound; b) hybridizing the nucleic acids of the treated biological sample with a probe comprising at least 10 20 contiguous nucleotides of a polynucleotide selected from the group consisting of i) a polynucleotide comprising a polynucleotide sequence selected from the group consisting of SEQ ID NO:19-36, ii) a polynucleotide comprising a naturally occurring polynucleotide sequence at least 90% identical to a polynucleotide sequence selected from the group consisting of SEQ ID NO:19-36, iii) a polynucleotide having a sequence complementary to i), iv) a polynucleotide complementary to the polynucleotide of ii), and v) an RNA equivalent of i)-iv). Hybridization occurs under conditions 15 whereby a specific hybridization complex is formed between said probe and a target polynucleotide in the biological sample, said target polynucleotide selected from the group consisting of i) a polynucleotide comprising a polynucleotide sequence selected from the group consisting of SEQ ID NO:19-36, ii) a polynucleotide comprising a naturally occurring polynucleotide sequence at least 20 90% identical to a polynucleotide sequence selected from the group consisting of SEQ ID NO:19-36, iii) a polynucleotide complementary to the polynucleotide of i), iv) a polynucleotide complementary to the polynucleotide of ii), and v) an RNA equivalent of i)-iv). Alternatively, the target 25 polynucleotide comprises a fragment of a polynucleotide sequence selected from the group consisting of i)-v) above; c) quantifying the amount of hybridization complex; and d) comparing the amount of hybridization complex in the treated biological sample with the amount of hybridization complex in an untreated biological sample, wherein a difference in the amount of hybridization complex in the treated biological sample is indicative of toxicity of the test compound.

#### BRIEF DESCRIPTION OF THE TABLES

30 Table 1 summarizes the nomenclature for the full length polynucleotide and polypeptide sequences of the present invention.

Table 2 shows the GenBank identification number and annotation of the nearest GenBank homolog for polypeptides of the invention. The probability score for the match between each polypeptide and its GenBank homolog is also shown.

35 Table 3 shows structural features of polypeptide sequences of the invention, including

predicted motifs and domains, along with the methods, algorithms, and searchable databases used for analysis of the polypeptides.

Table 4 lists the cDNA and/or genomic DNA fragments which were used to assemble polynucleotide sequences of the invention, along with selected fragments of the polynucleotide sequences.

Table 5 shows the representative cDNA library for polynucleotides of the invention.

Table 6 provides an appendix which describes the tissues and vectors used for construction of the cDNA libraries shown in Table 5.

Table 7 shows the tools, programs, and algorithms used to analyze the polynucleotides and polypeptides of the invention, along with applicable descriptions, references, and threshold parameters.

## DESCRIPTION OF THE INVENTION

Before the present proteins, nucleotide sequences, and methods are described, it is understood that this invention is not limited to the particular machines, materials and methods described, as these may vary. It is also to be understood that the terminology used herein is for the purpose of describing particular embodiments only, and is not intended to limit the scope of the present invention which will be limited only by the appended claims.

It must be noted that as used herein and in the appended claims, the singular forms "a," "an," and "the" include plural reference unless the context clearly dictates otherwise. Thus, for example, a reference to "a host cell" includes a plurality of such host cells, and a reference to "an antibody" is a reference to one or more antibodies and equivalents thereof known to those skilled in the art, and so forth.

Unless defined otherwise, all technical and scientific terms used herein have the same meanings as commonly understood by one of ordinary skill in the art to which this invention belongs. Although any machines, materials, and methods similar or equivalent to those described herein can be used to practice or test the present invention, the preferred machines, materials and methods are now described. All publications mentioned herein are cited for the purpose of describing and disclosing the cell lines, protocols, reagents and vectors which are reported in the publications and which might be used in connection with the invention. Nothing herein is to be construed as an admission that the invention is not entitled to antedate such disclosure by virtue of prior invention.

## DEFINITIONS

"DME" refers to the amino acid sequences of substantially purified DME obtained from any species, particularly a mammalian species, including bovine, ovine, porcine, murine, equine, and human, and from any source, whether natural, synthetic, semi-synthetic, or recombinant.

The term "agonist" refers to a molecule which intensifies or mimics the biological activity of DME. Agonists may include proteins, nucleic acids, carbohydrates, small molecules, or any other compound or composition which modulates the activity of DME either by directly interacting with DME or by acting on components of the biological pathway in which DME participates.

5 An "allelic variant" is an alternative form of the gene encoding DME. Allelic variants may result from at least one mutation in the nucleic acid sequence and may result in altered mRNAs or in polypeptides whose structure or function may or may not be altered. A gene may have none, one, or many allelic variants of its naturally occurring form. Common mutational changes which give rise to allelic variants are generally ascribed to natural deletions, additions, or substitutions of nucleotides.

10 Each of these types of changes may occur alone, or in combination with the others, one or more times in a given sequence.

"Altered" nucleic acid sequences encoding DME include those sequences with deletions, insertions, or substitutions of different nucleotides, resulting in a polypeptide the same as DME or a polypeptide with at least one functional characteristic of DME. Included within this definition are 15 polymorphisms which may or may not be readily detectable using a particular oligonucleotide probe of the polynucleotide encoding DME, and improper or unexpected hybridization to allelic variants, with a locus other than the normal chromosomal locus for the polynucleotide sequence encoding DME. The encoded protein may also be "altered," and may contain deletions, insertions, or substitutions of amino acid residues which produce a silent change and result in a functionally equivalent DME. Deliberate 20 amino acid substitutions may be made on the basis of similarity in polarity, charge, solubility, hydrophobicity, hydrophilicity, and/or the amphipathic nature of the residues, as long as the biological or immunological activity of DME is retained. For example, negatively charged amino acids may include aspartic acid and glutamic acid, and positively charged amino acids may include lysine and arginine. Amino acids with uncharged polar side chains having similar hydrophilicity values may 25 include: asparagine and glutamine; and serine and threonine. Amino acids with uncharged side chains having similar hydrophilicity values may include: leucine, isoleucine, and valine; glycine and alanine; and phenylalanine and tyrosine.

The terms "amino acid" and "amino acid sequence" refer to an oligopeptide, peptide, polypeptide, or protein sequence, or a fragment of any of these, and to naturally occurring or synthetic 30 molecules. Where "amino acid sequence" is recited to refer to a sequence of a naturally occurring protein molecule, "amino acid sequence" and like terms are not meant to limit the amino acid sequence to the complete native amino acid sequence associated with the recited protein molecule.

"Amplification" relates to the production of additional copies of a nucleic acid sequence. Amplification is generally carried out using polymerase chain reaction (PCR) technologies well known

in the art.

The term "antagonist" refers to a molecule which inhibits or attenuates the biological activity of DME. Antagonists may include proteins such as antibodies, nucleic acids, carbohydrates, small molecules, or any other compound or composition which modulates the activity of DME either by 5 directly interacting with DME or by acting on components of the biological pathway in which DME participates.

The term "antibody" refers to intact immunoglobulin molecules as well as to fragments thereof, such as Fab, F(ab')<sub>2</sub>, and Fv fragments, which are capable of binding an epitopic determinant. Antibodies that bind DME polypeptides can be prepared using intact polypeptides or using fragments 10 containing small peptides of interest as the immunizing antigen. The polypeptide or oligopeptide used to immunize an animal (e.g., a mouse, a rat, or a rabbit) can be derived from the translation of RNA, or synthesized chemically, and can be conjugated to a carrier protein if desired. Commonly used carriers that are chemically coupled to peptides include bovine serum albumin, thyroglobulin, and keyhole limpet hemocyanin (KLH). The coupled peptide is then used to immunize the animal.

15 The term "antigenic determinant" refers to that region of a molecule (i.e., an epitope) that makes contact with a particular antibody. When a protein or a fragment of a protein is used to immunize a host animal, numerous regions of the protein may induce the production of antibodies which bind specifically to antigenic determinants (particular regions or three-dimensional structures on the protein). An antigenic determinant may compete with the intact antigen (i.e., the immunogen used 20 to elicit the immune response) for binding to an antibody.

The term "antisense" refers to any composition capable of base-pairing with the "sense" (coding) strand of a specific nucleic acid sequence. Antisense compositions may include DNA; RNA; peptide nucleic acid (PNA); oligonucleotides having modified backbone linkages such as phosphorothioates, methylphosphonates, or benzylphosphonates; oligonucleotides having modified 25 sugar groups such as 2'-methoxyethyl sugars or 2'-methoxyethoxy sugars; or oligonucleotides having modified bases such as 5-methyl cytosine, 2'-deoxyuracil, or 7-deaza-2'-deoxyguanosine. Antisense molecules may be produced by any method including chemical synthesis or transcription. Once introduced into a cell, the complementary antisense molecule base-pairs with a naturally occurring 30 nucleic acid sequence produced by the cell to form duplexes which block either transcription or translation. The designation "negative" or "minus" can refer to the antisense strand, and the designation "positive" or "plus" can refer to the sense strand of a reference DNA molecule.

The term "biologically active" refers to a protein having structural, regulatory, or biochemical functions of a naturally occurring molecule. Likewise, "immunologically active" or "immunogenic" refers to the capability of the natural, recombinant, or synthetic DME, or of any oligopeptide thereof,

to induce a specific immune response in appropriate animals or cells and to bind with specific antibodies.

5 "Complementary" describes the relationship between two single-stranded nucleic acid sequences that anneal by base-pairing. For example, 5'-AGT-3' pairs with its complement, 3'-TCA-5'.

A "composition comprising a given polynucleotide sequence" and a "composition comprising a given amino acid sequence" refer broadly to any composition containing the given polynucleotide or amino acid sequence. The composition may comprise a dry formulation or an aqueous solution. Compositions comprising polynucleotide sequences encoding DME or fragments of DME may be 10 employed as hybridization probes. The probes may be stored in freeze-dried form and may be associated with a stabilizing agent such as a carbohydrate. In hybridizations, the probe may be deployed in an aqueous solution containing salts (e.g., NaCl), detergents (e.g., sodium dodecyl sulfate; SDS), and other components (e.g., Denhardt's solution, dry milk, salmon sperm DNA, etc.).

15 "Consensus sequence" refers to a nucleic acid sequence which has been subjected to repeated DNA sequence analysis to resolve uncalled bases, extended using the XL-PCR kit (Applied Biosystems, Foster City CA) in the 5' and/or the 3' direction, and resequenced, or which has been assembled from one or more overlapping cDNA, EST, or genomic DNA fragments using a computer program for fragment assembly, such as the GELVIEW fragment assembly system (GCG, Madison WI) or Phrap (University of Washington, Seattle WA). Some sequences have been both extended and 20 assembled to produce the consensus sequence.

25 "Conservative amino acid substitutions" are those substitutions that are predicted to least interfere with the properties of the original protein, i.e., the structure and especially the function of the protein is conserved and not significantly changed by such substitutions. The table below shows amino acids which may be substituted for an original amino acid in a protein and which are regarded as conservative amino acid substitutions.

	Original Residue	Conservative Substitution
30	Ala	Gly, Ser
	Arg	His, Lys
	Asn	Asp, Gln, His
	Asp	Asn, Glu
	Cys	Ala, Ser
	Gln	Asn, Glu, His
	Glu	Asp, Gln, His
35	Gly	Ala
	His	Asn, Arg, Gln, Glu
	Ile	Leu, Val
	Leu	Ile, Val
	Lys	Arg, Gln, Glu

	Met	Leu, Ile
	Phe	His, Met, Leu, Trp, Tyr
	Ser	Cys, Thr
	Thr	Ser, Val
5	Trp	Phe, Tyr
	Tyr	His, Phe, Trp
	Val	Ile, Leu, Thr

10       Conservative amino acid substitutions generally maintain (a) the structure of the polypeptide backbone in the area of the substitution, for example, as a beta sheet or alpha helical conformation, (b) the charge or hydrophobicity of the molecule at the site of the substitution, and/or (c) the bulk of the side chain.

15       A "deletion" refers to a change in the amino acid or nucleotide sequence that results in the absence of one or more amino acid residues or nucleotides.

16       The term "derivative" refers to a chemically modified polynucleotide or polypeptide. Chemical modifications of a polynucleotide can include, for example, replacement of hydrogen by an alkyl, acyl, hydroxyl, or amino group. A derivative polynucleotide encodes a polypeptide which retains at least one biological or immunological function of the natural molecule. A derivative polypeptide is one modified by glycosylation, pegylation, or any similar process that retains at least 20       one biological or immunological function of the polypeptide from which it was derived.

17       A "detectable label" refers to a reporter molecule or enzyme that is capable of generating a measurable signal and is covalently or noncovalently joined to a polynucleotide or polypeptide.

18       A "differential expression" refers to increased or upregulated; or decreased, downregulated, or absent gene or protein expression, determined by comparing at least two different samples. Such 25       comparisons may be carried out between, for example, a treated and an untreated sample, or a diseased and a normal sample.

19       A "fragment" is a unique portion of DME or the polynucleotide encoding DME which is identical in sequence to but shorter in length than the parent sequence. A fragment may comprise up to the entire length of the defined sequence, minus one nucleotide/amino acid residue. For example, 30       a fragment may comprise from 5 to 1000 contiguous nucleotides or amino acid residues. A fragment used as a probe, primer, antigen, therapeutic molecule, or for other purposes, may be at least 5, 10, 15, 16, 20, 25, 30, 40, 50, 60, 75, 100, 150, 250 or at least 500 contiguous nucleotides or amino acid residues in length. Fragments may be preferentially selected from certain regions of a molecule. For example, a polypeptide fragment may comprise a certain length of contiguous amino acids selected 35       from the first 250 or 500 amino acids (or first 25% or 50%) of a polypeptide as shown in a certain defined sequence. Clearly these lengths are exemplary, and any length that is supported by the specification, including the Sequence Listing, tables, and figures, may be encompassed by the

present embodiments.

A fragment of SEQ ID NO:19-36 comprises a region of unique polynucleotide sequence that specifically identifies SEQ ID NO:19-36, for example, as distinct from any other sequence in the genome from which the fragment was obtained. A fragment of SEQ ID NO:19-36 is useful, for 5 example, in hybridization and amplification technologies and in analogous methods that distinguish SEQ ID NO:19-36 from related polynucleotide sequences. The precise length of a fragment of SEQ ID NO:19-36 and the region of SEQ ID NO:19-36 to which the fragment corresponds are routinely determinable by one of ordinary skill in the art based on the intended purpose for the fragment.

A fragment of SEQ ID NO:1-18 is encoded by a fragment of SEQ ID NO:19-36. A 10 fragment of SEQ ID NO:1-18 comprises a region of unique amino acid sequence that specifically identifies SEQ ID NO:1-18. For example, a fragment of SEQ ID NO:1-18 is useful as an immunogenic peptide for the development of antibodies that specifically recognize SEQ ID NO:1-18. The precise length of a fragment of SEQ ID NO:1-18 and the region of SEQ ID NO:1-18 to which the fragment corresponds are routinely determinable by one of ordinary skill in the art based 15 on the intended purpose for the fragment.

A “full length” polynucleotide sequence is one containing at least a translation initiation codon (e.g., methionine) followed by an open reading frame and a translation termination codon. A “full length” polynucleotide sequence encodes a “full length” polypeptide sequence.

“Homology” refers to sequence similarity or, interchangeably, sequence identity, between two 20 or more polynucleotide sequences or two or more polypeptide sequences.

The terms “percent identity” and “% identity,” as applied to polynucleotide sequences, refer to the percentage of residue matches between at least two polynucleotide sequences aligned using a 25 standardized algorithm. Such an algorithm may insert, in a standardized and reproducible way, gaps in the sequences being compared in order to optimize alignment between two sequences, and therefore achieve a more meaningful comparison of the two sequences.

Percent identity between polynucleotide sequences may be determined using the default parameters of the CLUSTAL V algorithm as incorporated into the MEGALIGN version 3.12e sequence alignment program. This program is part of the LASERGENE software package, a suite of molecular biological analysis programs (DNASTAR, Madison WI). CLUSTAL V is described in 30 Higgins, D.G. and P.M. Sharp (1989) CABIOS 5:151-153 and in Higgins, D.G. et al. (1992) CABIOS 8:189-191. For pairwise alignments of polynucleotide sequences, the default parameters are set as follows: Ktuple=2, gap penalty=5, window=4, and “diagonals saved”=4. The “weighted” residue weight table is selected as the default. Percent identity is reported by CLUSTAL V as the “percent similarity” between aligned polynucleotide sequences.

Alternatively, a suite of commonly used and freely available sequence comparison algorithms is provided by the National Center for Biotechnology Information (NCBI) Basic Local Alignment Search Tool (BLAST) (Altschul, S.F. et al. (1990) J. Mol. Biol. 215:403-410), which is available from several sources, including the NCBI, Bethesda, MD, and on the Internet at

5 <http://www.ncbi.nlm.nih.gov/BLAST/>. The BLAST software suite includes various sequence analysis programs including "blastn," that is used to align a known polynucleotide sequence with other polynucleotide sequences from a variety of databases. Also available is a tool called "BLAST 2 Sequences" that is used for direct pairwise comparison of two nucleotide sequences. "BLAST 2 Sequences" can be accessed and used interactively at <http://www.ncbi.nlm.nih.gov/gorf/bl2.html>. The

10 "BLAST 2 Sequences" tool can be used for both blastn and blastp (discussed below). BLAST programs are commonly used with gap and other parameters set to default settings. For example, to compare two nucleotide sequences, one may use blastn with the "BLAST 2 Sequences" tool Version 2.0.12 (April-21-2000) set at default parameters. Such default parameters may be, for example:

15 *Matrix: BLOSUM62*  
*Reward for match: 1*  
*Penalty for mismatch: -2*  
*Open Gap: 5 and Extension Gap: 2 penalties*  
*Gap x drop-off: 50*  
*Expect: 10*  
20 *Word Size: 11*  
*Filter: on*

Percent identity may be measured over the length of an entire defined sequence, for example, as defined by a particular SEQ ID number, or may be measured over a shorter length, for example, over the length of a fragment taken from a larger, defined sequence, for instance, a fragment of at least 25 20, at least 30, at least 40, at least 50, at least 70, at least 100, or at least 200 contiguous nucleotides. Such lengths are exemplary only, and it is understood that any fragment length supported by the sequences shown herein, in the tables, figures, or Sequence Listing, may be used to describe a length over which percentage identity may be measured.

30 Nucleic acid sequences that do not show a high degree of identity may nevertheless encode similar amino acid sequences due to the degeneracy of the genetic code. It is understood that changes in a nucleic acid sequence can be made using this degeneracy to produce multiple nucleic acid sequences that all encode substantially the same protein.

The phrases "percent identity" and "% identity," as applied to polypeptide sequences, refer to the percentage of residue matches between at least two polypeptide sequences aligned using a

standardized algorithm. Methods of polypeptide sequence alignment are well-known. Some alignment methods take into account conservative amino acid substitutions. Such conservative substitutions, explained in more detail above, generally preserve the charge and hydrophobicity at the site of substitution, thus preserving the structure (and therefore function) of the polypeptide.

5 Percent identity between polypeptide sequences may be determined using the default parameters of the CLUSTAL V algorithm as incorporated into the MEGALIGN version 3.12e sequence alignment program (described and referenced above). For pairwise alignments of polypeptide sequences using CLUSTAL V, the default parameters are set as follows: Ktuple=1, gap penalty=3, window=5, and “diagonals saved”=5. The PAM250 matrix is selected as the default residue weight 10 table. As with polynucleotide alignments, the percent identity is reported by CLUSTAL V as the “percent similarity” between aligned polypeptide sequence pairs.

Alternatively the NCBI BLAST software suite may be used. For example, for a pairwise comparison of two polypeptide sequences, one may use the “BLAST 2 Sequences” tool Version 2.0.12 (April-21-2000) with blastp set at default parameters. Such default parameters may be, for example:

15 *Matrix: BLOSUM62*

*Open Gap: 11 and Extension Gap: 1 penalties*

*Gap x drop-off: 50*

*Expect: 10*

*Word Size: 3*

20 *Filter: on*

Percent identity may be measured over the length of an entire defined polypeptide sequence, for example, as defined by a particular SEQ ID number, or may be measured over a shorter length, for example, over the length of a fragment taken from a larger, defined polypeptide sequence, for instance, a fragment of at least 15, at least 20, at least 30, at least 40, at least 50, at least 70 or at least 150 25 contiguous residues. Such lengths are exemplary only, and it is understood that any fragment length supported by the sequences shown herein, in the tables, figures or Sequence Listing, may be used to describe a length over which percentage identity may be measured.

“Human artificial chromosomes” (HACs) are linear microchromosomes which may contain DNA sequences of about 6 kb to 10 Mb in size and which contain all of the elements required for 30 chromosome replication, segregation and maintenance.

The term “humanized antibody” refers to an antibody molecule in which the amino acid sequence in the non-antigen binding regions has been altered so that the antibody more closely resembles a human antibody, and still retains its original binding ability.

“Hybridization” refers to the process by which a polynucleotide strand anneals with a

complementary strand through base pairing under defined hybridization conditions. Specific hybridization is an indication that two nucleic acid sequences share a high degree of complementarity. Specific hybridization complexes form under permissive annealing conditions and remain hybridized after the "washing" step(s). The washing step(s) is particularly important in determining the 5 stringency of the hybridization process, with more stringent conditions allowing less non-specific binding, i.e., binding between pairs of nucleic acid strands that are not perfectly matched. Permissive conditions for annealing of nucleic acid sequences are routinely determinable by one of ordinary skill in the art and may be consistent among hybridization experiments, whereas wash conditions may be varied among experiments to achieve the desired stringency, and therefore hybridization specificity.

10 Permissive annealing conditions occur, for example, at 68°C in the presence of about 6 x SSC, about 1% (w/v) SDS, and about 100 µg/ml sheared, denatured salmon sperm DNA.

Generally, stringency of hybridization is expressed, in part, with reference to the temperature under which the wash step is carried out. Such wash temperatures are typically selected to be about 5°C to 20°C lower than the thermal melting point ( $T_m$ ) for the specific sequence at a defined ionic 15 strength and pH. The  $T_m$  is the temperature (under defined ionic strength and pH) at which 50% of the target sequence hybridizes to a perfectly matched probe. An equation for calculating  $T_m$  and conditions for nucleic acid hybridization are well known and can be found in Sambrook, J. et al. (1989) Molecular Cloning: A Laboratory Manual, 2<sup>nd</sup> ed., vol. 1-3, Cold Spring Harbor Press, Plainview NY; specifically see volume 2, chapter 9.

20 High stringency conditions for hybridization between polynucleotides of the present invention include wash conditions of 68°C in the presence of about 0.2 x SSC and about 0.1% SDS, for 1 hour. Alternatively, temperatures of about 65°C, 60°C, 55°C, or 42°C may be used. SSC concentration may be varied from about 0.1 to 2 x SSC, with SDS being present at about 0.1%. Typically, blocking 25 reagents are used to block non-specific hybridization. Such blocking reagents include, for instance, sheared and denatured salmon sperm DNA at about 100-200 µg/ml. Organic solvent, such as formamide at a concentration of about 35-50% v/v, may also be used under particular circumstances, such as for RNA:DNA hybridizations. Useful variations on these wash conditions will be readily apparent to those of ordinary skill in the art. Hybridization, particularly under high stringency conditions, may be suggestive of evolutionary similarity between the nucleotides. Such similarity is 30 strongly indicative of a similar role for the nucleotides and their encoded polypeptides.

The term "hybridization complex" refers to a complex formed between two nucleic acid sequences by virtue of the formation of hydrogen bonds between complementary bases. A hybridization complex may be formed in solution (e.g.,  $C_0t$  or  $R_0t$  analysis) or formed between one nucleic acid sequence present in solution and another nucleic acid sequence immobilized on a solid

support (e.g., paper, membranes, filters, chips, pins or glass slides, or any other appropriate substrate to which cells or their nucleic acids have been fixed).

The words "insertion" and "addition" refer to changes in an amino acid or nucleotide sequence resulting in the addition of one or more amino acid residues or nucleotides, respectively.

5 "Immune response" can refer to conditions associated with inflammation, trauma, immune disorders, or infectious or genetic disease, etc. These conditions can be characterized by expression of various factors, e.g., cytokines, chemokines, and other signaling molecules, which may affect cellular and systemic defense systems.

10 An "immunogenic fragment" is a polypeptide or oligopeptide fragment of DME which is capable of eliciting an immune response when introduced into a living organism, for example, a mammal. The term "immunogenic fragment" also includes any polypeptide or oligopeptide fragment of DME which is useful in any of the antibody production methods disclosed herein or known in the art.

15 The term "microarray" refers to an arrangement of a plurality of polynucleotides, polypeptides, or other chemical compounds on a substrate.

The terms "element" and "array element" refer to a polynucleotide, polypeptide, or other chemical compound having a unique and defined position on a microarray.

20 The term "modulate" refers to a change in the activity of DME. For example, modulation may cause an increase or a decrease in protein activity, binding characteristics, or any other biological, functional, or immunological properties of DME.

The phrases "nucleic acid" and "nucleic acid sequence" refer to a nucleotide, oligonucleotide, polynucleotide, or any fragment thereof. These phrases also refer to DNA or RNA of genomic or synthetic origin which may be single-stranded or double-stranded and may represent the sense or the antisense strand, to peptide nucleic acid (PNA), or to any DNA-like or RNA-like material.

25 "Operably linked" refers to the situation in which a first nucleic acid sequence is placed in a functional relationship with a second nucleic acid sequence. For instance, a promoter is operably linked to a coding sequence if the promoter affects the transcription or expression of the coding sequence. Operably linked DNA sequences may be in close proximity or contiguous and, where necessary to join two protein coding regions, in the same reading frame.

30 "Peptide nucleic acid" (PNA) refers to an antisense molecule or anti-gene agent which comprises an oligonucleotide of at least about 5 nucleotides in length linked to a peptide backbone of amino acid residues ending in lysine. The terminal lysine confers solubility to the composition. PNAs preferentially bind complementary single stranded DNA or RNA and stop transcript elongation, and may be pegylated to extend their lifespan in the cell.

"Post-translational modification" of an DME may involve lipidation, glycosylation, phosphorylation, acetylation, racemization, proteolytic cleavage, and other modifications known in the art. These processes may occur synthetically or biochemically. Biochemical modifications will vary by cell type depending on the enzymatic milieu of DME.

5 "Probe" refers to nucleic acid sequences encoding DME, their complements, or fragments thereof, which are used to detect identical, allelic or related nucleic acid sequences. Probes are isolated oligonucleotides or polynucleotides attached to a detectable label or reporter molecule. Typical labels include radioactive isotopes, ligands, chemiluminescent agents, and enzymes. "Primers" are short nucleic acids, usually DNA oligonucleotides, which may be annealed to a target 10 polynucleotide by complementary base-pairing. The primer may then be extended along the target DNA strand by a DNA polymerase enzyme. Primer pairs can be used for amplification (and identification) of a nucleic acid sequence, e.g., by the polymerase chain reaction (PCR).

15 Probes and primers as used in the present invention typically comprise at least 15 contiguous nucleotides of a known sequence. In order to enhance specificity, longer probes and primers may also be employed, such as probes and primers that comprise at least 20, 25, 30, 40, 50, 60, 70, 80, 90, 100, or at least 150 consecutive nucleotides of the disclosed nucleic acid sequences. Probes and primers may be considerably longer than these examples, and it is understood that any length supported by the specification, including the tables, figures, and Sequence Listing, may be used.

20 Methods for preparing and using probes and primers are described in the references, for example Sambrook, J. et al. (1989) Molecular Cloning: A Laboratory Manual, 2<sup>nd</sup> ed., vol. 1-3, Cold Spring Harbor Press, Plainview NY; Ausubel, F.M. et al. (1987) Current Protocols in Molecular Biology, Greene Publ. Assoc. & Wiley-Intersciences, New York NY; Innis, M. et al. (1990) PCR Protocols, A Guide to Methods and Applications, Academic Press, San Diego CA. PCR primer pairs 25 can be derived from a known sequence, for example, by using computer programs intended for that purpose such as Primer (Version 0.5, 1991, Whitehead Institute for Biomedical Research, Cambridge MA).

30 Oligonucleotides for use as primers are selected using software known in the art for such purpose. For example, OLIGO 4.06 software is useful for the selection of PCR primer pairs of up to 100 nucleotides each, and for the analysis of oligonucleotides and larger polynucleotides of up to 5,000 nucleotides from an input polynucleotide sequence of up to 32 kilobases. Similar primer selection programs have incorporated additional features for expanded capabilities. For example, the PrimOU primer selection program (available to the public from the Genome Center at University of Texas South West Medical Center, Dallas TX) is capable of choosing specific primers from megabase sequences and is thus useful for designing primers on a genome-wide scope. The Primer3 primer

selection program (available to the public from the Whitehead Institute/MIT Center for Genome Research, Cambridge MA) allows the user to input a “mispriming library,” in which sequences to avoid as primer binding sites are user-specified. Primer3 is useful, in particular, for the selection of oligonucleotides for microarrays. (The source code for the latter two primer selection programs may 5 also be obtained from their respective sources and modified to meet the user’s specific needs.) The PrimeGen program (available to the public from the UK Human Genome Mapping Project Resource Centre, Cambridge UK) designs primers based on multiple sequence alignments, thereby allowing selection of primers that hybridize to either the most conserved or least conserved regions of aligned nucleic acid sequences. Hence, this program is useful for identification of both unique and conserved 10 oligonucleotides and polynucleotide fragments. The oligonucleotides and polynucleotide fragments identified by any of the above selection methods are useful in hybridization technologies, for example, as PCR or sequencing primers, microarray elements, or specific probes to identify fully or partially complementary polynucleotides in a sample of nucleic acids. Methods of oligonucleotide selection are not limited to those described above.

15 A “recombinant nucleic acid” is a sequence that is not naturally occurring or has a sequence that is made by an artificial combination of two or more otherwise separated segments of sequence. This artificial combination is often accomplished by chemical synthesis or, more commonly, by the artificial manipulation of isolated segments of nucleic acids, e.g., by genetic engineering techniques such as those described in Sambrook, supra. The term recombinant includes nucleic acids that have 20 been altered solely by addition, substitution, or deletion of a portion of the nucleic acid. Frequently, a recombinant nucleic acid may include a nucleic acid sequence operably linked to a promoter sequence. Such a recombinant nucleic acid may be part of a vector that is used, for example, to transform a cell.

25 Alternatively, such recombinant nucleic acids may be part of a viral vector, e.g., based on a vaccinia virus, that could be used to vaccinate a mammal wherein the recombinant nucleic acid is expressed, inducing a protective immunological response in the mammal.

A “regulatory element” refers to a nucleic acid sequence usually derived from untranslated regions of a gene and includes enhancers, promoters, introns, and 5' and 3' untranslated regions (UTRs). Regulatory elements interact with host or viral proteins which control transcription, translation, or RNA stability.

30 “Reporter molecules” are chemical or biochemical moieties used for labeling a nucleic acid, amino acid, or antibody. Reporter molecules include radionuclides; enzymes; fluorescent, chemiluminescent, or chromogenic agents; substrates; cofactors; inhibitors; magnetic particles; and other moieties known in the art.

An “RNA equivalent,” in reference to a DNA sequence, is composed of the same linear

sequence of nucleotides as the reference DNA sequence with the exception that all occurrences of the nitrogenous base thymine are replaced with uracil, and the sugar backbone is composed of ribose instead of deoxyribose.

5 The term "sample" is used in its broadest sense. A sample suspected of containing DME, nucleic acids encoding DME, or fragments thereof may comprise a bodily fluid; an extract from a cell, chromosome, organelle, or membrane isolated from a cell; a cell; genomic DNA, RNA, or cDNA, in solution or bound to a substrate; a tissue; a tissue print; etc.

10 The terms "specific binding" and "specifically binding" refer to that interaction between a protein or peptide and an agonist, an antibody, an antagonist, a small molecule, or any natural or synthetic binding composition. The interaction is dependent upon the presence of a particular structure of the protein, e.g., the antigenic determinant or epitope, recognized by the binding molecule. For example, if an antibody is specific for epitope "A," the presence of a polypeptide comprising the epitope A, or the presence of free unlabeled A, in a reaction containing free labeled A and the antibody will reduce the amount of labeled A that binds to the antibody.

15 The term "substantially purified" refers to nucleic acid or amino acid sequences that are removed from their natural environment and are isolated or separated, and are at least 60% free, preferably at least 75% free, and most preferably at least 90% free from other components with which they are naturally associated.

20 A "substitution" refers to the replacement of one or more amino acid residues or nucleotides by different amino acid residues or nucleotides, respectively.

25 "Substrate" refers to any suitable rigid or semi-rigid support including membranes, filters, chips, slides, wafers, fibers, magnetic or nonmagnetic beads, gels, tubing, plates, polymers, microparticles and capillaries. The substrate can have a variety of surface forms, such as wells, trenches, pins, channels and pores, to which polynucleotides or polypeptides are bound.

30 A "transcript image" refers to the collective pattern of gene expression by a particular cell type or tissue under given conditions at a given time.

35 "Transformation" describes a process by which exogenous DNA is introduced into a recipient cell. Transformation may occur under natural or artificial conditions according to various methods well known in the art, and may rely on any known method for the insertion of foreign nucleic acid sequences into a prokaryotic or eukaryotic host cell. The method for transformation is selected based on the type of host cell being transformed and may include, but is not limited to, bacteriophage or viral infection, electroporation, heat shock, lipofection, and particle bombardment. The term "transformed cells" includes stably transformed cells in which the inserted DNA is capable of replication either as an autonomously replicating plasmid or as part of the host chromosome, as well as transiently

transformed cells which express the inserted DNA or RNA for limited periods of time.

A "transgenic organism," as used herein, is any organism, including but not limited to animals and plants, in which one or more of the cells of the organism contains heterologous nucleic acid introduced by way of human intervention, such as by transgenic techniques well known in the art. The nucleic acid is introduced into the cell, directly or indirectly by introduction into a precursor of the cell, by way of deliberate genetic manipulation, such as by microinjection or by infection with a recombinant virus. The term genetic manipulation does not include classical cross-breeding, or in vitro fertilization, but rather is directed to the introduction of a recombinant DNA molecule. The transgenic organisms contemplated in accordance with the present invention include bacteria, cyanobacteria, fungi, plants and animals. The isolated DNA of the present invention can be introduced into the host by methods known in the art, for example infection, transfection, transformation or transconjugation. Techniques for transferring the DNA of the present invention into such organisms are widely known and provided in references such as Sambrook et al. (1989), supra.

A "variant" of a particular nucleic acid sequence is defined as a nucleic acid sequence having at least 40% sequence identity to the particular nucleic acid sequence over a certain length of one of the nucleic acid sequences using blastn with the "BLAST 2 Sequences" tool Version 2.0.9 (May-07-1999) set at default parameters. Such a pair of nucleic acids may show, for example, at least 50%, at least 60%, at least 70%, at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% or greater sequence identity over a certain defined length. A variant may be described as, for example, an "allelic" (as defined above), "splice," "species," or "polymorphic" variant. A splice variant may have significant identity to a reference molecule, but will generally have a greater or lesser number of polynucleotides due to alternative splicing of exons during mRNA processing. The corresponding polypeptide may possess additional functional domains or lack domains that are present in the reference molecule. Species variants are polynucleotide sequences that vary from one species to another. The resulting polypeptides will generally have significant amino acid identity relative to each other. A polymorphic variant is a variation in the polynucleotide sequence of a particular gene between individuals of a given species. Polymorphic variants also may encompass "single nucleotide polymorphisms" (SNPs) in which the polynucleotide sequence varies by one nucleotide base. The presence of SNPs may be indicative of, for example, a certain population, a disease state, or a propensity for a disease state.

A "variant" of a particular polypeptide sequence is defined as a polypeptide sequence having at least 40% sequence identity to the particular polypeptide sequence over a certain length of one of the

polypeptide sequences using blastp with the "BLAST 2 Sequences" tool Version 2.0.9 (May-07-1999) set at default parameters. Such a pair of polypeptides may show, for example, at least 50%, at least 60%, at least 70%, at least 80%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% or greater sequence identity over a certain defined length of one of the polypeptides.

5

## THE INVENTION

The invention is based on the discovery of new human drug metabolizing enzymes (DME), the polynucleotides encoding DME, and the use of these compositions for the diagnosis, treatment, or 10 prevention of autoimmune/inflammatory, cell proliferative, developmental, endocrine, eye, metabolic, and gastrointestinal disorders, including liver disorders.

15 Table 1 summarizes the nomenclature for the full length polynucleotide and polypeptide sequences of the invention. Each polynucleotide and its corresponding polypeptide are correlated to a single Incyte project identification number (Incyte Project ID). Each polypeptide sequence is denoted by both a polypeptide sequence identification number (Polypeptide SEQ ID NO:) and an Incyte polypeptide sequence number (Incyte Polypeptide ID) as shown. Each polynucleotide sequence is denoted by both a polynucleotide sequence identification number (Polynucleotide SEQ ID NO:) and an Incyte polynucleotide consensus sequence number (Incyte Polynucleotide ID) as shown.

20 Table 2 shows sequences with homology to the polypeptides of the invention as identified by BLAST analysis against the GenBank protein (genpept) database. Columns 1 and 2 show the polypeptide sequence identification number (Polypeptide SEQ ID NO:) and the corresponding Incyte polypeptide sequence number (Incyte Polypeptide ID) for polypeptides of the invention. Column 3 shows the GenBank identification number (Genbank ID NO:) of the nearest GenBank homolog. Column 4 shows the probability score for the match between each polypeptide and its GenBank 25 homolog. Column 5 shows the annotation of the GenBank homolog along with relevant citations where applicable, all of which are expressly incorporated by reference herein.

30 Table 3 shows various structural features of the polypeptides of the invention. Columns 1 and 2 show the polypeptide sequence identification number (SEQ ID NO:) and the corresponding Incyte polypeptide sequence number (Incyte Polypeptide ID) for each polypeptide of the invention. Column 3 shows the number of amino acid residues in each polypeptide. Column 4 shows potential phosphorylation sites, and column 5 shows potential glycosylation sites, as determined by the MOTIFS program of the GCG sequence analysis software package (Genetics Computer Group, Madison WI). Column 6 shows amino acid residues comprising signature sequences, domains, and motifs. Column 7 shows analytical methods for protein structure/function analysis and in some cases, searchable

databases to which the analytical methods were applied.

Together, Tables 2 and 3 summarize the properties of polypeptides of the invention, and these properties establish that the claimed polypeptides are drug metabolizing enzymes. For example, SEQ ID NO:12 is 98% identical to rat neuregulin 2 (GenBank ID g1145789), a neuronal cell surface protein with a carboxylesterase-like domain, as determined by the Basic Local Alignment Search Tool (BLAST). (See Table 2.) The BLAST probability score is 0.0, which indicates the probability of obtaining the observed polypeptide sequence alignment by chance. SEQ ID NO:12 also contains carboxylesterase domains as determined by searching for statistically significant matches in the hidden Markov model (HMM)-based PFAM database of conserved protein family domains. (See Table 3.) Data from BLIMPS, MOTIFS, and PROFILESCAN analyses provide further corroborative evidence that SEQ ID NO:12 is a carboxylesterase.

In an alternative example, SEQ ID NO:3 is 46% identical to cytochrome P450 from Blaberus discoidalis (GenBank ID g155947) as determined by the Basic Local Alignment Search Tool (BLAST). (See Table 2.) The BLAST probability score is 1.2e-118, which indicates the probability of obtaining the observed polypeptide sequence alignment by chance. SEQ ID NO:3 also contains a cytochrome P450 active site domain as determined by searching for statistically significant matches in the hidden Markov model (HMM)-based PFAM database of conserved protein family domains. (See Table 3.) Data from BLIMPS, MOTIFS, and PROFILESCAN analyses provide further corroborative evidence that SEQ ID NO:3 is a cytochrome P450. In an alternative example, SEQ ID NO:5 is 75% identical to human cytochrome P-450LTBV, a form of cytochrome P-450 identified as a leukotriene B4 omega-hydroxylase (GenBank ID g391716), as determined by the Basic Local Alignment Search Tool (BLAST, see Table 2). The BLAST probability score is 7.1e-215, which indicates the probability of obtaining the observed polypeptide sequence alignment by chance. SEQ ID NO:5 also contains cytochrome P-450 signature sequences as determined by searching for statistically significant matches in the hidden Markov model (HMM)-based PFAM database of conserved protein family domains (see Table 3). Data from BLIMPS and PROFILESCAN analyses provide further corroborative evidence that SEQ ID NO:5 is a member of the cytochrome P-450 superfamily. In an alternative example, SEQ ID NO:10 is 36% identical to human UDP-galactose:2-acetamido-2-deoxy-D- glucose3beta-galactosyltransferase with a probability score of 7.1e-46; SEQ ID NO:11 is 49% identical to an N-acetyltransferase from Schizosaccharomyces pombe with a probability score of 1.4e-35; and SEQ ID NO:13 is 87% identical to mouse parathion hydrolase, a phosphotriesterase-related protein, with a probability score of 9.1e-167, based on BLAST analysis (see Table 2). In an alternative example, SEQ ID NO:14 is 34% identical to a rat gamma-glutamyltranspeptidase (GenBank ID g57806) as determined by the Basic Local Alignment Search

Tool, with a probability score of 3.6e-13. BLIMPS analysis provides additional evidence that SEQ ID NO:14 is a gamma-glutamyltranspeptidase. In an alternative example, SEQ ID NO:15 is 44% identical to a cytochrome P450 from cockroach (GenBank ID g155947), with a probability score of 8.8e-98. HMMER-PFAM data and BLIMPS, MOTIFS, and PROFILESCAN analyses provide 5 further corroborative evidence that SEQ ID NO:15 is a member of the cytochrome P450 superfamily. In an alternative example, SEQ ID NO:16 is 73% identical to human cytochrome P450 IIIA4 (GenBank ID g6644372) as determined by the Basic Local Alignment Search Tool (BLAST, see Table 2). The BLAST probability score is 6.3e-195, which indicates the probability of obtaining the 10 observed polypeptide sequence alignment by chance. SEQ ID NO:16 also contains a cytochrome P450 signature domain as determined by searching for statistically significant matches in the hidden Markov model (HMM)-based PFAM database of conserved protein family domains (see Table 3, also referred to as HMMER-PFAM data). Data from BLIMPS, MOTIFS, and PROFILESCAN analyses provide further corroborative evidence that SEQ ID NO:16 is a member of the cytochrome P450 superfamily. In an alternative example, SEQ ID NO:17 is 71% identical to a human chlordecone reductase (a 15 member of the aldo/keto reductase superfamily, GenBank ID g4261710), with a probability score of 1.9e-127. HMMER-PFAM data and BLIMPS, MOTIFS, and PROFILESCAN analyses provide further corroborative evidence that SEQ ID NO:17 is an aldo/keto reductase. In an alternative example, SEQ ID NO:18 is 91% identical to another human aldo/keto reductase (GenBank ID g3493209), with a probability score of 6.5e-157. HMMER-PFAM data and BLIMPS, MOTIFS, and 20 PROFILESCAN analyses provide further corroborative evidence that SEQ ID NO:18 is an aldo/keto reductase. SEQ ID NO:1-2, SEQ ID NO:4, and SEQ ID NO:6-9 were analyzed and annotated in a similar manner. The algorithms and parameters for the analysis of SEQ ID NO:1-18 are described in Table 7.

As shown in Table 4, the full length polynucleotide sequences of the present invention were 25 assembled using cDNA sequences or coding (exon) sequences derived from genomic DNA, or any combination of these two types of sequences. Columns 1 and 2 list the polynucleotide sequence identification number (Polynucleotide SEQ ID NO:) and the corresponding Incyte polynucleotide consensus sequence number (Incyte Polynucleotide ID) for each polynucleotide of the invention. Column 3 shows the length of each polynucleotide sequence in basepairs. Column 4 lists fragments of 30 the polynucleotide sequences which are useful, for example, in hybridization or amplification technologies that identify SEQ ID NO:19-36 or that distinguish between SEQ ID NO:19-36 and related polynucleotide sequences. Column 5 shows identification numbers corresponding to cDNA sequences, coding sequences (exons) predicted from genomic DNA, and/or sequence assemblages comprised of both cDNA and genomic DNA. These sequences were used to assemble the full length

polynucleotide sequences of the invention. Columns 6 and 7 of Table 4 show the nucleotide start (5') and stop (3') positions of the cDNA and/or genomic sequences in column 5 relative to their respective full length sequences.

The identification numbers in Column 5 of Table 4 may refer specifically, for example, to 5 Incyte cDNAs along with their corresponding cDNA libraries. For example, 6274461T8 is the identification number of an Incyte cDNA sequence, and BRAIFEN03 is the cDNA library from which it is derived. Incyte cDNAs for which cDNA libraries are not indicated were derived from pooled cDNA libraries. Alternatively, the identification numbers in column 5 may refer to GenBank cDNAs or ESTs (e.g., 71356628V1) which contributed to the assembly of the full length polynucleotide 10 sequences. In addition, the identification numbers in column 5 may identify sequences derived from the ENSEMBL (The Sanger Centre, Cambridge, UK) database (*i.e.*, those sequences including the designation "ENST"). Alternatively, the identification numbers in column 5 may be derived from the NCBI RefSeq Nucleotide Sequence Records Database (*i.e.*, those sequences including the designation "NM" or "NT") or the NCBI RefSeq Protein Sequence Records (*i.e.*, those sequences including the 15 designation "NP"). Alternatively, the identification numbers in column 5 may refer to assemblages of both cDNA and Genscan-predicted exons brought together by an "exon stitching" algorithm. For example, FL\_XXXXXX\_N<sub>1</sub>\_N<sub>2</sub>\_YYYYY\_N<sub>3</sub>\_N<sub>4</sub> represents a "stitched" sequence in which XXXXXX is the identification number of the cluster of sequences to which the algorithm was applied, and YYYY is the number of the prediction generated by the algorithm, and N<sub>1,2,3...</sub>, if present, represent specific exons 20 that may have been manually edited during analysis (See Example V). Alternatively, the identification numbers in column 5 may refer to assemblages of exons brought together by an "exon-stretching" algorithm. For example, FLXXXXXX\_gAAAAAA\_gBBBBB\_1\_N is the identification number of a "stretched" sequence, with XXXXXX being the Incyte project identification number, gAAAAAA being the GenBank identification number of the human genomic sequence to which the "exon-stretching" 25 algorithm was applied, gBBBBB being the GenBank identification number or NCBI RefSeq identification number of the nearest GenBank protein homolog, and N referring to specific exons (See Example V). In instances where a RefSeq sequence was used as a protein homolog for the "exon-stretching" algorithm, a RefSeq identifier (denoted by "NM," "NP," or "NT") may be used in place of the GenBank identifier (*i.e.*, gBBBBB).

30 Alternatively, a prefix identifies component sequences that were hand-edited, predicted from genomic DNA sequences, or derived from a combination of sequence analysis methods. The following Table lists examples of component sequence prefixes and corresponding sequence analysis methods associated with the prefixes (see Example IV and Example V).

Prefix	Type of analysis and/or examples of programs
GNN, GFG, ENST	Exon prediction from genomic sequences using, for example, GENSCAN (Stanford University, CA, USA) or FGENES (Computer Genomics Group, The Sanger Centre, Cambridge, UK).
GBI	Hand-edited analysis of genomic sequences.
5 FL	Stitched or stretched genomic sequences (see Example V).

In some cases, Incyte cDNA coverage redundant with the sequence coverage shown in column 5 was obtained to confirm the final consensus polynucleotide sequence, but the relevant Incyte cDNA identification numbers are not shown.

10 Table 5 shows the representative cDNA libraries for those full length polynucleotide sequences which were assembled using Incyte cDNA sequences. The representative cDNA library is the Incyte cDNA library which is most frequently represented by the Incyte cDNA sequences which were used to assemble and confirm the above polynucleotide sequences. The tissues and vectors which were used to construct the cDNA libraries shown in Table 5 are described in Table 6.

15 The invention also encompasses DME variants. A preferred DME variant is one which has at least about 80%, or alternatively at least about 90%, or even at least about 95% amino acid sequence identity to the DME amino acid sequence, and which contains at least one functional or structural characteristic of DME.

20 The invention also encompasses polynucleotides which encode DME. In a particular embodiment, the invention encompasses a polynucleotide sequence comprising a sequence selected from the group consisting of SEQ ID NO:19-36, which encodes DME. The polynucleotide sequences of SEQ ID NO:19-36, as presented in the Sequence Listing, embrace the equivalent RNA sequences, wherein occurrences of the nitrogenous base thymine are replaced with uracil, and the sugar backbone is composed of ribose instead of deoxyribose.

25 The invention also encompasses a variant of a polynucleotide sequence encoding DME. In particular, such a variant polynucleotide sequence will have at least about 70%, or alternatively at least about 85%, or even at least about 95% polynucleotide sequence identity to the polynucleotide sequence encoding DME. A particular aspect of the invention encompasses a variant of a polynucleotide sequence comprising a sequence selected from the group consisting of SEQ ID NO:19-36 which has at least about 70%, or alternatively at least about 85%, or even at least about 95% polynucleotide sequence identity to a nucleic acid sequence selected from the group consisting of SEQ ID NO:19-36. Any one of the polynucleotide variants described above can encode an amino acid sequence which contains at least one functional or structural characteristic of DME.

It will be appreciated by those skilled in the art that as a result of the degeneracy of the genetic code, a multitude of polynucleotide sequences encoding DME, some bearing minimal similarity to the polynucleotide sequences of any known and naturally occurring gene, may be produced. Thus, the invention contemplates each and every possible variation of polynucleotide sequence that could be 5 made by selecting combinations based on possible codon choices. These combinations are made in accordance with the standard triplet genetic code as applied to the polynucleotide sequence of naturally occurring DME, and all such variations are to be considered as being specifically disclosed.

Although nucleotide sequences which encode DME and its variants are generally capable of hybridizing to the nucleotide sequence of the naturally occurring DME under appropriately selected 10 conditions of stringency, it may be advantageous to produce nucleotide sequences encoding DME or its derivatives possessing a substantially different codon usage, e.g., inclusion of non-naturally occurring codons. Codons may be selected to increase the rate at which expression of the peptide occurs in a particular prokaryotic or eukaryotic host in accordance with the frequency with which particular codons are utilized by the host. Other reasons for substantially altering the nucleotide sequence 15 encoding DME and its derivatives without altering the encoded amino acid sequences include the production of RNA transcripts having more desirable properties, such as a greater half-life, than transcripts produced from the naturally occurring sequence.

The invention also encompasses production of DNA sequences which encode DME and DME derivatives, or fragments thereof, entirely by synthetic chemistry. After production, the synthetic 20 sequence may be inserted into any of the many available expression vectors and cell systems using reagents well known in the art. Moreover, synthetic chemistry may be used to introduce mutations into a sequence encoding DME or any fragment thereof.

Also encompassed by the invention are polynucleotide sequences that are capable of hybridizing to the claimed polynucleotide sequences, and, in particular, to those shown in SEQ ID 25 NO:19-36 and fragments thereof under various conditions of stringency. (See, e.g., Wahl, G.M. and S.L. Berger (1987) Methods Enzymol. 152:399-407; Kimmel, A.R. (1987) Methods Enzymol. 152:507-511.) Hybridization conditions, including annealing and wash conditions, are described in "Definitions."

Methods for DNA sequencing are well known in the art and may be used to practice any of the 30 embodiments of the invention. The methods may employ such enzymes as the Klenow fragment of DNA polymerase I, SEQUENASE (US Biochemical, Cleveland OH), Taq polymerase (Applied Biosystems), thermostable T7 polymerase (Amersham Pharmacia Biotech, Piscataway NJ), or combinations of polymerases and proofreading exonucleases such as those found in the ELONGASE amplification system (Life Technologies, Gaithersburg MD). Preferably, sequence preparation is

automated with machines such as the MICROLAB 2200 liquid transfer system (Hamilton, Reno NV), PTC200 thermal cycler (MJ Research, Watertown MA) and ABI CATALYST 800 thermal cycler (Applied Biosystems). Sequencing is then carried out using either the ABI 373 or 377 DNA sequencing system (Applied Biosystems), the MEGABACE 1000 DNA sequencing system (Molecular Dynamics, Sunnyvale CA), or other systems known in the art. The resulting sequences are analyzed using a variety of algorithms which are well known in the art. (See, e.g., Ausubel, F.M. (1997) Short Protocols in Molecular Biology, John Wiley & Sons, New York NY, unit 7.7; Meyers, R.A. (1995) Molecular Biology and Biotechnology, Wiley VCH, New York NY, pp. 856-853.)

The nucleic acid sequences encoding DME may be extended utilizing a partial nucleotide sequence and employing various PCR-based methods known in the art to detect upstream sequences, such as promoters and regulatory elements. For example, one method which may be employed, restriction-site PCR, uses universal and nested primers to amplify unknown sequence from genomic DNA within a cloning vector. (See, e.g., Sarkar, G. (1993) *PCR Methods Applic.* 2:318-322.) Another method, inverse PCR, uses primers that extend in divergent directions to amplify unknown sequence from a circularized template. The template is derived from restriction fragments comprising a known genomic locus and surrounding sequences. (See, e.g., Triglia, T. et al. (1988) *Nucleic Acids Res.* 16:8186.) A third method, capture PCR, involves PCR amplification of DNA fragments adjacent to known sequences in human and yeast artificial chromosome DNA. (See, e.g., Lagerstrom, M. et al. (1991) *PCR Methods Applic.* 1:111-119.) In this method, multiple restriction enzyme digestions and ligations may be used to insert an engineered double-stranded sequence into a region of unknown sequence before performing PCR. Other methods which may be used to retrieve unknown sequences are known in the art. (See, e.g., Parker, J.D. et al. (1991) *Nucleic Acids Res.* 19:3055-3060). Additionally, one may use PCR, nested primers, and PROMOTERFINDER libraries (Clontech, Palo Alto CA) to walk genomic DNA. This procedure avoids the need to screen libraries and is useful in finding intron/exon junctions. For all PCR-based methods, primers may be designed using commercially available software, such as OLIGO 4.06 primer analysis software (National Biosciences, Plymouth MN) or another appropriate program, to be about 22 to 30 nucleotides in length, to have a GC content of about 50% or more, and to anneal to the template at temperatures of about 68°C to 72°C.

When screening for full length cDNAs, it is preferable to use libraries that have been size-selected to include larger cDNAs. In addition, random-primed libraries, which often include sequences containing the 5' regions of genes, are preferable for situations in which an oligo d(T) library does not yield a full-length cDNA. Genomic libraries may be useful for extension of sequence into 5' non-transcribed regulatory regions.

Capillary electrophoresis systems which are commercially available may be used to analyze the size or confirm the nucleotide sequence of sequencing or PCR products. In particular, capillary sequencing may employ flowable polymers for electrophoretic separation, four different nucleotide-specific, laser-stimulated fluorescent dyes, and a charge coupled device camera for detection of the emitted wavelengths. Output/light intensity may be converted to electrical signal using appropriate software (e.g., GENOTYPER and SEQUENCE NAVIGATOR, Applied Biosystems), and the entire process from loading of samples to computer analysis and electronic data display may be computer controlled. Capillary electrophoresis is especially preferable for sequencing small DNA fragments which may be present in limited amounts in a particular sample.

In another embodiment of the invention, polynucleotide sequences or fragments thereof which encode DME may be cloned in recombinant DNA molecules that direct expression of DME, or fragments or functional equivalents thereof, in appropriate host cells. Due to the inherent degeneracy of the genetic code, other DNA sequences which encode substantially the same or a functionally equivalent amino acid sequence may be produced and used to express DME.

The nucleotide sequences of the present invention can be engineered using methods generally known in the art in order to alter DME-encoding sequences for a variety of purposes including, but not limited to, modification of the cloning, processing, and/or expression of the gene product. DNA shuffling by random fragmentation and PCR reassembly of gene fragments and synthetic oligonucleotides may be used to engineer the nucleotide sequences. For example, oligonucleotide-mediated site-directed mutagenesis may be used to introduce mutations that create new restriction sites, alter glycosylation patterns, change codon preference, produce splice variants, and so forth.

The nucleotides of the present invention may be subjected to DNA shuffling techniques such as MOLECULARBREEDING (Maxygen Inc., Santa Clara CA; described in U.S. Patent Number 5,837,458; Chang, C.-C. et al. (1999) *Nat. Biotechnol.* 17:793-797; Christians, F.C. et al. (1999) *Nat. Biotechnol.* 17:259-264; and Crameri, A. et al. (1996) *Nat. Biotechnol.* 14:315-319) to alter or improve the biological properties of DME, such as its biological or enzymatic activity or its ability to bind to other molecules or compounds. DNA shuffling is a process by which a library of gene variants is produced using PCR-mediated recombination of gene fragments. The library is then subjected to selection or screening procedures that identify those gene variants with the desired properties. These preferred variants may then be pooled and further subjected to recursive rounds of DNA shuffling and selection/screening. Thus, genetic diversity is created through "artificial" breeding and rapid molecular evolution. For example, fragments of a single gene containing random point mutations may be recombined, screened, and then reshuffled until the desired properties are optimized. Alternatively, fragments of a given gene may be recombined with fragments of

homologous genes in the same gene family, either from the same or different species, thereby maximizing the genetic diversity of multiple naturally occurring genes in a directed and controllable manner.

In another embodiment, sequences encoding DME may be synthesized, in whole or in part,

5 using chemical methods well known in the art. (See, e.g., Caruthers, M.H. et al. (1980) Nucleic Acids Symp. Ser. 7:215-223; and Horn, T. et al. (1980) Nucleic Acids Symp. Ser. 7:225-232.)

Alternatively, DME itself or a fragment thereof may be synthesized using chemical methods. For example, peptide synthesis can be performed using various solution-phase or solid-phase techniques.

(See, e.g., Creighton, T. (1984) Proteins, Structures and Molecular Properties, WH Freeman, New

10 York NY, pp. 55-60; and Roberge, J.Y. et al. (1995) Science 269:202-204.) Automated synthesis may be achieved using the ABI 431A peptide synthesizer (Applied Biosystems). Additionally, the amino acid sequence of DME, or any part thereof, may be altered during direct synthesis and/or combined with sequences from other proteins, or any part thereof, to produce a variant polypeptide or a polypeptide having a sequence of a naturally occurring polypeptide.

15 The peptide may be substantially purified by preparative high performance liquid chromatography. (See, e.g., Chiez, R.M. and F.Z. Regnier (1990) Methods Enzymol. 182:392-421.) The composition of the synthetic peptides may be confirmed by amino acid analysis or by sequencing. (See, e.g., Creighton, supra, pp. 28-53.)

20 In order to express a biologically active DME, the nucleotide sequences encoding DME or derivatives thereof may be inserted into an appropriate expression vector, i.e., a vector which contains the necessary elements for transcriptional and translational control of the inserted coding sequence in a suitable host. These elements include regulatory sequences, such as enhancers, constitutive and inducible promoters, and 5' and 3' untranslated regions in the vector and in polynucleotide sequences encoding DME. Such elements may vary in their strength and specificity. Specific initiation signals 25 may also be used to achieve more efficient translation of sequences encoding DME. Such signals include the ATG initiation codon and adjacent sequences, e.g. the Kozak sequence. In cases where sequences encoding DME and its initiation codon and upstream regulatory sequences are inserted into the appropriate expression vector, no additional transcriptional or translational control signals may be needed. However, in cases where only coding sequence, or a fragment thereof, is inserted, exogenous 30 translational control signals including an in-frame ATG initiation codon should be provided by the vector. Exogenous translational elements and initiation codons may be of various origins, both natural and synthetic. The efficiency of expression may be enhanced by the inclusion of enhancers appropriate for the particular host cell system used. (See, e.g., Scharf, D. et al. (1994) Results Probl. Cell Differ. 20:125-162.)

Methods which are well known to those skilled in the art may be used to construct expression vectors containing sequences encoding DME and appropriate transcriptional and translational control elements. These methods include in vitro recombinant DNA techniques, synthetic techniques, and in vivo genetic recombination. (See, e.g., Sambrook, J. et al. (1989) Molecular Cloning, A Laboratory Manual, Cold Spring Harbor Press, Plainview NY, ch. 4, 8, and 16-17; Ausubel, F.M. et al. (1995) Current Protocols in Molecular Biology, John Wiley & Sons, New York NY, ch. 9, 13, and 16.)

A variety of expression vector/host systems may be utilized to contain and express sequences encoding DME. These include, but are not limited to, microorganisms such as bacteria transformed with recombinant bacteriophage, plasmid, or cosmid DNA expression vectors; yeast transformed with yeast expression vectors; insect cell systems infected with viral expression vectors (e.g., baculovirus); plant cell systems transformed with viral expression vectors (e.g., cauliflower mosaic virus, CaMV, or tobacco mosaic virus, TMV) or with bacterial expression vectors (e.g., Ti or pBR322 plasmids); or animal cell systems. (See, e.g., Sambrook, supra; Ausubel, supra; Van Heeke, G. and S.M. Schuster (1989) *J. Biol. Chem.* 264:5503-5509; Engelhard, E.K. et al. (1994) *Proc. Natl. Acad. Sci. USA* 91:3224-3227; Sandig, V. et al. (1996) *Hum. Gene Ther.* 7:1937-1945; Takamatsu, N. (1987) *EMBO J.* 6:307-311; The McGraw Hill Yearbook of Science and Technology (1992) McGraw Hill, New York NY, pp. 191-196; Logan, J. and T. Shenk (1984) *Proc. Natl. Acad. Sci. USA* 81:3655-3659; and Harrington, J.J. et al. (1997) *Nat. Genet.* 15:345-355.) Expression vectors derived from retroviruses, adenoviruses, or herpes or vaccinia viruses, or from various bacterial plasmids, may be used for delivery of nucleotide sequences to the targeted organ, tissue, or cell population. (See, e.g., Di Nicola, M. et al. (1998) *Cancer Gen. Ther.* 5(6):350-356; Yu, M. et al. (1993) *Proc. Natl. Acad. Sci. USA* 90(13):6340-6344; Buller, R.M. et al. (1985) *Nature* 317(6040):813-815; McGregor, D.P. et al. (1994) *Mol. Immunol.* 31(3):219-226; and Verma, I.M. and N. Somia (1997) *Nature* 389:239-242.) The invention is not limited by the host cell employed.

In bacterial systems, a number of cloning and expression vectors may be selected depending upon the use intended for polynucleotide sequences encoding DME. For example, routine cloning, subcloning, and propagation of polynucleotide sequences encoding DME can be achieved using a multifunctional E. coli vector such as PBLUESCRIPT (Stratagene, La Jolla CA) or PSPORT1 plasmid (Life Technologies). Ligation of sequences encoding DME into the vector's multiple cloning site disrupts the *lacZ* gene, allowing a colorimetric screening procedure for identification of transformed bacteria containing recombinant molecules. In addition, these vectors may be useful for in vitro transcription, dideoxy sequencing, single strand rescue with helper phage, and creation of nested deletions in the cloned sequence. (See, e.g., Van Heeke, G. and S.M. Schuster (1989) *J. Biol. Chem.* 264:5503-5509.) When large quantities of DME are needed, e.g. for the production of antibodies,

vectors which direct high level expression of DME may be used. For example, vectors containing the strong, inducible SP6 or T7 bacteriophage promoter may be used.

Yeast expression systems may be used for production of DME. A number of vectors containing constitutive or inducible promoters, such as alpha factor, alcohol oxidase, and PGH promoters, may be used in the yeast Saccharomyces cerevisiae or Pichia pastoris. In addition, such vectors direct either the secretion or intracellular retention of expressed proteins and enable integration of foreign sequences into the host genome for stable propagation. (See, e.g., Ausubel, 1995, supra; Bitter, G.A. et al. (1987) Methods Enzymol. 153:516-544; and Scorer, C.A. et al. (1994) Bio/Technology 12:181-184.)

Plant systems may also be used for expression of DME. Transcription of sequences encoding DME may be driven by viral promoters, e.g., the 35S and 19S promoters of CaMV used alone or in combination with the omega leader sequence from TMV (Takamatsu, N. (1987) EMBO J. 6:307-311). Alternatively, plant promoters such as the small subunit of RUBISCO or heat shock promoters may be used. (See, e.g., Coruzzi, G. et al. (1984) EMBO J. 3:1671-1680; Broglie, R. et al. (1984) Science 224:838-843; and Winter, J. et al. (1991) Results Probl. Cell Differ. 17:85-105.) These constructs can be introduced into plant cells by direct DNA transformation or pathogen-mediated transfection. (See, e.g., The McGraw Hill Yearbook of Science and Technology (1992) McGraw Hill, New York NY, pp. 191-196.)

In mammalian cells, a number of viral-based expression systems may be utilized. In cases where an adenovirus is used as an expression vector, sequences encoding DME may be ligated into an adenovirus transcription/translation complex consisting of the late promoter and tripartite leader sequence. Insertion in a non-essential E1 or E3 region of the viral genome may be used to obtain infective virus which expresses DME in host cells. (See, e.g., Logan, J. and T. Shenk (1984) Proc. Natl. Acad. Sci. USA 81:3655-3659.) In addition, transcription enhancers, such as the Rous sarcoma virus (RSV) enhancer, may be used to increase expression in mammalian host cells. SV40 or EBV-based vectors may also be used for high-level protein expression.

Human artificial chromosomes (HACs) may also be employed to deliver larger fragments of DNA than can be contained in and expressed from a plasmid. HACs of about 6 kb to 10 Mb are constructed and delivered via conventional delivery methods (liposomes, polycationic amino polymers, or vesicles) for therapeutic purposes. (See, e.g., Harrington, J.J. et al. (1997) Nat. Genet. 15:345-355.)

For long term production of recombinant proteins in mammalian systems, stable expression of DME in cell lines is preferred. For example, sequences encoding DME can be transformed into cell lines using expression vectors which may contain viral origins of replication and/or endogenous

expression elements and a selectable marker gene on the same or on a separate vector. Following the introduction of the vector, cells may be allowed to grow for about 1 to 2 days in enriched media before being switched to selective media. The purpose of the selectable marker is to confer resistance to a selective agent, and its presence allows growth and recovery of cells which successfully express the 5 introduced sequences. Resistant clones of stably transformed cells may be propagated using tissue culture techniques appropriate to the cell type.

Any number of selection systems may be used to recover transformed cell lines. These include, but are not limited to, the herpes simplex virus thymidine kinase and adenine phosphoribosyltransferase genes, for use in *tk*<sup>+</sup> and *apr*<sup>+</sup> cells, respectively. (See, e.g., Wigler, M. et al. 10 (1977) Cell 11:223-232; Lowy, I. et al. (1980) Cell 22:817-823.) Also, antimetabolite, antibiotic, or herbicide resistance can be used as the basis for selection. For example, *dfr* confers resistance to methotrexate; *neo* confers resistance to the aminoglycosides neomycin and G-418; and *als* and *pat* confer resistance to chlorsulfuron and phosphinotricin acetyltransferase, respectively. (See, e.g., Wigler, M. et al. (1980) Proc. Natl. Acad. Sci. USA 77:3567-3570; Colbere-Garapin, F. et al. (1981) 15 J. Mol. Biol. 150:1-14.) Additional selectable genes have been described, e.g., *trpB* and *hisD*, which alter cellular requirements for metabolites. (See, e.g., Hartman, S.C. and R.C. Mulligan (1988) Proc. Natl. Acad. Sci. USA 85:8047-8051.) Visible markers, e.g., anthocyanins, green fluorescent proteins (GFP; Clontech),  $\beta$  glucuronidase and its substrate  $\beta$ -glucuronide, or luciferase and its substrate luciferin may be used. These markers can be used not only to identify transformants, but also to 20 quantify the amount of transient or stable protein expression attributable to a specific vector system. (See, e.g., Rhodes, C.A. (1995) Methods Mol. Biol. 55:121-131.)

Although the presence/absence of marker gene expression suggests that the gene of interest is also present, the presence and expression of the gene may need to be confirmed. For example, if the sequence encoding DME is inserted within a marker gene sequence, transformed cells containing 25 sequences encoding DME can be identified by the absence of marker gene function. Alternatively, a marker gene can be placed in tandem with a sequence encoding DME under the control of a single promoter. Expression of the marker gene in response to induction or selection usually indicates expression of the tandem gene as well.

In general, host cells that contain the nucleic acid sequence encoding DME and that express 30 DME may be identified by a variety of procedures known to those of skill in the art. These procedures include, but are not limited to, DNA-DNA or DNA-RNA hybridizations, PCR amplification, and protein bioassay or immunoassay techniques which include membrane, solution, or chip based technologies for the detection and/or quantification of nucleic acid or protein sequences.

Immunological methods for detecting and measuring the expression of DME using either

specific polyclonal or monoclonal antibodies are known in the art. Examples of such techniques include enzyme-linked immunosorbent assays (ELISAs), radioimmunoassays (RIAs), and fluorescence activated cell sorting (FACS). A two-site, monoclonal-based immunoassay utilizing monoclonal antibodies reactive to two non-interfering epitopes on DME is preferred, but a competitive binding 5 assay may be employed. These and other assays are well known in the art. (See, e.g., Hampton, R. et al. (1990) Serological Methods, a Laboratory Manual, APS Press, St. Paul MN, Sect. IV; Coligan, J.E. et al. (1997) Current Protocols in Immunology, Greene Pub. Associates and Wiley-Interscience, New York NY; and Pound, J.D. (1998) Immunochemical Protocols, Humana Press, Totowa NJ.)

A wide variety of labels and conjugation techniques are known by those skilled in the art and 10 may be used in various nucleic acid and amino acid assays. Means for producing labeled hybridization or PCR probes for detecting sequences related to polynucleotides encoding DME include oligolabeling, nick translation, end-labeling, or PCR amplification using a labeled nucleotide. Alternatively, the sequences encoding DME, or any fragments thereof, may be cloned into a vector for the production of an mRNA probe. Such vectors are known in the art, are commercially available, and may be used to 15 synthesize RNA probes in vitro by addition of an appropriate RNA polymerase such as T7, T3, or SP6 and labeled nucleotides. These procedures may be conducted using a variety of commercially available kits, such as those provided by Amersham Pharmacia Biotech, Promega (Madison WI), and US Biochemical. Suitable reporter molecules or labels which may be used for ease of detection include 20 radionuclides, enzymes, fluorescent, chemiluminescent, or chromogenic agents, as well as substrates, cofactors, inhibitors, magnetic particles, and the like.

Host cells transformed with nucleotide sequences encoding DME may be cultured under 25 conditions suitable for the expression and recovery of the protein from cell culture. The protein produced by a transformed cell may be secreted or retained intracellularly depending on the sequence and/or the vector used. As will be understood by those of skill in the art, expression vectors containing polynucleotides which encode DME may be designed to contain signal sequences which direct secretion of DME through a prokaryotic or eukaryotic cell membrane.

In addition, a host cell strain may be chosen for its ability to modulate expression of the 30 inserted sequences or to process the expressed protein in the desired fashion. Such modifications of the polypeptide include, but are not limited to, acetylation, carboxylation, glycosylation, phosphorylation, lipidation, and acylation. Post-translational processing which cleaves a "prepro" or "pro" form of the protein may also be used to specify protein targeting, folding, and/or activity. Different host cells which have specific cellular machinery and characteristic mechanisms for post-translational activities (e.g., CHO, HeLa, MDCK, HEK293, and WI38) are available from the American Type Culture Collection (ATCC, Manassas VA) and may be chosen to ensure the correct modification and

processing of the foreign protein.

In another embodiment of the invention, natural, modified, or recombinant nucleic acid sequences encoding DME may be ligated to a heterologous sequence resulting in translation of a fusion protein in any of the aforementioned host systems. For example, a chimeric DME protein containing a heterologous moiety that can be recognized by a commercially available antibody may facilitate the screening of peptide libraries for inhibitors of DME activity. Heterologous protein and peptide moieties may also facilitate purification of fusion proteins using commercially available affinity matrices. Such moieties include, but are not limited to, glutathione S-transferase (GST), maltose binding protein (MBP), thioredoxin (Trx), calmodulin binding peptide (CBP), 6-His, FLAG, *c-myc*, and hemagglutinin (HA). GST, MBP, Trx, CBP, and 6-His enable purification of their cognate fusion proteins on immobilized glutathione, maltose, phenylarsine oxide, calmodulin, and metal-chelate resins, respectively. FLAG, *c-myc*, and hemagglutinin (HA) enable immunoaffinity purification of fusion proteins using commercially available monoclonal and polyclonal antibodies that specifically recognize these epitope tags. A fusion protein may also be engineered to contain a proteolytic cleavage site located between the DME encoding sequence and the heterologous protein sequence, so that DME may be cleaved away from the heterologous moiety following purification. Methods for fusion protein expression and purification are discussed in Ausubel (1995, *supra*, ch. 10). A variety of commercially available kits may also be used to facilitate expression and purification of fusion proteins.

In a further embodiment of the invention, synthesis of radiolabeled DME may be achieved *in vitro* using the TNT rabbit reticulocyte lysate or wheat germ extract system (Promega). These systems couple transcription and translation of protein-coding sequences operably associated with the T7, T3, or SP6 promoters. Translation takes place in the presence of a radiolabeled amino acid precursor, for example, <sup>35</sup>S-methionine.

DME of the present invention or fragments thereof may be used to screen for compounds that specifically bind to DME. At least one and up to a plurality of test compounds may be screened for specific binding to DME. Examples of test compounds include antibodies, oligonucleotides, proteins (e.g., receptors), or small molecules.

In one embodiment, the compound thus identified is closely related to the natural ligand of DME, e.g., a ligand or fragment thereof, a natural substrate, a structural or functional mimetic, or a natural binding partner. (See, e.g., Coligan, J.E. et al. (1991) *Current Protocols in Immunology* 1(2): Chapter 5.) Similarly, the compound can be closely related to the natural receptor to which DME binds, or to at least a fragment of the receptor, e.g., the ligand binding site. In either case, the compound can be rationally designed using known techniques. In one embodiment, screening for these compounds involves producing appropriate cells which express DME, either as a secreted

protein or on the cell membrane. Preferred cells include cells from mammals, yeast, Drosophila, or E. coli. Cells expressing DME or cell membrane fractions which contain DME are then contacted with a test compound and binding, stimulation, or inhibition of activity of either DME or the compound is analyzed.

5 An assay may simply test binding of a test compound to the polypeptide, wherein binding is detected by a fluorophore, radioisotope, enzyme conjugate, or other detectable label. For example, the assay may comprise the steps of combining at least one test compound with DME, either in solution or affixed to a solid support, and detecting the binding of DME to the compound.

10 Alternatively, the assay may detect or measure binding of a test compound in the presence of a labeled competitor. Additionally, the assay may be carried out using cell-free preparations, chemical libraries, or natural product mixtures, and the test compound(s) may be free in solution or affixed to a solid support.

15 DME of the present invention or fragments thereof may be used to screen for compounds that modulate the activity of DME. Such compounds may include agonists, antagonists, or partial or inverse agonists. In one embodiment, an assay is performed under conditions permissive for DME activity, wherein DME is combined with at least one test compound, and the activity of DME in the presence of a test compound is compared with the activity of DME in the absence of the test compound. A change in the activity of DME in the presence of the test compound is indicative of a compound that modulates the activity of DME. Alternatively, a test compound is combined with an in 20 vitro or cell-free system comprising DME under conditions suitable for DME activity, and the assay is performed. In either of these assays, a test compound which modulates the activity of DME may do so indirectly and need not come in direct contact with the test compound. At least one and up to a plurality of test compounds may be screened.

25 In another embodiment, polynucleotides encoding DME or their mammalian homologs may be "knocked out" in an animal model system using homologous recombination in embryonic stem (ES) cells. Such techniques are well known in the art and are useful for the generation of animal models of human disease. (See, e.g., U.S. Patent Number 5,175,383 and U.S. Patent Number 5,767,337.) For example, mouse ES cells, such as the mouse 129/SvJ cell line, are derived from the early mouse embryo and grown in culture. The ES cells are transformed with a vector containing the gene of 30 interest disrupted by a marker gene, e.g., the neomycin phosphotransferase gene (neo; Capecchi, M.R. (1989) Science 244:1288-1292). The vector integrates into the corresponding region of the host genome by homologous recombination. Alternatively, homologous recombination takes place using the Cre-loxP system to knockout a gene of interest in a tissue- or developmental stage-specific manner (Marth, J.D. (1996) Clin. Invest. 97:1999-2002; Wagner, K.U. et al. (1997) Nucleic Acids Res.

25:4323-4330). Transformed ES cells are identified and microinjected into mouse cell blastocysts such as those from the C57BL/6 mouse strain. The blastocysts are surgically transferred to pseudopregnant dams, and the resulting chimeric progeny are genotyped and bred to produce heterozygous or homozygous strains. Transgenic animals thus generated may be tested with potential 5 therapeutic or toxic agents.

Polynucleotides encoding DME may also be manipulated *in vitro* in ES cells derived from human blastocysts. Human ES cells have the potential to differentiate into at least eight separate cell lineages including endoderm, mesoderm, and ectodermal cell types. These cell lineages differentiate into, for example, neural cells, hematopoietic lineages, and cardiomyocytes (Thomson, J.A. et al. 10 (1998) *Science* 282:1145-1147).

Polynucleotides encoding DME can also be used to create "knockin" humanized animals (pigs) or transgenic animals (mice or rats) to model human disease. With knockin technology, a region of a polynucleotide encoding DME is injected into animal ES cells, and the injected sequence integrates into the animal cell genome. Transformed cells are injected into blastulae, and the blastulae are implanted 15 as described above. Transgenic progeny or inbred lines are studied and treated with potential pharmaceutical agents to obtain information on treatment of a human disease. Alternatively, a mammal inbred to overexpress DME, e.g., by secreting DME in its milk, may also serve as a convenient source of that protein (Janne, J. et al. (1998) *Biotechnol. Annu. Rev.* 4:55-74).

#### THERAPEUTICS

20 Chemical and structural similarity, e.g., in the context of sequences and motifs, exists between regions of DME and drug metabolizing enzymes. In addition, the expression of DME is closely associated with adrenal tumor, fetal brain, breast tumor, diseased endometrial tissues, and rapidly proliferating cells (e.g., cells associated with invasive tumors and IL-5-activated lymphocytes). Therefore, DME appears to play a role in autoimmune/inflammatory, cell proliferative, 25 developmental, endocrine, eye, metabolic, and gastrointestinal disorders, including liver disorders. In the treatment of disorders associated with increased DME expression or activity, it is desirable to decrease the expression or activity of DME. In the treatment of disorders associated with decreased DME expression or activity, it is desirable to increase the expression or activity of DME.

Therefore, in one embodiment, DME or a fragment or derivative thereof may be 30 administered to a subject to treat or prevent a disorder associated with decreased expression or activity of DME. Examples of such disorders include, but are not limited to, an autoimmune/inflammatory disorder, such as acquired immunodeficiency syndrome (AIDS), Addison's disease, adult respiratory distress syndrome, allergies, ankylosing spondylitis, amyloidosis, anemia, asthma, atherosclerosis, autoimmune hemolytic anemia, autoimmune

thyroiditis, autoimmune polyendocrinopathy-candidiasis-ectodermal dystrophy (APECED), bronchitis, cholecystitis, contact dermatitis, Crohn's disease, atopic dermatitis, dermatomyositis, diabetes mellitus, emphysema, episodic lymphopenia with lymphocytotoxins, erythroblastosis fetalis, erythema nodosum, atrophic gastritis, glomerulonephritis, Goodpasture's syndrome, gout, 5 Graves' disease, Hashimoto's thyroiditis, hypereosinophilia, irritable bowel syndrome, multiple sclerosis, myasthenia gravis, myocardial or pericardial inflammation, osteoarthritis, osteoporosis, pancreatitis, polymyositis, psoriasis, Reiter's syndrome, rheumatoid arthritis, scleroderma, Sjögren's syndrome, systemic anaphylaxis, systemic lupus erythematosus, systemic sclerosis, thrombocytopenic purpura, ulcerative colitis, uveitis, Werner syndrome, complications of cancer, 10 hemodialysis, and extracorporeal circulation, viral, bacterial, fungal, parasitic, protozoal, and helminthic infections, and trauma; a cell proliferative disorder, such as actinic keratosis, arteriosclerosis, atherosclerosis, bursitis, cirrhosis, hepatitis, mixed connective tissue disease (MCTD), myelofibrosis, paroxysmal nocturnal hemoglobinuria, polycythemia vera, psoriasis, 15 primary thrombocythemia, and cancers including adenocarcinoma, leukemia, lymphoma, melanoma, myeloma, sarcoma, teratocarcinoma, and, in particular, cancers of the adrenal gland, bladder, bone, bone marrow, brain, breast, cervix, gall bladder, ganglia, gastrointestinal tract, heart, kidney, liver, lung, muscle, ovary, pancreas, parathyroid, penis, prostate, salivary glands, skin, spleen, testis, thymus, thyroid, and uterus; a developmental disorder, such as renal tubular acidosis, anemia, Cushing's syndrome, achondroplastic dwarfism, Duchenne and Becker muscular dystrophy, 20 epilepsy, gonadal dysgenesis, WAGR syndrome (Wilms' tumor, aniridia, genitourinary abnormalities, and mental retardation), Smith-Magenis syndrome, myelodysplastic syndrome, hereditary mucoepithelial dysplasia, hereditary keratodermas, hereditary neuropathies such as Charcot-Marie-Tooth disease and neurofibromatosis, hypothyroidism, hydrocephalus, seizure disorders such as Sydenham's chorea and cerebral palsy, spina bifida, anencephaly, 25 craniorachischisis, congenital glaucoma, cataract, and sensorineural hearing loss; an endocrine disorder, such as disorders of the hypothalamus and pituitary resulting from lesions such as primary brain tumors, adenomas, infarction associated with pregnancy, hypophysectomy, aneurysms, vascular malformations, thrombosis, infections, immunological disorders, and complications due to head trauma; disorders associated with hypopituitarism including hypogonadism, Sheehan syndrome, 30 diabetes insipidus, Kallman's disease, Hand-Schuller-Christian disease, Letterer-Siwe disease, sarcoidosis, empty sella syndrome, and dwarfism; disorders associated with hyperpituitarism including acromegaly, gigantism, and syndrome of inappropriate antidiuretic hormone (ADH) secretion (SIADH) often caused by benign adenoma; disorders associated with hypothyroidism including goiter, myxedema, acute thyroiditis associated with bacterial infection, subacute thyroiditis 35 associated with viral infection, autoimmune thyroiditis (Hashimoto's disease), and cretinism;

disorders associated with hyperthyroidism including thyrotoxicosis and its various forms, Grave's disease, pretibial myxedema, toxic multinodular goiter, thyroid carcinoma, and Plummer's disease; disorders associated with hyperparathyroidism including Conn disease (chronic hypercalcemia); pancreatic disorders such as Type I or Type II diabetes mellitus and associated complications;

5 disorders associated with the adrenals such as hyperplasia, carcinoma, or adenoma of the adrenal cortex, hypertension associated with alkalosis, amyloidosis, hypokalemia, Cushing's disease, Liddle's syndrome, and Arnold-Healy-Gordon syndrome, pheochromocytoma tumors, and Addison's disease; disorders associated with gonadal steroid hormones such as: in women, abnormal prolactin production, infertility, endometriosis, perturbations of the menstrual cycle, polycystic ovarian

10 disease, hyperprolactinemia, isolated gonadotropin deficiency, amenorrhea, galactorrhea, hermaphroditism, hirsutism and virilization, breast cancer, and, in post-menopausal women, osteoporosis; and, in men, Leydig cell deficiency, male climacteric phase, and germinal cell aplasia, hypergonadal disorders associated with Leydig cell tumors, androgen resistance associated with absence of androgen receptors, syndrome of 5  $\alpha$ -reductase, and gynecomastia; an eye disorder, such

15 as conjunctivitis, keratoconjunctivitis sicca, keratitis, episcleritis, iritis, posterior uveitis, glaucoma, amaurosis fugax, ischemic optic neuropathy, optic neuritis, Leber's hereditary optic neuropathy, toxic optic neuropathy, vitreous detachment, retinal detachment, cataract, macular degeneration, central serous chorioretinopathy, retinitis pigmentosa, melanoma of the choroid, retrobulbar tumor, and chiasmal tumor; a metabolic disorder, such as Addison's disease, cerebrotendinous

20 xanthomatosis, congenital adrenal hyperplasia, coumarin resistance, cystic fibrosis, diabetes, fatty hepatocirrhosis, fructose-1,6-diphosphatase deficiency, galactosemia, goiter, glucagonoma, glycogen storage diseases, hereditary fructose intolerance, hyperadrenalinism, hypoadrenalinism, hyperparathyroidism, hypoparathyroidism, hypercholesterolemia, hyperthyroidism, hypoglycemia, hypothyroidism, hyperlipidemia, hyperlipemia, lipid myopathies, lipodystrophies, lysosomal storage

25 diseases, mannosidosis, neuraminidase deficiency, obesity, pentosuria phenylketonuria, pseudovitamin D-deficiency rickets; and a gastrointestinal disorder, such as dysphagia, peptic esophagitis, esophageal spasm, esophageal stricture, esophageal carcinoma, dyspepsia, indigestion, gastritis, gastric carcinoma, anorexia, nausea, emesis, gastroparesis, antral or pyloric edema, abdominal angina, pyrosis, gastroenteritis, intestinal obstruction, infections of the intestinal tract,

30 peptic ulcer, cholelithiasis, cholecystitis, cholestasis, pancreatitis, pancreatic carcinoma, biliary tract disease, hepatitis, hyperbilirubinemia, hereditary hyperbilirubinemia, cirrhosis, passive congestion of the liver, hepatoma, infectious colitis, ulcerative colitis, ulcerative proctitis, Crohn's disease, Whipple's disease, Mallory-Weiss syndrome, colonic carcinoma, colonic obstruction, irritable bowel syndrome, short bowel syndrome, diarrhea, constipation, gastrointestinal hemorrhage, acquired

35 immunodeficiency syndrome (AIDS) enteropathy, jaundice, hepatic encephalopathy, hepatorenal

syndrome, hepatic steatosis, hemochromatosis, Wilson's disease, alpha<sub>1</sub>-antitrypsin deficiency, Reye's syndrome, primary sclerosing cholangitis, liver infarction, portal vein obstruction and thrombosis, centrilobular necrosis, peliosis hepatis, hepatic vein thrombosis, veno-occlusive disease, preeclampsia, eclampsia, acute fatty liver of pregnancy, intrahepatic cholestasis of pregnancy, and 5 hepatic tumors including nodular hyperplasias, adenomas, and carcinomas.

In another embodiment, a vector capable of expressing DME or a fragment or derivative thereof may be administered to a subject to treat or prevent a disorder associated with decreased expression or activity of DME including, but not limited to, those described above.

10 In a further embodiment, a composition comprising a substantially purified DME in conjunction with a suitable pharmaceutical carrier may be administered to a subject to treat or prevent a disorder associated with decreased expression or activity of DME including, but not limited to, those provided above.

15 In still another embodiment, an agonist which modulates the activity of DME may be administered to a subject to treat or prevent a disorder associated with decreased expression or activity of DME including, but not limited to, those listed above.

20 In a further embodiment, an antagonist of DME may be administered to a subject to treat or prevent a disorder associated with increased expression or activity of DME. Examples of such disorders include, but are not limited to, those autoimmune/inflammatory, cell proliferative, developmental, endocrine, eye, metabolic, and gastrointestinal disorders, including liver disorders described above. In one aspect, an antibody which specifically binds DME may be used directly as an antagonist or indirectly as a targeting or delivery mechanism for bringing a pharmaceutical agent to 25 cells or tissues which express DME.

25 In an additional embodiment, a vector expressing the complement of the polynucleotide encoding DME may be administered to a subject to treat or prevent a disorder associated with increased expression or activity of DME including, but not limited to, those described above.

30 In other embodiments, any of the proteins, antagonists, antibodies, agonists, complementary sequences, or vectors of the invention may be administered in combination with other appropriate therapeutic agents. Selection of the appropriate agents for use in combination therapy may be made by one of ordinary skill in the art, according to conventional pharmaceutical principles. The combination of therapeutic agents may act synergistically to effect the treatment or prevention of the various disorders described above. Using this approach, one may be able to achieve therapeutic efficacy with lower dosages of each agent, thus reducing the potential for adverse side effects.

An antagonist of DME may be produced using methods which are generally known in the art. In particular, purified DME may be used to produce antibodies or to screen libraries of pharmaceutical

agents to identify those which specifically bind DME. Antibodies to DME may also be generated using methods that are well known in the art. Such antibodies may include, but are not limited to, polyclonal, monoclonal, chimeric, and single chain antibodies, Fab fragments, and fragments produced by a Fab expression library. Neutralizing antibodies (i.e., those which inhibit dimer formation) are 5 generally preferred for therapeutic use.

For the production of antibodies, various hosts including goats, rabbits, rats, mice, humans, and others may be immunized by injection with DME or with any fragment or oligopeptide thereof which has immunogenic properties. Depending on the host species, various adjuvants may be used to increase immunological response. Such adjuvants include, but are not limited to, Freund's, mineral 10 gels such as aluminum hydroxide, and surface active substances such as lysolecithin, pluronic polyols, polyanions, peptides, oil emulsions, KLH, and dinitrophenol. Among adjuvants used in humans, BCG (bacilli Calmette-Guerin) and Corynebacterium parvum are especially preferable.

It is preferred that the oligopeptides, peptides, or fragments used to induce antibodies to DME have an amino acid sequence consisting of at least about 5 amino acids, and generally will consist of at 15 least about 10 amino acids. It is also preferable that these oligopeptides, peptides, or fragments are identical to a portion of the amino acid sequence of the natural protein. Short stretches of DME amino acids may be fused with those of another protein, such as KLH, and antibodies to the chimeric molecule may be produced.

Monoclonal antibodies to DME may be prepared using any technique which provides for the 20 production of antibody molecules by continuous cell lines in culture. These include, but are not limited to, the hybridoma technique, the human B-cell hybridoma technique, and the EBV-hybridoma technique. (See, e.g., Kohler, G. et al. (1975) *Nature* 256:495-497; Kozbor, D. et al. (1985) *J. Immunol. Methods* 81:31-42; Cote, R.J. et al. (1983) *Proc. Natl. Acad. Sci. USA* 80:2026-2030; and Cole, S.P. et al. (1984) *Mol. Cell Biol.* 62:109-120.)

In addition, techniques developed for the production of "chimeric antibodies," such as the 25 splicing of mouse antibody genes to human antibody genes to obtain a molecule with appropriate antigen specificity and biological activity, can be used. (See, e.g., Morrison, S.L. et al. (1984) *Proc. Natl. Acad. Sci. USA* 81:6851-6855; Neuberger, M.S. et al. (1984) *Nature* 312:604-608; and Takeda, S. et al. (1985) *Nature* 314:452-454.) Alternatively, techniques described for the production of single 30 chain antibodies may be adapted, using methods known in the art, to produce DME-specific single chain antibodies. Antibodies with related specificity, but of distinct idiotypic composition, may be generated by chain shuffling from random combinatorial immunoglobulin libraries. (See, e.g., Burton, D.R. (1991) *Proc. Natl. Acad. Sci. USA* 88:10134-10137.)

Antibodies may also be produced by inducing in vivo production in the lymphocyte population

or by screening immunoglobulin libraries or panels of highly specific binding reagents as disclosed in the literature. (See, e.g., Orlandi, R. et al. (1989) Proc. Natl. Acad. Sci. USA 86:3833-3837; Winter, G. et al. (1991) Nature 349:293-299.)

5 Antibody fragments which contain specific binding sites for DME may also be generated. For example, such fragments include, but are not limited to,  $F(ab')_2$  fragments produced by pepsin digestion of the antibody molecule and Fab fragments generated by reducing the disulfide bridges of the  $F(ab')_2$  fragments. Alternatively, Fab expression libraries may be constructed to allow rapid and easy identification of monoclonal Fab fragments with the desired specificity. (See, e.g., Huse, W.D. et al. (1989) Science 246:1275-1281.)

10 Various immunoassays may be used for screening to identify antibodies having the desired specificity. Numerous protocols for competitive binding or immunoradiometric assays using either polyclonal or monoclonal antibodies with established specificities are well known in the art. Such immunoassays typically involve the measurement of complex formation between DME and its specific antibody. A two-site, monoclonal-based immunoassay utilizing monoclonal antibodies reactive to two 15 non-interfering DME epitopes is generally used, but a competitive binding assay may also be employed (Pound, supra).

20 Various methods such as Scatchard analysis in conjunction with radioimmunoassay techniques may be used to assess the affinity of antibodies for DME. Affinity is expressed as an association constant,  $K_a$ , which is defined as the molar concentration of DME-antibody complex divided by the molar concentrations of free antigen and free antibody under equilibrium conditions. The  $K_a$  determined for a preparation of polyclonal antibodies, which are heterogeneous in their affinities for 25 multiple DME epitopes, represents the average affinity, or avidity, of the antibodies for DME. The  $K_a$  determined for a preparation of monoclonal antibodies, which are monospecific for a particular DME epitope, represents a true measure of affinity. High-affinity antibody preparations with  $K_a$  ranging from about  $10^9$  to  $10^{12}$  L/mole are preferred for use in immunoassays in which the DME-antibody complex must withstand rigorous manipulations. Low-affinity antibody preparations with  $K_a$  ranging from about  $10^6$  to  $10^7$  L/mole are preferred for use in immunopurification and similar procedures which ultimately require dissociation of DME, preferably in active form, from the antibody (Catty, D. (1988) Antibodies, Volume I: A Practical Approach, IRL Press, Washington DC; Liddell, J.E. and A. 30 Cryer (1991) A Practical Guide to Monoclonal Antibodies, John Wiley & Sons, New York NY).

The titer and avidity of polyclonal antibody preparations may be further evaluated to determine the quality and suitability of such preparations for certain downstream applications. For example, a polyclonal antibody preparation containing at least 1-2 mg specific antibody/ml, preferably 5-10 mg specific antibody/ml, is generally employed in procedures requiring precipitation of DME-

antibody complexes. Procedures for evaluating antibody specificity, titer, and avidity, and guidelines for antibody quality and usage in various applications, are generally available. (See, e.g., Catty, supra, and Coligan et al. supra.)

5 In another embodiment of the invention, the polynucleotides encoding DME, or any fragment or complement thereof, may be used for therapeutic purposes. In one aspect, modifications of gene expression can be achieved by designing complementary sequences or antisense molecules (DNA, RNA, PNA, or modified oligonucleotides) to the coding or regulatory regions of the gene encoding DME. Such technology is well known in the art, and antisense oligonucleotides or larger fragments can be designed from various locations along the coding or control regions of sequences encoding 10 DME. (See, e.g., Agrawal, S., ed. (1996) Antisense Therapeutics, Humana Press Inc., Totowa NJ.)

In therapeutic use, any gene delivery system suitable for introduction of the antisense sequences into appropriate target cells can be used. Antisense sequences can be delivered 15 intracellularly in the form of an expression plasmid which, upon transcription, produces a sequence complementary to at least a portion of the cellular sequence encoding the target protein. (See, e.g., Slater, J.E. et al. (1998) *J. Allergy Clin. Immunol.* 102(3):469-475; and Scanlon, K.J. et al. (1995) 9(13):1288-1296.) Antisense sequences can also be introduced intracellularly through the use of viral vectors, such as retrovirus and adeno-associated virus vectors. (See, e.g., Miller, A.D. (1990) *Blood* 76:271; Ausubel, supra; Uckert, W. and W. Walther (1994) *Pharmacol. Ther.* 63(3):323-347.) Other gene delivery mechanisms include liposome-derived systems, artificial viral envelopes, and 20 other systems known in the art. (See, e.g., Rossi, J.J. (1995) *Br. Med. Bull.* 51(1):217-225; Boado, R.J. et al. (1998) *J. Pharm. Sci.* 87(11):1308-1315; and Morris, M.C. et al. (1997) *Nucleic Acids Res.* 25(14):2730-2736.)

In another embodiment of the invention, polynucleotides encoding DME may be used for 25 somatic or germline gene therapy. Gene therapy may be performed to (i) correct a genetic deficiency (e.g., in the cases of severe combined immunodeficiency (SCID)-X1 disease characterized by X-linked inheritance (Cavazzana-Calvo, M. et al. (2000) *Science* 288:669-672), severe combined immunodeficiency syndrome associated with an inherited adenosine deaminase (ADA) deficiency (Blaese, R.M. et al. (1995) *Science* 270:475-480; Bordignon, C. et al. (1995) *Science* 270:470-475), cystic fibrosis (Zabner, J. et al. (1993) *Cell* 75:207-216; Crystal, R.G. et al. (1995) *Hum. Gene Therapy* 6:643-666; Crystal, R.G. et al. (1995) *Hum. Gene Therapy* 6:667-703), thalassamias, 30 familial hypercholesterolemia, and hemophilia resulting from Factor VIII or Factor IX deficiencies (Crystal, R.G. (1995) *Science* 270:404-410; Verma, I.M. and N. Somia (1997) *Nature* 389:239-242)), (ii) express a conditionally lethal gene product (e.g., in the case of cancers which result from unregulated cell proliferation), or (iii) express a protein which affords protection against intracellular

parasites (e.g., against human retroviruses, such as human immunodeficiency virus (HIV) (Baltimore, D. (1988) *Nature* 335:395-396; Poeschla, E. et al. (1996) *Proc. Natl. Acad. Sci. USA* 93:11395-11399), hepatitis B or C virus (HBV, HCV); fungal parasites, such as Candida albicans and Paracoccidioides brasiliensis; and protozoan parasites such as Plasmodium falciparum and Trypanosoma cruzi). In the case where a genetic deficiency in DME expression or regulation causes disease, the expression of DME from an appropriate population of transduced cells may alleviate the clinical manifestations caused by the genetic deficiency.

In a further embodiment of the invention, diseases or disorders caused by deficiencies in DME are treated by constructing mammalian expression vectors encoding DME and introducing these vectors by mechanical means into DME-deficient cells. Mechanical transfer technologies for use with cells in vivo or ex vitro include (i) direct DNA microinjection into individual cells, (ii) ballistic gold particle delivery, (iii) liposome-mediated transfection, (iv) receptor-mediated gene transfer, and (v) the use of DNA transposons (Morgan, R.A. and W.F. Anderson (1993) *Annu. Rev. Biochem.* 62:191-217; Ivics, Z. (1997) *Cell* 91:501-510; Boulay, J-L. and H. Récipon (1998) *Curr. Opin. Biotechnol.* 9:445-450).

Expression vectors that may be effective for the expression of DME include, but are not limited to, the PCDNA 3.1, EPITAG, PRCCMV2, PREP, PVAX vectors (Invitrogen, Carlsbad CA), PCMV-SCRIPT, PCMV-TAG, PEGSH/PERV (Stratagene, La Jolla CA), and PTET-OFF, PTET-ON, PTRE2, PTRE2-LUC, PTK-HYG (Clontech, Palo Alto CA). DME may be expressed using (i) a constitutively active promoter, (e.g., from cytomegalovirus (CMV), Rous sarcoma virus (RSV), SV40 virus, thymidine kinase (TK), or  $\beta$ -actin genes), (ii) an inducible promoter (e.g., the tetracycline-regulated promoter (Gossen, M. and H. Bujard (1992) *Proc. Natl. Acad. Sci. USA* 89:5547-5551; Gossen, M. et al. (1995) *Science* 268:1766-1769; Rossi, F.M.V. and H.M. Blau (1998) *Curr. Opin. Biotechnol.* 9:451-456), commercially available in the T-REX plasmid (Invitrogen); the ecdysone-inducible promoter (available in the plasmids PVGRXR and PIND; Invitrogen); the FK506/rapamycin inducible promoter; or the RU486/mifepristone inducible promoter (Rossi, F.M.V. and Blau, H.M. supra), or (iii) a tissue-specific promoter or the native promoter of the endogenous gene encoding DME from a normal individual.

Commercially available liposome transformation kits (e.g., the PERFECT LIPID TRANSFECTION KIT, available from Invitrogen) allow one with ordinary skill in the art to deliver polynucleotides to target cells in culture and require minimal effort to optimize experimental parameters. In the alternative, transformation is performed using the calcium phosphate method (Graham, F.L. and A.J. Eb (1973) *Virology* 52:456-467), or by electroporation (Neumann, E. et al. (1982) *EMBO J.* 1:841-845). The introduction of DNA to primary cells requires modification of these

standardized mammalian transfection protocols.

In another embodiment of the invention, diseases or disorders caused by genetic defects with respect to DME expression are treated by constructing a retrovirus vector consisting of (i) the polynucleotide encoding DME under the control of an independent promoter or the retrovirus long terminal repeat (LTR) promoter, (ii) appropriate RNA packaging signals, and (iii) a Rev-responsive element (RRE) along with additional retrovirus *cis*-acting RNA sequences and coding sequences required for efficient vector propagation. Retrovirus vectors (e.g., PFB and PFBNEO) are commercially available (Stratagene) and are based on published data (Riviere, I. et al. (1995) Proc. Natl. Acad. Sci. USA 92:6733-6737), incorporated by reference herein. The vector is propagated in an appropriate vector producing cell line (VPCL) that expresses an envelope gene with a tropism for receptors on the target cells or a promiscuous envelope protein such as VSVg (Armentano, D. et al. (1987) J. Virol. 61:1647-1650; Bender, M.A. et al. (1987) J. Virol. 61:1639-1646; Adam, M.A. and A.D. Miller (1988) J. Virol. 62:3802-3806; Dull, T. et al. (1998) J. Virol. 72:8463-8471; Zufferey, R. et al. (1998) J. Virol. 72:9873-9880). U.S. Patent Number 5,910,434 to Rigg ("Method for obtaining retrovirus packaging cell lines producing high transducing efficiency retroviral supernatant") discloses a method for obtaining retrovirus packaging cell lines and is hereby incorporated by reference. Propagation of retrovirus vectors, transduction of a population of cells (e.g., CD4<sup>+</sup> T-cells), and the return of transduced cells to a patient are procedures well known to persons skilled in the art of gene therapy and have been well documented (Ranga, U. et al. (1997) J. Virol. 71:7020-7029; Bauer, G. et al. (1997) Blood 89:2259-2267; Bonyhadi, M.L. (1997) J. Virol. 71:4707-4716; Ranga, U. et al. (1998) Proc. Natl. Acad. Sci. USA 95:1201-1206; Su, L. (1997) Blood 89:2283-2290).

In the alternative, an adenovirus-based gene therapy delivery system is used to deliver polynucleotides encoding DME to cells which have one or more genetic abnormalities with respect to the expression of DME. The construction and packaging of adenovirus-based vectors are well known to those with ordinary skill in the art. Replication defective adenovirus vectors have proven to be versatile for importing genes encoding immunoregulatory proteins into intact islets in the pancreas (Csete, M.E. et al. (1995) Transplantation 27:263-268). Potentially useful adenoviral vectors are described in U.S. Patent Number 5,707,618 to Armentano ("Adenovirus vectors for gene therapy"), hereby incorporated by reference. For adenoviral vectors, see also Antinozzi, P.A. et al. (1999) Annu. Rev. Nutr. 19:511-544 and Verma, I.M. and N. Somia (1997) Nature 18:389:239-242, both incorporated by reference herein.

In another alternative, a herpes-based, gene therapy delivery system is used to deliver polynucleotides encoding DME to target cells which have one or more genetic abnormalities with respect to the expression of DME. The use of herpes simplex virus (HSV)-based vectors may be

especially valuable for introducing DME to cells of the central nervous system, for which HSV has a tropism. The construction and packaging of herpes-based vectors are well known to those with ordinary skill in the art. A replication-competent herpes simplex virus (HSV) type 1-based vector has been used to deliver a reporter gene to the eyes of primates (Liu, X. et al. (1999) *Exp. Eye Res.* 169:385-395). The construction of a HSV-1 virus vector has also been disclosed in detail in U.S. Patent Number 5,804,413 to DeLuca ("Herpes simplex virus strains for gene transfer"), which is hereby incorporated by reference. U.S. Patent Number 5,804,413 teaches the use of recombinant HSV d92 which consists of a genome containing at least one exogenous gene to be transferred to a cell under the control of the appropriate promoter for purposes including human gene therapy. Also taught by this patent are the construction and use of recombinant HSV strains deleted for ICP4, ICP27 and ICP22. For HSV vectors, see also Goins, W.F. et al. (1999) *J. Virol.* 73:519-532 and Xu, H. et al. (1994) *Dev. Biol.* 163:152-161, hereby incorporated by reference. The manipulation of cloned herpesvirus sequences, the generation of recombinant virus following the transfection of multiple plasmids containing different segments of the large herpesvirus genomes, the growth and propagation of herpesvirus, and the infection of cells with herpesvirus are techniques well known to those of ordinary skill in the art.

In another alternative, an alphavirus (positive, single-stranded RNA virus) vector is used to deliver polynucleotides encoding DME to target cells. The biology of the prototypic alphavirus, Semliki Forest Virus (SFV), has been studied extensively and gene transfer vectors have been based on the SFV genome (Garoff, H. and K.-J. Li (1998) *Curr. Opin. Biotechnol.* 9:464-469). During alphavirus RNA replication, a subgenomic RNA is generated that normally encodes the viral capsid proteins. This subgenomic RNA replicates to higher levels than the full length genomic RNA, resulting in the overproduction of capsid proteins relative to the viral proteins with enzymatic activity (e.g., protease and polymerase). Similarly, inserting the coding sequence for DME into the alphavirus genome in place of the capsid-coding region results in the production of a large number of DME-coding RNAs and the synthesis of high levels of DME in vector transduced cells. While alphavirus infection is typically associated with cell lysis within a few days, the ability to establish a persistent infection in hamster normal kidney cells (BHK-21) with a variant of Sindbis virus (SIN) indicates that the lytic replication of alphaviruses can be altered to suit the needs of the gene therapy application (Dryga, S.A. et al. (1997) *Virology* 228:74-83). The wide host range of alphaviruses will allow the introduction of DME into a variety of cell types. The specific transduction of a subset of cells in a population may require the sorting of cells prior to transduction. The methods of manipulating infectious cDNA clones of alphaviruses, performing alphavirus cDNA and RNA transfections, and performing alphavirus infections, are well known to those with ordinary skill in the art.

Oligonucleotides derived from the transcription initiation site, e.g., between about positions -10 and +10 from the start site, may also be employed to inhibit gene expression. Similarly, inhibition can be achieved using triple helix base-pairing methodology. Triple helix pairing is useful because it causes inhibition of the ability of the double helix to open sufficiently for the binding of polymerases, transcription factors, or regulatory molecules. Recent therapeutic advances using triplex DNA have been described in the literature. (See, e.g., Gee, J.E. et al. (1994) in Huber, B.E. and B.I. Carr, Molecular and Immunologic Approaches, Futura Publishing, Mt. Kisco NY, pp. 163-177.) A complementary sequence or antisense molecule may also be designed to block translation of mRNA by preventing the transcript from binding to ribosomes.

10 Ribozymes, enzymatic RNA molecules, may also be used to catalyze the specific cleavage of RNA. The mechanism of ribozyme action involves sequence-specific hybridization of the ribozyme molecule to complementary target RNA, followed by endonucleolytic cleavage. For example, engineered hammerhead motif ribozyme molecules may specifically and efficiently catalyze endonucleolytic cleavage of sequences encoding DME.

15 Specific ribozyme cleavage sites within any potential RNA target are initially identified by scanning the target molecule for ribozyme cleavage sites, including the following sequences: GUA, GUU, and GUC. Once identified, short RNA sequences of between 15 and 20 ribonucleotides, corresponding to the region of the target gene containing the cleavage site, may be evaluated for secondary structural features which may render the oligonucleotide inoperable. The suitability of 20 candidate targets may also be evaluated by testing accessibility to hybridization with complementary oligonucleotides using ribonuclease protection assays.

Complementary ribonucleic acid molecules and ribozymes of the invention may be prepared by any method known in the art for the synthesis of nucleic acid molecules. These include techniques for chemically synthesizing oligonucleotides such as solid phase phosphoramidite chemical synthesis. 25 Alternatively, RNA molecules may be generated by in vitro and in vivo transcription of DNA sequences encoding DME. Such DNA sequences may be incorporated into a wide variety of vectors with suitable RNA polymerase promoters such as T7 or SP6. Alternatively, these cDNA constructs that synthesize complementary RNA, constitutively or inducibly, can be introduced into cell lines, cells, or tissues.

30 RNA molecules may be modified to increase intracellular stability and half-life. Possible modifications include, but are not limited to, the addition of flanking sequences at the 5' and/or 3' ends of the molecule, or the use of phosphorothioate or 2' O-methyl rather than phosphodiester linkages within the backbone of the molecule. This concept is inherent in the production of PNAs and can be extended in all of these molecules by the inclusion of nontraditional bases such as inosine, queosine,

and wybutosine, as well as acetyl-, methyl-, thio-, and similarly modified forms of adenine, cytidine, guanine, thymine, and uridine which are not as easily recognized by endogenous endonucleases.

An additional embodiment of the invention encompasses a method for screening for a compound which is effective in altering expression of a polynucleotide encoding DME. Compounds which may be effective in altering expression of a specific polynucleotide may include, but are not limited to, oligonucleotides, antisense oligonucleotides, triple helix-forming oligonucleotides, transcription factors and other polypeptide transcriptional regulators, and non-macromolecular chemical entities which are capable of interacting with specific polynucleotide sequences. Effective compounds may alter polynucleotide expression by acting as either inhibitors or promoters of polynucleotide expression. Thus, in the treatment of disorders associated with increased DME expression or activity, a compound which specifically inhibits expression of the polynucleotide encoding DME may be therapeutically useful, and in the treatment of disorders associated with decreased DME expression or activity, a compound which specifically promotes expression of the polynucleotide encoding DME may be therapeutically useful.

At least one, and up to a plurality, of test compounds may be screened for effectiveness in altering expression of a specific polynucleotide. A test compound may be obtained by any method commonly known in the art, including chemical modification of a compound known to be effective in altering polynucleotide expression; selection from an existing, commercially-available or proprietary library of naturally-occurring or non-natural chemical compounds; rational design of a compound based on chemical and/or structural properties of the target polynucleotide; and selection from a library of chemical compounds created combinatorially or randomly. A sample comprising a polynucleotide encoding DME is exposed to at least one test compound thus obtained. The sample may comprise, for example, an intact or permeabilized cell, or an *in vitro* cell-free or reconstituted biochemical system. Alterations in the expression of a polynucleotide encoding DME are assayed by any method commonly known in the art. Typically, the expression of a specific nucleotide is detected by hybridization with a probe having a nucleotide sequence complementary to the sequence of the polynucleotide encoding DME. The amount of hybridization may be quantified, thus forming the basis for a comparison of the expression of the polynucleotide both with and without exposure to one or more test compounds. Detection of a change in the expression of a polynucleotide exposed to a test compound indicates that the test compound is effective in altering the expression of the polynucleotide. A screen for a compound effective in altering expression of a specific polynucleotide can be carried out, for example, using a *Schizosaccharomyces pombe* gene expression system (Atkins, D. et al. (1999) U.S. Patent No. 5,932,435; Arndt, G.M. et al. (2000) Nucleic Acids Res. 28:E15) or a human cell line such as HeLa cell (Clarke, M.L. et al. (2000) Biochem. Biophys. Res. Commun. 268:8-13). A particular embodiment of the present invention involves screening a

combinatorial library of oligonucleotides (such as deoxyribonucleotides, ribonucleotides, peptide nucleic acids, and modified oligonucleotides) for antisense activity against a specific polynucleotide sequence (Bruice, T.W. et al. (1997) U.S. Patent No. 5,686,242; Bruice, T.W. et al. (2000) U.S. Patent No. 6,022,691).

5 Many methods for introducing vectors into cells or tissues are available and equally suitable for use in vivo, in vitro, and ex vivo. For ex vivo therapy, vectors may be introduced into stem cells taken from the patient and clonally propagated for autologous transplant back into that same patient. Delivery by transfection, by liposome injections, or by polycationic amino polymers may be achieved using methods which are well known in the art. (See, e.g., Goldman, C.K. et al. (1997) *Nat. Biotechnol.* 15:462-466.)

10 Any of the therapeutic methods described above may be applied to any subject in need of such therapy, including, for example, mammals such as humans, dogs, cats, cows, horses, rabbits, and monkeys.

15 An additional embodiment of the invention relates to the administration of a composition which generally comprises an active ingredient formulated with a pharmaceutically acceptable excipient. Excipients may include, for example, sugars, starches, celluloses, gums, and proteins. Various formulations are commonly known and are thoroughly discussed in the latest edition of Remington's Pharmaceutical Sciences (Maack Publishing, Easton PA). Such compositions may consist of DME, antibodies to DME, and mimetics, agonists, antagonists, or inhibitors of DME.

20 The compositions utilized in this invention may be administered by any number of routes including, but not limited to, oral, intravenous, intramuscular, intra-arterial, intramedullary, intrathecal, intraventricular, pulmonary, transdermal, subcutaneous, intraperitoneal, intranasal, enteral, topical, sublingual, or rectal means.

25 Compositions for pulmonary administration may be prepared in liquid or dry powder form. These compositions are generally aerosolized immediately prior to inhalation by the patient. In the case of small molecules (e.g. traditional low molecular weight organic drugs), aerosol delivery of fast-acting formulations is well-known in the art. In the case of macromolecules (e.g. larger peptides and proteins), recent developments in the field of pulmonary delivery via the alveolar region of the lung have enabled the practical delivery of drugs such as insulin to blood circulation (see, e.g., Patton, J.S. et al., U.S. Patent No. 5,997,848). Pulmonary delivery has the advantage of administration without needle injection, and obviates the need for potentially toxic penetration enhancers.

30 Compositions suitable for use in the invention include compositions wherein the active ingredients are contained in an effective amount to achieve the intended purpose. The determination of an effective dose is well within the capability of those skilled in the art.

Specialized forms of compositions may be prepared for direct intracellular delivery of macromolecules comprising DME or fragments thereof. For example, liposome preparations containing a cell-impermeable macromolecule may promote cell fusion and intracellular delivery of the macromolecule. Alternatively, DME or a fragment thereof may be joined to a short cationic N-terminal portion from the HIV Tat-1 protein. Fusion proteins thus generated have been found to transduce into the cells of all tissues, including the brain, in a mouse model system (Schwarze, S.R. et al. (1999) *Science* 285:1569-1572).

For any compound, the therapeutically effective dose can be estimated initially either in cell culture assays, e.g., of neoplastic cells, or in animal models such as mice, rats, rabbits, dogs, monkeys, 10 or pigs. An animal model may also be used to determine the appropriate concentration range and route of administration. Such information can then be used to determine useful doses and routes for administration in humans.

A therapeutically effective dose refers to that amount of active ingredient, for example DME or fragments thereof, antibodies of DME, and agonists, antagonists or inhibitors of DME, which 15 ameliorates the symptoms or condition. Therapeutic efficacy and toxicity may be determined by standard pharmaceutical procedures in cell cultures or with experimental animals, such as by calculating the ED<sub>50</sub> (the dose therapeutically effective in 50% of the population) or LD<sub>50</sub> (the dose lethal to 50% of the population) statistics. The dose ratio of toxic to therapeutic effects is the therapeutic index, which can be expressed as the LD<sub>50</sub>/ED<sub>50</sub> ratio. Compositions which exhibit large 20 therapeutic indices are preferred. The data obtained from cell culture assays and animal studies are used to formulate a range of dosage for human use. The dosage contained in such compositions is preferably within a range of circulating concentrations that includes the ED<sub>50</sub> with little or no toxicity. The dosage varies within this range depending upon the dosage form employed, the sensitivity of the patient, and the route of administration.

25 The exact dosage will be determined by the practitioner, in light of factors related to the subject requiring treatment. Dosage and administration are adjusted to provide sufficient levels of the active moiety or to maintain the desired effect. Factors which may be taken into account include the severity of the disease state, the general health of the subject, the age, weight, and gender of the subject, time and frequency of administration, drug combination(s), reaction sensitivities, and response 30 to therapy. Long-acting compositions may be administered every 3 to 4 days, every week, or biweekly depending on the half-life and clearance rate of the particular formulation.

Normal dosage amounts may vary from about 0.1  $\mu$ g to 100,000  $\mu$ g, up to a total dose of about 1 gram, depending upon the route of administration. Guidance as to particular dosages and methods of delivery is provided in the literature and generally available to practitioners in the art.

Those skilled in the art will employ different formulations for nucleotides than for proteins or their inhibitors. Similarly, delivery of polynucleotides or polypeptides will be specific to particular cells, conditions, locations, etc.

## DIAGNOSTICS

5 In another embodiment, antibodies which specifically bind DME may be used for the diagnosis of disorders characterized by expression of DME, or in assays to monitor patients being treated with DME or agonists, antagonists, or inhibitors of DME. Antibodies useful for diagnostic purposes may be prepared in the same manner as described above for therapeutics. Diagnostic assays for DME include methods which utilize the antibody and a label to detect DME in human body fluids or in  
10 extracts of cells or tissues. The antibodies may be used with or without modification, and may be labeled by covalent or non-covalent attachment of a reporter molecule. A wide variety of reporter molecules, several of which are described above, are known in the art and may be used.

15 A variety of protocols for measuring DME, including ELISAs, RIAs, and FACS, are known in the art and provide a basis for diagnosing altered or abnormal levels of DME expression. Normal or standard values for DME expression are established by combining body fluids or cell extracts taken from normal mammalian subjects, for example, human subjects, with antibodies to DME under  
20 conditions suitable for complex formation. The amount of standard complex formation may be quantitated by various methods, such as photometric means. Quantities of DME expressed in subject, control, and disease samples from biopsied tissues are compared with the standard values. Deviation between standard and subject values establishes the parameters for diagnosing disease.

25 In another embodiment of the invention, the polynucleotides encoding DME may be used for diagnostic purposes. The polynucleotides which may be used include oligonucleotide sequences, complementary RNA and DNA molecules, and PNAs. The polynucleotides may be used to detect and quantify gene expression in biopsied tissues in which expression of DME may be correlated with disease. The diagnostic assay may be used to determine absence, presence, and excess expression of DME, and to monitor regulation of DME levels during therapeutic intervention.

30 In one aspect, hybridization with PCR probes which are capable of detecting polynucleotide sequences, including genomic sequences, encoding DME or closely related molecules may be used to identify nucleic acid sequences which encode DME. The specificity of the probe, whether it is made from a highly specific region, e.g., the 5' regulatory region, or from a less specific region, e.g., a conserved motif, and the stringency of the hybridization or amplification will determine whether the probe identifies only naturally occurring sequences encoding DME, allelic variants, or related sequences.

Probes may also be used for the detection of related sequences, and may have at least 50%

sequence identity to any of the DME encoding sequences. The hybridization probes of the subject invention may be DNA or RNA and may be derived from the sequence of SEQ ID NO:19-36 or from genomic sequences including promoters, enhancers, and introns of the DME gene.

Means for producing specific hybridization probes for DNAs encoding DME include the cloning of polynucleotide sequences encoding DME or DME derivatives into vectors for the production of mRNA probes. Such vectors are known in the art, are commercially available, and may be used to synthesize RNA probes *in vitro* by means of the addition of the appropriate RNA polymerases and the appropriate labeled nucleotides. Hybridization probes may be labeled by a variety of reporter groups, for example, by radionuclides such as  $^{32}\text{P}$  or  $^{35}\text{S}$ , or by enzymatic labels, such as alkaline phosphatase coupled to the probe via avidin/biotin coupling systems, and the like.

10 Polynucleotide sequences encoding DME may be used for the diagnosis of disorders associated with expression of DME. Examples of such disorders include, but are not limited to, an autoimmune/inflammatory disorder, such as acquired immunodeficiency syndrome (AIDS), Addison's disease, adult respiratory distress syndrome, allergies, ankylosing spondylitis, 15 amyloidosis, anemia, asthma, atherosclerosis, autoimmune hemolytic anemia, autoimmune thyroiditis, autoimmune polyendocrinopathy-candidiasis-ectodermal dystrophy (APECED), bronchitis, cholecystitis, contact dermatitis, Crohn's disease, atopic dermatitis, dermatomyositis, diabetes mellitus, emphysema, episodic lymphopenia with lymphocytotoxins, erythroblastosis fetalis, erythema nodosum, atrophic gastritis, glomerulonephritis, Goodpasture's syndrome, gout, 20 Graves' disease, Hashimoto's thyroiditis, hypereosinophilia, irritable bowel syndrome, multiple sclerosis, myasthenia gravis, myocardial or pericardial inflammation, osteoarthritis, osteoporosis, pancreatitis, polymyositis, psoriasis, Reiter's syndrome, rheumatoid arthritis, scleroderma, Sjögren's syndrome, systemic anaphylaxis, systemic lupus erythematosus, systemic sclerosis, 25 thrombocytopenic purpura, ulcerative colitis, uveitis, Werner syndrome, complications of cancer, hemodialysis, and extracorporeal circulation, viral, bacterial, fungal, parasitic, protozoal, and helminthic infections, and trauma; a cell proliferative disorder, such as actinic keratosis, arteriosclerosis, atherosclerosis, bursitis, cirrhosis, hepatitis, mixed connective tissue disease (MCTD), myelofibrosis, paroxysmal nocturnal hemoglobinuria, polycythemia vera, psoriasis, 30 primary thrombocythemia, and cancers including adenocarcinoma, leukemia, lymphoma, melanoma, myeloma, sarcoma, teratocarcinoma, and, in particular, cancers of the adrenal gland, bladder, bone, bone marrow, brain, breast, cervix, gall bladder, ganglia, gastrointestinal tract, heart, kidney, liver, lung, muscle, ovary, pancreas, parathyroid, penis, prostate, salivary glands, skin, spleen, testis, thymus, thyroid, and uterus; a developmental disorder, such as renal tubular acidosis, anemia, Cushing's syndrome, achondroplastic dwarfism, Duchenne and Becker muscular dystrophy,

epilepsy, gonadal dysgenesis, WAGR syndrome (Wilms' tumor, aniridia, genitourinary abnormalities, and mental retardation), Smith-Magenis syndrome, myelodysplastic syndrome, hereditary mucoepithelial dysplasia, hereditary keratodermas, hereditary neuropathies such as Charcot-Marie-Tooth disease and neurofibromatosis, hypothyroidism, hydrocephalus, seizure disorders such as Sydenham's chorea and cerebral palsy, spina bifida, anencephaly, 5 craniorachischisis, congenital glaucoma, cataract, and sensorineural hearing loss; an endocrine disorder, such as disorders of the hypothalamus and pituitary resulting from lesions such as primary brain tumors, adenomas, infarction associated with pregnancy, hypophysectomy, aneurysms, vascular malformations, thrombosis, infections, immunological disorders, and complications due to 10 head trauma; disorders associated with hypopituitarism including hypogonadism, Sheehan syndrome, diabetes insipidus, Kallman's disease, Hand-Schuller-Christian disease, Letterer-Siwe disease, sarcoidosis, empty sella syndrome, and dwarfism; disorders associated with hyperpituitarism including acromegaly, giantism, and syndrome of inappropriate antidiuretic hormone (ADH) secretion (SIADH) often caused by benign adenoma; disorders associated with hypothyroidism 15 including goiter, myxedema, acute thyroiditis associated with bacterial infection, subacute thyroiditis associated with viral infection, autoimmune thyroiditis (Hashimoto's disease), and cretinism; disorders associated with hyperthyroidism including thyrotoxicosis and its various forms, Grave's disease, pretibial myxedema, toxic multinodular goiter, thyroid carcinoma, and Plummer's disease; disorders associated with hyperparathyroidism including Conn disease (chronic hypercalcemia); 20 pancreatic disorders such as Type I or Type II diabetes mellitus and associated complications; disorders associated with the adrenals such as hyperplasia, carcinoma, or adenoma of the adrenal cortex, hypertension associated with alkalosis, amyloidosis, hypokalemia, Cushing's disease, Liddle's syndrome, and Arnold-Healy-Gordon syndrome, pheochromocytoma tumors, and Addison's disease; disorders associated with gonadal steroid hormones such as: in women, abnormal prolactin 25 production, infertility, endometriosis, perturbations of the menstrual cycle, polycystic ovarian disease, hyperprolactinemia, isolated gonadotropin deficiency, amenorrhea, galactorrhea, hermaphroditism, hirsutism and virilization, breast cancer, and, in post-menopausal women, osteoporosis; and, in men, Leydig cell deficiency, male climacteric phase, and germinal cell aplasia, 30 hypergonadal disorders associated with Leydig cell tumors, androgen resistance associated with absence of androgen receptors, syndrome of 5  $\alpha$ -reductase, and gynecomastia; an eye disorder, such as conjunctivitis, keratoconjunctivitis sicca, keratitis, episcleritis, iritis, posterior uveitis, glaucoma, amaurosis fugax, ischemic optic neuropathy, optic neuritis, Leber's hereditary optic neuropathy, toxic optic neuropathy, vitreous detachment, retinal detachment, cataract, macular degeneration, central serous chorioretinopathy, retinitis pigmentosa, melanoma of the choroid, retrobulbar tumor, 35 and chiasmal tumor; a metabolic disorder, such as Addison's disease, cerebrotendinous

xanthomatosis, congenital adrenal hyperplasia, coumarin resistance, cystic fibrosis, diabetes, fatty hepatocirrhosis, fructose-1,6-diphosphatase deficiency, galactosemia, goiter, glucagonoma, glycogen storage diseases, hereditary fructose intolerance, hyperadrenalinism, hypoadrenalinism, hyperparathyroidism, hypoparathyroidism, hypercholesterolemia, hyperthyroidism, hypoglycemia, 5 hypothyroidism, hyperlipidemia, hyperlipemia, lipid myopathies, lipodystrophies, lysosomal storage diseases, mannosidosis, neuraminidase deficiency, obesity, pentosuria phenylketonuria, pseudovitamin D-deficiency rickets; and a gastrointestinal disorder, such as dysphagia, peptic esophagitis, esophageal spasm, esophageal stricture, esophageal carcinoma, dyspepsia, indigestion, gastritis, gastric carcinoma, anorexia, nausea, emesis, gastroparesis, antral or pyloric edema, 10 abdominal angina, pyrosis, gastroenteritis, intestinal obstruction, infections of the intestinal tract, peptic ulcer, cholelithiasis, cholecystitis, cholestasis, pancreatitis, pancreatic carcinoma, biliary tract disease, hepatitis, hyperbilirubinemia, hereditary hyperbilirubinemia, cirrhosis, passive congestion of the liver, hepatoma, infectious colitis, ulcerative colitis, ulcerative proctitis, Crohn's disease, Whipple's disease, Mallory-Weiss syndrome, colonic carcinoma, colonic obstruction, irritable bowel 15 syndrome, short bowel syndrome, diarrhea, constipation, gastrointestinal hemorrhage, acquired immunodeficiency syndrome (AIDS) enteropathy, jaundice, hepatic encephalopathy, hepatorenal syndrome, hepatic steatosis, hemochromatosis, Wilson's disease, alpha<sub>1</sub>-antitrypsin deficiency, Reye's syndrome, primary sclerosing cholangitis, liver infarction, portal vein obstruction and thrombosis, centrilobular necrosis, peliosis hepatitis, hepatic vein thrombosis, veno-occlusive disease, 20 preeclampsia, eclampsia, acute fatty liver of pregnancy, intrahepatic cholestasis of pregnancy, and hepatic tumors including nodular hyperplasias, adenomas, and carcinomas. The polynucleotide sequences encoding DME may be used in Southern or northern analysis, dot blot, or other membrane-based technologies; in PCR technologies; in dipstick, pin, and multiformat ELISA-like assays; and in microarrays utilizing fluids or tissues from patients to detect altered DME expression. 25 Such qualitative or quantitative methods are well known in the art.

In a particular aspect, the nucleotide sequences encoding DME may be useful in assays that detect the presence of associated disorders, particularly those mentioned above. The nucleotide sequences encoding DME may be labeled by standard methods and added to a fluid or tissue sample from a patient under conditions suitable for the formation of hybridization complexes. After a suitable 30 incubation period, the sample is washed and the signal is quantified and compared with a standard value. If the amount of signal in the patient sample is significantly altered in comparison to a control sample then the presence of altered levels of nucleotide sequences encoding DME in the sample indicates the presence of the associated disorder. Such assays may also be used to evaluate the efficacy of a particular therapeutic treatment regimen in animal studies, in clinical trials, or to monitor

the treatment of an individual patient.

In order to provide a basis for the diagnosis of a disorder associated with expression of DME, a normal or standard profile for expression is established. This may be accomplished by combining body fluids or cell extracts taken from normal subjects, either animal or human, with a sequence, or a 5 fragment thereof, encoding DME, under conditions suitable for hybridization or amplification.

Standard hybridization may be quantified by comparing the values obtained from normal subjects with values from an experiment in which a known amount of a substantially purified polynucleotide is used. Standard values obtained in this manner may be compared with values obtained from samples from patients who are symptomatic for a disorder. Deviation from standard values is used to establish the 10 presence of a disorder.

Once the presence of a disorder is established and a treatment protocol is initiated, hybridization assays may be repeated on a regular basis to determine if the level of expression in the patient begins to approximate that which is observed in the normal subject. The results obtained from successive assays may be used to show the efficacy of treatment over a period ranging from several 15 days to months.

With respect to cancer, the presence of an abnormal amount of transcript (either under- or overexpressed) in biopsied tissue from an individual may indicate a predisposition for the development of the disease, or may provide a means for detecting the disease prior to the appearance of actual clinical symptoms. A more definitive diagnosis of this type may allow health professionals to employ 20 preventative measures or aggressive treatment earlier thereby preventing the development or further progression of the cancer.

Additional diagnostic uses for oligonucleotides designed from the sequences encoding DME may involve the use of PCR. These oligomers may be chemically synthesized, generated 25 enzymatically, or produced in vitro. Oligomers will preferably contain a fragment of a polynucleotide encoding DME, or a fragment of a polynucleotide complementary to the polynucleotide encoding DME, and will be employed under optimized conditions for identification of a specific gene or condition. Oligomers may also be employed under less stringent conditions for detection or quantification of closely related DNA or RNA sequences.

In a particular aspect, oligonucleotide primers derived from the polynucleotide sequences 30 encoding DME may be used to detect single nucleotide polymorphisms (SNPs). SNPs are substitutions, insertions and deletions that are a frequent cause of inherited or acquired genetic disease in humans. Methods of SNP detection include, but are not limited to, single-stranded conformation polymorphism (SSCP) and fluorescent SSCP (fSSCP) methods. In SSCP, oligonucleotide primers derived from the polynucleotide sequences encoding DME are used to amplify DNA using the

polymerase chain reaction (PCR). The DNA may be derived, for example, from diseased or normal tissue, biopsy samples, bodily fluids, and the like. SNPs in the DNA cause differences in the secondary and tertiary structures of PCR products in single-stranded form, and these differences are detectable using gel electrophoresis in non-denaturing gels. In fSCCP, the oligonucleotide primers are 5 fluorescently labeled, which allows detection of the amplimers in high-throughput equipment such as DNA sequencing machines. Additionally, sequence database analysis methods, termed *in silico* SNP (isSNP), are capable of identifying polymorphisms by comparing the sequence of individual 10 overlapping DNA fragments which assemble into a common consensus sequence. These computer-based methods filter out sequence variations due to laboratory preparation of DNA and sequencing errors using statistical models and automated analyses of DNA sequence chromatograms. In the alternative, SNPs may be detected and characterized by mass spectrometry using, for example, the high throughput MASSARRAY system (Sequenom, Inc., San Diego CA).

Methods which may also be used to quantify the expression of DME include radiolabeling or biotinylating nucleotides, coamplification of a control nucleic acid, and interpolating results from 15 standard curves. (See, e.g., Melby, P.C. et al. (1993) *J. Immunol. Methods* 159:235-244; Duplaa, C. et al. (1993) *Anal. Biochem.* 212:229-236.) The speed of quantitation of multiple samples may be accelerated by running the assay in a high-throughput format where the oligomer or polynucleotide of interest is presented in various dilutions and a spectrophotometric or colorimetric response gives rapid 20 quantitation.

In further embodiments, oligonucleotides or longer fragments derived from any of the polynucleotide sequences described herein may be used as elements on a microarray. The microarray 25 can be used in transcript imaging techniques which monitor the relative expression levels of large numbers of genes simultaneously as described below. The microarray may also be used to identify genetic variants, mutations, and polymorphisms. This information may be used to determine gene function, to understand the genetic basis of a disorder, to diagnose a disorder, to monitor progression/regression of disease as a function of gene expression, and to develop and monitor the 30 activities of therapeutic agents in the treatment of disease. In particular, this information may be used to develop a pharmacogenomic profile of a patient in order to select the most appropriate and effective treatment regimen for that patient. For example, therapeutic agents which are highly effective and display the fewest side effects may be selected for a patient based on his/her pharmacogenomic profile.

In another embodiment, DME, fragments of DME, or antibodies specific for DME may be used as elements on a microarray. The microarray may be used to monitor or measure protein-protein interactions, drug-target interactions, and gene expression profiles, as described above.

A particular embodiment relates to the use of the polynucleotides of the present invention to

generate a transcript image of a tissue or cell type. A transcript image represents the global pattern of gene expression by a particular tissue or cell type. Global gene expression patterns are analyzed by quantifying the number of expressed genes and their relative abundance under given conditions and at a given time. (See Seilhamer et al., "Comparative Gene Transcript Analysis," U.S. Patent Number 5,840,484, expressly incorporated by reference herein.) Thus a transcript image may be generated by hybridizing the polynucleotides of the present invention or their complements to the totality of transcripts or reverse transcripts of a particular tissue or cell type. In one embodiment, the hybridization takes place in high-throughput format, wherein the polynucleotides of the present invention or their complements comprise a subset of a plurality of elements on a microarray. The 10 resultant transcript image would provide a profile of gene activity.

Transcript images may be generated using transcripts isolated from tissues, cell lines, biopsies, or other biological samples. The transcript image may thus reflect gene expression in vivo, as in the case of a tissue or biopsy sample, or in vitro, as in the case of a cell line.

Transcript images which profile the expression of the polynucleotides of the present invention 15 may also be used in conjunction with in vitro model systems and preclinical evaluation of pharmaceuticals, as well as toxicological testing of industrial and naturally-occurring environmental compounds. All compounds induce characteristic gene expression patterns, frequently termed molecular fingerprints or toxicant signatures, which are indicative of mechanisms of action and toxicity (Nuwaysir, E.F. et al. (1999) Mol. Carcinog. 24:153-159; Steiner, S. and N.L. Anderson 20 (2000) Toxicol. Lett. 112-113:467-471, expressly incorporated by reference herein). If a test compound has a signature similar to that of a compound with known toxicity, it is likely to share those toxic properties. These fingerprints or signatures are most useful and refined when they contain expression information from a large number of genes and gene families. Ideally, a genome-wide measurement of expression provides the highest quality signature. Even genes whose expression is not 25 altered by any tested compounds are important as well, as the levels of expression of these genes are used to normalize the rest of the expression data. The normalization procedure is useful for comparison of expression data after treatment with different compounds. While the assignment of gene function to elements of a toxicant signature aids in interpretation of toxicity mechanisms, knowledge of gene function is not necessary for the statistical matching of signatures which leads to 30 prediction of toxicity. (See, for example, Press Release 00-02 from the National Institute of Environmental Health Sciences, released February 29, 2000, available at <http://www.niehs.nih.gov/oc/news/toxchip.htm>.) Therefore, it is important and desirable in toxicological screening using toxicant signatures to include all expressed gene sequences.

In one embodiment, the toxicity of a test compound is assessed by treating a biological

sample containing nucleic acids with the test compound. Nucleic acids that are expressed in the treated biological sample are hybridized with one or more probes specific to the polynucleotides of the present invention, so that transcript levels corresponding to the polynucleotides of the present invention may be quantified. The transcript levels in the treated biological sample are compared 5 with levels in an untreated biological sample. Differences in the transcript levels between the two samples are indicative of a toxic response caused by the test compound in the treated sample.

Another particular embodiment relates to the use of the polypeptide sequences of the present invention to analyze the proteome of a tissue or cell type. The term proteome refers to the global pattern of protein expression in a particular tissue or cell type. Each protein component of a proteome 10 can be subjected individually to further analysis. Proteome expression patterns, or profiles, are analyzed by quantifying the number of expressed proteins and their relative abundance under given conditions and at a given time. A profile of a cell's proteome may thus be generated by separating and analyzing the polypeptides of a particular tissue or cell type. In one embodiment, the separation is achieved using two-dimensional gel electrophoresis, in which proteins from a sample are separated by 15 isoelectric focusing in the first dimension, and then according to molecular weight by sodium dodecyl sulfate slab gel electrophoresis in the second dimension (Steiner and Anderson, *supra*). The proteins are visualized in the gel as discrete and uniquely positioned spots, typically by staining the gel with an agent such as Coomassie Blue or silver or fluorescent stains. The optical density of each protein spot is generally proportional to the level of the protein in the sample. The optical densities of equivalently 20 positioned protein spots from different samples, for example, from biological samples either treated or untreated with a test compound or therapeutic agent, are compared to identify any changes in protein spot density related to the treatment. The proteins in the spots are partially sequenced using, for example, standard methods employing chemical or enzymatic cleavage followed by mass spectrometry. The identity of the protein in a spot may be determined by comparing its partial sequence, preferably 25 of at least 5 contiguous amino acid residues, to the polypeptide sequences of the present invention. In some cases, further sequence data may be obtained for definitive protein identification.

A proteomic profile may also be generated using antibodies specific for DME to quantify the levels of DME expression. In one embodiment, the antibodies are used as elements on a microarray, and protein expression levels are quantified by exposing the microarray to the sample and detecting the 30 levels of protein bound to each array element (Lueking, A. et al. (1999) *Anal. Biochem.* 270:103-111; Mendoza, L.G. et al. (1999) *Biotechniques* 27:778-788). Detection may be performed by a variety of methods known in the art, for example, by reacting the proteins in the sample with a thiol- or amino-reactive fluorescent compound and detecting the amount of fluorescence bound at each array element.

Toxicant signatures at the proteome level are also useful for toxicological screening, and

should be analyzed in parallel with toxicant signatures at the transcript level. There is a poor correlation between transcript and protein abundances for some proteins in some tissues (Anderson, N.L. and J. Seilhamer (1997) Electrophoresis 18:533-537), so proteome toxicant signatures may be useful in the analysis of compounds which do not significantly affect the transcript image, but which alter the proteomic profile. In addition, the analysis of transcripts in body fluids is difficult, due to rapid degradation of mRNA, so proteomic profiling may be more reliable and informative in such cases.

In another embodiment, the toxicity of a test compound is assessed by treating a biological sample containing proteins with the test compound. Proteins that are expressed in the treated biological sample are separated so that the amount of each protein can be quantified. The amount of each protein is compared to the amount of the corresponding protein in an untreated biological sample. A difference in the amount of protein between the two samples is indicative of a toxic response to the test compound in the treated sample. Individual proteins are identified by sequencing the amino acid residues of the individual proteins and comparing these partial sequences to the polypeptides of the present invention.

In another embodiment, the toxicity of a test compound is assessed by treating a biological sample containing proteins with the test compound. Proteins from the biological sample are incubated with antibodies specific to the polypeptides of the present invention. The amount of protein recognized by the antibodies is quantified. The amount of protein in the treated biological sample is compared with the amount in an untreated biological sample. A difference in the amount of protein between the two samples is indicative of a toxic response to the test compound in the treated sample.

Microarrays may be prepared, used, and analyzed using methods known in the art. (See, e.g., Brennan, T.M. et al. (1995) U.S. Patent No. 5,474,796; Schena, M. et al. (1996) Proc. Natl. Acad. Sci. USA 93:10614-10619; Baldeschweiler et al. (1995) PCT application WO95/251116; Shalon, D. et al. (1995) PCT application WO95/35505; Heller, R.A. et al. (1997) Proc. Natl. Acad. Sci. USA 94:2150-2155; and Heller, M.J. et al. (1997) U.S. Patent No. 5,605,662.) Various types of microarrays are well known and thoroughly described in DNA Microarrays: A Practical Approach, M. Schena, ed. (1999) Oxford University Press, London, hereby expressly incorporated by reference.

In another embodiment of the invention, nucleic acid sequences encoding DME may be used to generate hybridization probes useful in mapping the naturally occurring genomic sequence. Either coding or noncoding sequences may be used, and in some instances, noncoding sequences may be preferable over coding sequences. For example, conservation of a coding sequence among members of a multi-gene family may potentially cause undesired cross hybridization during chromosomal mapping. The sequences may be mapped to a particular chromosome, to a specific region of a

chromosome, or to artificial chromosome constructions, e.g., human artificial chromosomes (HACs), yeast artificial chromosomes (YACs), bacterial artificial chromosomes (BACs), bacterial P1 constructions, or single chromosome cDNA libraries. (See, e.g., Harrington, J.J. et al. (1997) *Nat. Genet.* 15:345-355; Price, C.M. (1993) *Blood Rev.* 7:127-134; and Trask, B.J. (1991) *Trends Genet.* 7:149-154.) Once mapped, the nucleic acid sequences of the invention may be used to develop genetic linkage maps, for example, which correlate the inheritance of a disease state with the inheritance of a particular chromosome region or restriction fragment length polymorphism (RFLP). (See, for example, Lander, E.S. and D. Botstein (1986) *Proc. Natl. Acad. Sci. USA* 83:7353-7357.)

Fluorescent *in situ* hybridization (FISH) may be correlated with other physical and genetic map data. (See, e.g., Heinz-Ulrich, et al. (1995) in Meyers, *supra*, pp. 965-968.) Examples of genetic map data can be found in various scientific journals or at the Online Mendelian Inheritance in Man (OMIM) World Wide Web site. Correlation between the location of the gene encoding DME on a physical map and a specific disorder, or a predisposition to a specific disorder, may help define the region of DNA associated with that disorder and thus may further positional cloning efforts.

*In situ* hybridization of chromosomal preparations and physical mapping techniques, such as linkage analysis using established chromosomal markers, may be used for extending genetic maps. Often the placement of a gene on the chromosome of another mammalian species, such as mouse, may reveal associated markers even if the exact chromosomal locus is not known. This information is valuable to investigators searching for disease genes using positional cloning or other gene discovery techniques. Once the gene or genes responsible for a disease or syndrome have been crudely localized by genetic linkage to a particular genomic region, e.g., ataxia-telangiectasia to 11q22-23, any sequences mapping to that area may represent associated or regulatory genes for further investigation. (See, e.g., Gatti, R.A. et al. (1988) *Nature* 336:577-580.) The nucleotide sequence of the instant invention may also be used to detect differences in the chromosomal location due to translocation, inversion, etc., among normal, carrier, or affected individuals.

In another embodiment of the invention, DME, its catalytic or immunogenic fragments, or oligopeptides thereof can be used for screening libraries of compounds in any of a variety of drug screening techniques. The fragment employed in such screening may be free in solution, affixed to a solid support, borne on a cell surface, or located intracellularly. The formation of binding complexes between DME and the agent being tested may be measured.

Another technique for drug screening provides for high throughput screening of compounds having suitable binding affinity to the protein of interest. (See, e.g., Geysen, et al. (1984) PCT application WO84/03564.) In this method, large numbers of different small test compounds are synthesized on a solid substrate. The test compounds are reacted with DME, or fragments thereof, and

washed. Bound DME is then detected by methods well known in the art. Purified DME can also be coated directly onto plates for use in the aforementioned drug screening techniques. Alternatively, non-neutralizing antibodies can be used to capture the peptide and immobilize it on a solid support.

5 In another embodiment, one may use competitive drug screening assays in which neutralizing antibodies capable of binding DME specifically compete with a test compound for binding DME. In this manner, antibodies can be used to detect the presence of any peptide which shares one or more antigenic determinants with DME.

10 In additional embodiments, the nucleotide sequences which encode DME may be used in any molecular biology techniques that have yet to be developed, provided the new techniques rely on properties of nucleotide sequences that are currently known, including, but not limited to, such properties as the triplet genetic code and specific base pair interactions.

15 Without further elaboration, it is believed that one skilled in the art can, using the preceding description, utilize the present invention to its fullest extent. The following embodiments are, therefore, to be construed as merely illustrative, and not limitative of the remainder of the disclosure in any way whatsoever.

The disclosures of all patents, applications and publications, mentioned above and below, including U.S. Ser. No. 60/216,804, U.S. Ser. No. 60/218,948, U.S. Ser. No. 60/220,037, and U.S. Ser. No. 60/221,837, are expressly incorporated by reference herein.

20

## EXAMPLES

### I. Construction of cDNA Libraries

25 Incyte cDNAs were derived from cDNA libraries described in the LIFESEQ GOLD database (Incyte Genomics, Palo Alto CA) and shown in Table 4, column 5. Some tissues were homogenized and lysed in guanidinium isothiocyanate, while others were homogenized and lysed in phenol or in a suitable mixture of denaturants, such as TRIZOL (Life Technologies), a monophasic solution of phenol and guanidine isothiocyanate. The resulting lysates were centrifuged over CsCl cushions or extracted with chloroform. RNA was precipitated from the lysates with either isopropanol or sodium acetate and ethanol, or by other routine methods.

30 Phenol extraction and precipitation of RNA were repeated as necessary to increase RNA purity. In some cases, RNA was treated with DNase. For most libraries, poly(A)+ RNA was isolated using oligo d(T)-coupled paramagnetic particles (Promega), OLIGOTEX latex particles (QIAGEN, Chatsworth CA), or an OLIGOTEX mRNA purification kit (QIAGEN). Alternatively, RNA was isolated directly from tissue lysates using other RNA isolation kits, e.g., the POLY(A)PURE mRNA purification kit (Ambion, Austin TX).

In some cases, Stratagene was provided with RNA and constructed the corresponding cDNA libraries. Otherwise, cDNA was synthesized and cDNA libraries were constructed with the UNIZAP vector system (Stratagene) or SUPERSCRIPT plasmid system (Life Technologies), using the recommended procedures or similar methods known in the art. (See, e.g., Ausubel, 1997, supra, units 5.1-6.6.) Reverse transcription was initiated using oligo d(T) or random primers. Synthetic oligonucleotide adapters were ligated to double stranded cDNA, and the cDNA was digested with the appropriate restriction enzyme or enzymes. For most libraries, the cDNA was size-selected (300-1000 bp) using SEPHACRYL S1000, SEPHAROSE CL2B, or SEPHAROSE CL4B column chromatography (Amersham Pharmacia Biotech) or preparative agarose gel electrophoresis. cDNAs 10 were ligated into compatible restriction enzyme sites of the polylinker of a suitable plasmid, e.g., PBLUESCRIPT plasmid (Stratagene), PSSPORT1 plasmid (Life Technologies), PCDNA2.1 plasmid (Invitrogen, Carlsbad CA), PBK-CMV plasmid (Stratagene), or pINCY (Incyte Genomics, Palo Alto CA), or derivatives thereof. Recombinant plasmids were transformed into competent *E. coli* cells 15 including XL1-Blue, XL1-BlueMRF, or SOLR from Stratagene or DH5 $\alpha$ , DH10B, or ElectroMAX DH10B from Life Technologies.

## II. Isolation of cDNA Clones

Plasmids obtained as described in Example I were recovered from host cells by *in vivo* excision using the UNIZAP vector system (Stratagene) or by cell lysis. Plasmids were purified using at least one of the following: a Magic or WIZARD Minipreps DNA purification system (Promega); an 20 AGTC Miniprep purification kit (Edge Biosystems, Gaithersburg MD); and QIAWELL 8 Plasmid, QIAWELL 8 Plus Plasmid, QIAWELL 8 Ultra Plasmid purification systems or the R.E.A.L. PREP 96 plasmid purification kit from QIAGEN. Following precipitation, plasmids were resuspended in 0.1 ml of distilled water and stored, with or without lyophilization, at 4°C.

Alternatively, plasmid DNA was amplified from host cell lysates using direct link PCR in a 25 high-throughput format (Rao, V.B. (1994) Anal. Biochem. 216:1-14). Host cell lysis and thermal cycling steps were carried out in a single reaction mixture. Samples were processed and stored in 384-well plates, and the concentration of amplified plasmid DNA was quantified fluorometrically using PICOGREEN dye (Molecular Probes, Eugene OR) and a FLUOROSKAN II fluorescence scanner (Labsystems Oy, Helsinki, Finland).

## III. Sequencing and Analysis

Incyte cDNA recovered in plasmids as described in Example II were sequenced as follows. Sequencing reactions were processed using standard methods or high-throughput instrumentation such as the ABI CATALYST 800 (Applied Biosystems) thermal cycler or the PTC-200 thermal cycler (MJ Research) in conjunction with the HYDRA microdispenser (Robbins Scientific) or the

MICROLAB 2200 (Hamilton) liquid transfer system. cDNA sequencing reactions were prepared using reagents provided by Amersham Pharmacia Biotech or supplied in ABI sequencing kits such as the ABI PRISM BIGDYE Terminator cycle sequencing ready reaction kit (Applied Biosystems). Electrophoretic separation of cDNA sequencing reactions and detection of labeled polynucleotides 5 were carried out using the MEGABACE 1000 DNA sequencing system (Molecular Dynamics); the ABI PRISM 373 or 377 sequencing system (Applied Biosystems) in conjunction with standard ABI protocols and base calling software; or other sequence analysis systems known in the art. Reading frames within the cDNA sequences were identified using standard methods (reviewed in Ausubel, 10 1997, *supra*, unit 7.7). Some of the cDNA sequences were selected for extension using the techniques disclosed in Example VIII.

The polynucleotide sequences derived from Incyte cDNAs were validated by removing vector, linker, and poly(A) sequences and by masking ambiguous bases, using algorithms and programs based on BLAST, dynamic programming, and dinucleotide nearest neighbor analysis. The Incyte cDNA sequences or translations thereof were then queried against a selection of public databases such as the 15 GenBank primate, rodent, mammalian, vertebrate, and eukaryote databases, and BLOCKS, PRINTS, DOMO, PRODOM, and hidden Markov model (HMM)-based protein family databases such as PFAM. (HMM is a probabilistic approach which analyzes consensus primary structures of gene families. See, for example, Eddy, S.R. (1996) *Curr. Opin. Struct. Biol.* 6:361-365.) The queries were performed using programs based on BLAST, FASTA, BLIMPS, and HMMER. The Incyte 20 cDNA sequences were assembled to produce full length polynucleotide sequences. Alternatively, GenBank cDNAs, GenBank ESTs, stitched sequences, stretched sequences, or Genscan-predicted coding sequences (see Examples IV and V) were used to extend Incyte cDNA assemblages to full length. Assembly was performed using programs based on Phred, Phrap, and Consed, and cDNA assemblages were screened for open reading frames using programs based on GeneMark, BLAST, and 25 FASTA. The full length polynucleotide sequences were translated to derive the corresponding full length polypeptide sequences. Alternatively, a polypeptide of the invention may begin at any of the methionine residues of the full length translated polypeptide. Full length polypeptide sequences were subsequently analyzed by querying against databases such as the GenBank protein databases (genpept), SwissProt, BLOCKS, PRINTS, DOMO, PRODOM, Prosite, and hidden Markov model 30 (HMM)-based protein family databases such as PFAM. Full length polynucleotide sequences are also analyzed using MACDNASIS PRO software (Hitachi Software Engineering, South San Francisco CA) and LASERGENE software (DNASTAR). Polynucleotide and polypeptide sequence alignments are generated using default parameters specified by the CLUSTAL algorithm as incorporated into the MEGALIGN multisequence alignment program (DNASTAR), which also calculates the percent

identity between aligned sequences.

Table 7 summarizes the tools, programs, and algorithms used for the analysis and assembly of Incyte cDNA and full length sequences and provides applicable descriptions, references, and threshold parameters. The first column of Table 7 shows the tools, programs, and algorithms used, the second column provides brief descriptions thereof, the third column presents appropriate references, all of which are incorporated by reference herein in their entirety, and the fourth column presents, where applicable, the scores, probability values, and other parameters used to evaluate the strength of a match between two sequences (the higher the score or the lower the probability value, the greater the identity between two sequences).

The programs described above for the assembly and analysis of full length polynucleotide and polypeptide sequences were also used to identify polynucleotide sequence fragments from SEQ ID NO:19-36. Fragments from about 20 to about 4000 nucleotides which are useful in hybridization and amplification technologies are described in Table 4, column 4.

#### IV. Identification and Editing of Coding Sequences from Genomic DNA

Putative drug metabolizing enzymes were initially identified by running the Genscan gene identification program against public genomic sequence databases (e.g., gbpri and gbhtg). Genscan is a general-purpose gene identification program which analyzes genomic DNA sequences from a variety of organisms (See Burge, C. and S. Karlin (1997) J. Mol. Biol. 268:78-94, and Burge, C. and S. Karlin (1998) Curr. Opin. Struct. Biol. 8:346-354). The program concatenates predicted exons to form an assembled cDNA sequence extending from a methionine to a stop codon. The output of Genscan is a FASTA database of polynucleotide and polypeptide sequences. The maximum range of sequence for Genscan to analyze at once was set to 30 kb. To determine which of these Genscan predicted cDNA sequences encode drug metabolizing enzymes, the encoded polypeptides were analyzed by querying against PFAM models for drug metabolizing enzymes. Potential drug metabolizing enzymes were also identified by homology to Incyte cDNA sequences that had been annotated as drug metabolizing enzymes. These selected Genscan-predicted sequences were then compared by BLAST analysis to the genpept and gbpri public databases. Where necessary, the Genscan-predicted sequences were then edited by comparison to the top BLAST hit from genpept to correct errors in the sequence predicted by Genscan, such as extra or omitted exons. BLAST analysis was also used to find any Incyte cDNA or public cDNA coverage of the Genscan-predicted sequences, thus providing evidence for transcription. When Incyte cDNA coverage was available, this information was used to correct or confirm the Genscan predicted sequence. Full length polynucleotide sequences were obtained by assembling Genscan-predicted coding sequences with Incyte cDNA sequences and/or public cDNA sequences using the assembly process described in Example III.

Alternatively, full length polynucleotide sequences were derived entirely from edited or unedited Genscan-predicted coding sequences.

#### V. Assembly of Genomic Sequence Data with cDNA Sequence Data

##### "Stitched" Sequences

5 Partial cDNA sequences were extended with exons predicted by the Genscan gene identification program described in Example IV. Partial cDNAs assembled as described in Example III were mapped to genomic DNA and parsed into clusters containing related cDNAs and Genscan exon predictions from one or more genomic sequences. Each cluster was analyzed using an algorithm based on graph theory and dynamic programming to integrate cDNA and genomic information, 10 generating possible splice variants that were subsequently confirmed, edited, or extended to create a full length sequence. Sequence intervals in which the entire length of the interval was present on more than one sequence in the cluster were identified, and intervals thus identified were considered to be equivalent by transitivity. For example, if an interval was present on a cDNA and two genomic sequences, then all three intervals were considered to be equivalent. This process allows unrelated but 15 consecutive genomic sequences to be brought together, bridged by cDNA sequence. Intervals thus identified were then "stitched" together by the stitching algorithm in the order that they appear along their parent sequences to generate the longest possible sequence, as well as sequence variants. Linkages between intervals which proceed along one type of parent sequence (cDNA to cDNA or genomic sequence to genomic sequence) were given preference over linkages which change parent type 20 (cDNA to genomic sequence). The resultant stitched sequences were translated and compared by BLAST analysis to the genpept and gbpri public databases. Incorrect exons predicted by Genscan were corrected by comparison to the top BLAST hit from genpept. Sequences were further extended with additional cDNA sequences, or by inspection of genomic DNA, when necessary.

##### "Stretched" Sequences

25 Partial DNA sequences were extended to full length with an algorithm based on BLAST analysis. First, partial cDNAs assembled as described in Example III were queried against public databases such as the GenBank primate, rodent, mammalian, vertebrate, and eukaryote databases using the BLAST program. The nearest GenBank protein homolog was then compared by BLAST analysis to either Incyte cDNA sequences or GenScan exon predicted sequences described in Example 30 IV. A chimeric protein was generated by using the resultant high-scoring segment pairs (HSPs) to map the translated sequences onto the GenBank protein homolog. Insertions or deletions may occur in the chimeric protein with respect to the original GenBank protein homolog. The GenBank protein homolog, the chimeric protein, or both were used as probes to search for homologous genomic sequences from the public human genome databases. Partial DNA sequences were therefore

"stretched" or extended by the addition of homologous genomic sequences. The resultant stretched sequences were examined to determine whether it contained a complete gene.

#### VI. Chromosomal Mapping of DME Encoding Polynucleotides

The sequences which were used to assemble SEQ ID NO:19-36 were compared with sequences from the Incyte LIFESEQ database and public domain databases using BLAST and other implementations of the Smith-Waterman algorithm. Sequences from these databases that matched SEQ ID NO:19-36 were assembled into clusters of contiguous and overlapping sequences using assembly algorithms such as Phrap (Table 7). Radiation hybrid and genetic mapping data available from public resources such as the Stanford Human Genome Center (SHGC), Whitehead Institute for Genome Research (WIGR), and Généthon were used to determine if any of the clustered sequences had been previously mapped. Inclusion of a mapped sequence in a cluster resulted in the assignment of all sequences of that cluster, including its particular SEQ ID NO:, to that map location.

Map locations are represented by ranges, or intervals, of human chromosomes. The map position of an interval, in centiMorgans, is measured relative to the terminus of the chromosome's p-arm. (The centiMorgan (cM) is a unit of measurement based on recombination frequencies between chromosomal markers. On average, 1 cM is roughly equivalent to 1 megabase (Mb) of DNA in humans, although this can vary widely due to hot and cold spots of recombination.) The cM distances are based on genetic markers mapped by Généthon which provide boundaries for radiation hybrid markers whose sequences were included in each of the clusters. Human genome maps and other resources available to the public, such as the NCBI "GeneMap'99" World Wide Web site (<http://www.ncbi.nlm.nih.gov/genemap/>), can be employed to determine if previously identified disease genes map within or in proximity to the intervals indicated above.

In this manner, SEQ ID NO:24 was mapped to chromosome 11 within the interval from 62.5 to 70.9 centiMorgans. SEQ ID NO:29 was mapped to chromosome 14 within the interval from 42.9 to 59.0 centiMorgans.

#### VII. Analysis of Polynucleotide Expression

Northern analysis is a laboratory technique used to detect the presence of a transcript of a gene and involves the hybridization of a labeled nucleotide sequence to a membrane on which RNAs from a particular cell type or tissue have been bound. (See, e.g., Sambrook, *supra*, ch. 7; Ausubel (1995) *supra*, ch. 4 and 16.)

Analogous computer techniques applying BLAST were used to search for identical or related molecules in cDNA databases such as GenBank or LIFESEQ (Incyte Genomics). This analysis is much faster than multiple membrane-based hybridizations. In addition, the sensitivity of the computer search can be modified to determine whether any particular match is categorized as exact or similar.

The basis of the search is the product score, which is defined as:

$$\frac{\text{BLAST Score} \times \text{Percent Identity}}{5 \times \min\{\text{length(Seq. 1)}, \text{length(Seq. 2)}\}}$$

5

The product score takes into account both the degree of similarity between two sequences and the length of the sequence match. The product score is a normalized value between 0 and 100, and is calculated as follows: the BLAST score is multiplied by the percent nucleotide identity and the product is divided by (5 times the length of the shorter of the two sequences). The BLAST score is calculated by assigning a score of +5 for every base that matches in a high-scoring segment pair (HSP), and -4 for every mismatch. Two sequences may share more than one HSP (separated by gaps). If there is more than one HSP, then the pair with the highest BLAST score is used to calculate the product score. The product score represents a balance between fractional overlap and quality in a BLAST alignment. For example, a product score of 100 is produced only for 100% identity over the entire length of the shorter of the two sequences being compared. A product score of 70 is produced either by 100% identity and 70% overlap at one end, or by 88% identity and 100% overlap at the other. A product score of 50 is produced either by 100% identity and 50% overlap at one end, or 79% identity and 100% overlap.

Alternatively, polynucleotide sequences encoding DME are analyzed with respect to the tissue sources from which they were derived. For example, some full length sequences are assembled, at least in part, with overlapping Incyte cDNA sequences (see Example III). Each cDNA sequence is derived from a cDNA library constructed from a human tissue. Each human tissue is classified into one of the following organ/tissue categories: cardiovascular system; connective tissue; digestive system; embryonic structures; endocrine system; exocrine glands; genitalia, female; genitalia, male; germ cells; hemic and immune system; liver; musculoskeletal system; nervous system; pancreas; respiratory system; sense organs; skin; stomatognathic system; unclassified/mixed; or urinary tract. The number of libraries in each category is counted and divided by the total number of libraries across all categories. Similarly, each human tissue is classified into one of the following disease/condition categories: cancer, cell line, developmental, inflammation, neurological, trauma, cardiovascular, pooled, and other, and the number of libraries in each category is counted and divided by the total number of libraries across all categories. The resulting percentages reflect the tissue- and disease-specific expression of cDNA encoding DME. cDNA sequences and cDNA library/tissue information are found in the LIFESEQ GOLD database (Incyte Genomics, Palo Alto CA).

### VIII. Extension of DME Encoding Polynucleotides

Full length polynucleotide sequences were also produced by extension of an appropriate fragment of the full length molecule using oligonucleotide primers designed from this fragment. One primer was synthesized to initiate 5' extension of the known fragment, and the other primer was synthesized to initiate 3' extension of the known fragment. The initial primers were designed using 5 OLIGO 4.06 software (National Biosciences), or another appropriate program, to be about 22 to 30 nucleotides in length, to have a GC content of about 50% or more, and to anneal to the target sequence at temperatures of about 68 °C to about 72 °C. Any stretch of nucleotides which would result in hairpin structures and primer-primer dimerizations was avoided.

10 Selected human cDNA libraries were used to extend the sequence. If more than one extension was necessary or desired, additional or nested sets of primers were designed.

High fidelity amplification was obtained by PCR using methods well known in the art. PCR was performed in 96-well plates using the PTC-200 thermal cycler (MJ Research, Inc.). The reaction mix contained DNA template, 200 nmol of each primer, reaction buffer containing Mg<sup>2+</sup>, (NH<sub>4</sub>)<sub>2</sub>SO<sub>4</sub>, and 2-mercaptoethanol, Taq DNA polymerase (Amersham Pharmacia Biotech), ELONGASE enzyme 15 (Life Technologies), and Pfu DNA polymerase (Stratagene), with the following parameters for primer pair PCI A and PCI B: Step 1: 94 °C, 3 min; Step 2: 94 °C, 15 sec; Step 3: 60 °C, 1 min; Step 4: 68 °C, 2 min; Step 5: Steps 2, 3, and 4 repeated 20 times; Step 6: 68 °C, 5 min; Step 7: storage at 4 °C. In the alternative, the parameters for primer pair T7 and SK+ were as follows: Step 1: 94 °C, 3 min; Step 2: 94 °C, 15 sec; Step 3: 57 °C, 1 min; Step 4: 68 °C, 2 min; Step 5: Steps 2, 3, and 4 repeated 20 times; 20 Step 6: 68 °C, 5 min; Step 7: storage at 4 °C.

25 The concentration of DNA in each well was determined by dispensing 100 µl PICOGREEN quantitation reagent (0.25% (v/v) PICOGREEN; Molecular Probes, Eugene OR) dissolved in 1X TE and 0.5 µl of undiluted PCR product into each well of an opaque fluorimeter plate (Corning Costar, Acton MA), allowing the DNA to bind to the reagent. The plate was scanned in a Fluoroskan II (Labsystems Oy, Helsinki, Finland) to measure the fluorescence of the sample and to quantify the concentration of DNA. A 5 µl to 10 µl aliquot of the reaction mixture was analyzed by electrophoresis on a 1 % agarose gel to determine which reactions were successful in extending the sequence.

30 The extended nucleotides were desalted and concentrated, transferred to 384-well plates, digested with CviJI cholera virus endonuclease (Molecular Biology Research, Madison WI), and sonicated or sheared prior to religation into pUC 18 vector (Amersham Pharmacia Biotech). For shotgun sequencing, the digested nucleotides were separated on low concentration (0.6 to 0.8%) agarose gels, fragments were excised, and agar digested with Agar ACE (Promega). Extended clones were religated using T4 ligase (New England Biolabs, Beverly MA) into pUC 18 vector (Amersham

Pharmacia Biotech), treated with Pfu DNA polymerase (Stratagene) to fill-in restriction site overhangs, and transfected into competent *E. coli* cells. Transformed cells were selected on antibiotic-containing media, and individual colonies were picked and cultured overnight at 37°C in 384-well plates in LB/2x carb liquid media.

5 The cells were lysed, and DNA was amplified by PCR using Taq DNA polymerase (Amersham Pharmacia Biotech) and Pfu DNA polymerase (Stratagene) with the following parameters: Step 1: 94°C, 3 min; Step 2: 94°C, 15 sec; Step 3: 60°C, 1 min; Step 4: 72°C, 2 min; Step 5: steps 2, 10 3, and 4 repeated 29 times; Step 6: 72°C, 5 min; Step 7: storage at 4°C. DNA was quantified by PICOGREEN reagent (Molecular Probes) as described above. Samples with low DNA recoveries were reamplified using the same conditions as described above. Samples were diluted with 20% dimethylsulfoxide (1:2, v/v), and sequenced using DYENAMIC energy transfer sequencing primers and the DYENAMIC DIRECT kit (Amersham Pharmacia Biotech) or the ABI PRISM BIGDYE Terminator cycle sequencing ready reaction kit (Applied Biosystems).

15 In like manner, full length polynucleotide sequences are verified using the above procedure or are used to obtain 5' regulatory sequences using the above procedure along with oligonucleotides designed for such extension, and an appropriate genomic library.

#### **IX. Labeling and Use of Individual Hybridization Probes**

20 Hybridization probes derived from SEQ ID NO:19-36 are employed to screen cDNAs, genomic DNAs, or mRNAs. Although the labeling of oligonucleotides, consisting of about 20 base pairs, is specifically described, essentially the same procedure is used with larger nucleotide fragments. Oligonucleotides are designed using state-of-the-art software such as OLIGO 4.06 software (National Biosciences) and labeled by combining 50 pmol of each oligomer, 250 µCi of [ $\gamma$ -<sup>32</sup>P] adenosine triphosphate (Amersham Pharmacia Biotech), and T4 polynucleotide kinase (DuPont NEN, Boston MA). The labeled oligonucleotides are substantially purified using a SEPHADEX G-25 superfine size exclusion dextran bead column (Amersham Pharmacia Biotech). An aliquot containing 10<sup>7</sup> counts per 25 minute of the labeled probe is used in a typical membrane-based hybridization analysis of human genomic DNA digested with one of the following endonucleases: Ase I, Bgl II, Eco RI, Pst I, Xba I, or Pvu II (DuPont NEN).

30 The DNA from each digest is fractionated on a 0.7% agarose gel and transferred to nylon membranes (Nytran Plus, Schleicher & Schuell, Durham NH). Hybridization is carried out for 16 hours at 40°C. To remove nonspecific signals, blots are sequentially washed at room temperature under conditions of up to, for example, 0.1 x saline sodium citrate and 0.5% sodium dodecyl sulfate. Hybridization patterns are visualized using autoradiography or an alternative imaging means and compared.

## X. Microarrays

The linkage or synthesis of array elements upon a microarray can be achieved utilizing photolithography, piezoelectric printing (ink-jet printing, See, e.g., Baldeschweiler, *supra*), mechanical microspotting technologies, and derivatives thereof. The substrate in each of the aforementioned

5 technologies should be uniform and solid with a non-porous surface (Schena (1999), *supra*).

Suggested substrates include silicon, silica, glass slides, glass chips, and silicon wafers. Alternatively, a procedure analogous to a dot or slot blot may also be used to arrange and link elements to the surface of a substrate using thermal, UV, chemical, or mechanical bonding procedures. A typical array may be produced using available methods and machines well known to those of ordinary skill in the art and 10 may contain any appropriate number of elements. (See, e.g., Schena, M. et al. (1995) *Science* 270:467-470; Shalon, D. et al. (1996) *Genome Res.* 6:639-645; Marshall, A. and J. Hodgson (1998) *Nat. Biotechnol.* 16:27-31.)

Full length cDNAs, Expressed Sequence Tags (ESTs), or fragments or oligomers thereof may comprise the elements of the microarray. Fragments or oligomers suitable for hybridization can be 15 selected using software well known in the art such as LASERGENE software (DNASTAR). The array elements are hybridized with polynucleotides in a biological sample. The polynucleotides in the biological sample are conjugated to a fluorescent label or other molecular tag for ease of detection. After hybridization, nonhybridized nucleotides from the biological sample are removed, and a fluorescence scanner is used to detect hybridization at each array element. Alternatively, laser 20 desorption and mass spectrometry may be used for detection of hybridization. The degree of complementarity and the relative abundance of each polynucleotide which hybridizes to an element on the microarray may be assessed. In one embodiment, microarray preparation and usage is described in detail below.

### Tissue or Cell Sample Preparation

25 Total RNA is isolated from tissue samples using the guanidinium thiocyanate method and poly(A)<sup>+</sup> RNA is purified using the oligo-(dT) cellulose method. Each poly(A)<sup>+</sup> RNA sample is reverse transcribed using MMLV reverse-transcriptase, 0.05 pg/ $\mu$ l oligo-(dT) primer (21mer), 1X first strand buffer, 0.03 units/ $\mu$ l RNase inhibitor, 500  $\mu$ M dATP, 500  $\mu$ M dGTP, 500  $\mu$ M dTTP, 40  $\mu$ M dCTP, 40  $\mu$ M dCTP-Cy3 (BDS) or dCTP-Cy5 (Amersham Pharmacia Biotech). The reverse 30 transcription reaction is performed in a 25 ml volume containing 200 ng poly(A)<sup>+</sup> RNA with GEMBRIGHT kits (Incyte). Specific control poly(A)<sup>+</sup> RNAs are synthesized by *in vitro* transcription from non-coding yeast genomic DNA. After incubation at 37°C for 2 hr, each reaction sample (one with Cy3 and another with Cy5 labeling) is treated with 2.5 ml of 0.5M sodium hydroxide and incubated for 20 minutes at 85°C to stop the reaction and degrade the RNA.

Samples are purified using two successive CHROMA SPIN 30 gel filtration spin columns (CLONTECH Laboratories, Inc. (CLONTECH), Palo Alto CA) and after combining, both reaction samples are ethanol precipitated using 1 ml of glycogen (1 mg/ml), 60 ml sodium acetate, and 300 ml of 100% ethanol. The sample is then dried to completion using a SpeedVAC (Savant Instruments Inc., Holbrook NY) and resuspended in 14  $\mu$ l 5X SSC/0.2% SDS.

#### Microarray Preparation

Sequences of the present invention are used to generate array elements. Each array element is amplified from bacterial cells containing vectors with cloned cDNA inserts. PCR amplification uses primers complementary to the vector sequences flanking the cDNA insert. Array elements are amplified in thirty cycles of PCR from an initial quantity of 1-2 ng to a final quantity greater than 5  $\mu$ g. Amplified array elements are then purified using SEPHACRYL-400 (Amersham Pharmacia Biotech).

Purified array elements are immobilized on polymer-coated glass slides. Glass microscope slides (Corning) are cleaned by ultrasound in 0.1% SDS and acetone, with extensive distilled water washes between and after treatments. Glass slides are etched in 4% hydrofluoric acid (VWR Scientific Products Corporation (VWR), West Chester PA), washed extensively in distilled water, and coated with 0.05% aminopropyl silane (Sigma) in 95% ethanol. Coated slides are cured in a 110°C oven.

Array elements are applied to the coated glass substrate using a procedure described in US Patent No. 5,807,522, incorporated herein by reference. 1  $\mu$ l of the array element DNA, at an average concentration of 100 ng/ $\mu$ l, is loaded into the open capillary printing element by a high-speed robotic apparatus. The apparatus then deposits about 5 nl of array element sample per slide.

Microarrays are UV-crosslinked using a STRATALINKER UV-crosslinker (Stratagene). Microarrays are washed at room temperature once in 0.2% SDS and three times in distilled water. Non-specific binding sites are blocked by incubation of microarrays in 0.2% casein in phosphate buffered saline (PBS) (Tropix, Inc., Bedford MA) for 30 minutes at 60°C followed by washes in 0.2% SDS and distilled water as before.

#### Hybridization

Hybridization reactions contain 9  $\mu$ l of sample mixture consisting of 0.2  $\mu$ g each of Cy3 and Cy5 labeled cDNA synthesis products in 5X SSC, 0.2% SDS hybridization buffer. The sample mixture is heated to 65°C for 5 minutes and is aliquoted onto the microarray surface and covered with an 1.8 cm<sup>2</sup> coverslip. The arrays are transferred to a waterproof chamber having a cavity just slightly larger than a microscope slide. The chamber is kept at 100% humidity internally by the addition of 140  $\mu$ l of 5X SSC in a corner of the chamber. The chamber containing the arrays is incubated for about 6.5 hours at 60°C. The arrays are washed for 10 min at 45°C in a first wash

buffer (1X SSC, 0.1% SDS), three times for 10 minutes each at 45°C in a second wash buffer (0.1X SSC), and dried.

**Detection**

Reporter-labeled hybridization complexes are detected with a microscope equipped with an  
5 Innova 70 mixed gas 10 W laser (Coherent, Inc., Santa Clara CA) capable of generating spectral lines at 488 nm for excitation of Cy3 and at 632 nm for excitation of Cy5. The excitation laser light is focused on the array using a 20X microscope objective (Nikon, Inc., Melville NY). The slide containing the array is placed on a computer-controlled X-Y stage on the microscope and raster-scanned past the objective. The 1.8 cm x 1.8 cm array used in the present example is scanned with a  
10 resolution of 20 micrometers.

In two separate scans, a mixed gas multiline laser excites the two fluorophores sequentially. Emitted light is split, based on wavelength, into two photomultiplier tube detectors (PMT R1477, Hamamatsu Photonics Systems, Bridgewater NJ) corresponding to the two fluorophores. Appropriate filters positioned between the array and the photomultiplier tubes are used to filter the  
15 signals. The emission maxima of the fluorophores used are 565 nm for Cy3 and 650 nm for Cy5. Each array is typically scanned twice, one scan per fluorophore using the appropriate filters at the laser source, although the apparatus is capable of recording the spectra from both fluorophores simultaneously.

The sensitivity of the scans is typically calibrated using the signal intensity generated by a  
20 cDNA control species added to the sample mixture at a known concentration. A specific location on the array contains a complementary DNA sequence, allowing the intensity of the signal at that location to be correlated with a weight ratio of hybridizing species of 1:100,000. When two samples from different sources (e.g., representing test and control cells), each labeled with a different fluorophore, are hybridized to a single array for the purpose of identifying genes that are  
25 differentially expressed, the calibration is done by labeling samples of the calibrating cDNA with the two fluorophores and adding identical amounts of each to the hybridization mixture.

The output of the photomultiplier tube is digitized using a 12-bit RTI-835H analog-to-digital (A/D) conversion board (Analog Devices, Inc., Norwood MA) installed in an IBM-compatible PC computer. The digitized data are displayed as an image where the signal intensity is mapped using a  
30 linear 20-color transformation to a pseudocolor scale ranging from blue (low signal) to red (high signal). The data is also analyzed quantitatively. Where two different fluorophores are excited and measured simultaneously, the data are first corrected for optical crosstalk (due to overlapping emission spectra) between the fluorophores using each fluorophore's emission spectrum.

A grid is superimposed over the fluorescence signal image such that the signal from each  
35 spot is centered in each element of the grid. The fluorescence signal within each element is then

integrated to obtain a numerical value corresponding to the average intensity of the signal. The software used for signal analysis is the GEMTOOLS gene expression analysis program (Incyte).

#### XI. Complementary Polynucleotides

Sequences complementary to the DME-encoding sequences, or any parts thereof, are used to 5 detect, decrease, or inhibit expression of naturally occurring DME. Although use of oligonucleotides comprising from about 15 to 30 base pairs is described, essentially the same procedure is used with smaller or with larger sequence fragments. Appropriate oligonucleotides are designed using OLIGO 4.06 software (National Biosciences) and the coding sequence of DME. To inhibit transcription, a complementary oligonucleotide is designed from the most unique 5' sequence and used to prevent 10 promoter binding to the coding sequence. To inhibit translation, a complementary oligonucleotide is designed to prevent ribosomal binding to the DME-encoding transcript.

#### XII. Expression of DME

Expression and purification of DME is achieved using bacterial or virus-based expression systems. For expression of DME in bacteria, cDNA is subcloned into an appropriate vector 15 containing an antibiotic resistance gene and an inducible promoter that directs high levels of cDNA transcription. Examples of such promoters include, but are not limited to, the *trp-lac (tac)* hybrid promoter and the T5 or T7 bacteriophage promoter in conjunction with the *lac* operator regulatory element. Recombinant vectors are transformed into suitable bacterial hosts, e.g., BL21(DE3).

Antibiotic resistant bacteria express DME upon induction with isopropyl beta-D-thiogalactopyranoside 20 (IPTG). Expression of DME in eukaryotic cells is achieved by infecting insect or mammalian cell lines with recombinant Autographica californica nuclear polyhedrosis virus (AcMNPV), commonly known as baculovirus. The nonessential polyhedrin gene of baculovirus is replaced with cDNA 25 encoding DME by either homologous recombination or bacterial-mediated transposition involving transfer plasmid intermediates. Viral infectivity is maintained and the strong polyhedrin promoter drives high levels of cDNA transcription. Recombinant baculovirus is used to infect Spodoptera frugiperda (Sf9) insect cells in most cases, or human hepatocytes, in some cases. Infection of the latter requires additional genetic modifications to baculovirus. (See Engelhard, E.K. et al. (1994) Proc. Natl. Acad. Sci. USA 91:3224-3227; Sandig, V. et al. (1996) Hum. Gene Ther. 7:1937-1945.)

In most expression systems, DME is synthesized as a fusion protein with, e.g., glutathione S- 30 transferase (GST) or a peptide epitope tag, such as FLAG or 6-His, permitting rapid, single-step, affinity-based purification of recombinant fusion protein from crude cell lysates. GST, a 26-kilodalton enzyme from Schistosoma japonicum, enables the purification of fusion proteins on immobilized glutathione under conditions that maintain protein activity and antigenicity (Amersham Pharmacia Biotech). Following purification, the GST moiety can be proteolytically cleaved from DME at

specifically engineered sites. FLAG, an 8-amino acid peptide, enables immunoaffinity purification using commercially available monoclonal and polyclonal anti-FLAG antibodies (Eastman Kodak). 6-His, a stretch of six consecutive histidine residues, enables purification on metal-chelate resins (QIAGEN). Methods for protein expression and purification are discussed in Ausubel (1995, supra, 5 ch. 10 and 16). Purified DME obtained by these methods can be used directly in the assays shown in Examples XVI, XVII, and XVIII, where applicable.

### XIII. Functional Assays

DME function is assessed by expressing the sequences encoding DME at physiologically elevated levels in mammalian cell culture systems. cDNA is subcloned into a mammalian expression 10 vector containing a strong promoter that drives high levels of cDNA expression. Vectors of choice include PCMV SPORT (Life Technologies) and PCR3.1 (Invitrogen, Carlsbad CA), both of which contain the cytomegalovirus promoter. 5-10  $\mu$ g of recombinant vector are transiently transfected into a human cell line, for example, an endothelial or hematopoietic cell line, using either liposome formulations or electroporation. 1-2  $\mu$ g of an additional plasmid containing sequences encoding a 15 marker protein are co-transfected. Expression of a marker protein provides a means to distinguish transfected cells from nontransfected cells and is a reliable predictor of cDNA expression from the recombinant vector. Marker proteins of choice include, e.g., Green Fluorescent Protein (GFP; Clontech), CD64, or a CD64-GFP fusion protein. Flow cytometry (FCM), an automated, laser optics-based technique, is used to identify transfected cells expressing GFP or CD64-GFP and to evaluate the 20 apoptotic state of the cells and other cellular properties. FCM detects and quantifies the uptake of fluorescent molecules that diagnose events preceding or coincident with cell death. These events include changes in nuclear DNA content as measured by staining of DNA with propidium iodide; changes in cell size and granularity as measured by forward light scatter and 90 degree side light scatter; down-regulation of DNA synthesis as measured by decrease in bromodeoxyuridine uptake; 25 alterations in expression of cell surface and intracellular proteins as measured by reactivity with specific antibodies; and alterations in plasma membrane composition as measured by the binding of fluorescein-conjugated Annexin V protein to the cell surface. Methods in flow cytometry are discussed in Ormerod, M.G. (1994) Flow Cytometry, Oxford, New York NY.

The influence of DME on gene expression can be assessed using highly purified populations of 30 cells transfected with sequences encoding DME and either CD64 or CD64-GFP. CD64 and CD64-GFP are expressed on the surface of transfected cells and bind to conserved regions of human immunoglobulin G (IgG). Transfected cells are efficiently separated from nontransfected cells using magnetic beads coated with either human IgG or antibody against CD64 (DYNAL, Lake Success NY). mRNA can be purified from the cells using methods well known by those of skill in the art.

Expression of mRNA encoding DME and other genes of interest can be analyzed by northern analysis or microarray techniques.

#### XIV. Production of DME Specific Antibodies

DME substantially purified using polyacrylamide gel electrophoresis (PAGE; see, e.g., 5 Harrington, M.G. (1990) *Methods Enzymol.* 182:488-495), or other purification techniques, is used to immunize rabbits and to produce antibodies using standard protocols.

Alternatively, the DME amino acid sequence is analyzed using LASERGENE software (DNASTAR) to determine regions of high immunogenicity, and a corresponding oligopeptide is synthesized and used to raise antibodies by means known to those of skill in the art. Methods for 10 selection of appropriate epitopes, such as those near the C-terminus or in hydrophilic regions are well described in the art. (See, e.g., Ausubel, 1995, *supra*, ch. 11.)

Typically, oligopeptides of about 15 residues in length are synthesized using an ABI 431A peptide synthesizer (Applied Biosystems) using Fmoc chemistry and coupled to KLH (Sigma-Aldrich, St. Louis MO) by reaction with N-maleimidobenzoyl-N-hydroxysuccinimide ester (MBS) to 15 increase immunogenicity. (See, e.g., Ausubel, 1995, *supra*.) Rabbits are immunized with the oligopeptide-KLH complex in complete Freund's adjuvant. Resulting antisera are tested for antipeptide and anti-DME activity by, for example, binding the peptide or DME to a substrate, blocking with 1% BSA, reacting with rabbit antisera, washing, and reacting with radio-iodinated goat anti-rabbit IgG.

#### 20 XV. Purification of Naturally Occurring DME Using Specific Antibodies

Naturally occurring or recombinant DME is substantially purified by immunoaffinity chromatography using antibodies specific for DME. An immunoaffinity column is constructed by 25 covalently coupling anti-DME antibody to an activated chromatographic resin, such as CNBr-activated SEPHAROSE (Amersham Pharmacia Biotech). After the coupling, the resin is blocked and washed according to the manufacturer's instructions.

Media containing DME are passed over the immunoaffinity column, and the column is washed under conditions that allow the preferential absorbance of DME (e.g., high ionic strength buffers in the presence of detergent). The column is eluted under conditions that disrupt antibody/DME binding (e.g., a buffer of pH 2 to pH 3, or a high concentration of a chaotropic, such as urea or thiocyanate 30 ion), and DME is collected.

#### XVI. Identification of Molecules Which Interact with DME

DME, or biologically active fragments thereof, are labeled with <sup>125</sup>I Bolton-Hunter reagent. (See, e.g., Bolton A.E. and W.M. Hunter (1973) *Biochem. J.* 133:529-539.) Candidate molecules previously arrayed in the wells of a multi-well plate are incubated with the labeled DME, washed, and

any wells with labeled DME complex are assayed. Data obtained using different concentrations of DME are used to calculate values for the number, affinity, and association of DME with the candidate molecules.

5 Alternatively, molecules interacting with DME are analyzed using the yeast two-hybrid system as described in Fields, S. and O. Song (1989) *Nature* 340:245-246, or using commercially available kits based on the two-hybrid system, such as the MATCHMAKER system (Clontech).

DME may also be used in the PATHCALLING process (CuraGen Corp., New Haven CT) which employs the yeast two-hybrid system in a high-throughput manner to determine all interactions between the proteins encoded by two large libraries of genes (Nandabalan, K. et al. (2000) U.S. Patent 10 No. 6,057,101).

## XVII. Demonstration of DME Activity

Cytochrome P450 activity of DME is measured using the 4-hydroxylation of aniline. Aniline is converted to 4-aminophenol by the enzyme, and has an absorption maximum at 630 nm (Gibson and Skett, *supra*). This assay is a convenient measure, but underestimates the total hydroxylation, which also occurs at the 2- and 3- positions. Assays are performed at 37 °C and contain an aliquot of the enzyme and a suitable amount of aniline (approximately 2 mM) in reaction buffer. For this reaction, the buffer must contain NADPH or an NADPH-generating cofactor system. One formulation for this reaction buffer includes 85 mM Tris pH 7.4, 15 mM MgCl<sub>2</sub>, 50 mM 20 nicotinamide, 40 mg trisodium isocitrate, and 2 units isocitrate dehydrogenase, with 8 mg NADP<sup>+</sup> added to a 10 mL reaction buffer stock just prior to assay. Reactions are carried out in an optical cuvette, and the absorbance at 630 nm is measured. The rate of increase in absorbance is proportional to the enzyme activity in the assay. A standard curve can be constructed using known concentrations of 4-aminophenol.

25 Flavin-containing monooxygenase activity of DME is measured by chromatographic analysis of metabolic products. For example, Ring, B. J. et al. (1999; *Drug Metab. Dis.* 27:1099-1103) incubated FMO in 0.1 M sodium phosphate buffer (pH 7.4 or 8.3) and 1 mM NADPH at 37 °C, stopped the reaction with an organic solvent, and determined product formation by HPLC. Alternatively, activity is measured by monitoring oxygen uptake using a Clark-type electrode. For 30 example, Ziegler, D. M. and Poulsen, L. L. (1978; *Methods Enzymol.* 52:142-151) incubated the enzyme at 37 °C in an NADPH-generating cofactor system (similar to the one described above) containing the substrate methimazole. The rate of oxygen uptake is proportional to enzyme activity.

35 UDP glucuronyltransferase activity of DME is measured using a colorimetric determination of free amine groups (Gibson and Skett, *supra*). An amine-containing substrate, such as 2-aminophenol, is incubated at 37 °C with an aliquot of the enzyme in a reaction buffer containing the

necessary cofactors (40 mM Tris pH 8.0, 7.5 mM MgCl<sub>2</sub>, 0.025% Triton X-100, 1 mM ascorbic acid, 0.75 mM UDP-glucuronic acid). After sufficient time, the reaction is stopped by addition of ice-cold 20% trichloroacetic acid in 0.1 M phosphate buffer pH 2.7, incubated on ice, and centrifuged to clarify the supernatant. Any unreacted 2-aminophenol is destroyed in this step. Sufficient freshly-  
5 prepared sodium nitrite is then added; this step allows formation of the diazonium salt of the glucuronidated product. Excess nitrite is removed by addition of sufficient ammonium sulfamate, and the diazonium salt is reacted with an aromatic amine (for example, N-naphthylethylene diamine) to produce a colored azo compound which can be assayed spectrophotometrically (at 540 nm for the example). A standard curve can be constructed using known concentrations of aniline, which will  
10 form a chromophore with similar properties to 2-aminophenol glucuronide.

Sulfotransferase activity of DME is measured using the incorporation of <sup>35</sup>S from [<sup>35</sup>S]PAPS into a model substrate such as phenol (Folds, A. and Meek, J. L. (1973) *Biochim. Biophys. Acta* 327:365-374). An aliquot of enzyme is incubated at 37 °C with 1 mL of 10 mM phosphate buffer pH 6.4, 50 µM phenol, 0.4-4.0 µM [<sup>35</sup>S]PAPS. After sufficient time for 5-20% of the radiolabel to be  
15 transferred to the substrate, 0.2 mL of 0.1 M barium acetate is added to precipitate protein and phosphate buffer. Then 0.2 mL of 0.1 M Ba(OH)<sub>2</sub> is added, followed by 0.2 mL ZnSO<sub>4</sub>. The supernatant is cleared by centrifugation, which removes proteins as well as unreacted [<sup>35</sup>S]PAPS. Radioactivity in the supernatant is measured by scintillation. The enzyme activity is determined from the number of moles of radioactivity in the reaction product.

20 Glutathione S-transferase activity of DME is measured using a model substrate, such as 2,4-dinitro-1-chlorobenzene, which reacts with glutathione to form a product, 2,4-dinitrophenyl-glutathione, that has an absorbance maximum at 340 nm. It is important to note that GSTs have differing substrate specificities, and the model substrate should be selected based on the substrate preferences of the GST of interest. Assays are performed at ambient temperature and contain an  
25 aliquot of the enzyme in a suitable reaction buffer (for example, 1 mM glutathione, 1 mM dinitrochlorobenzene, 90 mM potassium phosphate buffer pH 6.5). Reactions are carried out in an optical cuvette, and the absorbance at 340 nm is measured. The rate of increase in absorbance is proportional to the enzyme activity in the assay.

30 N-acyltransferase activity of DME is measured using radiolabeled amino acid substrates and measuring radiolabel incorporation into conjugated products. Enzyme is incubated in a reaction buffer containing an unlabeled acyl-CoA compound and radiolabeled amino acid, and the radiolabeled acyl-conjugates are separated from the unreacted amino acid by extraction into n-butanol or other appropriate organic solvent. For example, Johnson, M. R. et al. (1990; *J. Biol. Chem.* 266:10227-10233) measured bile acid-CoA:amino acid N-acyltransferase activity by  
35 incubating the enzyme with cholyl-CoA and <sup>3</sup>H-glycine or <sup>3</sup>H-taurine, separating the tritiated cholate

conjugate by extraction into n-butanol, and measuring the radioactivity in the extracted product by scintillation. Alternatively, N-acyltransferase activity is measured using the spectrophotometric determination of reduced CoA (CoASH) described below.

N-acetyltransferase activity of DME is measured using the transfer of radiolabel from [<sup>14</sup>C]acetyl-CoA to a substrate molecule (for example, see Deguchi, T. (1975) *J. Neurochem.* 24:1083-5). Alternatively, a newer spectrophotometric assay based on DTNB (5,5'-dithio-bis(2-nitrobenzoic acid; Ellman's reagent) reaction with CoASH may be used. Free thiol-containing CoASH is formed during N-acetyltransferase catalyzed transfer of an acetyl group to a substrate. CoASH is detected using the absorbance of DTNB conjugate at 412 nm (De Angelis, J. et al. (1997) *J. Biol. Chem.* 273:3045-3050). Enzyme activity is proportional to the rate of radioactivity incorporation into substrate, or the rate of absorbance increase in the spectrophotometric assay.

Aldo/keto reductase activity of DME is measured using the decrease in absorbance at 340 nm as NADPH is consumed. A standard reaction mixture is 135 mM sodium phosphate buffer (pH 6.2-7.2 depending on enzyme), 0.2 mM NADPH, 0.3 M lithium sulfate, 0.5-2.5 µg enzyme and an appropriate level of substrate. The reaction is incubated at 30 °C and the reaction is monitored continuously with a spectrophotometer. Enzyme activity is calculated as mol NADPH consumed / µg of enzyme.

Alcohol dehydrogenase activity of DME is measured using the increase in absorbance at 340 nm as NAD<sup>+</sup> is reduced to NADH. A standard reaction mixture is 50 mM sodium phosphate, pH 7.5, and 0.25 mM EDTA. The reaction is incubated at 25 °C and monitored using a spectrophotometer. Enzyme activity is calculated as mol NADH produced / µg of enzyme.

### XVIII. Identification of DME Inhibitors

Compounds to be tested are arrayed in the wells of a multi-well plate in varying concentrations along with an appropriate buffer and substrate, as described in the assays in Example XVII. DME activity is measured for each well and the ability of each compound to inhibit DME activity can be determined, as well as the dose-response profiles. This assay could also be used to identify molecules which enhance DME activity.

Various modifications and variations of the described methods and systems of the invention will be apparent to those skilled in the art without departing from the scope and spirit of the invention. Although the invention has been described in connection with certain embodiments, it should be understood that the invention as claimed should not be unduly limited to such specific embodiments. Indeed, various modifications of the described modes for carrying out the invention which are obvious to those skilled in molecular biology or related fields are intended to be within the scope of the following claims.

Table 1

Incyte Project ID	Polypeptide SEQ ID NO:	Incyte Polypeptide ID	Polynucleotide SEQ ID NO:	Incyte Polynucleotide ID
6274461	1	6274461CD1	19	6274461CB1
7477262	2	7477262CD1	20	7477262CB1
8097779	3	8097779CD1	21	8097779CB1
6963993	4	6963993CD1	22	6963993CB1
7474404	5	7474404CD1	23	7474404CB1
7474438	6	7474438CD1	24	7474438CB1
7476298	7	7476298CD1	25	7476298CB1
7477555	8	7477555CD1	26	7477555CB1
1527520	9	1527520CD1	27	1527520CB1
3419318	10	3419318CD1	28	3419318CB1
3815272	11	3815272CD1	29	3815272CB1
7473875	12	7473875CD1	30	7473875CB1
7478099	13	7478099CD1	31	7478099CB1
1962105	14	1962105CD1	32	1962105CB1
5643401	15	5643401CD1	33	5643401CB1
7478053	16	7478053CD1	34	7478053CB1
7478994	17	7478994CD1	35	7478994CB1
7478577	18	7478577CD1	36	7478577CB1

Table 2

Polypeptide SEQ ID NO:	Incyte Polypeptide ID	GenBank ID NO:	Probability score	GenBank Homolog
1	6274461CD1	g6318548	3.10E-22	[Homo sapiens] retinal short-chain dehydrogenase/reductase
2	7477262CD1	g190142	1.00E-166	[Homo sapiens] phenylethanolamine N-methyltransferase Kaneda, N. et al. (1988) J. Biol. Chem. 263:7672-7677.
3	8097779CD1	g155947	1.2E-118	[Mus musculus] family 4 cytochrome P450
4	6963993CD1	g1698718	1.00E-121	[Mus musculus] aldo-keto reductase
5	7474404CD1	g391716	7.1E-215	[Homo sapiens] cytochrome P-450L(TBV) (leukotriene 84 omega-hydroxylase) Kikuta, Y. et al. (1993) J. Biol. Chem. 268:9376-9380.
6	7474438CD1	g2828262	3.00E-63	[Bos taurus] aralkyl acyl-CoA:amino acid N-acyltransferase Vessey, D.A. and Lau, E. (1996) J. Biochem. Toxicol. 11:211-215.
7	7476298CD1	g13774338	0	[Homo sapiens] cytochrome P450 subfamily IIIA polypeptide 43 (AF337813)
8	7477555CD1	g6435330	1.00E-103	[Macaca fascicularis] (AF200710) glutathione S-transferase mu-class subunit M2
9	1527520CD1	g7768662	9.00E-88	[Homo sapiens] chondroitin 4-sulfotransferase
10	3419318CD1	g2791315	7.10E-46	[Homo sapiens] UDP-galactose:2-acetamido-2-deoxy-D-glucose 3 beta-galactosyltransferase Kolbinger, F. et al. (1998) J. Biol. Chem. 273:433-440.
10	3419318CD1	g14039836	0	[Homo sapiens] (AF368169) beta 1,3 N-acetylglucosaminyltransferase Lc3 synthase [Schizosaccharomyces pombe] N-acetyltransferase
11	3815272CD1	g3451464	1.40E-35	

Table 2 (cont.)

Polyypeptide SEQ ID NO:	Incyte Polypeptide ID	GenBank ID NO:	Probability score	GenBank Homolog
12	7473875CD1	g1145789	0	[Rattus norvegicus] neuroligin 2 Ichtchenko, K. et al. (1996) J. Biol. Chem. 271:2676-2682.
13	7478099CD1	g881499	9.1E-167	[Mus musculus] parathion hydrolase (phosphotriesterase)-related protein
14	1962105CD1	g57806	9.00E-19	[Rattus sp.] gamma-glutamyltranspeptidase (AA 1-568) Griffiths, S.A. and Manson, M.M. (1989) Cancer Lett. 46:69-74.
15	5643401CD1	g13161409	8.8E-98	[Mus musculus] family 4 cytochrome P450
16	7478053CD1	g6644372	6.3E-195	[Homo sapiens] (AF337813) cytochrome P450 subfamily IIIA polypeptide 43
17	7478994CD1	g4261710	1.9E-127	[Homo sapiens] chlordecone reductase Qin, K.N. (1993) J. Steroid Biochem. Mol. Biol. 46:673-679.
18	7478577CD1	g3493209	6.5E-157	[Homo sapiens] aldo-keto reductase

Table 3

SEQ ID NO:	Incyte Polypeptide ID	Amino Acid Residues	Potential Phosphorylation Sites	Potential Glycosylation Sites	Potential Glycosylation Sites	Signature Sequences, Domains and Motifs
1	6274461CD1	351	S208 S320 S343 S85 T212	N134 N187 N200	DM00034   P54554   1-237:V47-E246	BLAST_DOMO BLIMPS_BLOCKS
2	7477262CD1	332	S121 S142 S285 S52 T124 T148 T25 T314 Y306	N172	BL00061A:G126-S136 BL00061B:G179-E216 BL00061C:D220-G229	BLIMPS_PRINTS

Table 3 (cont.)

SEQ ID NO:	Incute Polypeptide ID	Amino Acid Residues	Potential Phosphorylation Sites	Potential Glycosylation Sites	Signature Sequences, Domains and Motifs	Analytical Methods and Databases
					NNMT_PNMT_TEMT family of methyltransferases:	BLIMPS_BLOCKS
2					BL01100A:Y77-V103 BL01100B:L108-D151 BL01100C:F152-W173 BL01100D:Y176-R200 BL01100E:P224-L267 BL01100F:E268-V300 BL01100G:M308-R329	
					NNMT_PNMT_TEMT family: P64-L332	HMMER_PFAM
					Nnmt_Pnmt_Temt: L125-C141	MOTIFS
3	8097779CD1	525	S114 S145 S213 S305 S315 S347 S366 S401 T157 T307 T371 T388	N339	CYTOCHROME P450: DM00022 P29981 79-497:G95-I513 CYTOCHROME P450: PD000021:M166-D405	BLAST_DOMO BLAST_PRODOM BLIMPS_PRINTS
					E-class P450 group I signature: PR00463A:E83-L102 PR00463C:C195-S213 PR00463E:I338-G364 PR00463F:E382-R400 PR00463G:I422-P446 PR00463H:Y457-C467 PR00463I:C467-I490	

Table 3 (cont.)

SEQ NO:	Incyte Polypeptide ID	Amino Acid Residues	Potential Phosphorylation Sites	Potential Glycosylation Sites	Signature Sequences, Domains and Motifs	Signature Sequences, Domains and Motifs	Analytical Methods and Databases BLIMPS_PRINTS	
3					E-class P450 group II signature: PR00464A:G140-E160 PR00464B:L194-Q212 PR00464C:D318-G346 PR00464D:S347-G364 PR00464E:K377-L397 PR00464F:G416-R431 PR00464G:Y432-E447 PR00464H:P454-C467 PR00464I:C467-I490	E-class P450 group IV signature: PR00465A:I50-K67 PR00465C:R320-G346 PR00465D:L378-S394 PR00465F:H427-F445 PR00465G:G451-C467 PR00465H:C467-L485	E-class P450 group IV signature: PR00465A:I50-K67 PR00465C:R320-G346 PR00465D:L378-S394 PR00465F:H427-F445 PR00465G:G451-C467 PR00465H:C467-L485	BLIMPS_PRINTS
4	6963993CD1	304	S103 S141 S94 T18 T199 T283 Y47 Y54		Cytochrome P450 cytochrome heme-iron ligand signature: cytochrome_p450.prf:F439-F488 signal_peptide:M1-S20 Cytochrome P450: p450:I50-R519 signal_cleavage:M1-A25 Cytochrome_P450:F460-G469 ALDO/KETO REDUCTASE FAMILY: DM00192 P07943 1-297:Q29-L299 ALDEHYDE REDUCTASE: PD000288:V35-P233	Cytochrome P450 cytochrome heme-iron ligand signature: cytochrome_p450.prf:F439-F488 signal_peptide:M1-S20 Cytochrome P450: p450:I50-R519 signal_cleavage:M1-A25 Cytochrome_P450:F460-G469 ALDO/KETO REDUCTASE FAMILY: DM00192 P07943 1-297:Q29-L299 ALDEHYDE REDUCTASE: PD000288:V35-P233	PROFILESCAN HMMER HMMER_PFAM SPSCAN MOTIFS BLAST_DOMO BLAST_PRODOM	

Table 3 (cont.)

SEQ ID NO:	Incyte Polypeptide ID	Amino Acid Residues	Potential Phosphorylation Sites	Potential Glycosylation Sites	Signature Sequences, Domains and Motifs	Analytical Methods and Databases
4					Aldo/keto reductase family: BL00798B:A42-I66 BL00798C:V75-W87 BL00798D:A99-Y115 BL00798E:R184-G221 BL00798F:A239-M287	BLIMPS_BLOCKS
					Aldo-keto reductase signature: PR00069A:A42-I66 PR00069B:K102-P120 PR00069C:M152-F169 PR00069D:L188-Y217 PR00069E:L229-F253	BLIMPS_PRINTS
					Aldo/keto reductase family: aldo_ket_red:Q29-R298 Aldo/keto reductase family signatures: aldo_keto_reductase_2.prf:L130-Q191 aldo_keto_reductase_3.prf:I235-R298 Aldoketo_Reductase_1:G46-G63 Aldoketo_Reductase_2:M152-F169 signal_cleavage:M1-V35	HMMER_PFAM
						PROFILESCAN
						MOTIFS
						SPSCAN

Table 3 (cont.)

SEQ ID NO:	Incyte Polypeptide ID	Amino Acid Residues	Potential Phosphorylation Sites	Potential Glycosylation Sites	Signature Sequences, Domains and Motifs	Analytical Methods and Databases
5	7474404CD1	521	Y83, S139, S186, S229, T274, S311, S385	N168, N262	CYTOCHROME P450   DM00022   Q08477   108-511: P109-L509 CYTOCHROME P450 OXIDOREDUCTASE MONO-OXYGENASE ELECTRON TRANSPORT MEMBRANE HEME MICROSOME ENDOPLASMIC: PD008467: M1-M74	BLAST-DOMO
					Mitochondrial cytochrome P450 signature: PR0408I: C465-K476; PR0408B: S139-H149; PR0408D: G325-A342; PR0408E: R343-Q356; PR0408F: A373-P391	BLIMPS-PRINTS
					E-class cytochrome P450 group II: PR0464A: G141-K161; PR0464B: L197-Q215; PR0464C: N314-A342; PR0464D: R343-K360; PR0464E: Q374-R394; PR0464F: G414-S429; PR0464G: V430-E445; PR0464H: P452-C465; PR0464I: C465-V488	BLIMPS-PRINTS
					E-class cytochrome P450 group IV: PR00465D: L375-P391; PR00465F: H425-D443; PR00465H: C465-L483	BLIMPS-PRINTS
					Cytochrome P450 cysteine heme-iron ligand proteins: BL00086: F455-F486	BLIMPS-BLOCKS
					Cytochrome P450 cysteine heme-iron ligand signature (cytochrome_p450.prf) : N427-R485	PROFILESCAN
					Signal peptide (signal_peptide) : M1-A36	HMMER
					Transmembrane domain (transmembrane domain) : L9-W29	HMMER
					Cytochrome P450: K120-L516	HMMER-PPAM
					Signal cleavage (signal_cleavage) : M1-A32	SPSCAN

Table 3 (cont.)

SEQ NO:	Incyte Polypeptide ID	Amino Acid Residues	Potential Phosphorylation Sites	Potential Glycosylation Sites	Signature Sequences, Domains and Motifs	Analytical Methods and Databases
6	7474438CD1	302	S7, S20, S24, S48, S109, S122, T144, S151, S194, S265, S278	N5, N145, N175, N243	TRANSFERASE ACYLTRANSFERASE N-ACYLTRANS- FERASE PUTATIVE GLYCINE-N-ACYLTRANSFERASE ARALKYL ACYL-COA:AMINO ACID GLYCINE ARYLACETYL: PD0222048: M1-K140 Signal cleavage (signal_cleavage): M1-P22	BLAST-PRODOM SPSCAN
7	7476298CD1	502		S28, S118, S138, S158, S285, S290, T322, T362, T408, S419, Y431, S463	CYTOCHROME P450 DM00022 P08684 59-488: F59- I488 CYTOCHROME P450 MONOOXYGENASE OXIDOREDUCTASE HEME ELECTRON TRANSPORT MEMBRANE MICROSOME ENDOPLASMIC PD000021: D181-V369; H401-R495; W57-T283; L349-D424; P38-E96	BLAST-PRODOM

Table 3 (cont.)

SEQ ID NO:	Incyte Polypeptide ID	Amino Acid Residues	Potential Phosphorylation Sites	Potential Glycosylation Sites	Signature Sequences, Domains and Motifs	Analytical Methods and Databases
8	7477555CD1	217	S27, T90, T154, S186,		GLUTATHIONE TRANSFERASE   DM00127   P09488   76-190 : I80-E192 Glutathione S-transferases: L5-E192 Glutathione S-transferase signature: PF00043: N59-G88 Signal cleavage (signal_cleavage) : M1-E29	BLAST-DOPO HMMER-PFAM BLIMPS-PFAM SPSCAN

Table 3 (cont.)

SEQ ID NO:	Incyte Polypeptide ID	Amino Acid Residues	Potential Phosphorylation Sites	Potential Glycosylation Sites	Signature Sequences, Domains and Motifs	Analytical Methods and Databases
9	1527520CD1	341	S29, S85, S139, S151, S156, Y231, T237, T269	N331	HNK1 SULFOTRANSFERASE TRANSFERASE PRECURSOR SIGNAL: PD041629: L44-L338 Sulfatase proteins: BL00523G: L55-S64 Signal peptide (signal peptide): M1-R28 Signal cleavage (signal cleavage): M1-R31 RGD domain: R132-D134	BLAST-PRODOM BLIMPS-BLOCKS HMMER SPSCAN MOTIFS
10	3419318CD1	378	S6, S47, S63, T96, T169, Y153, T191, S234, S366	N59, N167, N276, N335	PROTEIN TRANSFERASE, GALACTOSYLTRANSFERASE, UDPGAL: BETA GLCNAC: PD004190: R103-I295 Galactosyltransferase (Galactosyl-T): D102-T321	BLAST-PRODOM HMMER-PFAM

Table 3 (cont.)

SEQ ID NO:	Incyte Polypeptide ID	Amino Acid Residues	Potential Phosphorylation Sites	Potential Glycosylation Sites	Signature Sequences, Domains and Motifs	Analytical Methods and Databases
11	3815272CD1	361	S39, S100, S107, T117, S151, T172, S195, S200, T211, T242, T324	N325	ARD1; COMPLEX; ACETYLTRANSFERASE; TERMINAL; DM04629   P36416   1-192: Q222-R361; Acetyltransferase (GNAT) : PF00583A: V288-G298; PF00583B: A328-F337; Acetyltransferase (GNAT) family, Acetyltransf: V215-V338	BLAST- DOMO; BLIMPS- PFAM; HMMER- PFAM
12	7473875CD1	801	S35, T156, S187, S223, S334, S404, T430, T450, T467, S524, S780, T619, T640, Y672, S713, S765, S770	N98, N136, N522	CARBOXYESTERASES TYPE-B DM00175   P23141   20-362: E151-E386; P42-K158; ESTERASE HYDROLASE PRECURSOR SIGNAL GLYCOPROTEIN SERINE PROTEIN CARBOXYESTERASE FAMILY MULTIGENE PD00169: L31-V338; C317-W601	BLAST- PRODOM; BLAST- DOMO

Table 3 (cont.)

SEQ ID NO:	Incyte Polypeptide ID	Amino Acid Residues	Potential Phosphorylation Sites	Potential Glycosylation Sites	Signature Sequences, Domains and Motifs	Analytical Methods and Databases
13	7478099CD1	349	S161, S179, S205 S229, S5, S66 T109, T177, T234 T347	N98	TRPS; PARATHION HYDROLASE (related to phosphotriesterases) DM06515   P45548   1-291; K68-W345; G21-L29 HYDROLASE, PHOSPHOTRIESTERASE, ZINC PROTEIN, PARATHION 3-D STRUCTURE HOMOLOGY, RELATED HYDROLASE-RELATED PRECURSOR PD009461: E76-W345; S18-L29 Phosphotriesterase family (PTE): K19-M31; E45-W345	BLAST-DOMO
14	1962105CD1	499	Y10, S22, S45, S413, T417,	N167, N376	GAMMA-GLUTAMYL TRANSPEPTIDASE: DM01065   JC4570   44-568: A114-L229, L359-N394 Gamma-glutamyltranspeptidase proteins: BL00462: G108-T150, L183-F219	BLAST-DOMO BLIMPS-BLOCKS

Table 3 (cont.)

SEQ NO:	Incyte Polypeptide ID	Amino Acid Residues	Potential Phosphorylation Sites	Potential Glycosylation Sites	Signature Sequences, Domains and Motifs	Analytical Methods and Databases
15	5643401CD1	532	S131, S153, T165, S312, T314, S322, S354, S373, T378, T395, S408	N346	CYTOCHROME P450: DM00022   P29981   79-497: G95-I520 CYTOCHROME P450 MONOXYGENASE OXIDOREDUCTASE HEME ELECTRON TRANSPORT MEMBRANE MICROSOME ENDOPLASMIC: PD000021: E260-D412, G371-N455, H434-F495, P49-Q191	BLAST-DOMO BLAST-PRODOM
					Cytochrome P450 cysteine heme-iron ligand proteins: BL00086: Y464-F495	BLIMPPS-BLOCKS
					E-class P450 group I signature: PRO0463: Y464-C474, C474-I497, E83-L102, I345-G371, E389-R407, I429-P453	BLIMPPS-PRINTS
					E-class P450 group II signature: PRO0464: G148-E168, D325-G353, S354-G371, K384-L404, G423-R438, Y439-E454, P461-C474, C474-I497	BLIMPPS-PRINTS
					E-class P450 group IV signature: PRO0465: R327-G353, L385-S401, H434-F452, G458-C474, C474-L492	BLIMPPS-PRINTS
					Signal peptide (signal peptide): M1-S20	HMMER
					Cytochrome P450 (p450): I50-R526	HMMER-PFAM
					Cytochrome P450 (Cytochrome_P450): F467-G476	MOTIFS
					Cytochrome P450 cysteine heme-iron ligand signature (cytochrome_p450.prf): F446-F495	PROFILESCAN
					Signal cleavage (signal cleavage): M1-A25	SPSCAN

Table 3 (cont.)

SEQ ID NO:	Incyte Polypeptide ID	Amino Acid Residues	Potential Phosphorylation Sites	Potential Glycosylation Sites	Signature Sequences, Domains and Motifs	Analytical Methods and Databases
16	7478053CD1	508	S28, T58, S124, S144, S164, S291, S296, T328, T368, T414, S425, S469, Y437	N366, N467	CYTOCHROME P450: DM00022   P08684   58-487: E61-I494 CYTOCHROME P450 MONOOXYGENASE OXIDOREDUCTASE HEME ELECTRON TRANSPORT MEMBRANE MICROSOME ENDOPLASMIC PD00021: D187-V375, H407-R501, P38-T289, L355-D430 Cytochrome P450 cysteine heme-iron ligand proteins: BL00086: Y437-F468 P450 superfamily signature: PR00385: A310-A327, T328-D341, M363-V374, I438-C447, C447-K458	BLAST-DOMO BLAST-PRODOM BLIMPS-BLOCKS BLIMPS-PRINTS
17	7478994CD1	323	Y53, T73, Y81, T82, S102, S221, S249, T289	N198	ALDO/KETO REDUCTASE FAMILY: DM00192   JH0575   5-305: Q6-Y305 PROTEIN OXIDOREDUCTASE REDUCTASE CHANNEL NADP DEHYDROGENASE ALDEHYDE IONIC ALDOSE BUTYLATIVE PD000288: E36-L308, L10-V85 Aldo/keto reductase family signature: BL00798: L10-Y24, A41-I65, V74-K86, A98-E114, K183-G220, A245-M293	BLAST-DOMO BLAST-PRODOM BLIMPS-BLOCKS PROFILES CAN SPSCAN

Table 3 (cont.)

SEQ ID NO:	Incyte Polypeptide ID	Amino Acid Residues	Potential Phosphorylation Sites	Potential Glycosylation Sites	Signature Sequences, Domains and Motifs	Analytical Methods and Databases
17					Aldo-keto reductase signature: PR00069: A41-I65, R101-P119, L151-F168, T187-Y216, L235-Y259 Aldo/keto reductase family (aldo_ket_red): L10-R304	BLIMPS-PRINTS HMMER-PFAM
18	7478577CD1	316	T3, S8, T20, Y40, Y47, T82, T96, S103, T118, S133, T137, S227, T245, S282, S305	N257	ALDO/KETO REDUCTASE FAMILY DM00192   P21300   1-297: A2-A298 PROTEIN OXIDOREDUCTASE REDUCTASE CHANNEL NADP DEHYDROGENASE ALDEHYDE TONIC ALDOSE PD000288: V2.8-N295, E272-M286 Aldo/keto reductase family: BL00798: L7-W21, A35-I59, V68-W80, A92-Y108, K177-G214, A238-M286 Aldo-keto reductase signature: PR00069: A35-I59, K95-P113, M145-F162, V181-Y210, L228-F252 Aldo/keto reductase family (aldo_ket_red): L7-R297 Aldo-keto reductase: Aldoketo_Reductase_2: M145-F162 Aldo/keto reductase family signatures: aldoketo_reductase_2.prf: D120-Q184; aldoketo_reductase_3.prf: I234-A298 Signal cleavage (signal_cleavage): M1-G26	MOTIFS BLIMPS-PRINTS HMMER-PFAM PROFILESCAN BLAST-DOMO BLAST-PRODOM BLIMPS-BLOCKS BLIMPS-PRINTS HMMER-PFAM MOTIFS PROFILESCAN SPSCAN

Table 4

Polynucleotide SEQ ID NO:	Incyte Polynucleotide ID	Sequence Length	Selected Fragment(s)	Sequence Fragments	5' Position	3' Position
19	6274461CB1	1154	879-1154, 1-129, 255-825	6274461T8 (BRAIFENO3)	365	1154
20	7477262CB1	1324	1-278, 1225-1324	6274461F8 (BRAIFENO3)	1	586
				7355965H1 (HEARNON03)	1	517
				71356628V1 (BRANDINO1)	641	1219
				6330747H1 (BRANDINO1)	776	1324
21	8097779CB1	2498	1-159, 1065- 1106, 2155-2498	71357045V1 (COLTDIT04)	441	1036
				5872309F8 (COLTDIT04)	1994	2498
				71704341V1 (SINTDIE01)	1519	2148
				7635661H1 (SINTDIE01)	1	603
				FL8097779_g6573826_- 000012_g7331756	501	2078
22	6963993CB1	1158	1-218	FL6963993_g7549607_- 000014_g1698718	135	1049
				g6503584 6963993H1	763	1158
				(SKINDIA01)	1	510
23	7474404CB1	2075	153-339, 1552- 1704, 2050-2075	4860766T7 (PROSTUT09)	1315	2048
				GNN.97458736_000008 006.edit	199	1106
				71137969V1 71919271V1	1406	2075
				GBI.97458736_000004 .edit	681	1347
				GNN.96604369_018.ed it	1304	1549
				GNN.97458736_000008 004.edit	54	343
				GNN.98118775_edit 606547H1	1	180
24	7474438CB1	909	1-26	GNN.98118775_edit (BRSTTUT01)	1	909
				FL7476298_g8051573_- g2388529	326	630
25	7476298CB1	1613	1-265	g2077679	1	1509
					1154	1613

Table 4 (cont.)

Polynucleotide SEQ ID NO:	Incyte Polynucleotide ID	Sequence Length	Selected Fragment(s)	Sequence Fragments	5' Position	3' Position
26	7477555CB1	654		GB1.g7798789.edit	1	654
27	1527520CB1	2064	359-491, 873-941, 1462-1572	7725684H1 (THYRDIE01) g6701373 6825605J1 (SINTNOR01) 6792569H1 (LIVRTXS02) GB1.g98389356_000001 .edit	610 1 1031 438	1245 358 1858 976 2057
28	3419318CB1	4071	1-1479	7335641H1 (CONFETDN02) 6571230H1 (MCLEDTXN05)	-1625 1	2064 548
				71983691V1 71983936V1 71985484V1 6083160F8 (LUNLTUT11) 7747230H1 (NOSEDINO1) 7307661H2 (MMLR1DT01) 71987012V1 FL3419318_g7342002- 000024_g2791315	3505 3428 1034 2795 3485 2795 349 1791 1903 4755	4066 4056 1813 3485 3485 3485 4071 2478 2757 1611
29	3815272CB1	4444	1-417, 1806-2889	1289787F1 (BRAINOT11) 2247387R6 (HILPONON02) 2590489F6 (LUNGNOT22) 7622959H1 (HEARFEE03) 1851878F6 (LUNGFET03) 7989404H1 (UTRCDIC01) 4823313T9 (PROSTUT17)	2697 2791 2288 2616 2616 3184 3234 2752 1243 1814 3176 3744 1483 2102 3775 4344	3434 3234 2752 3184 3184 3744 2102 4344

Table 4 (cont.)

Polynucleotide SEQ ID NO:	Incyte Polynucleotide ID	Sequence Length	Selected Fragment(s)	Sequence Fragments	5' Position	3' Position
29	3815272CB1	4444	1-417, 1806-2889	93678761	1058	1417
				95664396	418	897
				1289872T6	3982	4414
				(BRAINOT11)		
				2590489T6	3874	4411
				(LUNGNOT22)		
				70740815V1	3320	3798
				7737516J1	2077	2737
				(BRAITUE01)		
				7030220H1	756	1314
				(BRAAXTDR12)		
				97799388_edit	1	425
				55030272H1	1690	2375
				(FLPPX0025)		
				96505262	138	567
				6911386H1	1165	1728
				(PITUDIRO1)		
				7397979H1	1923	2553
				(KIDDEUNE02)		
				8016020J1	215	560
				(BMARTXE01)		
				6911386J1	1253	1899
				(PITUDIRO1)		
				55005920J1	361	1169
				(GFCRDNV19)		
				6324474H1	2431	2663
				(LUNGDIN02)		
				6753582J1	567	1266
				(SINTTFER02)		
				3320618T6	2686	3391
				(PROSBPT03)		
				6044534H1	1770	2310
				(BRAABDIR02)		
				3320618F6	1562	2257
				(PROSBPT03)		
				71580251V1	80	862
				418644T6	2351	2940
				(BRSTNOT01)		
				2743371F6	3415	3944
				(BRSTITUT14)		

Table 4 (cont.)

Polynucleotide SEQ ID NO:	Incyte Polynucleotide ID	Sequence Length	Selected Fragment(s)	Sequence Fragments	5' Position	3' Position
31	7478099CB1	3944	2950-3944, 1-855	6044392J1 (BRABDI02)	1062	1595
				2768878H1 (COLANOT02)	1	253
				71580273V1	398	929
				3705837T6 (PENCNOT07)	2249	2922
				1505116T6 (BRAITUT07)	3052	3678
32	1962105CB1	2053	1915-1947, 1-141, 554-1072	71584625V1 (LSUBDMC01)	670	1414
				72003862V1	510	1168
				1328936F6 (PANCNOT07)	1	393
				7978288H1	301	1013
				72001471V1	1320	2053
				72001589V1	1294	2006
33	5643401CB1	2019	1676-2019, 328-435, 589-693	5872309F8 (COLTDT04)	1515	2019
				FL5643401_g6573826_-1		1599
				000012_g7301993		
34	7478053CB1	1631	1-283	FL7478053_g8051573_-1		1527
				9510086		
35	7478994CB1	969	926-969, 253-272, 195-220	GBI:g8517842	1	969
				g2077679	1172	1631
36	7478577CB1	951		4104879F6 (BRSTRT017)	171	897
				g8920499_edit	1	951

Table 5

Polynucleotide SEQ ID NO:	Incyte Project ID	Representative Library
19	6274461CB1	BRAIFENO3
20	7477262CB1	ADRETUT06
21	8097779CB1	UTREDIT07
22	6963993CB1	BRSTTUT17
23	7474404CB1	PROSTUT09
24	7474438CB1	BRSTTUT01
25	7476298CB1	BLADTUT08
27	1527520CB1	UCMCL5T01
28	3419318CB1	BRONDIT01
29	3815272CB1	PROSTUT12
30	7473875CB1	KIDEUNE02
31	7478099CB1	BRSTNOT01
32	1962105CB1	PANCNOT07
33	5643401CB1	UTREDIT07
34	7478053CB1	BLADTUT08
36	7478577CB1	BRSTTUT17

Table 6

Library	Vector	Library Description
ADRETUT06	PINCY	Library was constructed using RNA isolated from adrenal tumor tissue removed from a 57-year-old Caucasian female during a unilateral right adrenalectomy. Pathology indicated pheochromocytoma, forming a nodular mass completely replacing the medulla of the adrenal gland.
BLADTUT08	PINCY	Library was constructed using RNA isolated from bladder tumor tissue removed from a 72-year-old Caucasian male during a radical cystectomy and prostatectomy. Pathology indicated an invasive grade 3 (of 3) transitional cell carcinoma in the right bladder base. Patient history included pure hypercholesterolemia and tobacco abuse. Family history included myocardial infarction, cerebrovascular disease, and brain cancer.
BRAIFEN03	PINCY	This normalized fetal brain tissue library was constructed from 3.26 million independent clones from a fetal brain library. Starting RNA was made from brain tissue removed from a Caucasian male fetus, who was stillborn with a hypoplastic left heart at 23 weeks' gestation. The library was normalized in 2 rounds using conditions adapted from Soares et al., PNAS (1994) 91:9228 and Bonaldo et al., Genome Research (1996) 6:791, except that a significantly longer (48 hours/round) reannealing hybridization was used.
BRONDIT01	PINCY	Library was constructed using RNA isolated from right lower lobe bronchial tissue removed from a pool of 3 asthmatic Caucasian male and female donors, 22- to 51-years-old during bronchial pinch biopsies. Patient history included atopy as determined by positive skin tests to common aero-allergens.
BRSTNOT01	PBLUESCRIPT	Library was constructed using RNA isolated from the breast tissue of a 56-year-old Caucasian female who died in a motor vehicle accident.
BRSTTUT17	PINCY	Library was constructed using RNA isolated from left breast tumor tissue removed from a 65-year-old Caucasian female during a unilateral radical mastectomy. Pathology indicated invasive and in situ grade 3, nuclear grade 2 ductal carcinoma. Patient history included hyperlipidemia and uterine leiomyoma. Family history included stomach cancer, myocardial infarction, atherosclerotic coronary artery disease, prostate cancer, benign hypertension, breast cancer, and hyperlipidemia.
BRSTTUT01	PSBPORT1	Library was constructed using RNA isolated from breast tumor tissue removed from a 55-year-old Caucasian female during a unilateral extended simple mastectomy. Pathology indicated invasive grade 4 mammary adenocarcinoma of mixed lobular and ductal type, extensively involving the left breast. The tumor was identified in the deep dermis near the lactiferous ducts with extracapsular extension. Seven mid and low and five high axillary lymph nodes were positive for tumor. Proliferative fibrocytic changes were characterized by apocrine metaplasia, sclerosing adenosis, cyst formation, and ductal hyperplasia without atypia.

Library	Vector	Library Description
KIDEUNE02	PINCY	This 5' biased random primed library was constructed using RNA isolated from an untreated transformed embryonal cell line (293-EBNA) derived from kidney epithelial tissue (Invitrogen). The cells were transformed with adenovirus 5 DNA.
PANCNOT07	PINCY	Library was constructed using RNA isolated from the pancreatic tissue of a Caucasian male fetus, who died at 23 weeks' gestation.
PROSTUT09	PINCY	Library was constructed using RNA isolated from prostate tumor tissue removed from a 66-year-old Caucasian male during a radical prostatectomy, radical cystectomy, and urinary diversion. Pathology indicated grade 3 transitional cell carcinoma. The patient presented with prostatic inflammatory disease. Patient history included lung neoplasm, and benign hypertension. Family history included a malignant breast neoplasm, tuberculosis, cerebrovascular disease, atherosclerotic coronary artery disease and lung cancer.
PROSTUT12	PINCY	Library was constructed using RNA isolated from prostate tumor tissue removed from a 65-year-old Caucasian male during a radical prostatectomy. Pathology indicated an adenocarcinoma (Gleason grade 2+2). Adenofibromatous hyperplasia was also present. The patient presented with elevated prostate specific antigen (PSA).
UCMCL5T01	PBLUESCRIPT	Library was constructed using RNA isolated from mononuclear cells obtained from the umbilical cord blood of 12 individuals. The cells were cultured for 12 days with IL-5 before RNA was obtained from the pooled lysates.
UTREDIT07	PINCY	Library was constructed using RNA isolated from diseased endometrial tissue removed from a female during endometrial biopsy. Pathology indicated in phase endometrium with missing beta 3, Type II defects.

Table 7

Program	Description	Reference	Parameter Threshold
ABI FACTURA	A program that removes vector sequences and masks ambiguous bases in nucleic acid sequences.	Applied Biosystems, Foster City, CA.	
ABI/PARACEL FDF	A Fast Data Finder useful in comparing and annotating amino acid or nucleic acid sequences.	Applied Biosystems, Foster City, CA; Paracel Inc., Pasadena, CA.	Mismatch <50%
ABI AutoAssembler	A program that assembles nucleic acid sequences.	Applied Biosystems, Foster City, CA.	
BLAST	A Basic Local Alignment Search Tool useful in sequence similarity search for amino acid and nucleic acid sequences. BLAST includes five functions: blastp, blastn, blastx, tblastn, and tblastx.	Altschul, S.F. et al. (1990) J. Mol. Biol. 215:403-410; Altschul, S.F. et al. (1997) Nucleic Acids Res. 25:3389-3402.	ESTs: Probability value= 1.0E-8 or less <i>Full Length sequences</i> : Probability value= 1.0E-10 or less
FASTA	A Pearson and Lipman algorithm that searches for similarity between a query sequence and a group of sequences of the same type. FASTA comprises at least five functions: fasta, tfasta, fastx, tfastx, and ssearch.	Pearson, W.R. and D.J. Lipman (1988) Proc. Natl. Acad. Sci. USA 85:2444-2448; Pearson, W.R. (1990) Methods Enzymol. 183:63-98; and Smith, T.F. and M.S. Waterman (1981) Adv. Appl. Math. 2:482-489.	ESTs: fasta E value=1.06E-6 Assembled ESTs: fasta Identity= 95% or greater and Match length=200 bases or greater; fastx E value=1.0E-8 or less <i>Full Length sequences</i> : fastx score=100 or greater
BLIMPS	A BLocks IMProved Searcher that matches a sequence against those in BLOCKS, PRINTS, DOMO, PRODOM, and PFAM databases to search for gene families, sequence homology, and structural fingerprint regions.	Henikoff, S. and J.G. Henikoff (1991) Nucleic Acids Res. 19:6565-6572; Henikoff, J.G. and S. Henikoff (1996) Methods Enzymol. 266:88-105; and Atwood, T.K. et al. (1997) J. Chem. Inf. Comput. Sci. 37:417-424.	Probability value= 1.0E-3 or less
HMMER	An algorithm for searching a query sequence against hidden Markov model (HMM)-based databases of protein family consensus sequences, such as PFAM.	Krogh, A. et al. (1994) J. Mol. Biol. 235:1501-1531; Sonnhammer, E.L.L. et al. (1988) Nucleic Acids Res. 26:320-322; Durbin, R. et al. (1998) <i>Our World View</i> , in a Nutshell, Cambridge Univ. Press, pp. 1-350.	PFAM hits: Probability value= 1.0E-3 or less <i>Signal peptide hits</i> : Score= 0 or greater

Table 7 (cont.)

Program	Description	Reference	Parameter Threshold
ProfileScan	An algorithm that searches for structural and sequence motifs in protein sequences that match sequence patterns defined in Prosite.	Gribskov, M. et al. (1988) CABIOS 4:61-66; Gribskov, M. et al. (1989) Methods Enzymol. 183:146-159; Bairoch, A. et al. (1997) Nucleic Acids Res. 25:217-221.	Normalized quality score $\geq$ GCGr-specified "HIGH" value for that particular Prosite motif. Generally, score=1.4-2.1.
Phred	A base-calling algorithm that examines automated sequencer traces with high sensitivity and probability.	Ewing, B. et al. (1998) Genome Res. 8:175-185; Ewing, B. and P. Green (1998) Genome Res. 8:186-194.	
Phrap	A Phils Revised Assembly Program including SWAT and CrossMatch, programs based on efficient implementation of the Smith-Waterman algorithm, useful in searching sequence homology and assembling DNA sequences.	Smith, T.F. and M.S. Waterman (1981) Adv. Appl. Math. 2:482-489; Smith, T.F. and M.S. Waterman (1981) J. Mol. Biol. 147:195-197; and Green, P., University of Washington, Seattle, WA.	Score=120 or greater; Match length= 56 or greater
Consed	A graphical tool for viewing and editing Phrap assemblies.	Gordon, D. et al. (1998) Genome Res. 8:195-202.	
SPScan	A weight matrix analysis program that scans protein sequences for the presence of secretory signal peptides.	Nielson, H. et al. (1997) Protein Engineering 10:1-6; Claverie, J.M. and S. Audic (1997) CABIOS 12:431-439.	Score=3.5 or greater
TMAP	A program that uses weight matrices to delineate transmembrane segments on protein sequences and determine orientation.	Persson, B. and P. Argos (1994) J. Mol. Biol. 237:182-192; Persson, B. and P. Argos (1996) Protein Sci. 5:363-371.	
TMHMMER	A program that uses a hidden Markov model (HMM) to delineate transmembrane segments on protein sequences and determine orientation.	Sonnhammer, E.L. et al. (1998) Proc. Sixth Int'l. Conf. on Intelligent Systems for Mol. Biol., Glasgow et al., eds., The Am. Assoc. for Artificial Intelligence Press, Menlo Park, CA, pp. 175-182.	
Motifs	A program that searches amino acid sequences for patterns that matched those defined in Prosite.	Bairoch, A. et al. (1997) Nucleic Acids Res. 25:217-221; Wisconsin Package Program Manual, version 9, page M51-59, Genetics Computer Group, Madison, WI.	

What is claimed is:

1. An isolated polypeptide selected from the group consisting of:
  - a) a polypeptide comprising an amino acid sequence selected from the group consisting of SEQ ID NO:1-18,
  - b) a polypeptide comprising a naturally occurring amino acid sequence at least 90% identical to an amino acid sequence selected from the group consisting of SEQ ID NO:1-18,
  - c) a biologically active fragment of a polypeptide having an amino acid sequence selected from the group consisting of SEQ ID NO:1-18, and
  - d) an immunogenic fragment of a polypeptide having an amino acid sequence selected from the group consisting of SEQ ID NO:1-18.
2. An isolated polypeptide of claim 1 selected from the group consisting of SEQ ID NO:1-18.
3. An isolated polynucleotide encoding a polypeptide of claim 1.
4. An isolated polynucleotide encoding a polypeptide of claim 2.
5. An isolated polynucleotide of claim 4 selected from the group consisting of SEQ ID NO:19-36.
6. A recombinant polynucleotide comprising a promoter sequence operably linked to a polynucleotide of claim 3.
7. A cell transformed with a recombinant polynucleotide of claim 6.
8. A transgenic organism comprising a recombinant polynucleotide of claim 6.
9. A method for producing a polypeptide of claim 1, the method comprising:
  - a) culturing a cell under conditions suitable for expression of the polypeptide, wherein said cell is transformed with a recombinant polynucleotide, and said recombinant polynucleotide comprises a promoter sequence operably linked to a polynucleotide encoding the polypeptide of claim 1, and
  - b) recovering the polypeptide so expressed.

10. An isolated antibody which specifically binds to a polypeptide of claim 1.
11. An isolated polynucleotide selected from the group consisting of:
  - a) a polynucleotide comprising a polynucleotide sequence selected from the group consisting of SEQ ID NO:19-36,
  - 5 b) a polynucleotide comprising a naturally occurring polynucleotide sequence at least 90% identical to a polynucleotide sequence selected from the group consisting of SEQ ID NO:19-36,
  - c) a polynucleotide complementary to a polynucleotide of a),
  - d) a polynucleotide complementary to a polynucleotide of b), and
  - 10 e) an RNA equivalent of a)-d).
12. An isolated polynucleotide comprising at least 60 contiguous nucleotides of a polynucleotide of claim 11.
- 15 13. A method for detecting a target polynucleotide in a sample, said target polynucleotide having a sequence of a polynucleotide of claim 11, the method comprising:
  - a) hybridizing the sample with a probe comprising at least 20 contiguous nucleotides comprising a sequence complementary to said target polynucleotide in the sample, and which probe specifically hybridizes to said target polynucleotide, under conditions whereby a hybridization complex is formed between said probe and said target polynucleotide or fragments thereof, and
  - 20 b) detecting the presence or absence of said hybridization complex, and, optionally, if present, the amount thereof.
14. A method of claim 13, wherein the probe comprises at least 60 contiguous nucleotides.
- 25 15. A method for detecting a target polynucleotide in a sample, said target polynucleotide having a sequence of a polynucleotide of claim 11, the method comprising:
  - a) amplifying said target polynucleotide or fragment thereof using polymerase chain reaction amplification, and
  - 30 b) detecting the presence or absence of said amplified target polynucleotide or fragment thereof, and, optionally, if present, the amount thereof.
16. A composition comprising a polypeptide of claim 1 and a pharmaceutically acceptable excipient.

17. A composition of claim 16, wherein the polypeptide has an amino acid sequence selected from the group consisting of SEQ ID NO:1-18.

18. A method for treating a disease or condition associated with decreased expression of functional DME, comprising administering to a patient in need of such treatment the composition of claim 16.

19. A method for screening a compound for effectiveness as an agonist of a polypeptide of claim 1, the method comprising:

- 10 a) exposing a sample comprising a polypeptide of claim 1 to a compound, and
- b) detecting agonist activity in the sample.

20. A composition comprising an agonist compound identified by a method of claim 19 and a pharmaceutically acceptable excipient.

15

21. A method for treating a disease or condition associated with decreased expression of functional DME, comprising administering to a patient in need of such treatment a composition of claim 20.

20

22. A method for screening a compound for effectiveness as an antagonist of a polypeptide of claim 1, the method comprising:

- a) exposing a sample comprising a polypeptide of claim 1 to a compound, and
- b) detecting antagonist activity in the sample.

25

23. A composition comprising an antagonist compound identified by a method of claim 22 and a pharmaceutically acceptable excipient.

30

24. A method for treating a disease or condition associated with overexpression of functional DME, comprising administering to a patient in need of such treatment a composition of claim 23.

25. A method of screening for a compound that specifically binds to the polypeptide of claim 1, said method comprising the steps of:

- 35 a) combining the polypeptide of claim 1 with at least one test compound under suitable conditions, and

b) detecting binding of the polypeptide of claim 1 to the test compound, thereby identifying a compound that specifically binds to the polypeptide of claim 1.

26. A method of screening for a compound that modulates the activity of the polypeptide of claim 1, said method comprising:

a) combining the polypeptide of claim 1 with at least one test compound under conditions permissive for the activity of the polypeptide of claim 1,

b) assessing the activity of the polypeptide of claim 1 in the presence of the test compound, and

10 c) comparing the activity of the polypeptide of claim 1 in the presence of the test compound with the activity of the polypeptide of claim 1 in the absence of the test compound, wherein a change in the activity of the polypeptide of claim 1 in the presence of the test compound is indicative of a compound that modulates the activity of the polypeptide of claim 1.

15 27. A method for screening a compound for effectiveness in altering expression of a target polynucleotide, wherein said target polynucleotide comprises a sequence of claim 5, the method comprising:

a) exposing a sample comprising the target polynucleotide to a compound, under conditions suitable for the expression of the target polynucleotide,

20 b) detecting altered expression of the target polynucleotide, and

c) comparing the expression of the target polynucleotide in the presence of varying amounts of the compound and in the absence of the compound.

28. A method for assessing toxicity of a test compound, said method comprising:

25 a) treating a biological sample containing nucleic acids with the test compound;

b) hybridizing the nucleic acids of the treated biological sample with a probe comprising at least 20 contiguous nucleotides of a polynucleotide of claim 11 under conditions whereby a specific hybridization complex is formed between said probe and a target polynucleotide in the biological sample, said target polynucleotide comprising a polynucleotide sequence of a polynucleotide of claim 11 or fragment thereof;

c) quantifying the amount of hybridization complex; and

d) comparing the amount of hybridization complex in the treated biological sample with the amount of hybridization complex in an untreated biological sample, wherein a difference in the amount of hybridization complex in the treated biological sample is indicative of toxicity of the test

compound.

29. A diagnostic test for a condition or disease associated with the expression of DME in a biological sample comprising the steps of:

5           a) combining the biological sample with an antibody of claim 10, under conditions suitable for the antibody to bind the polypeptide and form an antibody:polypeptide complex; and  
              b) detecting the complex, wherein the presence of the complex correlates with the presence of the polypeptide in the biological sample.

10           30. The antibody of claim 10, wherein the antibody is:

              a) a chimeric antibody,  
              b) a single chain antibody,  
              c) a Fab fragment,  
              d) a F(ab')<sub>2</sub> fragment, or  
              e) a humanized antibody.

15

31. A composition comprising an antibody of claim 10 and an acceptable excipient.

20           32. A method of diagnosing a condition or disease associated with the expression of DME in a subject, comprising administering to said subject an effective amount of the composition of claim 31.

25           33. A composition of claim 31, wherein the antibody is labeled.

34. A method of diagnosing a condition or disease associated with the expression of DME in a subject, comprising administering to said subject an effective amount of the composition of claim 33.

30           35. A method of preparing a polyclonal antibody with the specificity of the antibody of claim 10 comprising:

              a) immunizing an animal with a polypeptide having an amino acid sequence selected from the group consisting of SEQ ID NO:1-18, or an immunogenic fragment thereof, under conditions to elicit an antibody response;  
              b) isolating antibodies from said animal; and

c) screening the isolated antibodies with the polypeptide, thereby identifying a polyclonal antibody which binds specifically to a polypeptide having an amino acid sequence selected from the group consisting of SEQ ID NO:1-18.

5 36. An antibody produced by a method of claim 35.

37. A composition comprising the antibody of claim 36 and a suitable carrier.

38. A method of making a monoclonal antibody with the specificity of the antibody of claim  
10 10 comprising:

a) immunizing an animal with a polypeptide having an amino acid sequence selected from the group consisting of SEQ ID NO:1-18, or an immunogenic fragment thereof, under conditions to elicit an antibody response;

b) isolating antibody producing cells from the animal;

15 c) fusing the antibody producing cells with immortalized cells to form monoclonal antibody-producing hybridoma cells;

d) culturing the hybridoma cells; and

e) isolating from the culture monoclonal antibody which binds specifically to a polypeptide having an amino acid sequence selected from the group consisting of SEQ ID NO:1-18.

20

39. A monoclonal antibody produced by a method of claim 38.

40. A composition comprising the antibody of claim 39 and a suitable carrier.

25 41. The antibody of claim 10, wherein the antibody is produced by screening a Fab expression library:

42. The antibody of claim 10, wherein the antibody is produced by screening a recombinant immunoglobulin library.

30

43. A method for detecting a polypeptide having an amino acid sequence selected from the group consisting of SEQ ID NO:1-18 in a sample, comprising the steps of:

a) incubating the antibody of claim 10 with a sample under conditions to allow specific binding of the antibody and the polypeptide; and

5 b) detecting specific binding, wherein specific binding indicates the presence of a polypeptide having an amino acid sequence selected from the group consisting of SEQ ID NO:1-18 in the sample.

10 44. A method of purifying a polypeptide having an amino acid sequence selected from the group consisting of SEQ ID NO:1-18 from a sample, the method comprising:

a) incubating the antibody of claim 10 with a sample under conditions to allow specific binding of the antibody and the polypeptide; and

15 b) separating the antibody from the sample and obtaining the purified polypeptide having an amino acid sequence selected from the group consisting of SEQ ID NO:1-18.

45. A polypeptide of claim 1, comprising the amino acid sequence of SEQ ID NO:1.

15 46. A polypeptide of claim 1, comprising the amino acid sequence of SEQ ID NO:2.

47. A polypeptide of claim 1, comprising the amino acid sequence of SEQ ID NO:3.

48. A polypeptide of claim 1, comprising the amino acid sequence of SEQ ID NO:4.

20 49. A polypeptide of claim 1, comprising the amino acid sequence of SEQ ID NO:5.

50. A polypeptide of claim 1, comprising the amino acid sequence of SEQ ID NO:6.

25 51. A polypeptide of claim 1, comprising the amino acid sequence of SEQ ID NO:7.

52. A polypeptide of claim 1, comprising the amino acid sequence of SEQ ID NO:8.

53. A polypeptide of claim 1, comprising the amino acid sequence of SEQ ID NO:9.

30 54. A polypeptide of claim 1, comprising the amino acid sequence of SEQ ID NO:10.

55. A polypeptide of claim 1, comprising the amino acid sequence of SEQ ID NO:11.

56. A polypeptide of claim 1, comprising the amino acid sequence of SEQ ID NO:12.

57. A polypeptide of claim 1, comprising the amino acid sequence of SEQ ID NO:13.
58. A polypeptide of claim 1, comprising the amino acid sequence of SEQ ID NO:14.
59. A polypeptide of claim 1, comprising the amino acid sequence of SEQ ID NO:15.
60. A polypeptide of claim 1, comprising the amino acid sequence of SEQ ID NO:16.
61. A polypeptide of claim 1, comprising the amino acid sequence of SEQ ID NO:17.
- 10 62. A polypeptide of claim 1, comprising the amino acid sequence of SEQ ID NO:18.
63. A polynucleotide of claim 11, comprising the polynucleotide sequence of SEQ ID NO:19.
- 15 64. A polynucleotide of claim 11, comprising the polynucleotide sequence of SEQ ID NO:20.
65. A polynucleotide of claim 11, comprising the polynucleotide sequence of SEQ ID NO:21.
- 20 66. A polynucleotide of claim 11, comprising the polynucleotide sequence of SEQ ID NO:22.
- 25 67. A polynucleotide of claim 11, comprising the polynucleotide sequence of SEQ ID NO:23.
68. A polynucleotide of claim 11, comprising the polynucleotide sequence of SEQ ID NO:24.
- 30 69. A polynucleotide of claim 11, comprising the polynucleotide sequence of SEQ ID NO:25.
70. A polynucleotide of claim 11, comprising the polynucleotide sequence of SEQ ID

NO:26.

71. A polynucleotide of claim 11, comprising the polynucleotide sequence of SEQ ID NO:27.

5

72. A polynucleotide of claim 11, comprising the polynucleotide sequence of SEQ ID NO:28.

10 73. A polynucleotide of claim 11, comprising the polynucleotide sequence of SEQ ID NO:29.

74. A polynucleotide of claim 11, comprising the polynucleotide sequence of SEQ ID NO:30.

15 75. A polynucleotide of claim 11, comprising the polynucleotide sequence of SEQ ID NO:31.

76. A polynucleotide of claim 11, comprising the polynucleotide sequence of SEQ ID NO:32.

20 77. A polynucleotide of claim 11, comprising the polynucleotide sequence of SEQ ID NO:33.

78. A polynucleotide of claim 11, comprising the polynucleotide sequence of SEQ ID NO:34.

79. A polynucleotide of claim 11, comprising the polynucleotide sequence of SEQ ID NO:35.

30 80. A polynucleotide of claim 11, comprising the polynucleotide sequence of SEQ ID NO:36.

<110> INCYTE GENOMICS, INC.  
BAUGHN, Mariah R.  
BRUNS, Christopher M.  
DAS, Debopriya Das  
DING, Li  
ELLIOTT, Vicki S.  
GANDHI, Ameena R.  
HAFALIA, April  
KEARNEY, Liam  
KHAN, Farrah A.  
LAL, Preeti  
LEE, Ernestine A.  
LU, Dzung Aina M.  
LU, Yan  
DANNIEL, Nguyen B.  
PATTERSON, Chandra  
RAMKUMAR, Jayalaxmi  
RING, Huijun Z.  
SANJANWALA, Madhu S.  
TANG, Y. Tom  
THANGAVELU, Kavitha  
THORNTON, Michael  
TRIBOULEY, Catherine M.  
WALIA, Narinder K.  
XU, Yuming  
YANG, Junming  
YAO, Monique G.  
YUE, Henry

<120> Drug Metabolizing Enzymes

<130> PI-0151 PCT

<140> To Be Assigned  
<141> Herewith

<150> 60/216,804; 60/218,948; 60/220,037; 60/221,837  
<151> 2000-07-07; 2000-07-14; 2000-07-21; 2000-07-28

<160> 36

<170> PERL Program

<210> 1  
<211> 351  
<212> PRT  
<213> Homo sapiens

<220>  
<221> misc\_feature  
<223> Incyte ID No: 6274461CD1

<400> 1  
Met Leu Gly Met Ser Arg Thr Gly Leu Ala Gly Ala Ala Leu Arg  
1 5 10 15  
Val Ala Leu Thr Ala Leu Leu Pro Leu Val Leu Pro Ala Tyr Tyr  
20 25 30  
Val Tyr Lys Leu Thr Thr Tyr Leu Leu Gly Ala Val Phe Pro Glu  
35 40 45  
Asp Val Ala Gly Lys Val Val Leu Ile Thr Gly Ala Ser Ser Gly  
50 55 60  
Ile Gly Glu His Leu Ala Tyr Glu Tyr Ala Lys Arg Gly Ala Tyr  
65 70 75  
Leu Ala Leu Val Ala Arg Arg Glu Ala Ser Leu Arg Glu Val Gly  
80 85 90  
Asp Val Ala Leu Gly Leu Gly Ser Pro Gly Val Leu Val Leu Pro  
95 100 105

Ala	Asp	Val	Ser	Lys	Pro	Arg	Asp	Cys	Glu	Gly	Phe	Ile	Asp	Asp
				110					115					120
Thr	Ile	Ser	Tyr	Phe	Gly	Arg	Leu	Asp	His	Leu	Val	Asn	Asn	Ala
				125					130					135
Ser	Ile	Trp	Gln	Val	Cys	Lys	Phe	Glu	Glu	Ile	Gln	Asp	Val	Arg
				140					145					150
His	Leu	Arg	Ala	Leu	Met	Asp	Ile	Asn	Phe	Trp	Gly	His	Val	Tyr
				155					160					165
Pro	Thr	Arg	Leu	Ala	Ile	Pro	His	Leu	Arg	Arg	Ser	Arg	Gly	Arg
				170					175					180
Ile	Val	Gly	Val	Thr	Ser	Asn	Ser	Ser	Tyr	Ile	Phe	Ile	Gly	Arg
				185					190					195
Asn	Thr	Phe	Tyr	Asn	Ala	Ser	Lys	Ala	Ala	Ala	Leu	Ser	Phe	Tyr
				200					205					210
Asp	Thr	Leu	Arg	Met	Glu	Leu	Gly	Ser	Asp	Ile	Arg	Ile	Thr	Glu
				215					220					225
Val	Val	Pro	Gly	Val	Val	Glu	Ser	Glu	Ile	Thr	Lys	Gly	Lys	Met
				230					235					240
Leu	Thr	Lys	Gly	Gly	Glu	Met	Lys	Val	Asp	Gln	Asp	Glu	Arg	Asp
				245					250					255
Val	Arg	His	Pro	Gly	Ala	Asp	Ala	Gly	Arg	Ala	Arg	Gly	Arg	Leu
				260					265					270
Arg	Gln	Asp	Arg	Gly	Ala	Arg	Arg	Val	Pro	Gly	Arg	Glu	Val	Arg
				275					280					285
Val	Arg	Ala	Gln	Val	Val	Met	Gly	Val	Tyr	Leu	Leu	Arg	Ala	Cys
				290					295					300
Leu	Pro	Glu	Val	Leu	Ala	Trp	Asn	Ser	Arg	Leu	Leu	Thr	Val	Asp
				305					310					315
Thr	Val	Gly	Ala	Ser	Thr	Thr	Asp	Thr	Leu	Gly	Lys	Trp	Leu	Val
				320					325					330
Glu	Leu	Pro	Gly	Val	Arg	Arg	Val	Val	Gln	Pro	Pro	Ser	Leu	Arg
				335					340					345
Ser	Pro	Glu	Ile	Lys	Asp									
				350										

<210> 2  
<211> 332  
<212> PRT  
<213> Homo sapiens

<220>  
<221> misc\_feature  
<223> Incyte ID No: 7477262CD1

Met	Asn	Gly	Trp	Gly	Gly	Cys	Gly	Ala	His	Gly	Pro	Gly	Arg	Leu
1				5					10					15
Gly	Gly	Gln	Leu	Pro	Pro	Pro	Gln	Arg	Thr	Gly	Arg	Gly	Gly	
				20					25					30
Arg	Ala	Val	Glu	Lys	Arg	Ala	Ala	Arg	Arg	Ala	Gly	His	Trp	Ala
				35					40					45
Asp	Arg	Gly	Gly	Ser	Met	Ser	Gly	Ala	Asp	Arg	Ser	Pro	Asn	Ala
				50					55					60
Gly	Ala	Ala	Pro	Asp	Ser	Ala	Pro	Gly	Gln	Ala	Ala	Val	Ala	Ser
				65					70					75
Ala	Tyr	Gln	Arg	Phe	Glu	Pro	Arg	Ala	Tyr	Leu	Arg	Asn	Asn	Tyr
				80					85					90
Ala	Pro	Pro	Arg	Gly	Asp	Leu	Cys	Asn	Pro	Asn	Gly	Val	Gly	Pro
				95					100					105
Trp	Lys	Leu	Arg	Cys	Leu	Ala	Gln	Thr	Phe	Ala	Thr	Gly	Glu	Val
				110					115					120
Ser	Gly	Arg	Thr	Leu	Ile	Asp	Ile	Gly	Ser	Gly	Pro	Thr	Val	Tyr
				125					130					135
Gln	Leu	Leu	Ser	Ala	Cys	Ser	His	Phe	Glu	Asp	Ile	Thr	Met	Thr
				140					145					150
Asp	Phe	Leu	Glu	Val	Asn	Arg	Gln	Glü	Leu	Gly	Arg	Trp	Leu	Gln
				155					160					165

Glu	Glu	Pro	Gly	Ala	Phe	Asn	Trp	Ser	Met	Tyr	Ser	Gln	His	Ala
				170					175					180
Cys	Leu	Ile	Glu	Gly	Lys	Gly	Glu	Cys	Trp	Gln	Asp	Lys	Glu	Arg
				185					190					195
Gln	Leu	Arg	Ala	Arg	Val	Lys	Arg	Val	Leu	Pro	Ile	Asp	Val	His
				200					205					210
Gln	Pro	Gln	Pro	Leu	Gly	Ala	Gly	Ser	Pro	Ala	Pro	Leu	Pro	Ala
				215					220					225
Asp	Ala	Leu	Val	Ser	Ala	Phe	Cys	Leu	Glu	Ala	Val	Ser	Pro	Asp
				230					235					240
Leu	Ala	Ser	Phe	Gln	Arg	Ala	Leu	Asp	His	Ile	Thr	Thr	Leu	Leu
				245					250					255
Arg	Pro	Gly	Gly	His	Leu	Leu	Leu	Ile	Gly	Ala	Leu	Glu	Glu	Ser
				260					265					270
Trp	Tyr	Leu	Ala	Gly	Glu	Ala	Arg	Leu	Thr	Val	Val	Pro	Val	Ser
				275					280					285
Glu	Glu	Glu	Val	Arg	Glu	Ala	Leu	Val	Arg	Ser	Gly	Tyr	Lys	Val
				290					295					300
Arg	Asp	Leu	Arg	Thr	Tyr	Ile	Met	Pro	Ala	His	Leu	Gln	Thr	Gly
				305					310					315
Val	Asp	Asp	Val	Lys	Gly	Val	Phe	Phe	Ala	Trp	Ala	Gln	Lys	Val
				320					325					330
Gly Leu														

<210> 3  
 <211> 525  
 <212> PRT  
 <213> Homo sapiens

<220>  
 <221> misc\_feature  
 <223> Incyte ID No: 8097779CD1

<400> 3															
Met	Ala	Gly	Leu	Trp	Leu	Gly	Leu	Val	Trp	Gln	Lys	Leu	Leu	Leu	
1					5				10					15	
Trp	Gly	Ala	Ala	Ser	Ala	Leu	Ser	Leu	Ala	Gly	Ala	Ser	Leu	Val	
					20				25					30	
Leu	Ser	Leu	Leu	Gln	Arg	Val	Ala	Ser	Tyr	Ala	Arg	Lys	Trp	Gln	
				35					40					45	
Gln	Met	Arg	Pro	Ile	Pro	Thr	Val	Ala	Arg	Ala	Tyr	Pro	Leu	Val	
				50					55					60	
Gly	His	Ala	Leu	Leu	Met	Lys	Pro	Asp	Gly	Arg	Glu	Phe	Phe	Gln	
				65					70					75	
Gln	Ile	Ile	Glu	Tyr	Thr	Glu	Glu	Tyr	Arg	His	Met	Pro	Leu	Leu	
				80					85					90	
Lys	Leu	Trp	Val	Gly	Pro	Val	Pro	Met	Val	Ala	Leu	Tyr	Asn	Ala	
				95					100					105	
Glu	Asn	Val	Glu	Val	Ile	Leu	Thr	Ser	Ser	Lys	Gln	Ile	Asp	Lys	
				110					115					120	
Ser	Ser	Met	Tyr	Lys	Phe	Leu	Glu	Pro	Trp	Leu	Gly	Leu	Gly	Leu	
				125					130					135	
Leu	Thr	Ser	Thr	Gly	Asn	Lys	Trp	Arg	Ser	Arg	Arg	Lys	Met	Leu	
				140					145					150	
Thr	Pro	Thr	Phe	His	Phe	Thr	Ile	Leu	Glu	Asp	Phe	Leu	Asp	Ile	
				155					160					165	
Met	Asn	Glu	Gln	Ala	Asn	Ile	Leu	Val	Lys	Lys	Leu	Glu	Lys	His	
				170					175					180	
Ile	Asn	Gln	Glu	Ala	Phe	Asn	Cys	Phe	Phe	Tyr	Ile	Thr	Leu	Cys	
				185					190					195	
Ala	Leu	Asp	Ile	Ile	Cys	Glu	Thr	Ala	Met	Gly	Lys	Asn	Ile	Gly	
				200					205					210	
Ala	Gln	Ser	Asn	Asp	Asp	Ser	Glu	Tyr	Val	Arg	Ala	Ile	Tyr	Arg	
				215					220					225	
Met	Ser	Glu	Met	Ile	Phe	Arg	Arg	Ile	Lys	Met	Pro	Trp	Leu	Trp	
				230					235					240	

Leu	Asp	Leu	Trp	Tyr	Leu	Met	Phe	Lys	Glu	Gly	Trp	Glu	His	Lys
				245				250				255		
Lys	Ser	Leu	Gln	Ile	Leu	His	Thr	Phe	Thr	Asn	Ser	Val	Ile	Ala
				260				265				270		
Glu	Arg	Ala	Asn	Glu	Met	Asn	Ala	Asn	Glu	Asp	Cys	Arg	Gly	Asp
				275				280				285		
Gly	Arg	Gly	Ser	Ala	Pro	Ser	Lys	Asn	Lys	Arg	Arg	Ala	Phe	Leu
				290				295				300		
Asp	Leu	Leu	Leu	Ser	Val	Thr	Asp	Asp	Glu	Gly	Asn	Arg	Leu	Ser
				305				310				315		
His	Glu	Asp	Ile	Arg	Glu	Glu	Val	Asp	Thr	Phe	Met	Phe	Glu	Gly
				320				325				330		
His	Asp	Thr	Thr	Ala	Ala	Ala	Ile	Asn	Trp	Ser	Leu	Tyr	Leu	Leu
				335				340				345		
Gly	Ser	Asn	Pro	Glu	Val	Gln	Lys	Lys	Val	Asp	His	Glu	Leu	Asp
				350				355				360		
Asp	Val	Phe	Gly	Lys	Ser	Asp	Arg	Pro	Ala	Thr	Val	Glu	Asp	Leu
				365				370				375		
Lys	Lys	Leu	Arg	Tyr	Leu	Glu	Cys	Val	Ile	Lys	Glu	Thr	Leu	Arg
				380				385				390		
Leu	Phe	Pro	Ser	Val	Pro	Leu	Phe	Ala	Arg	Ser	Val	Ser	Glu	Asp
				395				400				405		
Cys	Glu	Val	Ala	Gly	Tyr	Arg	Val	Leu	Lys	Gly	Thr	Glu	Ala	Val
				410				415				420		
Ile	Ile	Pro	Tyr	Ala	Leu	His	Arg	Asp	Pro	Arg	Tyr	Phe	Pro	Asn
				425				430				435		
Pro	Glu	Glu	Phe	Gln	Pro	Glu	Arg	Phe	Phe	Pro	Glu	Asn	Ala	Gln
				440				445				450		
Gly	Arg	His	Pro	Tyr	Ala	Tyr	Val	Pro	Phe	Ser	Ala	Gly	Pro	Arg
				455				460				465		
Asn	Cys	Ile	Gly	Gln	Lys	Phe	Ala	Val	Met	Glu	Glu	Lys	Thr	Ile
				470				475				480		
Leu	Ser	Cys	Ile	Leu	Arg	His	Phe	Trp	Ile	Glu	Ser	Asn	Gln	Lys
				485				490				495		
Arg	Glu	Glu	Leu	Gly	Leu	Glu	Gly	Gln	Leu	Ile	Leu	Arg	Pro	Ser
				500				505				510		
Asn	Gly	Ile	Trp	Ile	Lys	Leu	Lys	Arg	Arg	Asn	Ala	Asp	Glu	Arg
				515				520				525		

<210> 4  
 <211> 304  
 <212> PRT  
 <213> Homo sapiens

<220>  
 <221> misc\_feature  
 <223> Incyte ID No: 6963993CD1

<400> 4

Met	Leu	Ser	Thr	Cys	Leu	Gly	Glu	Arg	Gly	Asp	Leu	Cys	Trp	Ile
1				5				10				15		
Pro	Leu	Thr	Val	Arg	Arg	His	Phe	Val	Leu	Leu	Val	Leu	Gln	Ala
				20				25				30		
Ser	Pro	Gly	Lys	Val	Thr	Glu	Ala	Val	Lys	Glu	Ala	Ile	Asp	Ala
				35				40				45		
Gly	Tyr	Arg	His	Phe	Asp	Cys	Ala	Tyr	Phe	Tyr	His	Asn	Glu	Arg
				50				55				60		
Glu	Val	Gly	Ala	Gly	Ile	Arg	Cys	Lys	Ile	Lys	Glu	Gly	Ala	Val
				65				70				75		
Arg	Arg	Glu	Asp	Leu	Phe	Ile	Ala	Thr	Lys	Leu	Trp	Cys	Thr	Cys
				80				85				90		
His	Lys	Lys	Ser	Leu	Val	Glu	Thr	Ala	Cys	Arg	Lys	Ser	Leu	Lys
				95				100				105		
Ala	Leu	Lys	Leu	Asn	Tyr	Leu	Asp	Leu	Tyr	Leu	Ile	His	Trp	Pro
				110				115				120		
Met	Gly	Phe	Lys	Pro	Arg	Val	Gln	Asp	Leu	Pro	Leu	Asp	Glu	Ser

	125		130		135									
Asn	Met	Val	Ile	Pro	Ser	Asp	Thr	Asp	Phe	Leu	Asp	Thr	Trp	Gly
	140								145					150
Ala	Met	Glu	Asp	Leu	Val	Ile	Thr	Gly	Leu	Val	Lys	Asn	Ile	Gly
														155
									160					165
Val	Ser	Asn	Phe	Asn	His	Glu	Gln	Leu	Glu	Arg	Leu	Leu	Asn	Lys
														170
									175					180
Pro	Gly	Leu	Arg	Phe	Lys	Pro	Leu	Thr	Asn	Gln	Ile	Glu	Cys	His
														185
									190					195
Pro	Tyr	Leu	Thr	Gln	Lys	Asn	Leu	Ile	Ser	Phe	Cys	Gln	Ser	Arg
										205				200
Asp	Val	Ser	Val	Thr	Ala	Tyr	Arg	Pro	Leu	Gly	Gly	Ser	Cys	Glu
										220				215
Gly	Val	Asp	Leu	Ile	Asp	Asn	Pro	Val	Ile	Lys	Arg	Ile	Ala	Lys
										235				230
Glu	His	Gly	Lys	Ser	Pro	Ala	Gln	Ile	Leu	Ile	Arg	Phe	Gln	Ile
										250				245
Gln	Arg	Asn	Val	Ile	Val	Ile	Pro	Gly	Ser	Ile	Thr	Pro	Ser	His
										265				260
Ile	Lys	Glu	Asn	Ile	Gln	Val	Phe	Asp	Phe	Glu	Leu	Thr	Gln	His
										280				275
Asp	Met	Asp	Asn	Ile	Leu	Ser	Leu	Asn	Arg	Asn	Leu	Arg	Leu	Ala
										295				290
Met	Phe	Pro	Met											

&lt;210&gt; 5

&lt;211&gt; 521

&lt;212&gt; PRT

&lt;213&gt; Homo sapiens

&lt;220&gt;

&lt;221&gt; misc\_feature

&lt;223&gt; Incyte ID No: 7474404CD1

&lt;400&gt; 5

Met	Ser	Leu	Leu	Ser	Leu	Ser	Trp	Leu	Gly	Leu	Gly	Pro	Val	Ala
1					5				10					15
Ala	Ser	Pro	Trp	Leu	Leu	Leu	Leu	Leu	Val	Gly	Ala	Ser	Trp	Leu
									25					30
Leu	Ala	Arg	Val	Leu	Ala	Trp	Thr	Tyr	Ala	Phe	Tyr	Asp	Asn	Cys
									40					45
His	Arg	Leu	Gln	Cys	Phe	Gln	Gln	Pro	Pro	Lys	Arg	Asn	Cys	Phe
									55					60
Gly	Gly	His	Leu	Ser	Leu	Met	Arg	Gly	Asn	Glu	Glu	Asp	Met	Arg
									70					75
Leu	Met	Glu	Asp	Leu	Gly	His	Tyr	Phe	Arg	Asp	Val	Gln	Leu	Trp
									85					90
Trp	Leu	Gly	Ser	Phe	Tyr	Pro	Val	Leu	His	Leu	Val	His	Pro	Thr
									95					105
Phe	Thr	Ala	Pro	Val	Leu	Gln	Ala	Ser	Ala	Ala	Val	Ala	Lys	
									110					120
Asp	Met	Ser	Phe	Tyr	Gly	Phe	Leu	Lys	Pro	Trp	Leu	Gly	Asp	Gly
									125					135
Leu	Leu	Ile	Ser	Ala	Gly	Asp	Lys	Trp	Arg	Trp	His	Arg	His	Leu
									140					150
Leu	Thr	Pro	Ala	Phe	His	Phe	Lys	Ile	Leu	Lys	Pro	Tyr	Val	Lys
									155					165
Ile	Phe	Asn	Glu	Ser	Thr	Asn	Ile	Met	His	Ala	Lys	Trp	Gln	Arg
									170					180
Leu	Ala	Leu	Glu	Gly	Ser	Val	Arg	Leu	Glu	Met	Phe	Glu	His	Ile
									185					195
Ser	Leu	Met	Thr	Leu	Asp	Ser	Leu	Gln	Lys	Cys	Ile	Phe	Ser	Phe
									200					210
Asp	Ser	Asn	Cys	Gln	Asp	Glu	Tyr	Ile	Asp	Ala	Ile	Leu	Glu	Leu
									215					225
Ser	Ala	Leu	Ser	Leu	Lys	Arg	His	Gln	His	Ile	Phe	Leu	Leu	Thr

Asp	Phe	Leu	Tyr	Phe	Leu	Thr	Pro	Asn	Gly	Arg	Arg	Phe	Cys	Arg
230														
245									250					255
Ala	Cys	Asp	Ile	Val	His	Asn	Phe	Thr	Asp	Ala	Val	Ile	Gln	Glu
260									265					270
Arg	Arg	Arg	Thr	Leu	Thr	Ser	Gln	Gly	Val	Asp	Asp	Phe	Leu	Gln
275									280					285
Ala	Lys	Ala	Lys	Ser	Lys	Thr	Leu	Asp	Phe	Ile	Asp	Val	Leu	Leu
290									295					300
Leu	Ala	Lys	Asp	Glu	Asn	Gly	Lys	Lys	Leu	Ser	Asp	Glu	Asn	Ile
305									310					315
Arg	Ala	Glu	Ala	Asp	Thr	Phe	Met	Ser	Gly	Gly	His	Asp	Thr	Ser
320									325					330
Ala	Ser	Gly	Leu	Ser	Trp	Val	Leu	Tyr	Asn	Leu	Ala	Arg	Tyr	Pro
335									340					345
Glu	Tyr	Gln	Glu	His	Cys	Arg	Gln	Glu	Val	Gln	Glu	Leu	Leu	Lys
350									355					360
Asn	Gly	Asp	Pro	Lys	Glu	Ile	Glu	Trp	Asp	Asp	Leu	Ala	Gln	Leu
365									370					375
Pro	Phe	Leu	Thr	Met	Cys	Leu	Lys	Glu	Ser	Leu	Arg	Leu	His	Ser
380									385					390
Pro	Val	Ser	Arg	Ile	His	Arg	Cys	Cys	Pro	Gln	Asp	Gly	Val	Leu
395									400					405
Pro	Asp	Gly	Arg	Val	Ile	Pro	Lys	Gly	Asn	Thr	Cys	Thr	Ile	Ser
410									415					420
Ile	Phe	Gly	Ile	His	His	Asn	Pro	Ser	Val	Trp	Pro	Asp	Pro	Glu
425									430					435
Val	Tyr	Asp	Pro	Phe	Arg	Phe	Asp	Pro	Glu	Asn	Leu	Gln	Lys	Thr
440									445					450
Ser	Pro	Leu	Ala	Phe	Ile	Pro	Phe	Ser	Ala	Val	Pro	Gly	Asn	Cys
455									460					465
Ile	Gly	Gln	Thr	Phe	Ala	Met	Ala	Glu	Met	Lys	Val	Val	Leu	Ala
470									475					480
Leu	Thr	Leu	Leu	Arg	Phe	Arg	Val	Leu	Pro	Asp	His	Ala	Glu	Pro
485									490					495
Arg	Arg	Lys	Leu	Glu	Leu	Ile	Val	Arg	Ala	Glu	Asp	Gly	Leu	Trp
500									505					510
Leu	Arg	Val	Glu	Pro	Leu	Ser	Ala	Asp	Leu	Gln				
515									520					

<210> 6  
 <211> 302  
 <212> PRT  
 <213> Homo sapiens

<220>  
 <221> misc\_feature  
 <223> Incyte ID No: 7474438CD1

Met	Ile	Leu	Leu	Asn	Asn	Ser	Glu	Arg	Leu	Leu	Ala	Leu	Phe	Lys
1				5					10					15
Ser	Leu	Ala	Arg	Ser	Ile	Pro	Glu	Ser	Leu	Lys	Val	Tyr	Gly	Ser
					20				25					30
Leu	Phe	His	Ile	Asn	His	Gly	Asn	Pro	Phe	Asn	Met	Glu	Val	Leu
					35				40					45
Val	Asp	Ser	Trp	Pro	Glu	Tyr	Gln	Met	Val	Ile	Ile	Arg	Pro	Gln
					50				55					60
Lys	Gln	Glu	Met	Thr	Asp	Asp	Met	Asp	Ser	Tyr	Thr	Asn	Val	Tyr
					65				70					75
Arg	Val	Phe	Ser	Lys	Asp	Pro	Gln	Lys	Ser	Gln	Glu	Val	Leu	Lys
					80				85					90
Asn	Ser	Glu	Ile	Ile	Asn	Trp	Lys	Gln	Lys	Leu	Gln	Ile	Gln	Gly
					95				100					105
Phe	Gln	Glu	Ser	Leu	Gly	Glu	Gly	Ile	Arg	Ala	Ala	Ala	Phe	Ser
					110				115					120
Asn	Ser	Val	Lys	Val	Glu	His	Ser	Arg	Ala	Leu	Leu	Phe	Val	Thr

	125		130		135									
Glu	Asp	Ile	Leu	Lys	Leu	Tyr	Ala	Thr	Asn	Lys	Ser	Lys	Leu	Gly
	140					145								150
Ser	Trp	Ala	Glu	Thr	Gly	His	Pro	Asp	Asp	Glu	Leu	Glu	Ser	Glu
	155					160								165
Thr	Pro	Asn	Phe	Lys	Tyr	Ala	Gln	Leu	Asn	Val	Ser	Tyr	Ser	Gly
	170					175								180
Leu	Val	Asn	Asp	Asn	Trp	Lys	Leu	Gly	Met	Asn	Lys	Arg	Ser	Leu
	185					190								195
Arg	Tyr	Ile	Lys	Arg	Cys	Leu	Gly	Ala	Leu	Pro	Ala	Ala	Cys	Met
	200					205								210
Leu	Gly	Pro	Glu	Gly	Val	Pro	Val	Ser	Trp	Val	Thr	Met	Asp	Pro
	215					220								225
Ser	Cys	Glu	Ile	Gly	Met	Gly	Tyr	Ser	Val	Glu	Lys	Tyr	Arg	Arg
	230					235								240
Arg	Gly	Asn	Gly	Thr	Arg	Leu	Ile	Met	Arg	Cys	Met	Lys	Tyr	Leu
	245					250								255
Cys	Gln	Lys	Asn	Ile	Pro	Phe	Tyr	Gly	Ser	Val	Leu	Glu	Glu	Asn
	260					265								270
Gln	Gly	Val	Ile	Arg	Lys	Thr	Ser	Ala	Leu	Gly	Phe	Leu	Glu	Ala
	275					280								285
Ser	Cys	Gln	Trp	His	Gln	Trp	Asn	Cys	Tyr	Pro	Gln	Asn	Leu	Val
	290					295								300
Pro	Leu													

<210> 7  
<211> 502  
<212> PRT  
<213> Homo sapiens

<220>  
<221> misc\_feature  
<223> Incyte ID No: 7476298CD1

	<400> 7													
Met	Ser	Gly	Gln	Pro	Leu	Ile	Tyr	Lys	Val	Thr	Ile	Ser	Val	Thr
						5			10					15
Trp	Leu	Ser	Leu	Leu	Phe	Tyr	Ser	Tyr	Gly	Thr	His	Ser	His	Lys
						20			25					30
Leu	Phe	Lys	Lys	Leu	Gly	Ile	Pro	Gly	Pro	Thr	Pro	Leu	Pro	Phe
						35			40					45
Leu	Gly	Thr	Ile	Leu	Phe	Tyr	Leu	Arg	Gly	Leu	Trp	Asn	Phe	Asp
						50			55					60
Arg	Glu	Cys	Asn	Glu	Lys	Tyr	Gly	Glu	Met	Trp	Gly	Leu	Tyr	Glu
						65			70					75
Gly	Gln	Gln	Pro	Met	Leu	Val	Ile	Met	Asp	Pro	Asp	Met	Ile	Lys
						80			85					90
Thr	Val	Leu	Val	Lys	Glu	Cys	Tyr	Ser	Val	Phe	Thr	Asn	Gln	Met
						95			100					105
Pro	Leu	Gly	Pro	Met	Gly	Phe	Leu	Lys	Ser	Ala	Leu	Ser	Phe	Ala
						110			115					120
Glu	Asp	Glu	Glu	Trp	Lys	Arg	Ile	Arg	Thr	Leu	Leu	Ser	Pro	Ala
						125			130					135
Phe	Thr	Ser	Val	Lys	Phe	Lys	Glu	Met	Val	Pro	Ile	Ile	Ser	Gln
						140			145					150
Cys	Gly	Asp	Met	Leu	Val	Arg	Ser	Leu	Arg	Gln	Glu	Ala	Glu	Asn
						155			160					165
Ser	Lys	Ser	Ile	Asn	Leu	Lys	Asp	Phe	Phe	Gly	Ala	Tyr	Thr	Met
						170			175					180
Asp	Val	Ile	Thr	Gly	Thr	Leu	Phe	Gly	Val	Asn	Leu	Asp	Ser	Leu
						185			190					195
Asn	Asn	Pro	Gln	Asp	Pro	Phe	Leu	Lys	Asn	Met	Lys	Lys	Leu	Leu
						200			205					210
Lys	Leu	Asp	Phe	Leu	Asp	Pro	Phe	Leu	Leu	Ile	Ser	Leu	Phe	
						215			220					225
Pro	Phe	Leu	Thr	Pro	Val	Phe	Glu	Ala	Leu	Asn	Ile	Gly	Leu	Phe

230	235	240
Pro Lys Asp Val Thr His Phe Leu Lys Asn Ser Ile Glu Arg Met		
245	250	255
Lys Glu Ser Arg Leu Lys Asp Lys Gln Lys His Arg Val Asp Phe		
260	265	270
Phe Gln Gln Met Ile Asp Ser Gln Asn Ser Lys Glu Thr Lys Ser		
275	280	285
His Lys Ala Leu Ser Asp Leu Glu Leu Val Ala Gln Ser Ile Ile		
290	295	300
Ile Ile Phe Ala Ala Tyr Asp Thr Thr Ser Thr Thr Leu Pro Phe		
305	310	315
Ile Met Tyr Glu Leu Ala Thr His Pro Asp Val Gln Gln Lys Leu		
320	325	330
Gln Glu Glu Ile Asp Ala Val Leu Pro Asn Lys Ala Pro Val Thr		
335	340	345
Tyr Asp Ala Leu Val Gln Met Glu Tyr Leu Asp Met Val Val Asn		
350	355	360
Glu Thr Leu Arg Leu Phe Pro Val Val Ser Arg Val Thr Arg Val		
365	370	375
Cys Lys Lys Asp Ile Glu Ile Asn Gly Val Phe Ile Pro Lys Gly		
380	385	390
Leu Ala Val Met Val Pro Ile Tyr Ala Leu His His Asp Pro Lys		
395	400	405
Tyr Trp Thr Glu Pro Glu Lys Phe Cys Pro Glu Arg Phe Ser Lys		
410	415	420
Lys Asn Lys Asp Ser Ile Asp Leu Tyr Arg Tyr Ile Pro Phe Gly		
425	430	435
Ala Gly Pro Arg Asn Cys Ile Gly Met Arg Phe Ala Leu Thr Asn		
440	445	450
Ile Lys Leu Ala Val Ile Arg Ala Leu Gln Asn Phe Ser Phe Lys		
455	460	465
Pro Cys Lys Glu Thr Gln Ile Pro Leu Lys Leu Asp Asn Leu Pro		
470	475	480
Ile Leu Gln Pro Glu Lys Pro Ile Val Leu Lys Val His Leu Arg		
485	490	495
Asp Gly Ile Thr Ser Gly Pro		
500		

<210> 8  
 <211> 217  
 <212> PRT  
 <213> Homo sapiens

<220>  
 <221> misc\_feature  
 <223> Incyte ID No: 7477555CD1

<400> 8

Met Pro Val Thr Leu Gly Tyr Trp Asp Ile Arg Gly Leu Ala His		
1 5 10 15		
Ala Val Cys Leu Leu Leu Gln Tyr Thr Asp Leu Ser Tyr Glu Glu		
20 25 30		
Lys Lys Tyr Met Met Gly Asp Ala Pro Asp Tyr Asp Arg Ser Gln		
35 40 45		
Trp Leu Asn Glu Lys Phe Lys Leu Gly Leu Asp Phe Pro Asn Leu		
50 55 60		
Pro Tyr Leu Ile Asp Gly Ala His Lys Ile Thr Gln Ser Lys Ala		
65 70 75		
Ile Leu Gly Cys Ile Ala Tyr Lys His Asn Leu Cys Gly Glu Thr		
80 85 90		
Glu Gly Glu Lys Ile Trp Glu Asp Ile Leu Glu Asn Gln Leu Val		
95 100 105		
Asp Asn His Val Gln Leu Ala Arg Leu Cys Tyr Asn Pro Asp Phe		
110 115 120		
Lys Lys Leu Lys Pro Glu Tyr Leu Glu Ala Leu Pro Ala Met Leu		
125 130 135		
Lys Leu Tyr Ser Gln Phe Leu Gly Lys Gln Leu Leu Phe Leu Gly		

Asp	Lys	Ile	Thr	Leu	Val	Asp	Phe	Ile	Ala	Tyr	Gly	Ile	Leu	Glu
				140					145					150
				155					160					165
Arg	Asn	Gln	Val	Phe	Glu	Pro	Lys	Trp	Leu	Asp	Ala	Phe	Pro	Asn
									170	175				180
Leu	Lys	Asp	Phe	Ile	Ser	Arg	Phe	Glu	Gly	Leu	Glu	Ile	Ser	Ala
					185				190					195
Tyr	Met	Lys	Ser	Ser	Cys	Phe	Leu	Leu	Arg	Pro	Val	Phe	Thr	Lys
					200				205					210
Met	Ala	Val	Trp	Gly	Asn	Lys								
				215										

<210> 9  
 <211> 341  
 <212> PRT  
 <213> Homo sapiens

<220>  
 <221> misc\_feature  
 <223> Incyte ID No: 1527520CD1

<400> 9															
Met	Gly	Arg	Arg	Cys	Cys	Arg	Arg	Arg	Val	Leu	Ala	Ala	Ala	Cys	
1				5					10					15	
Leu	Gly	Ala	Ala	Leu	Leu	Leu	Leu	Cys	Ala	Ala	Pro	Arg	Ser	Leu	
					20				25					30	
Arg	Pro	Ala	Phe	Gly	Asn	Arg	Ala	Leu	Gly	Ser	Ser	Trp	Leu	Gly	
					35				40					45	
Gly	Glu	Lys	Arg	Ser	Pro	Leu	Gln	Lys	Leu	Tyr	Asp	Leu	Asp	Gln	
					50				55					60	
Asp	Pro	Arg	Ser	Thr	Leu	Ala	Lys	Val	His	Arg	Gln	Arg	Arg	Asp	
					65				70					75	
Leu	Leu	Asn	Ser	Ala	Cys	Ser	Arg	His	Ser	Arg	Arg	Gln	Arg	Leu	
					80				85					90	
Leu	Gln	Pro	Glu	Asp	Leu	Arg	His	Val	Leu	Val	Asp	Asp	Ala	His	
					95				100					105	
Gly	Leu	Leu	Tyr	Cys	Tyr	Val	Pro	Lys	Val	Ala	Cys	Thr	Asn	Trp	
					110				115					120	
Lys	Arg	Val	Leu	Leu	Ala	Leu	Ser	Gly	Gln	Ala	Arg	Gly	Asp	Pro	
					125				130					135	
Arg	Ala	Ile	Ser	Ala	Gln	Glu	Ala	His	Ala	Pro	Gly	Arg	Leu	Pro	
					140				145					150	
Ser	Leu	Ala	Asp	Phe	Ser	Pro	Ala	Glu	Ile	Asn	Arg	Arg	Leu	Arg	
					155				160					165	
Ala	Tyr	Leu	Ala	Phe	Leu	Phe	Val	Arg	Glu	Pro	Phe	Glu	Arg	Leu	
					170				175					180	
Ala	Ser	Ala	Tyr	Arg	Asn	Lys	Leu	Ala	Arg	Pro	Tyr	Ser	Ala	Ala	
					185				190					195	
Phe	Gln	Arg	Arg	Tyr	Gly	Ala	Arg	Ile	Val	Gln	Arg	Leu	Arg	Pro	
					200				205					210	
Arg	Ala	Leu	Pro	Asp	Ala	Arg	Ala	Arg	Gly	His	Asp	Val	Arg	Phe	
					215				220					225	
Ala	Glu	Phe	Leu	Ala	Tyr	Leu	Leu	Asp	Pro	Arg	Thr	Arg	Arg	Glu	
					230				235					240	
Glu	Pro	Phe	Asn	Glu	His	Trp	Glu	Arg	Ala	His	Ala	Leu	Cys	His	
					245				250					255	
Pro	Cys	Arg	Leu	Arg	Tyr	Asp	Val	Val	Gly	Lys	Phe	Glu	Thr	Leu	
					260				265					270	
Ala	Glu	Asp	Ala	Ala	Phe	Val	Leu	Gly	Leu	Ala	Gly	Ala	Ser	Asp	
					275				280					285	
Leu	Ser	Phe	Pro	Gly	Pro	Pro	Arg	Pro	Arg	Gly	Ala	Ala	Ala	Ser	
					290				295					300	
Arg	Asp	Leu	Ala	Ala	Arg	Leu	Phe	Arg	Asp	Ile	Ser	Pro	Phe	Tyr	
					305				310					315	
Gln	Arg	Arg	Leu	Phe	Asp	Leu	Tyr	Lys	Met	Asp	Phe	Leu	Leu	Phe	
					320				325					330	
Asn	Tyr	Ser	Ala	Pro	Ser	Tyr	Leu	Arg	Leu	Leu					

335

340

<210> 10  
 <211> 378  
 <212> PRT  
 <213> Homo sapiens

<220>  
 <221> misc\_feature  
 <223> Incyte ID No: 3419318CD1

<220>  
 <221> unsure  
 <222> 1  
 <223> unknown or other

&lt;400&gt; 10

Xaa	Arg	Met	Leu	Val	Ser	Gly	Arg	Arg	Val	Lys	Lys	Trp	Gln	Leu
1														15
					5				10					
Ile	Ile	Gln	Leu	Phe	Ala	Thr	Cys	Phe	Leu	Ala	Ser	Leu	Met	Phe
														30
					20				25					
Phe	Trp	Glu	Pro	Ile	Asp	Asn	His	Ile	Val	Ser	His	Met	Lys	Ser
														45
					35				40					
Tyr	Ser	Tyr	Arg	Tyr	Leu	Ile	Asn	Ser	Tyr	Asp	Phe	Val	Asn	Asp
					50				55					60
Thr	Leu	Ser	Leu	Lys	His	Thr	Ser	Ala	Gly	Pro	Arg	Tyr	Gln	Tyr
					65				70					75
Leu	Ile	Asn	His	Lys	Glu	Lys	Cys	Gln	Ala	Gln	Asp	Val	Leu	Leu
					80				85					90
Leu	Leu	Phe	Val	Lys	Thr	Ala	Pro	Glu	Asn	Tyr	Asp	Arg	Arg	Ser
					95				100					105
Gly	Ile	Arg	Arg	Thr	Trp	Gly	Asn	Glu	Asn	Tyr	Val	Arg	Ser	Gln
					110				115					120
Leu	Asn	Ala	Asn	Ile	Lys	Thr	Leu	Phe	Ala	Leu	Gly	Thr	Pro	Asn
					125				130					135
Pro	Leu	Glu	Gly	Glu	Glu	Leu	Gln	Arg	Lys	Leu	Ala	Trp	Glu	Asp
					140				145					150
Gln	Arg	Tyr	Asn	Asp	Ile	Ile	Gln	Gln	Asp	Phe	Val	Asp	Ser	Phe
					155				160					165
Tyr	Asn	Leu	Thr	Leu	Lys	Leu	Leu	Met	Gln	Phe	Ser	Trp	Ala	Asn
					170				175					180
Thr	Tyr	Cys	Pro	His	Ala	Lys	Phe	Leu	Met	Thr	Ala	Asp	Asp	Asp
					185				190					195
Ile	Phe	Ile	His	Met	Pro	Asn	Leu	Ile	Glu	Tyr	Leu	Gln	Ser	Leu
					200				205					210
Glu	Gln	Ile	Gly	Val	Gln	Asp	Phe	Trp	Ile	Gly	Arg	Val	His	Arg
					215				220					225
Gly	Ala	Pro	Pro	Ile	Arg	Asp	Lys	Ser	Ser	Lys	Tyr	Tyr	Val	Ser
					230				235					240
Tyr	Glu	Met	Tyr	Gln	Trp	Pro	Ala	Tyr	Pro	Asp	Tyr	Thr	Ala	Gly
					245				250					255
Ala	Ala	Tyr	Val	Ile	Ser	Gly	Asp	Val	Ala	Ala	Lys	Val	Tyr	Glu
					260				265					270
Ala	Ser	Gln	Thr	Leu	Asn	Ser	Ser	Leu	Tyr	Ile	Asp	Asp	Val	Phe
					275				280					285
Met	Gly	Leu	Cys	Ala	Asn	Lys	Ile	Gly	Ile	Val	Pro	Gln	Asp	His
					290				295					300
Val	Phe	Phe	Ser	Gly	Glu	Gly	Lys	Thr	Pro	Tyr	His	Pro	Cys	Ile
					305				310					315
Tyr	Glu	Lys	Met	Met	Thr	Ser	His	Gly	His	Leu	Glu	Asp	Leu	Gln
					320				325					330
Asp	Leu	Trp	Lys	Asn	Ala	Thr	Asp	Pro	Lys	Val	Lys	Thr	Ile	Ser
					335				340					345
Lys	Gly	Phe	Phe	Gly	Gln	Ile	Tyr	Cys	Arg	Leu	Met	Lys	Ile	Ile
					350				355					360
Leu	Leu	Cys	Lys	Ile	Ser	Tyr	Val	Asp	Thr	Tyr	Pro	Cys	Arg	Ala
					365				370					375

Ala Phe Ile

<210> 11  
 <211> 361  
 <212> PRT  
 <213> Homo sapiens

<220>  
 <221> misc\_feature  
 <223> Incyte ID No: 3815272CD1

<400> 11

Met	Ala	Glu	Val	Pro	Pro	Gly	Pro	Ser	Ser	Leu	Leu	Pro	Pro	Pro	
1				5					10			15			
Ala	Pro	Pro	Ala	Pro	Ala	Ala	Val	Glu	Pro	Arg	Cys	Pro	Phe	Pro	
				20					25			30			
Ala	Gly	Ala	Ala	Leu	Ala	Cys	Cys	Ser	Glu	Asp	Glu	Glu	Asp	Asp	
				35					40			45			
Glu	Glu	His	Glu	Gly	Gly	Gly	Ser	Arg	Ser	Pro	Ala	Gly	Gly	Glu	
				50					55			60			
Ser	Ala	Thr	Val	Ala	Ala	Lys	Gly	His	Pro	Cys	Leu	Arg	Cys	Pro	
				65					70			75			
Gln	Pro	Pro	Gln	Glu	Gln	Gln	Leu	Asn	Gly	Leu	Ile	Ser	Pro		
				80					85			90			
Glu	Leu	Arg	His	Leu	Arg	Ala	Ala	Ala	Ser	Leu	Lys	Ser	Lys	Val	
				95					100			105			
Leu	Ser	Val	Ala	Glu	Val	Ala	Ala	Thr	Thr	Ala	Thr	Leu	Thr	Glu	
				110					115			120			
Ala	Pro	Glu	Arg	Leu	Gln	Gln	Lys	Glu	Pro	Gly	Tyr	Thr	Arg	Ala	
				125					130			135			
Arg	Gly	Pro	Leu	Thr	Pro	Ser	Leu	Asn	Ala	Arg	Thr	Ala	Val	Pro	
				140					145			150			
Ser	Pro	Val	Glu	Ala	Ala	Ala	Ser	Asp	Pro	Ala	Ala	Ala	Arg		
				155					160			165			
Asn	Gly	Leu	Ala	Glu	Gly	Thr	Glu	Gln	Glu	Glu	Glu	Glu	Asp		
				170					175			180			
Glu	Gln	Val	Arg	Leu	Leu	Ser	Ser	Ser	Leu	Thr	Ala	Asp	Cys	Ser	
				185					190			195			
Leu	Arg	Ser	Pro	Ser	Gly	Arg	Glu	Val	Glu	Pro	Gly	Glu	Asp	Arg	
				200					205			210			
Thr	Ile	Arg	Tyr	Val	Arg	Tyr	Glu	Ser	Glu	Leu	Gln	Met	Pro	Asp	
				215					220			225			
Ile	Met	Arg	Leu	Ile	Thr	Lys	Asp	Leu	Ser	Glu	Pro	Tyr	Ser	Ile	
				230					235			240			
Tyr	Thr	Tyr	Arg	Tyr	Phe	Ile	His	Asn	Trp	Pro	Gln	Leu	Cys	Phe	
				245					250			255			
Leu	Ala	Met	Val	Gly	Glu	Glu	Cys	Val	Gly	Ala	Ile	Val	Cys	Lys	
				260					265			270			
Leu	Asp	Met	His	Lys	Lys	Met	Phe	Arg	Arg	Gly	Tyr	Ile	Ala	Met	
				275					280			285			
Leu	Ala	Val	Asp	Ser	Lys	Tyr	Arg	Arg	Asn	Gly	Ile	Gly	Thr	Asn	
				290					295			300			
Leu	Val	Lys	Lys	Ala	Ile	Tyr	Ala	Met	Val	Glu	Gly	Asp	Cys	Asp	
				305					310			315			
Glu	Val	Val	Leu	Glu	Thr	Glu	Ile	Thr	Asn	Lys	Ser	Ala	Leu	Lys	
				320					325			330			
Leu	Tyr	Glu	Asn	Leu	Gly	Phe	Val	Arg	Asp	Lys	Arg	Leu	Phe	Arg	
				335					340			345			
Tyr	Tyr	Leu	Asn	Gly	Val	Asp	Ala	Leu	Arg	Leu	Lys	Leu	Trp	Leu	
				350					355			360			
Arg															

<210> 12  
 <211> 801  
 <212> PRT

&lt;213&gt; Homo sapiens

&lt;220&gt;

&lt;221&gt; misc\_feature

&lt;223&gt; Incyte ID No: 7473875CD1

&lt;400&gt; 12

Met	Trp	Leu	Leu	Ala	Leu	Cys	Leu	Val	Gly	Leu	Ala	Gly	Ala	Gln	
1					5				10						15
Arg	Gly	Gly	Gly	Gly	Pro	Gly	Gly	Gly	Ala	Pro	Gly	Gly	Pro	Gly	
					20				25						30
Leu	Gly	Leu	Gly	Ser	Leu	Gly	Glu	Glu	Arg	Phe	Pro	Val	Val	Asn	
					35				40						45
Thr	Ala	Tyr	Gly	Arg	Val	Arg	Gly	Val	Arg	Arg	Glu	Leu	Asn	Asn	
					50				55						60
Glu	Ile	Leu	Gly	Pro	Val	Val	Gln	Phe	Leu	Gly	Val	Pro	Tyr	Ala	
					65				70						75
Thr	Pro	Pro	Leu	Gly	Ala	Arg	Arg	Phe	Gln	Pro	Pro	Glu	Ala	Pro	
					80				85						90
Ala	Ser	Trp	Pro	Gly	Val	Arg	Asn	Ala	Thr	Thr	Leu	Pro	Pro	Ala	
					95				100						105
Cys	Pro	Gln	Asn	Leu	His	Gly	Ala	Leu	Pro	Ala	Ile	Met	Leu	Pro	
					110				115						120
Val	Trp	Phe	Thr	Asp	Asn	Leu	Glu	Ala	Ala	Ala	Thr	Tyr	Val	Gln	
					125				130						135
Asn	Gln	Ser	Glu	Asp	Cys	Leu	Tyr	Leu	Asn	Leu	Tyr	Val	Pro	Thr	
					140				145						150
Glu	Asp	Gly	Pro	Leu	Thr	Lys	Lys	Arg	Asp	Glu	Ala	Thr	Leu	Asn	
					155				160						165
Pro	Pro	Asp	Thr	Asp	Ile	Arg	Asp	Pro	Gly	Lys	Lys	Pro	Val	Met	
					170				175						180
Leu	Phe	Leu	His	Gly	Gly	Ser	Tyr	Met	Glu	Gly	Thr	Gly	Asn	Met	
					185				190						195
Phe	Asp	Gly	Ser	Val	Leu	Ala	Ala	Tyr	Gly	Asn	Val	Ile	Val	Ala	
					200				205						210
Thr	Leu	Asn	Tyr	Arg	Leu	Gly	Val	Leu	Gly	Phe	Leu	Ser	Thr	Gly	
					215				220						225
Asp	Gln	Ala	Ala	Lys	Gly	Asn	Tyr	Gly	Leu	Leu	Asp	Gln	Ile	Gln	
					230				235						240
Ala	Leu	Arg	Trp	Leu	Ser	Glu	Asn	Ile	Ala	His	Phe	Gly	Gly	Asp	
					245				250						255
Pro	Glu	Arg	Ile	Thr	Ile	Phe	Gly	Ser	Gly	Ala	Gly	Ala	Ser	Cys	
					260				265						270
Val	Asn	Leu	Leu	Ile	Leu	Ser	His	His	Ser	Glu	Gly	Leu	Phe	Gln	
					275				280						285
Lys	Ala	Ile	Ala	Gln	Ser	Gly	Thr	Ala	Ile	Ser	Ser	Trp	Ser	Val	
					290				295						300
Asn	Tyr	Gln	Pro	Leu	Lys	Tyr	Thr	Arg	Leu	Leu	Ala	Ala	Lys	Val	
					305				310						315
Gly	Cys	Asp	Arg	Glu	Asp	Ser	Ala	Glu	Ala	Val	Glu	Cys	Leu	Arg	
					320				325						330
Arg	Lys	Pro	Ser	Arg	Glu	Leu	Val	Asp	Gln	Asp	Val	Gln	Pro	Ala	
					335				340						345
Arg	Tyr	His	Ile	Ala	Phe	Gly	Pro	Val	Val	Asp	Gly	Asp	Val	Val	
					350				355						360
Pro	Asp	Asp	Pro	Glu	Ile	Leu	Met	Gln	Gln	Gly	Glu	Phe	Leu	Asn	
					365				370						375
Tyr	Asp	Met	Leu	Ile	Gly	Val	Asn	Gln	Gly	Glu	Gly	Leu	Lys	Phe	
					380				385						390
Val	Glu	Asp	Ser	Ala	Glu	Ser	Glu	Asp	Gly	Val	Ser	Ala	Ser	Ala	
					395				400						405
Phe	Asp	Phe	Thr	Val	Ser	Asn	Phe	Val	Asp	Asn	Leu	Tyr	Gly	Tyr	
					410				415						420
Pro	Glu	Gly	Lys	Asp	Val	Leu	Arg	Glu	Thr	Ile	Lys	Phe	Met	Tyr	
					425				430						435
Thr	Asp	Trp	Ala	Asp	Arg	Asp	Asn	Gly	Glu	Met	Arg	Arg	Lys	Thr	
					440				445						450

Leu Leu Ala Leu Phe Thr Asp His Gln Trp Val Ala Pro Ala Val  
 455 460 465  
 Ala Thr Ala Lys Leu His Ala Asp Tyr Gln Ser Pro Val Tyr Phe  
 470 475 480  
 Tyr Thr Phe Tyr His His Cys Gln Ala Glu Gly Arg Pro Glu Trp  
 485 490 495  
 Ala Asp Ala Ala His Gly Asp Glu Leu Pro Tyr Val Phe Gly Val  
 500 505 510  
 Pro Met Val Gly Ala Thr Asp Leu Phe Pro Cys Asn Phe Ser Lys  
 515 520 525  
 Asn Asp Val Met Leu Ser Ala Val Val Met Thr Tyr Trp Thr Asn  
 530 535 540  
 Phe Ala Lys Thr Gly Asp Pro Asn Gln Pro Val Pro Gln Asp Thr  
 545 550 555  
 Lys Phe Ile His Thr Lys Pro Asn Arg Phe Glu Glu Val Val Trp  
 560 565 570  
 Ser Lys Phe Asn Ser Lys Glu Lys Gln Tyr Leu His Ile Gly Leu  
 575 580 585  
 Lys Pro Arg Val Arg Asp Asn Tyr Arg Ala Asn Lys Val Ala Phe  
 590 595 600  
 Trp Leu Glu Leu Val Pro His Leu His Asn Leu His Thr Glu Leu  
 605 610 615  
 Phe Thr Thr Thr Arg Leu Pro Pro Tyr Ala Thr Arg Trp Pro  
 620 625 630  
 Pro Arg Pro Pro Ala Gly Ala Pro Gly Thr Arg Arg Pro Pro Pro  
 635 640 645  
 Pro Ala Thr Leu Pro Pro Glu Pro Glu Pro Glu Pro Gly Pro Arg  
 650 655 660  
 Ala Tyr Asp Arg Phe Pro Gly Asp Ser Arg Asp Tyr Ser Thr Glu  
 665 670 675  
 Leu Ser Val Thr Val Ala Val Gly Ala Ser Leu Leu Phe Leu Asn  
 680 685 690  
 Ile Leu Ala Phe Ala Ala Leu Tyr Tyr Lys Arg Asp Arg Arg Gln  
 695 700 705  
 Glu Leu Arg Cys Arg Arg Leu Ser Pro Pro Gly Gly Ser Gly Ser  
 710 715 720  
 Gly Val Pro Gly Gly Gly Pro Leu Leu Pro Ala Ala Gly Arg Glu  
 725 730 735  
 Leu Pro Pro Glu Glu Glu Leu Val Ser Leu Gln Leu Lys Arg Gly  
 740 745 750  
 Gly Gly Val Gly Ala Asp Pro Ala Ala Val Gly Arg Arg Gly Ser  
 755 760 765  
 Ser Phe Thr Ser Ser Pro Arg Leu Lys Pro Leu Ser Ser Leu Ser  
 770 775 780  
 Gly Pro Asp Gln Arg Phe Pro His Pro Trp Gly Gln Pro Cys Arg  
 785 790 795  
 Cys Val Ser Phe Val Ser  
 800

<210> 13  
 <211> 349  
 <212> PRT  
 <213> Homo sapiens

<220>  
 <221> misc\_feature  
 <223> Incyte ID No: 7478099CD1

<400> 13  
 Met Ser Ser Leu Ser Gly Lys Val Gln Thr Val Leu Gly Leu Val  
 1 5 10 15  
 Glu Pro Ser Lys Leu Gly Arg Thr Leu Thr His Glu His Leu Ala  
 20 25 30  
 Met Thr Phe Asp Cys Cys Tyr Cys Pro Pro Pro Pro Cys Gln Glu  
 35 40 45  
 Ala Ile Ser Lys Glu Pro Ile Val Met Lys Asn Leu Tyr Trp Ile  
 50 55 60

Gln Lys Asn Ala Tyr Ser His Lys Glu Asn Leu Gln Leu Asn Gln  
       65                   70                   75  
 Glu Thr Glu Ala Ile Lys Glu Glu Leu Leu Tyr Phe Lys Ala Asn  
       80                   85                   90  
 Gly Gly Gly Ala Leu Val Glu Asn Thr Thr Thr Gly Ile Ser Arg  
       95                   100                   105  
 Asp Thr Gln Thr Leu Lys Arg Leu Ala Glu Glu Thr Gly Val His  
       110                   115                   120  
 Ile Ile Ser Gly Ala Gly Phe Tyr Val Asp Ala Thr His Ser Ser  
       125                   130                   135  
 Glu Thr Arg Ala Met Ser Val Glu Gln Leu Thr Asp Val Leu Met  
       140                   145                   150  
 Asn Glu Ile Leu His Gly Ala Asp Gly Thr Ser Ile Lys Cys Gly  
       155                   160                   165  
 Ile Ile Gly Glu Ile Gly Cys Ser Trp Pro Leu Thr Glu Ser Glu  
       170                   175                   180  
 Arg Lys Val Leu Gln Ala Thr Ala His Ala Gln Ala Gln Leu Gly  
       185                   190                   195  
 Cys Pro Val Ile Ile His Pro Gly Arg Ser Ser Arg Ala Pro Phe  
       200                   205                   210  
 Gln Ile Ile Arg Ile Leu Gln Glu Ala Gly Ala Asp Ile Ser Lys  
       215                   220                   225  
 Thr Val Met Ser His Leu Asp Arg Thr Ile Leu Asp Lys Lys Glu  
       230                   235                   240  
 Leu Leu Glu Phe Ala Gln Leu Gly Cys Tyr Leu Glu Tyr Asp Leu  
       245                   250                   255  
 Phe Gly Thr Glu Leu Leu His Tyr Gln Leu Gly Pro Asp Ile Asp  
       260                   265                   270  
 Met Pro Asp Asp Asn Lys Arg Ile Arg Arg Val Arg Leu Leu Val  
       275                   280                   285  
 Glu Glu Gly Cys Glu Asp Arg Ile Leu Val Ala His Asp Ile His  
       290                   295                   300  
 Thr Lys Thr Arg Leu Met Lys Tyr Gly Gly His Gly Tyr Ser His  
       305                   310                   315  
 Ile Leu Thr Asn Val Val Pro Lys Met Leu Leu Arg Gly Ile Thr  
       320                   325                   330  
 Glu Asn Val Leu Asp Lys Ile Leu Ile Glu Asn Pro Lys Gln Trp  
       335                   340                   345  
 Leu Thr Phe Lys

<210> 14  
 <211> 499  
 <212> PRT  
 <213> Homo sapiens

<220>  
 <221> misc\_feature  
 <223> Incyte ID No: 1962105CD1

<400> 14

Met Glu Arg Ala Glu Glu Pro Val Val Tyr Gln Lys Leu Leu Pro  
       1                   5                   10                   15  
 Trp Glu Pro Ser Leu Glu Ser Glu Glu Glu Val Glu Glu Glu  
       20                   25                   30  
 Thr Ser Glu Ala Leu Val Leu Asn Pro Arg Arg His Gln Asp Ser  
       35                   40                   45  
 Ser Arg Asn Lys Ala Gly Gly Leu Pro Gly Thr Trp Ala Arg Val  
       50                   55                   60  
 Val Ala Ala Leu Leu Leu Ala Val Gly Cys Ser Leu Ala Val  
       65                   70                   75  
 Arg Gln Leu Gln Asn Gln Gly Arg Ser Thr Gly Ser Leu Gly Ser  
       80                   85                   90  
 Val Ala Pro Pro Pro Gly Gly His Ser His Gly Pro Gly Val Tyr  
       95                   100                   105  
 His His Gly Ala Ile Ile Ser Pro Ala Ala Thr Cys Ser His Leu  
       110                   115                   120

Gly Arg Glu Leu Leu Val Ala Gly Gly Asn Val Val Asp Ala Gly  
 125 130 135  
 Val Gly Ala Ala Leu Cys Leu Ala Val Val His Pro His Ala Thr  
 140 145 150  
 Gly Leu Gly Ala Met Phe Trp Gly Leu Phe His Asp Ser Ser Ser  
 155 160 165  
 Gly Asn Ser Thr Ala Leu Thr Ser Gly Pro Ala Gln Thr Leu Ala  
 170 175 180  
 Pro Gly Leu Gly Leu Pro Ala Ala Leu Pro Thr Leu His Leu Leu  
 185 190 195  
 His Ala Arg Phe Gly Arg Leu Pro Trp Pro Arg Leu Leu Val Gly  
 200 205 210  
 Pro Thr Thr Leu Ala Gln Glu Gly Phe Leu Val Asp Thr Pro Leu  
 215 220 225  
 Ala Arg Ala Leu Val Ala Arg Gly Thr Glu Gly Leu Cys Pro Leu  
 230 235 240  
 Leu Cys His Ala Asp Gly Thr Pro Leu Gly Ala Gly Ala Arg Ala  
 245 250 255  
 Thr Asn Pro Gln Leu Ala Ala Val Leu Arg Ser Ala Ala Leu Ala  
 260 265 270  
 Pro Thr Ser Asp Leu Ala Gly Asp Ala Leu Leu Ser Leu Leu Ala  
 275 280 285  
 Gly Asp Leu Gly Val Glu Val Pro Ser Ala Val Pro Arg Pro Thr  
 290 295 300  
 Leu Glu Pro Ala Glu Gln Leu Pro Val Pro Gln Gly Ile Leu Phe  
 305 310 315  
 Thr Thr Pro Ser Pro Ser Ala Gly Pro Glu Leu Leu Ala Leu Leu  
 320 325 330  
 Glu Ala Ala Leu Arg Ser Gly Ala Pro Ile Pro Asp Pro Cys Pro  
 335 340 345  
 Pro Phe Leu Gln Thr Ala Val Ser Pro Glu Ser Ser Ala Leu Ala  
 350 355 360  
 Ala Val Asp Ser Ser Gly Ser Val Leu Leu Leu Thr Ser Ser Leu  
 365 370 375  
 Asn Cys Ser Phe Gly Ser Ala His Leu Ser Pro Ser Thr Gly Val  
 380 385 390  
 Leu Leu Ser Asn Leu Val Ala Lys Ser Thr Thr Ser Ala Trp Ala  
 395 400 405  
 Cys Pro Leu Ile Leu Arg Gly Ser Leu Asp Asp Thr Glu Ala Asp  
 410 415 420  
 Val Leu Gly Leu Val Ala Ser Gly Thr Pro Asp Val Ala Arg Ala  
 425 430 435  
 Met Thr His Thr Leu Leu Arg His Leu Ala Ala Arg Pro Pro Thr  
 440 445 450  
 Gln Ala Gln His Gln His Gln Gly Gln Gln Glu Pro Thr Glu His  
 455 460 465  
 Pro Ser Thr Cys Gly Gln Gly Thr Leu Leu Gln Val Ala Ala His  
 470 475 480  
 Thr Glu His Ala His Val Ser Ser Val Pro His Ala Cys Cys Pro  
 485 490 495  
 Phe Gln Gly Phè

<210> 15  
 <211> 532  
 <212> PRT  
 <213> Homo sapiens

<220>  
 <221> misc\_feature  
 <223> Incyte ID No: 5643401CD1

<400> 15  
 Met Ala Gly Leu Trp Leu Gly Leu Val Trp Gln Lys Leu Leu Leu  
 1 5 10 15  
 Trp Gly Ala Ala Ser Ala Val Ser Leu Ala Gly Ala Ser Leu Val  
 20 25 30

Leu Ser Leu Leu Gln Arg Val Ala Ser Tyr Ala Arg Lys Trp Gln  
                   35                  40                  45  
 Gln Met Arg Pro Ile Pro Thr Val Ala Arg Ala Tyr Pro Leu Val  
                   50                  55                  60  
 Gly His Ala Leu Leu Met Lys Pro Asp Gly Arg Glu Phe Phe Gln  
                   65                  70                  75  
 Gln Ile Ile Glu Tyr Thr Glu Glu Tyr Arg His Met Pro Leu Leu  
                   80                  85                  90  
 Lys Leu Trp Val Gly Pro Val Pro Met Val Ala Leu Tyr Asn Ala  
                   95                  100                 105  
 Glu Asn Val Glu Leu Val Leu Ile Glu Val Gly Val Val Asp Ala  
                   110                  115                 120  
 Asp Gly Asp Leu Ser Arg Val Gly Asp Leu Ser Lys Lys Pro Asp  
                   125                  130                 135  
 Ile Phe Phe Val Thr Thr Tyr Phe Ile Ser Ser Thr Gly Asn Lys  
                   140                  145                 150  
 Trp Arg Ser Arg Arg Lys Met Leu Thr Pro Thr Phe His Phe Thr  
                   155                  160                 165  
 Ile Leu Glu Asp Phe Leu Asp Ile Met Asn Glu Gln Ala Asn Ile  
                   170                  175                 180  
 Leu Val Lys Lys Leu Glu Lys His Ile Asn Gln Glu Ala Phe Asn  
                   185                  190                 195  
 Cys Phe Phe Tyr Ile Thr Leu Cys Ala Leu Asp Ile Ile Cys Ala  
                   200                  205                 210  
 Arg Phe Tyr Asp Arg Thr Gly Leu Leu Arg Ser Ser Ser His Ala  
                   215                  220                 225  
 Gln Gly Cys Glu Trp Gly Arg Met Ser Glu Met Ile Phe Arg Arg  
                   230                  235                 240  
 Ile Lys Met Pro Trp Leu Trp Leu Asp Leu Trp Tyr Leu Met Phe  
                   245                  250                 255  
 Lys Glu Gly Trp Glu His Lys Lys Ser Leu Gln Ile Leu His Thr  
                   260                  265                 270  
 Phe Thr Asn Ser Val Ile Ala Glu Arg Ala Asn Glu Met Asn Ala  
                   275                  280                 285  
 Asn Glu Asp Cys Arg Gly Asp Gly Arg Gly Ser Ala Pro Ser Lys  
                   290                  295                 300  
 Asn Lys Arg Arg Ala Phe Leu Asp Leu Leu Ser Val Thr Asp  
                   305                  310                 315  
 Asp Glu Gly Asn Arg Leu Ser His Glu Asp Ile Arg Glu Glu Val  
                   320                  325                 330  
 Asp Thr Phe Met Phe Glu Gly His Asp Thr Thr Ala Ala Ala Ile  
                   335                  340                 345  
 Asn Trp Ser Leu Tyr Leu Leu Gly Ser Asn Pro Glu Val Gln Lys  
                   350                  355                 360  
 Lys Val Asp His Glu Leu Asp Asp Val Phe Gly Lys Ser Asp Arg  
                   365                  370                 375  
 Pro Ala Thr Val Glu Asp Leu Lys Lys Leu Arg Tyr Leu Glu Cys  
                   380                  385                 390  
 Val Ile Lys Glu Thr Leu Arg Leu Phe Pro Ser Val Pro Leu Phe  
                   395                  400                 405  
 Ala Arg Ser Val Ser Glu Asp Cys Glu Val Ala Gly Tyr Arg Val  
                   410                  415                 420  
 Leu Lys Gly Thr Glu Ala Val Ile Ile Pro Tyr Ala Leu His Arg  
                   425                  430                 435  
 Asp Pro Arg Tyr Phe Pro Asn Pro Glu Glu Phe Gln Pro Glu Arg  
                   440                  445                 450  
 Phe Phe Pro Glu Asn Ala Gln Gly Arg His Pro Tyr Ala Tyr Val  
                   455                  460                 465  
 Pro Phe Ser Ala Gly Pro Arg Asn Cys Ile Gly Gln Lys Phe Ala  
                   470                  475                 480  
 Val Met Glu Glu Lys Thr Ile Leu Ser Cys Ile Leu Arg His Phe  
                   485                  490                 495  
 Trp Ile Glu Ser Asn Gln Lys Arg Glu Glu Leu Gly Leu Glu Gly  
                   500                  505                 510  
 Gln Leu Ile Leu Arg Pro Ser Asn Gly Ile Trp Ile Lys Leu Lys  
                   515                  520                 525  
 Arg Arg Asn Ala Asp Glu Arg

<210> 16  
 <211> 508  
 <212> PRT  
 <213> Homo sapiens

<220>  
 <221> misc\_feature  
 <223> Incyte ID No: 7478053CD1

<400> 16  
 Met Ser Gly Gln Pro Leu Ile Tyr Lys Val Thr Ile Ser Val Thr  
 1 5 10 15  
 Trp Leu Ser Leu Leu Phe Tyr Ser Tyr Gly Thr His Ser His Lys  
 20 25 30  
 Leu Phe Lys Lys Leu Gly Ile Pro Gly Pro Thr Pro Leu Pro Phe  
 35 40 45  
 Leu Gly Thr Ile Leu Phe Tyr Leu Arg Val Lys Thr Thr Tyr Ala  
 50 55 60  
 Glu Met Lys Thr His Gln Lys Asp Asn Glu Leu Leu Ser Val His  
 65 70 75  
 Arg Gln Lys Leu Tyr Glu Gly Gln Gln Pro Met Leu Val Ile Met  
 80 85 90  
 Asp Pro Asp Met Ile Lys Thr Val Leu Val Lys Glu Cys Tyr Ser  
 95 100 105  
 Val Phe Thr Asn Gln Met Pro Leu Gly Pro Met Gly Phe Leu Lys  
 110 115 120  
 Ser Ala Leu Ser Phe Ala Glu Asp Glu Glu Trp Lys Arg Ile Arg  
 125 130 135  
 Thr Leu Leu Ser Pro Ala Phe Thr Ser Val Lys Phe Lys Glu Met  
 140 145 150  
 Val Pro Ile Ile Ser Gln Cys Gly Asp Met Leu Val Arg Ser Leu  
 155 160 165  
 Arg Gln Glu Ala Glu Asn Ser Lys Ser Ile Asn Leu Lys Asp Phe  
 170 175 180  
 Phe Gly Ala Tyr Thr Met Asp Val Ile Thr Gly Thr Leu Phe Gly  
 185 190 195  
 Val Asn Leu Asp Ser Leu Asn Asn Pro Gln Asp Pro Phe Leu Lys  
 200 205 210  
 Asn Met Lys Lys Leu Leu Lys Leu Asp Phe Leu Asp Pro Phe Leu  
 215 220 225  
 Leu Leu Ile Ser Leu Phe Pro Phe Leu Thr Pro Val Phe Glu Ala  
 230 235 240  
 Leu Asn Ile Gly Leu Phe Pro Lys Asp Val Thr His Phe Leu Lys  
 245 250 255  
 Asn Ser Ile Glu Arg Met Lys Glu Ser Arg Leu Lys Asp Lys Gln  
 260 265 270  
 Lys His Arg Val Asp Phe Phe Gln Gln Met Ile Asp Ser Gln Asn  
 275 280 285  
 Ser Lys Glu Thr Lys Ser His Lys Ala Leu Ser Asp Leu Glu Leu  
 290 295 300  
 Val Ala Gln Ser Ile Ile Ile Phe Ala Ala Tyr Asp Thr Thr  
 305 310 315  
 Ser Thr Thr Leu Pro Phe Ile Met Tyr Glu Leu Ala Thr His Pro  
 320 325 330  
 Asp Val Gln Gln Lys Leu Gln Glu Glu Ile Asp Ala Val Leu Pro  
 335 340 345  
 Asn Lys Ala Pro Val Thr Tyr Asp Ala Leu Val Gln Met Glu Tyr  
 350 355 360  
 Leu Asp Met Val Val Asn Glu Thr Leu Arg Leu Phe Pro Val Val  
 365 370 375  
 Ser Arg Val Thr Arg Val Cys Lys Lys Asp Ile Glu Ile Asn Gly  
 380 385 390  
 Val Phe Ile Pro Lys Gly Leu Ala Val Met Val Pro Ile Tyr Ala  
 395 400 405  
 Leu His His Asp Pro Lys Tyr Trp Thr Glu Pro Glu Lys Phe Cys

410	415	420
Pro Glu Arg Phe Ser Lys Lys Asn Lys	Asp Ser Ile Asp Leu	Tyr
425	430	435
Arg Tyr Ile Pro Phe Gly Ala Gly Pro	Arg Asn Cys Ile Gly	Met
440	445	450
Arg Phe Ala Leu Thr Asn Ile Lys Leu	Ala Val Ile Arg Ala	Leu
455	460	465
Gln Asn Phe Ser Phe Lys Pro Cys Lys	Glu Thr Gln Ile Pro	Leu
470	475	480
Lys Leu Asp Asn Leu Pro Ile Leu Gln	Pro Glu Lys Pro Ile	Val
485	490	495
Leu Lys Val His Leu Arg Asp Gly Ile	Thr Ser Gly Pro	
500	505	

&lt;210&gt; 17

&lt;211&gt; 323

&lt;212&gt; PRT

&lt;213&gt; Homo sapiens

&lt;220&gt;

&lt;221&gt; misc\_feature

&lt;223&gt; Incyte ID No: 7478994CD1

&lt;400&gt; 17

Met Asp Pro Lys Tyr Gln Arg Val Glu Leu Asn Asp Gly His Phe			
1	5	10	15
Met Pro Val Leu Gly Phe Gly Thr Tyr Ala	Pro Pro Glu Val Pro		
20	25		30
Lys Ser Gln Ala Ala Glu Ala Thr Lys Val	Ala Ile Asp Val Gly		
35	40		45
Phe Arg His Ile Asp Ser Ala Tyr Leu Tyr	Gln Asn Glu Glu Glu		
50	55		60
Val Gly Gln Ala Ile Trp Glu Lys Ile Ala	Asp Gly Thr Val Lys		
65	70		75
Arg Glu Glu Ile Phe Tyr Thr Ile Lys Val	Lys Val Leu Cys Val		
80	85		90
Gln Ala Glu Leu Val His Pro Ala Leu Glu	Arg Ser Leu Lys Lys		
95	100		105
Leu Gly Pro Asp Tyr Val Asp Leu Phe Ile	Ile His Val Pro Phe		
110	115		120
Ala Phe Gln Pro Gly Glu Glu Leu Leu	Pro Lys Asp Ala Ser Gly		
125	130		135
Asn Ile Ile Phe Asp Thr Val Asp Leu Arg	Asp Thr Trp Glu Ala		
140	145		150
Leu Glu Lys Cys Lys Glu Ala Gly Leu Thr	Lys Ser Ile Gly Val		
155	160		165
Ser Asn Phe Asn His Lys Leu Leu Glu Leu	Ile Leu Asn Lys Pro		
170	175		180
Gly Leu Lys Tyr Lys Pro Thr Cys Asn Gln	Val Glu Cys His Pro		
185	190		195
Tyr Leu Asn Gln Ser Lys Leu Leu Glu Phe	Cys Lys Ser Lys Asp		
200	205		210
Ile Val Leu Val Ala Tyr Ser Ala Leu Gly	Ser Gln Arg Asp Pro		
215	220		225
Gln Trp Val Asp Pro Asp Cys Pro His	Leu Leu Glu Glu Pro Ile		
230	235		240
Leu Lys Ser Ile Ala Lys Lys His Ser Gly	Ser Pro Gly Gln Val		
245	250		255
Ala Leu Arg Tyr Gln Leu Gln Arg Gly Val	Val Val Leu Ala Lys		
260	265		270
Ser Phe Ser Gln Glu Arg Ile Lys Ser Ser	Phe Gln Val Phe Asp		
275	280		285
Phe Glu Leu Thr Pro Glu Asp Met Lys Ala	Thr Asp Gly Leu Asn		
290	295		300
Arg Asn Phe Arg Tyr Ala Lys Leu Gln Leu	Leu Met Asp His Pro		
305	310		315
Asp Tyr Pro Phe Ser Asp Glu Tyr			

gacctttccg acgcccctga ccccgcatcc cgaggcggcc ggaagtgtcg ccggcctcct 180  
 cccggcgcag cctccgggccc tcccgtgcaa tcactacgcc ctggggcccg gaaaccgttt 240  
 tccggtctt cgcttcggc tggggcgtgg aggccgcggg gctgcgttagg ccggccggg 300  
 cgcaggaaca gccccgtggc gcccctctg gccgcctgccc cggcggggaa acgtcggtcc 360  
 ggggaccggg cgaccggcga gccccggagcg cgccagggtcc ggcggggaa gtggccgggt 420  
 tgcggccggc accgcctcgc accacgcccc cgccggcccg cactttcccg gagtgcaccc 480  
 cgccggccgcg agccggggcg atggcggggc tctggctggg gctgcgtgtgg cagaagctgc 540  
 tgctgtgggg cgccggcaggt gcccattccc tgccggcgc cagtcgtgtc ctgagcctgc 600  
 tgcagagggt ggcgagctac gcgcggaaat ggcagcagat gcccggccatc cccacgggtgg 660  
 cccgcgccta cccactgggt ggccacgcgc tgctgatgaa gccggacggg cgagaatttt 720  
 ttcagcagat cattgagtac acagaggaat accgcccacat gccgcgtctg aagctctggg 780  
 tcgggcccagt gcccattggg gcccattata gtcagaaaaa tggaggtta attttaacta 840  
 gttcaagca aattgacaaa tcctctatgt acaagttttt agaaccatgg ctggccctag 900  
 gacttctac aagtactgga aacaaatggc gctccaggag aaagatgtta acaccactt 960  
 tccatttac cattctggaa gatttcttag atatcatgaa tgaacaagca aatataattgg 1020  
 ttaagaaaact tgaaaaaacac attaaccagg aagcattta ctgcgttttt tacatcactc 1080  
 tttgtgcctt agatatcatc tggaaacagg ctatggggaa gaatattggt gctcaaaagta 1140  
 atgatgattc cgagtatgtc cgtgcaattt atagaatgag tggatgata ttgcagaa 1200  
 taaagatgcc ctggctttgg cttgatctt ggtacctt gttaaagaa ggatgggaac 1260  
 aaaaaaagag cttcagatc ctacatactt ttaccaacag tggatggcag gggtctgtcc 1320  
 atgaaatgaa cggcaatgaa gactgttagag ataaacgcag ggcctttttt gttgtgac tgatgacgaa 1380  
 taagtcatga agatattcga gaagaagttt acacccatcat gtttggggg cacgatacaa 1440  
 ctgcagctgc aataaaactgg tccttatacc aagtgatca tgaattggat gacgtgtttt 1500  
 acctgaagaa acttcggat ctggatgtg ctgttcctt atttgcggcgt agttagtgc 1560  
 taaaaggcac tgaagccgtc atcattccct ggaagtctga ccgtcccgct acagtagaa 1620  
 ccaaccccgaa ggagtccag cctgagcggg catatgccta cgtgccccttc tctgtggcc 1680  
 tgatggaaga aaagaccatt ctttctgtca ccaggaactg tataaggtaa aagtttgc 1920  
 agaaaagaga agagcttgcg ttagaaggac atgcatttgc ctttgaggca cttttggata 1980  
 ggatcaagtt gaagaggaga aatgcagatg ttcattttttt ttacaaatttta cagatcatga 2040  
 tatcatgaga aagtttttta ttttaagaga gttcaatatg cttgaatccc cttagaccaa 2100  
 aagtctaaca aagaaaaagt tttgagttt tttttttttt tttttttttt 2160  
 ttttttttga aaccgggttc tcactctgtc gcccaggctg gaggagttgc agtgggtgtga 2220  
 tctcagcttc acgtgcaccc tccacccccc aggtcaagc aattttctg ctcagccctc 2340  
 ccaagttagc tgggattaca ggtgcctgccc accatgcgtt ggctaatgtt ttggttttttt 2400  
 tagtagaaac aggttgcac cagttttggc cagactgg 2460  
 tagtagaaac aggttgcac cagttttggc cagactgg 2498

<210> 22  
 <211> 1158  
 <212> DNA  
 <213> Homo sapiens

<220>  
 <221> misc\_feature  
 <223> Incyte ID No: 6963993CB1

<400> 22  
 ggatagtttt ttttcccaa aatatgtaaa ggagttggaa cttagattat tcataaattc 60  
 cttcataact gatattgcct gtttttagac tgattatact agtacccaaat tagtgcattt 120  
 atttttatg tattatgttg tccacatgtc tgggtgaag gggagattt gttggattt 180  
 ctctgactgt gagaagacac tttttttgt tggtttgc ggccttcga gggaaagtga 240  
 ccgaggcgtt gaaagaggcc attgacgcgt ggtaccggca cttcgactgt gtttactttt 300  
 accacaatga gaggggagggtt ggaggcaggga tccgttgc gataaggaa ggcgtgttaa 360  
 gacgggagga tctgttcatt gccactaagc tgggtgtcac ctggccataag aagtccttgg 420  
 tggaaacagc atgcagaaag agtctcaagg ctttgaagct gaactattt gaccttacc 480  
 tcatacactg gccccatggg ttcagccctc gaggcgttgc cttgcctctg gacgagagca 540  
 acatggttat tcccaagtgc acggacttcc tggacacgttggaggccatg gaggacttgg 600  
 tgatcaccgg gctggtgaag aacatcgcccc ggcctttgaa taaggcctggg ttgagggttca agccactaac caaccaggatt gaggcgcacc 660  
 cttacccgtcc ttttggtggc tcgtgtgagg ggggttgcactt gatagacaac cctgtgtatca 720  
 agaggattgc aaaggagcac ggcaagtctc ctgctcagat tttgatccga tttcaaatcc 780  
 agaggaatgt gatagtgtatcc cccggatcta tcaccccaag tcacattaaa gagaatatcc 840  
 900  
 960

aggtgtttga ttttgaatta acacagcacg atatggataa catcctcagc ctaaacagga 1020  
 atctccgact gcccatgttc cccatgtaaa tatggctcct tccttttaaa acagagggaa 1080  
 gaatatacag attgaatgtat cggtgtctga ataggtattt atcatacaca ttttagatta 1140  
 attaaacctt ctcattat 1158

<210> 23  
 <211> 2075  
 <212> DNA  
 <213> Homo sapiens

<220>  
 <221> misc\_feature  
 <223> Incyte ID No: 7474404CB1

<400> 23  
 atgtcgctgc tgagcctgtc ctggctgggc ctcggccgg tggcagcata cccatggctg 60  
 ctccctgctgc tggcggggc ctcctggctc ctggcccgtg tcctggctg gacgtacgcc 120  
 ttctatgaca actgccaccc cctccagtgt ttccagcagc ctccaaaacg gaactgcttt 180  
 ggaggtcacc tgagcctgtat gcccccaat gaggaggaca tgaggctgtat ggaggatctg 240  
 ggccactact tccgtgatgt ccaactctgg tggctgggt ctttctaccc tgtccctgcat 300  
 ctcgtccacc ctacgttac ctcggctgtg ctccaggctt cagctgtgt tgcactcaag 360  
 gatatgagtt tctatggcctt cctgaagccc tggctggggg atgggctcct gattagtgcc 420  
 ggtgacaagt ggagatggca cgcacacccg ctcacacctg cttccactt caaaatctg 480  
 aaggccatgt tgaagatttt caatgagagc acgaacatca tgacacgcca atggcaacgc 540  
 ctggccttgg agggcagtgtt cctgtctggaa atgtttgagc acatcagcct catgacctt 600  
 gacagtctgc agaaatgtat cttagcttt gacagcaatt gtcaggacga atataattgtat 660  
 gccatcttgg agctcagtgcc ctcagtgctg aaacggcacc agcacatctt cctgctcagc 720  
 gacttcttgc acttcctcac tcccaatggg cgacgcttct gcaggccctg tgacatagt 780  
 cacaacttca cagatgtgt catccaggag cggcgtcgca ccctcaactag ccaggggtgc 840  
 gatgacttcc tgcaggccaa ggccaaatgtcc aagactttgg acttcattga cgtgcttgc 900  
 ctggccaagg atgaaaatgg aaagaatgtt tcaatgaga acataagagc ggaggctgac 960  
 accttcatgt ctggggggca tgacacccgt gccagtggc ttccttgggt cctgtacaac 1020  
 ctcgcgggt acccagaatcc ccaggagcac tgccgacagg aggtgcaaga gctcctgaag 1080  
 aacgggtgatc taaaagagat tgaatggat gacctggccc agttgcctt cctgaccatg 1140  
 tgcctgaagg agagcctgat gtcattcc ccagtcttca ggatccaccc ctgctgcccc 1200  
 caggacgggg tgctcccgaa tggccgggtc atccccaaag ggaacacttgc caccatcagc 1260  
 atcttggga tccatcacaa cccttcagtc tggccggacc cggaggtcta tgacccttt 1320  
 cgcttcgacc cagaaaatct ccagaagaca tcacctctgg ctttatttcc ttctcagca 1380  
 gtgcccggga actgcattcg ccagacgttc gccatggctg agatgaagg ggtcctggcg 1440  
 ctcacgtgc tgcgttccg cgtctgtcc gaccacgtgg agccccgcag gaagtggag 1500  
 ctgatcgatc ggcggggagga tggactttgg ctacgggtgg agccccctgag cgcggatctg 1560  
 cagtgaccca ccactgtcag gtctcagac caccgcgccc ctccctcaggc acctttgcag 1620  
 attccggggaa atcaatctgt gcctgatgtt cacaacacgc cagcagggggg cgtcggagaa 1680  
 ctgcaggat ccaggccctg gcgaggggaa ggcggagtt ttctgagcca agaccctgac 1740  
 agcctctgtt gttgatcaca gtggccccgt gctgagggcg ggttgccttca gagcgcaggt 1800  
 ggggacagta tcctgtggc gatagggagc catggcggtt gtttgcggcag gagagggacc 1860  
 agggttgagg aggcacat gggcgaggat tgaggctgt agtcactgag gaaaaccaga 1920  
 gccggactac atccccggcc ctcgatctca attctcatct cctaatacat ccagtgttt 1980  
 ttttcctct cacctcaggat ttctcaccg tttcatgtt tcttaaccga gtgcactt 2040  
 taaacaatag tagctggat tttacaaaaaaa aaaaaa 2075

<210> 24  
 <211> 909  
 <212> DNA  
 <213> Homo sapiens

<220>  
 <221> misc\_feature  
 <223> Incyte ID No: 7474438CB1

<400> 24  
 atgattctat tgaataattc cgagcggctg ctggccctat tcaaatactt agcaaggagc 60  
 attcctgagt ccctgaaggt gtatggctt ctgtttcaca tcaatcacgg gaacccttc 120  
 aacatggaaat gtttgcggcc gatggatcaga tggttattat ccgacccatca 180  
 aaacaggaga tgcactgtat catggattca tacactaatg tataatgtt attctccaaa 240  
 gaccctcaaa aatcacaaga agtttgaaa aattctgaga tccataactg gaaacagaaa 300  
 ctccaaatcc aaggtttca agaaagttt ggtgaggggta taagagcagc tgcattttca 360

320

<210> 18  
 <211> 316  
 <212> PRT  
 <213> Homo sapiens

<220>  
 <221> misc\_feature  
 <223> Incyte ID No: 7478577CD1

<400> 18

Met	Ala	Thr	Phe	Val	Glu	Leu	Ser	Thr	Lys	Ala	Lys	Met	Pro	Ile	
1				5					10						15
Val	Gly	Leu	Gly	Thr	Trp	Arg	Ser	Leu	Leu	Gly	Lys	Val	Lys	Glu	
				20					25						30
Ala	Val	Lys	Val	Ala	Ile	Asp	Ala	Glu	Tyr	Arg	His	Ile	Asp	Cys	
				35					40						45
Ala	Tyr	Phe	Tyr	Glu	Asn	Gln	His	Glu	Val	Gly	Glu	Ala	Ile	Gln	
				50					55						60
Glu	Lys	Ile	Gln	Glu	Lys	Ala	Val	Met	Arg	Glu	Asp	Leu	Phe	Ile	
				65					70						75
Val	Ser	Lys	Val	Trp	Pro	Thr	Phe	Phe	Glu	Arg	Pro	Leu	Val	Arg	
				80					85						90
Lys	Ala	Phe	Glu	Lys	Thr	Leu	Lys	Asp	Leu	Lys	Leu	Ser	Tyr	Leu	
				95					100						105
Asp	Val	Tyr	Leu	Ile	His	Trp	Pro	Gln	Gly	Phe	Lys	Thr	Gly	Asp	
				110					115						120
Asp	Phe	Phe	Pro	Lys	Asp	Asp	Lys	Gly	Asn	Met	Ile	Ser	Gly	Lys	
				125					130						135
Gly	Thr	Phe	Leu	Asp	Ala	Trp	Glu	Ala	Met	Glu	Glu	Leu	Val	Asp	
				140					145						150
Glu	Gly	Leu	Val	Lys	Ala	Leu	Gly	Val	Ser	Asn	Phe	Asn	His	Phe	
				155					160						165
Gln	Ile	Glu	Arg	Leu	Leu	Asn	Lys	Pro	Gly	Leu	Lys	Tyr	Lys	Pro	
				170					175						180
Val	Thr	Asn	Gln	Val	Glu	Cys	His	Pro	Tyr	Leu	Thr	Gln	Glu	Lys	
				185					190						195
Leu	Ile	Gln	Tyr	Cys	His	Ser	Lys	Gly	Ile	Thr	Val	Thr	Ala	Tyr	
				200					205						210
Ser	Pro	Leu	Gly	Ser	Pro	Asp	Arg	Pro	Trp	Ala	Lys	Pro	Glu	Asp	
				215					220						225
Pro	Ser	Leu	Leu	Glu	Asp	Pro	Lys	Ile	Lys	Glu	Ile	Ala	Ala	Lys	
				230					235						240
His	Lys	Lys	Thr	Thr	Ala	Gln	Val	Leu	Ile	Arg	Phe	His	Ile	Gln	
				245					250						255
Arg	Asn	Val	Thr	Val	Ile	Pro	Lys	Ser	Met	Thr	Pro	Ala	His	Ile	
				260					265						270
Val	Glu	Asn	Ile	Gln	Val	Phe	Asp	Phe	Lys	Leu	Ser	Asp	Glu		
				275					280						285
Met	Ala	Thr	Ile	Leu	Ser	Phe	Asn	Arg	Asn	Trp	Arg	Ala	Phe	Asp	
				290					295						300
Phe	Lys	Glu	Phe	Ser	His	Leu	Glu	Asp	Phe	Pro	Phe	Asp	Ala	Glu	
				305					310						315
Tyr															

<210> 19  
 <211> 1154  
 <212> DNA  
 <213> Homo sapiens

<220>  
 <221> misc\_feature  
 <223> Incyte ID No: 6274461CB1

<400> 19

ccttgatgct gggcatgagc aggacggggt tggccggagc ggcgctgcgg gtggcgctga 60  
 cggcgctgct gcecgctggc ctgcggcggt actacgtgta caagctgacc acgtacacctc 120  
 tcggcgccgt ctcccccgag gacgtcgccg acgtcgccgactcaaccatcacc ggcgcctcct 180  
 cccgcacatcg cgagcacctg gcctatgagt acgcgaagcg gggagccctac ctggcgctgg 240  
 tggcgaggag ggaggcgagc ctccgcgagg tcggcgacgt cgcgctgggg ctggcgctgc 300  
 cgggcgtcct cgtcctcccg gctgacgtct ccaagccctcg ggactgcgag ggcttcatcg 360  
 acgacacgt tagctacttc ggtagactgg atcacctggt gaacaacgcg tccatctggc 420  
 aagtgtgcaa gttcgaagag atccaggacg tcaggcaactt gagagccctg atggacatca 480  
 acttctgggg ccacgtgtac ccaacccggc tcgcatccc tcacctcagg agaagccgtg 540  
 gccggatcggt gggcgtcacc tccaactcgat cctacatatt catcgggagg aacaccttct 600  
 acaatggccag caaggcgccg ggcgtcagct tctacgacac cctgaggatg gagctggca 660  
 gcgacatccg catcaccggag gtggtgccag gcgtgggtga gtcgtgagatc accaagggga 720  
 agatgtcactac caagggagggc gagatgaagg tggaccagga cggaaagagac gtacggccatc 780  
 ctggggccga cgccggccga gcccgtggc gacttcgcca ggaccgtggt ggcgcacgtg 840  
 tggcgggggcg cgaggtacgt gttcgagccc aggtggtaat gggcgctcact ttgtgtcgccc 900  
 cctgcctccc ggaagtccctg gccttggaaact cccgcctgct cactgtcgac acgggtcgccg 960  
 cgtccaccac gacacgcgtc ggaaagtggc tggtcgagct gcccggcgtg cgccggcgtc 1020  
 tgcagccgccc gtgcgtcccg tcggcgagaa tcaaggacta gtgacgggtga tcgtgtacgt 1080  
 tctgtggcca tggatagcac tacctgtatg agaccgaagt tccttaaca taaacacgag 1140  
 tataaagact catc 1154

&lt;210&gt; 20

&lt;211&gt; 1324

&lt;212&gt; DNA

&lt;213&gt; Homo sapiens

&lt;220&gt;

&lt;221&gt; misc\_feature

&lt;223&gt; Incyte ID No: 7477262CB1

&lt;400&gt; 20

gactcggggc ggggcaggcg aggccggaggg cgagggctgc gggagcaagt acggagccgg 60  
 ggggtgtgggg gacgattgcc gctgcagccg cccggacact aaggagatg gatgaatggg cccgcctccact cacctccagt gtgtctgcag 120  
 cggctcgccg gtcagctgcc gccccccacag tggggaggat gcccgcaca tggccccggg 180  
 gaaaaaaaggcgcccgaggcg agcggggcac cggaccggtc gccccatgc gggcgccagcc 240  
 gcttcggcct accagcgctt cgagccgcgc tggccatccc gcaacaacta cgcgcctcc 300  
 cgcggggacc tggcaacccc gaaacggcgcc tggccatccc gcaacaacta cgcgcctcc 360  
 accttcgcca cccgtgaagt gtccggacgc gcttgcgttgc tcaccatgac agatttcctg 420  
 gtgttaccaggc gtcgtcgttgc ctgcagccac gaggtaacc gcccggagct ggggcgtgg 480  
 agcatgtaca gccaacatgc ctgcctcatt gaggcccgcc tggccatccc gcaacaacta cgcgcctcc 540  
 gagcgcacgc tggcagccag ggtgaaacgg tttgaggaca tcaccatgac agatttcctg 600  
 cccctgggtg ctgggagccc agctccctg ctgcgttgc tcaccatgac agatttcctg 660  
 ttggaggctg tgagccaga tcttgcagc gaggcaagg gggatgtcg gcaggataag 720  
 ctgctgaggc ctggggggca cctccctc tggccatccc gcaacaacta cgcgcctcc 780  
 gctggggagg ccaggctgac ggtgggtgcca tggccatccc gcaacaacta cgcgcctcc 840  
 gtgcgttagt gctacaaggctt ccgggaccc ttcagccggg ccctggacca catcaccacg 900  
 acaggcgtag atgatgtcaa gggcgcttcc ttcagccggg ccctggacca catcaccacg 960  
 gggctgtacc tggtgccttgc tggcccccac ttcagccggg ccctggacca catcaccacg 1020  
 acctaataaaa gaaataatac cctgaaaaaaaaaa aaaaacaaaa acaagaaaaaa aaaaaaaaaaca 1080  
 aaaagaaaaaa acaaacacaa gaaaaaacga aagaagaggg aaaaaaaaaaaga cgaggggggg 1140  
 gaaa 1200  
 1320  
 1324

&lt;210&gt; 21

&lt;211&gt; 2498

&lt;212&gt; DNA

&lt;213&gt; Homo sapiens

&lt;220&gt;

&lt;221&gt; misc\_feature

&lt;223&gt; Incyte ID No: 8097779CB1

&lt;400&gt; 21

agccggatgc gccttcctt cctctccaga gcaggctgcc cgcccgccga atccgcacg 60  
 tagagcaacc tcgcagcacc ctcagaacag ccccgctggg ggcgcgggg ctggcgctgg 120

aattcagtga aggttagagca ttcgagagca ctcccttttgc ttacggaaga tattcctgaag 420  
 ctctatgcca ccaataaaaag caagcttggaa agctgggctg agacaggcca cccagatgac 480  
 gaattggaga gcgagactcc gaactttaag tatgcccagc tgaatgtgtc ttattctggg 540  
 ctggtaaatg acaactggaa gcttagggatg aataagagga gcctgcgtta catcaagcgc 600  
 tgcctaggag ccctgcacgc agcctgtatg ctgggcccag agggggtccc ggtctcatgg 660  
 gtaaccatgg accccttcttgc tgaaatagga atgggctaca gtgtggaaaa ataccgaagg 720  
 agaggcaatg ggacacggct gatcatgcga tgcatgaagt atctgtgtca gaagaatatt 780  
 ccattttacg gctctgtgt ggaagaaaaat caaggcgctca tcagaaagac tagtgcacta 840  
 ggtttccttgc aggccctctg tcagtggcac caatggaact gctacccaca gaatcttgg 900  
 ccattttag 909

<210> 25  
 <211> 1613  
 <212> DNA  
 <213> Homo sapiens

<220>  
 <221> misc\_feature  
 <223> Incyte ID No: 7476298CB1

<400> 25  
 atgtctggcc aacccttat ctataaagt acaatttctg taacctggct ttctctttta 60  
 tttttagtt atgggaccca ttccacataaa ctttttaaga agctggaaat tcctgggcca 120  
 acccctctgc cttttctggg aactatttgc ttctacccttta ggggtctttg gaattttgac 180  
 agagaatgtt aatggaaaata cggagaaaatg tgggggctgt atgaggggca acagcccatg 240  
 ctggcatca tggatcccgaa catgatcaaa acagtgttag tggaaagaaatg ttactctgtc 300  
 ttccacaaacc agatgcctt aggtccaaatg ggatttctga aaagtgcctt aagtttgct 360  
 gaagatgaag aatggaaagag aatacgaaca ttcaaggaaa tggtccccat catttcccaa 420  
 caggaagcag agaacagcaa gtccatcaac gatgtatca ctggcacatt atttggagtg 480  
 cccttctga aaaatatgaa gaagctttta ttaatatcac tctttccatt tcttacccca 540  
 caaaagatg ttaccattt tttaaaaaaat aaagataaac aaaagcatcg agtagatttgc 600  
 aaagaaacaa agtcccataa agctctgtct atcattttg ctgcctatga cacaacttgc 660  
 gccacttcacc ctgtatgtcc gcagaaactg aaggcacctg tcacatcgaa tgccctggta 720  
 gaaacgtca gattattccc agttgttagt gaaatcaatg gagtgttcat tcccaaagg 780  
 caccatgacc caaagtactg gacagagct aagaacaagg acagcataga tctttacaga 840  
 tgcattggca tgagggttgc tctcacaaac aacttctcct tcaaaccctt taaagagact 900  
 attctcaac cagaaaaacc tattgttcta ggaccctgac tttccctaag gacttccact 960  
 agacaactca aattgttttgc tgaataaaaac ttgttcaaga aagctgttac 1020  
 tcagaaatgttgcact taagagatgg gattacaatg 1080  
 ttgttcaaga aagctgttac 1140  
 tcagaaatgttgcact taatcttactc 1200  
 ttgttcaaga aagctgttac 1260  
 tcacatctt tggagctgg accccgaaac 1320  
 ataaaacttgc tgcatttgcact 1380  
 cagatcccac tggaaatttgc 1440  
 aaagtgcact taagagatgg gattacaatg 1500  
 ttgttcaaga aagctgttac 1560  
 tcagaaatgttgcact 1613

<210> 26  
 <211> 654  
 <212> DNA  
 <213> Homo sapiens

<220>  
 <221> misc\_feature  
 <223> Incyte ID No: 7477555CB1

<400> 26  
 atgcccgtga cactggggta ctgggacatc cgagggctgg cccacgcccgt ctgcctgtctc 60  
 ctgcaataca cagacttaag ctatgaggaa aagaagtaca tggatggggta cgctcctgac 120  
 tatgacagaa gccagtggct gaatggaaaa ttcaagctgg gcctggactt tcccaatctg 180  
 ccctacttgc ttgatggggc tcacaagatc accccagagca aggccatcct gggctgcatt 240  
 gcctacaagg acaacactgtg tggggagaca gaaggggaga agattggga agacattttg 300  
 gagaaccagg ttgtggacaa ccacgtgcac 360  
 aagaaactga agccagaata cctggaggca tccctgca tgcgtgaagct ctactcacag 420  
 tttctggggta agcagctatt gtttcttggg gacaagatca cacttggca tttcatcgac 480

tatggcatcc ttgagagaaaa ccaagtattt gagcccaagt ggttggacgc cttccaaac 540  
 ctgaaggact tcatctcccg atttgagggc ttggagatct ctgcctacat gaaatccagc 600  
 tgcttcctcc tgagacctgt gttcacaaag atggctgtct gggcaacaa gtag 654

<210> 27  
 <211> 2064  
 <212> DNA  
 <213> Homo sapiens

<220>  
 <221> misc\_feature  
 <223> Incyte ID No: 1527520CB1

<400> 27  
 agggggcgcccc cccagaggcg aggggcttcc ccaatcagtc tccgcccctag cgccctggac 60  
 ttccggccca ttccattggg tgagggtggg ggcacgaaaa gaggagcgcc cttgcggccc 120  
 caccgtgtcc cgcctctca gtccccagcg actcgcagg gctgggtggg ctggggtcca 180  
 gtcgcgcgc tccccgtccc tgccgcgcgc cgcgcgtctt ggttaggcgt ggcgtgcgg 240  
 ggccgggtcc tggggccagtg caactcccgccc cccagccgtta tccagcgac tgcctcccg 300  
 cgcgcgcgc ggcacagcat ggggaggcgcc tgctctggcg cgcgcgtctt ggcggccattt 360  
 ggcgcgcgc gtcctctcg gtcctatgc ggtggggaga agagaagccc ctcgcagaag 480  
 gaaacacagag ccctgggtc cagctggctt accttggcga aggtgcaccc tcagcgccgc 540  
 ctctatgacc tggatcagga ccgcgcgtcg gacgtgtca acagcgctg tagccgcac 600  
 gacgtcgccg acgtgtcggt ggacgcgcg catggctc tctactgtca cgtgcacaag 660  
 gtggcctgca ccaactggaa ggcgtgtcg ccgcgcgcac ttcagcccgcc cgcgcgtcg 720  
 ccgcgcgcac tctccgcga agaggcgcac ggcgtacaa ccggcgccgt 840  
 gagcccttcg agcgcctggc atcggcttac gccttccaga ggcgtacgg tgacgcata 900  
 gacgcgcgcg cccgcggcca cgacgtgcgc ttcagcgcc tgcggccgcg cgcgtccccc 960  
 ccgcgcacgc ggcgtgagga gcccgtcaac caccgtgtc gcctccgcata cgacgtcg 1020  
 gccttcgtgc tgggcctggc gggcgcatcc cggggagccg cgcgcgtccgc tccggacat 1080  
 taccagcgcc ggcgttgcgca cctctacaag ccctcttacc tgcggctgt ctagegggtcc 1320  
 cctttccgac aagacccccc gggaatgcag agccactgcg tgcacttacc tggccgcgg 1380  
 cttggggcgc gcccgttca ggtggccctg gaggcctgtcttccactt gtcgcgtcg 1440  
 caaggacttg ataaccaggg ttttaggttttgcgcgc gccagcgccg 1500  
 cctgaacctg ttcatgggtc atcagaacat gcctgtgtcc tccccacccgc ctcgcgtgt 1560  
 cctcccttgg ctggcctcaac gatggggccg tgcgcgttcc cccaggacc cctcttcaag 1620  
 ctgcgcgttgc gtcctcttc ctctccacag ttcagtctg gcaagacgtt gtcgcgttcc 1680  
 gtcgcgttcc gtttatggg actttggta aatgtcgaca ccgggtgtcag tgcgttcc 1740  
 gcaaggacag ctgcggccaa ggacgaaagc 1800  
 tcccgggagc caggtggag ctgccttcca cggctggccc taccaggcg ccaccccg 1860  
 gtcgcgttcc gtttatggg actttggta aatgtcgaca ccgggtgtcag tgcgttcc 1920  
 gtcgcgttcc gtttatggg actttggta aatgtcgaca ccgggtgtcag tgcgttcc 1980  
 gtcgcgttcc gtttatggg actttggta aatgtcgaca ccgggtgtcag tgcgttcc 2040  
 attttggta tttctgaaaa aaaa 2064

<210> 28  
 <211> 4071  
 <212> DNA  
 <213> Homo sapiens

<220>  
 <221> misc\_feature  
 <223> Incyte ID No: 3419318CB1

<400> 28  
 ccgtccatcc ctgcggccaa atttaaagcc cgcaagggtt tggctttag accagcgact 60  
 ttagtccga tgcgggaagg aaagccgacc tccgatttgg acatttaag agctggcctt 120  
 gaacttcgtg agtttcgtcc taaactgcgg ttgaaatgaa gctggacttg gaggtggcat 180  
 ggaatattca catggggagag ccgcgtatggg ccgcgcacca cgcgttccgtaa aggatgcgg 240  
 tggaaagaa ttttgacgtg ccagtgtctt ctttctacag ggtgttccat tcttccgca 300  
 ttcagaaaa atgggactaa aagaaactat tttgtaaaat aagaagactt ccattttaa 360  
 tgaccaacat gtatggat ggacacccat tctacgaaac acaaaggctt atggcttcg 420

agaagcccggt gcctgtttaa aactgatcct aactaaaaac agacttgagt ggatatgaga 480  
 atgttggtaa gtggcagaag agtcaaaaaa tggcagttaa ttattcagtt atttgcact 540  
 tggttttag cgagcctcat gtttttgg gaaccaatcg ataatcacat tgtgaccat 600  
 atgaagtcat attccttacag atacctcata aatagctatg actttgtgaa tgataccctg 660  
 tctctaagc acacctcagc ggggcctcgc tacaatact tgattaacca caagggaaaag 720  
 tgtcaagctc aagacgtctc cctttactg tttgtaaaaa ctgtccctga aaactatgat 780  
 cgacgttccg gaattagaag gacgtggggc aatgaaaatt atgttcggtc tcagctgaat 840  
 gccaacatca aaactctgtt tgcccttagga actcctaattc cactggaggg agaagaacta 900  
 caaagaaaac tggcttggga agatcaaagg tacaatgata taattcagca agactttgtt 960  
 gattcttct acaatcttac tctgaaaatta cttatgcagt tcagttggc aaatacctat 1020  
 tgtccacatg ccaaatttct tatgactgct gatgatgaca tatttattca catgccaaat 1080  
 ctgattgagt accttcaaaag tttagaacaa attgggttca aagactttt gattggcgt 1140  
 gttcatcgtg gtgcccctcc cattagagat aaaagcagca aatactacgt gtcctatgaa 1200  
 atgtaccagt ggccagctt ccctgactac acagccggag ctgcctatgt aatctccggt 1260  
 gatgtagctg ccaaagtcta tgaggcatca cagacactaa attcaagtct ttacatagac 1320  
 gatgttca tgggcctctg tgccaaataaa atagggatag taccgcagga ccatgtgtt 1380  
 ttttctggag agggtaaaaac tccttatcat ccctgcattc atgaaaaaat gatgacatct 1440  
 catggacact tagaagatct ccaggacctt tggagaatg ctacagatcc taaagtaaaa 1500  
 accatttcca aaggttttt tggtcaaataa tactgcagat taatgaagat aattctccctt 1560  
 tgtaaaatta gctatgtgaa cacataccct tggggctgt cgtttatcta atagtaacttg 1620  
 aatgttgtat gttttcactg tcactgagtc aaacctggat gaaaaaaacc tttaaatgtt 1680  
 cgtctatacc ctaagtaaaa tgaggacgaa agacaatatt tttgaaagcc tagtccatca 1740  
 gaatgttct ttgatttag aagctgttta atatcactta tctacttcat tgccctaagt 1800  
 catttcaaag aatttgtatt tagaaaaaggt ttatattatt agtggaaaaca aaactaaagg 1860  
 gaagttcaag ttctcatgta atgcccacata tatacttgag gttagagat gttattaaga 1920  
 agtttgatg tttagaataat tgctttggaa aaataccaaa tgaacgtaca gtacaacatt 1980  
 tcaaggaaat gaatataatg ttagaccagg taagcaagtt tattttgtt aaagagcact 2040  
 tggtgagggt agtagggcga gggaaaggc agcataaggag agaaagttca tgaatctgg 2100  
 aaaacagtct cttgttcttta agaggagatg tagaaaaatg tgacataatgt tattataaac 2160  
 agacaaatca cgtcttacca catccatgtc gctactggc ttagagtcata taaaataacct 2220  
 tttttgcattt ctttttccaa agttaatgt gaaactttttag aaaagtgtt aatgttgc 2280  
 taatacttta tatgtttta atggattttt tttaagtat tagaaaatga cacataacac 2340  
 gggcagctgg ttgctcataag ggtcctctc tagggagaaa ccattgtttaa ttcaaataaag 2400  
 ctgattttaa tgacgttttca aactggttt taaatattca atattggct gtgttaagt 2460  
 ttgttattttg aatgttaattt acatagagga atataataat ggagagactt caaatggaaa 2520  
 gacagaacat tacaagccta atgtctccat aattttataa aatgaaatct tagtgcctaa 2580  
 atccttgtac tgattactaa aattaacca ctcctcccca acaaggtctt ataaaccaca 2640  
 gcacttggt ccaagttcaag agttaatct tgagagcatt aaacatcaaa gttataat 2700  
 ctaaaacaaat ttattttca tcaataactg tcagagggtga tcttttattt ctaaatattt 2760  
 caaacttgaa aacagagtaa aaaagtgata gaaaagtgc cagtttgggg taaaagcatt 2820  
 tttaaagctg catgttccctt gtaatcaag acatttattt tacaacagcg gataaaaaatg agatgtgtc gagatctat agatgtt 2880  
 acatttattt tacaacagcg gataaaaaatg tggctataat acacactacc tcccttact 2940  
 acagaaagaa cttaggtggt tctactgcta gggagattat atgaaggcca aaataatgac 3000  
 ttcagcaaga gtgactgaac tcactctaag gccttgcact gcagaggcac ctgttagga 3060  
 aaatcagatg tctcatataa taaggtgatg tcgaaacac gcaaaacaaa acggaaaaaag 3120  
 atttctcagt atacacaact gaatgtatgat acttacaatt ttagcaggt agctttttaa 3180  
 tgtttacaga aatttttaatt ttttctatt ttgaaatttg aggcttggtt acattgctt 3240  
 gataatttag aatttttaac taatgtcaaa actacagtgt caaacattct aggtttagt 3300  
 tactttcaga gtgatcacag ggttttagat cattacagtt taagtttct gaccaattaa 3360  
 aaaaacatag agaacaaaag catattgc caagcaacaa gcttataatt aatttttatt 3420  
 agttgattga ttaatgtatg attgcctttt gcccataat accctgtgtc tctataactg 3480  
 gaagtgttta aggttgcatt tggttggaaa cataagtgtc tctggccatc aaagtgtatct 3540  
 tgtttacagc agtgcttttgc tggatcacattt atttatttgc tgaaagagct cttctgaact 3600  
 gtgtccctttt aatttttgc tggatcacattt tggaacaagt taaaattca agggaaatatg 3660  
 aaggcaacttc cttttttctt aagaaggaaag ttgcttagatg attccttcat cacacttact 3720  
 taaagtactg agaagagat tctgtaaataa aagggttcca accttttaaa aaagaaggaa 3780  
 aaaactttt ggtgctccag tggatggcta tttttttaaa aaatgtcaac aaaggggaaaa 3840  
 taaactatca gcttggatgg tcacttgaat agaagatgtt tatacacatg gttattgtt 3900  
 aaattttttt accttttgc tggatggcat cttttttcca tattgttaat tttataccaa 3960  
 aatgttaaatt atttgttattt ctgtaaattt gctcttgcattt ggcaaaataa ttgtgagtt 4020  
 taaaaaaaaat otatagtttcaataaaacaa ctgaaaaattt aaaaaaaaaa a 4071

&lt;210&gt; 29

&lt;211&gt; 4444

&lt;212&gt; DNA

&lt;213&gt; Homo sapiens

<220>  
<221> misc\_feature  
<223> Incyte ID No: 3815272CB1

<400> 29

agcgcttac ggcgacggcg gctgagttag aacctggcg gctgtggagg ctgccgggc 60  
tgcgaaggag gggcgccgg tggcgagga agaggagtag cgccagccgc ggcggggacc 120  
cgtgcgggga tggcgaggt accgcctggg cctagcagcc tcctcccacc accagcacct 180  
ccggccccgg cggcggtcgaa gccccgtgt cccttcccg cggggggccgc cctcgctgc 240  
tgcagcgagg acgaggagga cgacgaagag cacgaaggcg gccgcagcag gagccggcg 300  
ggcggagagt cggcgacggg ggcggccaag gggcatccgt gcctccgctg ccctcagccg 360  
ccgcaggagc agcagcagct caacggattt attagccccg aactgcggca cctccggcg 420  
gcccctccc tcaagagcaa ggtcctgagc gtacgagagg tggccgcac cacagccacc 480  
ctgacggagg ccccagagcg actgcaacaa aaggagccgg ggtacactcg ggcgagaggc 540  
cccctcactc cctctctaaa tgcaagaact ggggtccccca gcccgggtgaa ggcagccggc 600  
gcgagcgatc cggcgccggc cggcaatggc ctggccgagg gcaccgagca ggaggaggag 660  
gaggaagacg agcaggtgcg gctgctgtc tcgtccctga ccggcactg cagcttaaga 720  
agcccttcgg gcagggaggt tgagcttggg gaggatcgaa cgatacgata tgcgatgat 780  
gaatccgagc tacaaatgcc cgatatcatg agactgatca ccaaagatct gtcgaaccc 840  
tactccatt atacctatacg atattttatc cacaactggc cacagctgtg cttcttggcc 900  
atggtagggg aggagtgtgt aggtggccatc gtttgcagaat tggatatgcg caaaaagatg 960  
ttccgcagag gttatatacg catgttagcc gtggattcca aatacaggag aaatggcatt 1020  
ggtaactact tggttaagaa agctatatac gccatggttg agggagactg tgcgatgtt 1080  
gtttggaaa cggaaataaac aaataagtcc gcttgcggaaat ttatgaaaaa tcttggtttt 1140  
gttcgagata agaggctgtt cagatactat ttaatggag ttgatgcact gcgacttaaa 1200  
ctgtggctgc gttgagaaac tgacatcaag gaacaactat catccacaca gatcgaccc 1260  
ttgcatgca tgcaattttg acagaatgtc ttgcgggtt gatttagtaa tttccatgtca 1320  
gctcttacct gtcagtgctt cattgagtgt cgcacaaat ttgttgcact ttggcatggc 1380  
acatttgttc tgaattaaaaa gattttttt aacttcagga gtttgcactt tccaaacaag 1440  
atgtgccagt tgatagccaa gatttatgtt ttcatttgcg aagtctgtg acaatgtt 1500  
ttacacagt atcattttat cacagaacca gtaagtggaa cataattttt gttccctaaa 1560  
aaagccaatg tggattgtaa aagtctttaa gtatactaac atttcacaca aaacctgccc 1620  
tagtttctg aagtgggtga gggagacgct tcagttttt gtttgcattt tcaatatttt 1680  
aattttccat tcttgaatat tggtaacctca gtgatttagt aatggaaaaaa atgttaggtg 1740  
ggtatgtctt acaatgagta aaggtaacaa ttaatattt tctgccatgtg ctttgcattt 1800  
taagtatatt tgcatttcattc tccagttttt gaatgcatgc tatctttcc tttctttaa 1860  
ggccttgcg agcaaaaccc ttgttttatt taaattctaa atttgataaa ttatccatgt 1920  
tttttataat ttggataact ttttcagggt aatggaaaaaa tggtttactt tagatgtt 1980  
tttttcctta cagtaacaag ttgaatctac ttggaaaatt gagaatggc ttttgcattt 2040  
taagaaaagt tgatggagcc gggaaattgtt ggggttttaga tgcactttt ttttgcattt 2100  
taagggaaatg ttggaaaag aatggaaaat tagtgcattt tgatatgatt ttatccatgt 2160  
aaaattactg ctacgctgcg aagaacagct ttacaaatgt agctgaattt gttttccca 2220  
cttgatttgg attcacattt ctttcatttca taaaatgtc tcacttcagg ttcttggct 2280  
tggaaataaa ttcaaggtg cattgtatcc attttaaatgt gcttttattt attttcactt 2340  
gtatgagcaa attttgggg gagcttgc tttcttgc cagaaaaaca aaagggggaa 2400  
atggaaaatct ttggaaat tggatctgtt ggttttctta acagccacca tggtttattt 2460  
ttacattgtg tttggccaa tcagtgcaat gtaacaaattt ttacagttt ttgttgcattt 2520  
ttgagtctgtt aacactgtga tagataattt atttaactgg aaaacactagg ttttgcattt 2580  
aaaaaaagatt cattctctgt gaaaactgtt ggaatctgtt gtttttca ttttgcattt 2640  
ctctactct gctctgtat ttgggttggaa atatatttt tggctcaat ttttgcattt 2700  
ttaaaaaacc tacccattt aacagttgtt aaggccccct tttcaggaaa tactgttattt 2760  
ttttttttt tttaaagga aactgtctt tgcctcagta tagtggttt ttttgcattt 2820  
tagtaacaaa tactttaaa ataaagatac acaattttt ttttgcattt 2880  
gctgggtggaa ttattttat ttctttttt ttttgcattt 2940  
tcttgcattt ttaatgagca gaatacaata ctgggttataa taaaatatg gtaaccacac 3000  
agtactcagc cttcaatattt gttttggc aacacttcatt taggcacttag catttagaag 3060  
aataccaatc acagtgtatgc ttttgcattt taatatgaaag gaaatggaaac taaaacattt 3120  
atgtcatcaa atttttttac ttctttttt atttgacttgc ctgggtgata cataatggtt 3180  
gatgaacata tatttgcattt aatcactaat aggatgggtt gtaaagttaga tagatcattt 3240  
gttcaaccat ttttagtgc ttttgcattt aacacttcatt taggcacttag gacctttcc 3300  
tccaaaattt ccaaattgac tgaactgggtt ggggtttttt aaagatgacg ttaactgtgt 3360  
gactaaaaag tcagatgggtt gccatattgtt ttggaaatatg ttgaatgtca gttgtatgcct 3420  
tatgtcttta atgggtatg caaaaaattt ttacttaag tagattaaaaa ttttgcattt 3480  
tagcatgaaa acccagcacc aacactgaaa gactccattt aggtgaagt ttttgcattt 3540  
agtaatttac ttttgcattt taggctgtt ttttgcattt ataagcttaa ttttgcattt 3600  
tctgaaattt gtagcatggg ttcacttgc tacaactgag caaaatagat ttttgcattt 3660  
tttaatgggg tgcgtgcctt ttaggactga ctgtacttgc cactgacact ggtttggcag 3720

ttggtaactgc tgaacatttt tatacatgct accatgaagc tatatatgtt agtattgaag 3780  
 aagctaacgg gtatactatac attttgatg tggggctga ttataatttc ctgtattcc 3840  
 tgtacattgg gatgaaaacta ctttagcaaa gtccacagat cagaaccag acggtagttt 3900  
 ttgaagttga aaccagcaaa ataagaaaaaa ataaaaaaatc gatttaata tttctgcct 3960  
 ctttccaaa ttacccttc cactgctcg acaaatttat gtaaagcgt ttgtttttc 4020  
 atgtttaac ttacatttc cctgtgttat ggtactggct gacatgtcta agactggatg 4080  
 tgtatattta ttatgggtgc taaaaatcat gaagttcattc acttttcagg agtataagata 4140  
 aaatcaaatt ggttagtacat cagagttact tttcagtgc ccatgacatc actaaaaatga 4200  
 gtgctgtaat gttacagggc tttcaggttt gtaaaaacat aaccataaat tatattgacg 4260  
 tcagatatga gttgagtatac tataaaatat cacgtgtatc tcaaaatatt ggactgctgt 4320  
 ttgactggat attgctgcat aattttcttc tattgtccca tattttttt gagagagatt 4380  
 taatggatt tgaaaatgtgc aagctgtcta aataagatgc agtcaaataa agtatggta 4440  
 agtt 4444

&lt;210&gt; 30

&lt;211&gt; 2663

&lt;212&gt; DNA

&lt;213&gt; Homo sapiens

&lt;220&gt;

&lt;221&gt; misc\_feature

&lt;223&gt; Incyte ID No: 7473875CB1

&lt;400&gt; 30

gagagaaaata gactccttctt ctgtcccttc taacccaggt ccctaccgt acccctccctc 60  
 ctcccttcc ccgccccccctc ctccctccctg gggcgagggg ggcctccctc cctctcccc 120  
 ccttcctctc ctcccgaggggg ggggtcaggg gagggagggg gggtccccca atcagcatgt 180  
 ggctcctggc gttgtgtctg gtggggctgg gcggccggcgc cccggggcgc cccggcctgg 240  
 cgggtgtgaa cacggcctac gggcgagtgc tccctggccc ctgcgtgcag ttcttggcg 300  
 gcccgttcca gcccgttgcag gcccgttgcct ctggccgttcca gtttccatgcg 360  
 tgccgttccgc ctgcccgcag aacctgcacg gtttccatgcg 420  
 gtttccatgcg 360  
 gtttccatgcg 420  
 gtttccatgcg 480  
 gggcgcttcca ctggccgttgcag aacctgcacg gtttccatgcg 540  
 cctacgttcca gtttccatgcg 600  
 acgggttttcca gtttccatgcg 660  
 acgggttttcca gtttccatgcg 720  
 cccggaaacat gtttccatgcg 780  
 ctggccgttcca ctggccgttgcag aacctgcacg gtttccatgcg 840  
 tcagccatgg ggaccaggct gtttccatgcg 900  
 tggcttccgg ctttccatgcg 960  
 ttgggttccgg ggcggggcc ttttccatgcg 1020  
 ggcttccatgcg 1020  
 accggccgttcca ctggccgttgcag aacctgcacg gtttccatgcg 1080  
 gtttccatgcg 1080  
 gtttccatgcg 1140  
 agccctcccg gtttccatgcg 1200  
 gggccgttcca ctggccgttgcag aacctgcacg gtttccatgcg 1260  
 gtttccatgcg 1260  
 aatttccatgcg 1320  
 aggacttgcg 1380  
 acttttgcg 1440  
 agtttccatgcg 1500  
 tggccgttcca ctggccgttgcag aacctgcacg gtttccatgcg 1560  
 cccacttcca gtttccatgcg 1620  
 ggccttcccg gtttccatgcg 1680  
 tggcttccatgcg 1740  
 cccgttccatgcg 1800  
 cccacttcca gtttccatgcg 1860  
 aatttccatgcg 1920  
 acttttgcg 1980  
 acacgggttcca ctggccgttgcag aacctgcacg gtttccatgcg 2040  
 gtttccatgcg 2100  
 agccctcccg gtttccatgcg 2160  
 actccacggc gtttccatgcg 2220  
 tggccgttcca ctggccgttgcag aacctgcacg gtttccatgcg 2280  
 accggccgttcca ctggccgttgcag aacctgcacg gtttccatgcg 2340  
 tggccgttcca ctggccgttgcag aacctgcacg gtttccatgcg 2400  
 tggccgttcca ctggccgttgcag aacctgcacg gtttccatgcg 2460  
 gacgggggttcca ctggccgttgcag aacctgcacg gtttccatgcg 2520  
 cagaccaaaatccatgcg 2580

aatctttat ttttcttagga catgttatgc ctccatttc aattaaaata aagttatcg 2640  
attacaccac caaaaaaaaaaaa' aaa 2663

<210> 31  
<211> 3944  
<212> DNA  
<213> *Homo sapiens*

<220>  
<221> misc\_feature  
<223> Incyte ID No: 7478099CB1

<400> 31  
agggagaagg cagcgcgtt taccggagtt acctgttagtc aaccacagtc tgaaaaatatt 60  
aaggattttt aagacagaaaa gagagagagg agagaaaaccg cattcacaaa aaagaaatcc 120  
tctttttaga acatctctt gttgtaccat cagaaatgtc ttcccttaagt gaaaaagtcc 180  
aaaccgtttt gggccttgc gggcaagca aactggccg taccctgacc catgaacacc 240  
tggccatgac cttgactgc tglactgtc cacccccc gtgcaggaa gctatttcca 300  
aagaacctat cgtgatgaaa aatttatatt ggattcagaa aaacgcctat tcccataaag 360  
aaaacccctca attaaatca gggacagaag ccataaagga agaactgtt tattttaaag 420  
ctaattgtgg agggctttt gtggaaaaca caaccactgg gattagccga gacacacaga 480  
cggtgaagag gcttgcagaa gagactggcg tccatatcat atctggagcc gggttttatg 540  
tggatgcaac tcactcctca gagaccaggc ccatgtca gggagcagctt accgatgtcc 600  
ttatgaatga aattctccat ggagctgtat gaaccagtat caagtgtgc attattggag 660  
aaattgttg ctccctggcct ttgactgaga gtgaaagaaaa ggttctccag gccacagctc 720  
atgcccaggc tcagcttggt tgcctgtt ttatccatcc tggacggagc tccagggcac 780  
cattcagat tatccgaata ttgcaagaag caggcgcaga catctccaaa acagtcatgt 840  
cacaccttgg taggactatt ttgataaga aagagcttt ggagtttgc cagcttggct 900  
gctacttgg atatgatctc ttggactgt aactacttca ttaccaactc ggcccagata 960  
ttgacatgcc tgatgataac aaaagaatta gaagggtgcg tctcctggtg gaagagggtct 1020  
gtgaagatcg aattcttggt gcacatgaca tacatacga aaccggctg atgaaatatg 1080  
gaggttcacgg ctatctcat atactcacca atggttgc taaaatgtt ctgagaggca 1140  
taactgagaa tggatgtt aagattctaa tagagaaaccc taagcaatgg ctaacttca 1200  
aataggatgg ttgctttaga attcacacct tgagtataaa acttgcagag aacattcagc 1260  
gatttcaggc ccactgttagt atattaatca ttacacttgc ttttgcattc gatcatttcc 1320  
ttctgtatgag aacttaggagg gtttgcattc tctgagacca gctattacca ctgtgcctct 1380  
agggagttac tcagcctaat tgacccctat tattttact taacaaaata aatacagaag 1440  
tacctatttc taaacaatga tttaaagtct atatcccata agcggagttt ttgttttct 1500  
ccctaattctc tcagctgcac tacttggagaa aattttaaatg gtttctagtt aaatttatttc 1560  
cttcttggc gatctaattgt ttcttgcattt attgtatgtc ctactaatta tcctgctgtt 1620  
ctttaattaa tgcttaatga ataataatggc actgtaaaat agttctgc acaagggaaag 1680  
ttaaattttg agactttttt ccccaaaagga tactgactgt aatacaattt ccaatttcaca 1740  
atgataaaaaa tattttgaaa gtttaattttt atactgttca cctatctata tatttgcgtt 1800  
ctgaaatgtat ttgatattct ttggctttcc ggtatctatt ttgcctata aatcataaaaa 1860  
tttgcctaaatg ttgtataaga acacataaca ctactgaatt ataaaaattt aatcataaaaa 1920  
gtcaaaaatattt attacataat atagtttaat gaatcattac atttataata acaaaggcca 1980  
caatttaattt aatttggtaag atataatgca aaaaaaaaaaa gagaaatgtt tgccttatgt 2040  
atattccctt tattttcctt acctttgtt tttccttggg cctaaacaga gaaaataatg 2100  
cttatgtatc tgaagaaaaag gtcagatctt ttggaaaatgtc cagcccgata ttgagcctc 2160  
ctctttaaaaa ggtatccagc cctgtatattt tggatggaaaataa aacgtttttt aaaaacctgtt 2220  
agttaaaaaca cttaggtgtat gggcactgtt gcttataat tcatcttttg gttgaatcct 2280  
caactatgtca ttgggtaccc aaaaatattt cccaaaccc tgcgtccagt tcctcttga 2340  
taaatatata gttattcaaa aaaaaatcc attgtcaattt attttatgtt tatcttacat 2400  
atccaaaga ccaatttagaa ttgtcattt ttcttgcattt agagtctgtt ttaatcata 2460  
aaaatcatga cgttactca gacccaggca tttcaacaga gctaacacca ctttcagata 2520  
ggcacacccat gcataactct tgggaagttt agctttgtt aataaaaagat atttctgtt 2580  
atcaaagatg atcaagctt ctgttattt gaaacagaaag taacaaagag gaatgagcca 2640  
ggagaacaaaa ctaattccctt taaaataataa aaaaaaaaaaa atgcaaatgtt ctttcaccag 2700  
taaaggcaagc aaatttttaa aatctctgtt ttggaaaatctt actctgtcaaa gaggatccatg 2760  
aggcaatgaa aggggaacag atttttcattt gtaatagttt aagttgtgtt atagtttaga 2820  
gatataaca tgcattttt atctttccct tagatgaaaag agatggctt tggcagttgt 2880  
ttctaaccag aaagaaagga ttgttatttac totccaaatc tactgtactg tcaacttca 2940  
tccacccgtt gaaaaagaaa aaaaatttgc tagctcaat gcatgttattt cataaacact 3000  
gcaaaaggaga gcacttggt gtctgcagtc ctcattttaa cagttgtca cagaatgcag 3060  
ttaaaggatatt gattggcata ttggtaataga gcaaccatag ccttaactta cagacctgtt 3120  
aaataaaaggg cattttgacc taatacaattt aattttctgg ataactctt aagagaagtc 3180  
attttaactg tttttgtctac tccatataattt gtcattcaaa atatattttt aaccaaaaata 3240

agttaaataa tttgtgcatg tttgtgtgt tatatatgca tacactttt tatattaaaa 3300  
 ttttgggtt atacagccac tggccctgt ggaataaagc catatatata aatgttttat 3360  
 atgtatatgt ttatatacatataaaaacat ttcatctaat atatatatgt gtgtgtgagt 3420  
 atatgtgtgc atgtttacag atatttgtat aaaataaaa cactctgttg tcataattggc 3480  
 tataatgcgaa attgttaatt taaaataaac ctcaggccac agactttagt taatcatttg 3540  
 aaggcctcac ctatgtcccc ctgggtgacg tatgcacgag ctcaaaattaa accttggc 3600  
 attgggttat gaataatctt ttcttccaaa gatggcaaaa gcctcggtt gatttgatac 3660  
 taaagaataa atttctctga ctcccagt gaatctaaat gtattcagtt gacaaaatgg 3720  
 acacataagg gcttttcta aataaccgtac ataattacac atttcacac ttagagggta 3780  
 atcctatgtat acactgtcaa tctctatattt aaaagactat caccagaaaa gagagaaaaag 3840  
 aaattcatat aagaaaaaaga aatgtaaaaa gatcataggc ttggaaatc cctcaaattcc 3900  
 agaaaattca ggttaaggcc ttgagttgaa tcattccag gtcc 3944

<210> 32  
 <211> 2053  
 <212> DNA  
 <213> Homo sapiens

<220>  
 <221> misc\_feature  
 <223> Incyte ID No: 1962105CB1

<400> 32  
 cggaaaggct ggcaggcagg agggctgggg cgagcaactgg gggccatgg agcggcaga 60  
 agagccctgt gtctatcaga agctgctgcc ctggagcca agcttggagt cggaggagga 120  
 agtggaggag gaggagacat cagaggcgtt gttctaaac ccccgaggc accaggactc 180  
 ttccaggaac aaggctggcg ggctgccccg aacctggcc cgttagtgg cagccctgt 240  
 gctgctggct gttggctgt ccctggctgt gaggcagctc cagaatcagg gcaggctgac 300  
 aggaagcttgg ctgctctgtt ccctccacc cggcgacac tcccacggcc ctggctata 360  
 ccaccacggt gccatcatca gcccgcgc cacaatgtcc cacctaggcc gagactgtct 420  
 tggccgggg ggcaacgtcg tggatgtgg agttggagct gcattgtgcc tggcagtgg 480  
 gcatcctcat gccacggggc taggtgccc gtttggggc ctctccacag atagctctc 540  
 aggcaattcc acggccctga catcaggccc agcacagacc ctggccccc gcctggggct 600  
 gcccggct ctgcccaccc tgacacctgt gcatgcacgc ttggccggcc tggccctggcc 660  
 acgcctgtca gtggggccca ccacgctggc tcaggagggc ttctgggtgg acacacccct 720  
 ggcaaggcgt ctggggctc gggcacaga caccacccctgt ccactacttt gccatgtca 780  
 tgggacaccc ctggggctgt gggcccgagc cacaaccca caactggcag ctgtgttcg 840  
 cagcgcagcc ctgcgtccca cctcagacact tgctgggat gctctactga gtctactggc 900  
 gggagacctg ggggtggagg tgccctggc tgcccaggccc accactttgg aaccagcaga 960  
 gcagacttgcgt gtcggccagg gcacccatgtt caccacccctgt ccactacttt gtcggccaga 1020  
 actgtggca ctgtggagg cagccctgcg ctccggggcg cccatccctg accccctgccc 1080  
 accgttctgt cagactgtg tgacccctga gaggcgtcc ctggccggcc tggacagcag 1140  
 cggctctgt ctccctctca cctcctcgct caactgtcc ttggctctg cacacctgtc 1200  
 ccaagact ggggtctgc tcagcaacact ggtggccaag ttaccacta gtgcctggcc 1260  
 ctgccccctc atcctccgt gcaacccatgt tgacacagag gctgatgtgt tggggcttgc 1320  
 ggcttcaggg accccctgtatg tggccaggcc catgactcac accctactca ggcacatggc 1380  
 agcaaggccc cctacccagg cccagcacca gcatcagggt cagcaagaac caacagagca 1440  
 tcccagact tggccaaag ggaccctgtt ccagggtggca gcccacacag agcacacccca 1500  
 tgtctccagt gtcccccattt cctgctgccc ttccaggggg ttctaaacagg atgggggtgg 1560  
 gtctggcaga aggcaagat atctgaagca tggggccagg agcagagcag acacagcagc 1620  
 aatggagtgt gcaaccccgag ggtgtgtgc ctcacacctg taatctcagc actttgggtg 1680  
 gtcaaggcag gaagataacct cgaggccagg agtttggaaac tagcctagac aacaaagcaa 1740  
 gatctcatct gtactaaaaa tttaaaaattt ggcaggggc ggtggcacat gcctgtgtc 1800  
 ccagctgtttt gggaggctga ggcaggaaagc tcgcttgagc tcaggagttc aaggctgcag 1860  
 agagcttaga tcacaccact gcactccagc ctggacaaca gagtggaaac ctgtttttaa 1920  
 aataataataa ataataataa aaaaatagct ggtgtgggtg gctcatgcct gtaatccag 1980  
 cactttggga ggccaaggca ggtggatcac ctgaggctag gagttcgaga ccagcttgag 2040  
 aacatgcgaa ccg 2053

<210> 33  
 <211> 2019  
 <212> DNA  
 <213> Homo sapiens

<220>  
 <221> misc\_feature  
 <223> Incyte ID No: 5643401CB1

<400> 33  
atggcggggc tctggctggg gctcggtgg cagaagctgc tgctgtgggg cgccggcaggt 60  
gccgttccc tggccggcgc cagtcgtgtc ctgagcctgc tgcaaggggt ggcgagctac 120  
gcgcgaaaat ggcagcagat gcggcccatc cccacgggtt cccgcgccta cccactgggt 180  
ggccacgcgc tgctgatgaa gccggacggg cgagaatttt ttcagcagat cattgagttac 240  
acagaggaat accgccccat gccgctgctg aagctctggg tcggccagtt gcccatgggt 300  
gcctttata atgcagaaaa tggagacta gtgttaatag aagttgggtt ggtggatgca 360  
gatggagatc tggcagatg aggggacttg agcaagaagc ctgatataatt tttgttaacc 420  
acatattttt tttctagttac tggaaacaaa tggcgctcca ggagaaagat gttaacaccc 480  
actttccatt ttaccattct ggaagatttc ttagatatca tgaatgaaca agcaaataata 540  
ttggtaaga aactgaaaaa acacattaac caagaagcat ttaactgctt ttttacatc 600  
actcttgcg ccttagatat catctgtgcg cggttctacg accgcactgg cttctgagg 660  
agcagcagcc acgcccaggg ctgtgagtgg ggcagaatga gtgagatgat atttgcaga 720  
ataaaagatgc cctggctttg gcttgatctc tggtaacctt tggtaaaga aggatggaa 780  
cacaaaaaga gccttcagat cctacatact ttaccaaca gtgtcatcg tgaacgggcc 840  
aatgaaaatga acgccaatga agactgtaga ggtgtatggca ggggtctgc cccctccaaa 900  
aataaacgca gggccttct tgacttgctt ttaagtgtga ctgatgacga agggAACAGG 960  
ctaagtcatg aagatattcg agaagaagtt gacacccctca tggggatggg gcacgataca 1020  
actgcagctg caataaaactg gtccttatac ctgttggtt ctaaaccaga agtccagaaaa 1080  
aaagtggatc atgaatttggg tgacgtgtt gggaaagtctg accgtcccgc tacagtagaa 1140  
gacctgaaga aacttcggta tctggaatgt gttattaaagg agacccctcg ctttttcct 1200  
tctgttccct tattttcccg tagtgttagt gaagattgtg aagtggcagg ttacagagtt 1260  
ctaaaaggca ctgaagccgt catcattccc tatgcattgc acagagatcc gagatactc 1320  
cccaaccccg aggagttcca gcctgagccg ttcttcccg agaatgcaca agggcggcat 1380  
ccatatgcct acgtggccct ctctgtggc cccaggaact gtataggtca aaagtggatct 1440  
gtgatggaaag aaaagaccat tctttctgc atctcgaggt acctttggat agaatccaa 1500  
cagaaaaagag aagagcttgg tctagaagga cagttgatc ttgcgtccaaat taatggcct 1560  
tggatcaagt tgaagaggag aaatgcagat gaacgcataac tatattattt ggttggcct 1620  
ttatcatgag aaaggctttt attttaagag atcctgtca tttacaattt acagatcatg 1680  
agttcaatat gcttgaatcc cctagaccta atttttccct gatccccactg atcttgacat 1740  
caagtctaac aaagaaaaag ttttgagttt tggatccaaat tttttctttt ttcttttattt 1800  
tttttttttgg aacccgggtt ctcactctgt cgccccaggtt ggaggagttt cagttgggt 1860  
atctcagctt cacgtgcaac ctccacccctc caggttcaag caattttct gcctcagcct 1920  
cccaagtttag ctgggattac aggtggctgc caccatgcgg tggctaatgt tttggtattt 1980  
tttagtagaaaa caggttgtca ccagtgttgg ccagactgg 2019

<210> 34  
<211> 1631  
<212> DNA  
<213> *Homo sapiens*

<220>  
<221> misc\_feature  
<223> Incyte ID No: 7478053CB1

cctgaaagg	tcagtaagaa	gaacaaggac	agcatagatc	tttacagata	cataccttt	1320
ggagctggac	cccgaaactg	cattggcatg	aggtttgc	tcacaaacat	aaaacttgct	1380
gtcatttagag	cactgcagaa	cttctcc	aaaccttgc	aagagactca	gatcccactg	1440
aaatttagaca	atctaccaat	tcttcaacca	aaaaaaccta	ttgttctaaa	agtgcactt	1500
agagatggg	ttacaagtgg	accctgactt	tccctaagga	cttccactt	gttcaagaaa	1560
gctgtatccc	agaacactag	acacttcaaa	ttgttttg	aataaaaactc	agaaatgaag	1620
atgagcttaa	a					1631

<210> 35  
<211> 969  
<212> DNA  
<213> *Homo sapiens*

<220>  
<221> misc\_feature  
<223> Incyte ID No: 7478994CB1

```

<400> 35
atggatcccc aatatcagcg tgttagagcta aatgatggtc acttcatgcc cgtattggga 60
tttggcacct atgcacccctc agaggtaccc aaaaggccagg ctgccgaggc caccaaagtg 120
gctattgacg taggcttccg ccatattgtat tcagcatact tataccaaaa tgaggaggag 180
gttggacagg ccatttggga gaagatcgct gatggtaccg tcaagagaga gggaaatattc 240
tacaccatca aggtgaaagt tctgtgtta caggcagaat tggttcaccc gcccctagaa 300
aggtcaactga agaaacttgg accggactat gtagatctct tcattattca tgtaccattt 360
gctttccagc ctggggagga attgctgcct aaggatgcc a ttttttgcgtt 420
actgtggatc ttctgtgacac atgggaggcc ctggagaagt gcaaagaagc aggtttaacc 480
aagtccatcg ggggtgtccaa ttcaatcac aaactgctgg aactcatctt caacaagcc 540
gggctcaagt acaagcccac ctgcaaccag gtggaatgtc acccttaccc caaccagagc 600
aaactccctgg agttctgcaa gtccaaaggac attgttcttag ttgcctacag tgccctggga 660
tcccaaaggag acccacagtg ggtggatccc gactggccac atctcttggg gggccgcgt 720
ttgaaatcca ttgccaagaa acacagtggaa agcccaggcc aggtgcctt ggcgttaccag 780
ctgcagcggg gagtgggtgtt gctggccaag agttctctc aggagagaat caaatcttcc 840
tttcaggtt ttgactttga gttgactccaa gaggacatgaa aagccactga tggcctcaac 900
agaaatttcc gatatgctaa gttacaatttgc cttatggacc atcctgatta tccatatttca 960
gatgaatattt

```

<210> 36  
<211> 951  
<212> DNA  
<213> *Homo sapiens*

<220>  
<221> misc\_feature  
<223> Incyte ID No: 7478577CB1

```

<400> 36
atggccacgt ttgtggagct cagtacaaaa gccaagatgc ccattgtggg cctggggcact 60
tggagggtctc ttctcggcaa agtgaaaagaa gcgggtgaagg tggcattga tgcagaatat 120
cgccacattg actgtgccta tttctatgag aatcaacatg aggtgggaga agccatccaa 180
gagaagatcc aagagaaggc tgtgatgcgg gaggacctgt tcatacgtag caaggtgtgg 240
cccactttct tttagagagacc cttgtgagg aaagccttt agaagaccct caaggacactg 300
aagctgagct atctggacgt ctatcttatt cactggccac agggattcaa gactggggat 360
gacttttcc ccaaagatga taaaggtaat atgatcagtg gaaaaggaac gttcttgat 420
gcctgggagg ccatggagga gctgggtggac gaggggctgg tgaaaagccct tggggctca 480
aatttcaacc acttccagat cgagaggctc ttgaacaaac ctggactgaa atataaaacca 540
gtgactaacc aggtttagtgc tcaccctatac ctcacgcagg agaaaactgat ccagtactgc 600
cactccaagg gcatcaccgt tacggcctac agccccctgg gctctccgga tagaccttgg 660
gccaaacctg aggacccttc cctgctggag gatcccaaga ttaaggagat tgctgcaag 720
cacaaaaaaaaa ccacagccca gtttctgatc cgtttccata tccagaggaa tggacagtg 780
atcccccaagt ctatgacacc agcacacatt gttgagaaca ttcaggtctt tgactttaaa 840
ttgagtgtatc aggagatggc aaccatactc agcttcaaca gaaactggag ggcctttgac 900
ttcaaggaat tctctcattt ggaggactt cccttcgatc cagaatattg a 951

```



A small, dark, irregular mark or smudge located near the bottom center of the page. It has a jagged, somewhat V-shaped or hook-like shape with a dark, irregular base and a lighter, irregular top.